US20060106034A1 - Drug efflux pump inhibitor - Google Patents
Drug efflux pump inhibitor Download PDFInfo
- Publication number
- US20060106034A1 US20060106034A1 US11/320,229 US32022905A US2006106034A1 US 20060106034 A1 US20060106034 A1 US 20060106034A1 US 32022905 A US32022905 A US 32022905A US 2006106034 A1 US2006106034 A1 US 2006106034A1
- Authority
- US
- United States
- Prior art keywords
- group
- thiazol
- pyrido
- mmol
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 229940079593 drug Drugs 0.000 title claims description 24
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 358
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 44
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 43
- 125000005843 halogen group Chemical group 0.000 claims abstract description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 35
- 125000003118 aryl group Chemical group 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 208000015181 infectious disease Diseases 0.000 claims abstract description 26
- 125000006165 cyclic alkyl group Chemical group 0.000 claims abstract description 24
- 125000003277 amino group Chemical group 0.000 claims abstract description 18
- 230000000813 microbial effect Effects 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 15
- 230000002378 acidificating effect Effects 0.000 claims abstract description 13
- 230000003449 preventive effect Effects 0.000 claims abstract description 13
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 11
- LUYJUDUSMXAUPU-UHFFFAOYSA-N 5-ethenylidene-1,3-thiazolidine-2,4-dione Chemical compound C=C=C1SC(=O)NC1=O LUYJUDUSMXAUPU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 111
- 229920006395 saturated elastomer Polymers 0.000 claims description 73
- 125000004432 carbon atom Chemical group C* 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 51
- -1 cyanomethyl group Chemical group 0.000 claims description 42
- 239000004599 antimicrobial Substances 0.000 claims description 37
- 125000001424 substituent group Chemical group 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 29
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 244000005700 microbiome Species 0.000 claims description 20
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 462
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 420
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 412
- 238000005160 1H NMR spectroscopy Methods 0.000 description 354
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 285
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 232
- 238000006243 chemical reaction Methods 0.000 description 202
- 239000000243 solution Substances 0.000 description 191
- 230000002829 reductive effect Effects 0.000 description 180
- 239000002904 solvent Substances 0.000 description 173
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 172
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 158
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 156
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 144
- 239000011541 reaction mixture Substances 0.000 description 141
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 139
- 238000010898 silica gel chromatography Methods 0.000 description 131
- 239000012044 organic layer Substances 0.000 description 113
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 104
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 103
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 98
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 82
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 74
- 239000013078 crystal Substances 0.000 description 72
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 69
- 238000001816 cooling Methods 0.000 description 69
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 66
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 66
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 64
- 235000019341 magnesium sulphate Nutrition 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 63
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 53
- 235000017557 sodium bicarbonate Nutrition 0.000 description 46
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 46
- 239000007787 solid Substances 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 41
- 238000001914 filtration Methods 0.000 description 40
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 40
- 238000010438 heat treatment Methods 0.000 description 38
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 38
- 239000010410 layer Substances 0.000 description 36
- 239000000843 powder Substances 0.000 description 36
- 229910052938 sodium sulfate Inorganic materials 0.000 description 34
- 235000011152 sodium sulphate Nutrition 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 32
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 30
- 238000012746 preparative thin layer chromatography Methods 0.000 description 29
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 28
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 26
- 239000000126 substance Substances 0.000 description 26
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 25
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 235000019441 ethanol Nutrition 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 239000003242 anti bacterial agent Substances 0.000 description 16
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 14
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 14
- 235000019270 ammonium chloride Nutrition 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- ZWZUFQPXYVYAFO-UHFFFAOYSA-N Tert-butyl (triphenylphosphoranylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC(C)(C)C)C1=CC=CC=C1 ZWZUFQPXYVYAFO-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000012299 nitrogen atmosphere Substances 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000008096 xylene Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 9
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- WTNDXFLMNZOYAV-ONEGZZNKSA-N 2-hydroxy-8-[(E)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C=C(O)N=3)=O)C=C2)=N1 WTNDXFLMNZOYAV-ONEGZZNKSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 208000035473 Communicable disease Diseases 0.000 description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 7
- 239000004280 Sodium formate Substances 0.000 description 7
- 239000012300 argon atmosphere Substances 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 7
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 7
- 235000019254 sodium formate Nutrition 0.000 description 7
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 6
- XGGMTLLYGOPCKR-UHFFFAOYSA-N 3-oxo-3-(2,3,4-trichlorophenoxy)propanoic acid Chemical compound OC(=O)CC(=O)OC1=CC=C(Cl)C(Cl)=C1Cl XGGMTLLYGOPCKR-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- YJTSEYDGJPGJPR-UHFFFAOYSA-N (4-propan-2-yl-1,3-thiazol-2-yl)methanol Chemical compound CC(C)C1=CSC(CO)=N1 YJTSEYDGJPGJPR-UHFFFAOYSA-N 0.000 description 5
- GHOSTUJAIVKHKU-GQCTYLIASA-N (e)-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 GHOSTUJAIVKHKU-GQCTYLIASA-N 0.000 description 5
- WANVWFTXAKNTNO-UHFFFAOYSA-N 2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 WANVWFTXAKNTNO-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- QYDFQWNKSXHMIB-UHFFFAOYSA-N 3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]-4-oxopyrido[1,2-a]pyrimidine-8-carboxylic acid Chemical compound C1=CC(OC)=CC=C1CN1N=C(C=2C(N3C=CC(=CC3=NC=2)C(O)=O)=O)N=N1 QYDFQWNKSXHMIB-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- JJMVEQQEEBFBPC-UHFFFAOYSA-N 4-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyridin-2-amine Chemical compound CC(C)C1=CSC(CCC=2C=C(N)N=CC=2)=N1 JJMVEQQEEBFBPC-UHFFFAOYSA-N 0.000 description 5
- 238000007239 Wittig reaction Methods 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- ZKAHFQMBXSIUEL-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-2,4-dioxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C=2C=CN3C(=O)CC(=O)N=C3C=2)=N1 ZKAHFQMBXSIUEL-UHFFFAOYSA-N 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- VNQIEKXUBYBTPS-UHFFFAOYSA-N 2-acetamidopyridine-4-carboxylic acid Chemical compound CC(=O)NC1=CC(C(O)=O)=CC=N1 VNQIEKXUBYBTPS-UHFFFAOYSA-N 0.000 description 4
- UJXHPFDJZCXTQR-UHFFFAOYSA-N 3-(iodomethyl)oxolane Chemical compound ICC1CCOC1 UJXHPFDJZCXTQR-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- JGDLAGLWCQUNGW-UHFFFAOYSA-N ethyl 2-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]acetate Chemical compound N1=C(CC(=O)OCC)N=NN1CC1=CC=C(OC)C=C1 JGDLAGLWCQUNGW-UHFFFAOYSA-N 0.000 description 4
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- PVSJXEDBEXYLML-UHFFFAOYSA-N methyl 2-[bis(2,2,2-trifluoroethoxy)phosphoryl]acetate Chemical compound COC(=O)CP(=O)(OCC(F)(F)F)OCC(F)(F)F PVSJXEDBEXYLML-UHFFFAOYSA-N 0.000 description 4
- AVBNQCPLEGJJBS-UHFFFAOYSA-N methyl 4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidine-3-carboxylate Chemical compound C1=CN2C(=O)C(C(=O)OC)=CN=C2C=C1CCC1=NC(C(C)C)=CS1 AVBNQCPLEGJJBS-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- WDORQTFPEPWOBE-VQHVLOKHSA-N tert-butyl (E)-3-[2-hydroxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(O)N=3)=O)C=C2)=N1 WDORQTFPEPWOBE-VQHVLOKHSA-N 0.000 description 4
- SABMAMDNSRZJBK-UHFFFAOYSA-N tert-butyl n-(4-methylpyridin-2-yl)carbamate Chemical compound CC1=CC=NC(NC(=O)OC(C)(C)C)=C1 SABMAMDNSRZJBK-UHFFFAOYSA-N 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- HCTHZZSYUGOKAD-FNORWQNLSA-N (e)-3-[2-methoxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=CN2C(=O)C(\C=C\C(O)=O)=C(OC)N=C2C=C1CCC1=NC(C(C)C)=CS1 HCTHZZSYUGOKAD-FNORWQNLSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- CMZGCZXYRZFLLT-UHFFFAOYSA-N 2-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]acetyl chloride Chemical compound C1=CC(OC)=CC=C1CN1N=C(CC(Cl)=O)N=N1 CMZGCZXYRZFLLT-UHFFFAOYSA-N 0.000 description 3
- ODPHLRQTQFMNJQ-UHFFFAOYSA-N 2-bromo-1-cyclobutylethanone Chemical compound BrCC(=O)C1CCC1 ODPHLRQTQFMNJQ-UHFFFAOYSA-N 0.000 description 3
- KEHMKMCNALLPLR-UHFFFAOYSA-N 2-hydroxy-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C=C(O)N=3)=O)C=C2)=N1 KEHMKMCNALLPLR-UHFFFAOYSA-N 0.000 description 3
- FUMJUVZYMMLGMA-UHFFFAOYSA-N 2-morpholin-4-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C=C(N=3)N3CCOCC3)=O)C=C2)=N1 FUMJUVZYMMLGMA-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- SLGVJLNVPYQNNK-UHFFFAOYSA-N 3h-cinnolin-4-one Chemical compound C1=CC=C2C(=O)CN=NC2=C1 SLGVJLNVPYQNNK-UHFFFAOYSA-N 0.000 description 3
- URUMQJSLFUBCEK-ONEGZZNKSA-N 4-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyridin-2-amine Chemical compound CC(C)C1=CSC(\C=C\C=2C=C(N)N=CC=2)=N1 URUMQJSLFUBCEK-ONEGZZNKSA-N 0.000 description 3
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical class CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 3
- NPKAPESKYCZDBB-UHFFFAOYSA-N 4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=O)=CN=3)=O)C=C2)=N1 NPKAPESKYCZDBB-UHFFFAOYSA-N 0.000 description 3
- ZBXWEZOZGAWXMO-UHFFFAOYSA-N 8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-hydroxypyrido[1,2-a]pyrimidin-4-one Chemical compound C=1C2=NC(O)=CC(=O)N2C=CC=1CCC(SC=1)=NC=1C1CCC1 ZBXWEZOZGAWXMO-UHFFFAOYSA-N 0.000 description 3
- CDBXXQWDTHQXIS-UHFFFAOYSA-N 8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound C1=CN2C(=O)C(C=O)=C(N3CCOCC3)N=C2C=C1CCC(SC=1)=NC=1C1CCC1 CDBXXQWDTHQXIS-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- SAKMUIFBKKSUDP-UHFFFAOYSA-N [4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-2-yl] trifluoromethanesulfonate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C=C(OS(=O)(=O)C(F)(F)F)N=3)=O)C=C2)=N1 SAKMUIFBKKSUDP-UHFFFAOYSA-N 0.000 description 3
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 3
- 125000006575 electron-withdrawing group Chemical group 0.000 description 3
- AXZWOACHSQCIOG-UHFFFAOYSA-N ethyl 3-(dimethylamino)-2-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]prop-2-enoate Chemical compound N1=C(C(=CN(C)C)C(=O)OCC)N=NN1CC1=CC=C(OC)C=C1 AXZWOACHSQCIOG-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- WHANRZJVBOBVCC-UHFFFAOYSA-N n,n-dimethylpiperidine-3-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN(C)C(=O)C1CCCNC1 WHANRZJVBOBVCC-UHFFFAOYSA-N 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- QXURGFBUJMIRGR-UHFFFAOYSA-N n-(4-cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound C=1C2=NC(=O)CC(=O)N2C=CC=1C(=O)NC(SC=1)=NC=1C1CCC1 QXURGFBUJMIRGR-UHFFFAOYSA-N 0.000 description 3
- GWMFAQRPQVEGDN-UHFFFAOYSA-N n-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(3-hydroxypiperidin-1-yl)-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound C1C(O)CCCN1C1=CC(=O)N(C=CC(=C2)C(=O)NC=3SC=C(N=3)C3CCC3)C2=N1 GWMFAQRPQVEGDN-UHFFFAOYSA-N 0.000 description 3
- WINZRFPREQTSKW-UHFFFAOYSA-N n-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(4-methylpiperazin-1-yl)-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound C1CN(C)CCN1C1=CC(=O)N(C=CC(=C2)C(=O)NC=3SC=C(N=3)C3CCC3)C2=N1 WINZRFPREQTSKW-UHFFFAOYSA-N 0.000 description 3
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- MDZIAJUGTHULKN-GFULKKFKSA-N tert-butyl (e)-3-[2-(3-formyloxypiperidin-1-yl)-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CC(CCC4)OC=O)N=3)=O)C=C2)=N1 MDZIAJUGTHULKN-GFULKKFKSA-N 0.000 description 3
- BIYSEVQHHMXTBS-GFULKKFKSA-N tert-butyl (e)-3-[2-(3-hydroxypiperidin-1-yl)-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CC(O)CCC4)N=3)=O)C=C2)=N1 BIYSEVQHHMXTBS-GFULKKFKSA-N 0.000 description 3
- BIYSEVQHHMXTBS-QDWQJTLLSA-N tert-butyl (e)-3-[2-[(3r)-3-hydroxypiperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4C[C@H](O)CCC4)N=3)=O)C=C2)=N1 BIYSEVQHHMXTBS-QDWQJTLLSA-N 0.000 description 3
- BIYSEVQHHMXTBS-TZWVMONCSA-N tert-butyl (e)-3-[2-[(3s)-3-hydroxypiperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4C[C@@H](O)CCC4)N=3)=O)C=C2)=N1 BIYSEVQHHMXTBS-TZWVMONCSA-N 0.000 description 3
- ZGKFCMKAJXDUOQ-PKNBQFBNSA-N tert-butyl (e)-3-[7-fluoro-2-(3-hydroxypiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC=2C(=CN3C(=O)C(\C=C\C(=O)OC(C)(C)C)=C(N4CC(O)CCC4)N=C3C=2)F)=N1 ZGKFCMKAJXDUOQ-PKNBQFBNSA-N 0.000 description 3
- CWOBIUIWTCOKBN-QZEKMECESA-N tert-butyl (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3r)-3-hydroxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3C[C@H](O)CCC3)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 CWOBIUIWTCOKBN-QZEKMECESA-N 0.000 description 3
- CWOBIUIWTCOKBN-BBVFFXRHSA-N tert-butyl (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3s)-3-hydroxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3C[C@@H](O)CCC3)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 CWOBIUIWTCOKBN-BBVFFXRHSA-N 0.000 description 3
- CCXHFJJMWLETQD-UHFFFAOYSA-N tert-butyl n-[4-(3-amino-3-sulfanylidenepropyl)pyridin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(CCC(N)=S)=CC=N1 CCXHFJJMWLETQD-UHFFFAOYSA-N 0.000 description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 3
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- PPTBORVTNMLJHR-UHFFFAOYSA-N (4-ethylthiophen-2-yl)methanol Chemical compound CCC1=CSC(CO)=C1 PPTBORVTNMLJHR-UHFFFAOYSA-N 0.000 description 2
- OQMKVPYMYZSPCO-UHFFFAOYSA-N (4-tert-butyl-1,3-thiazol-2-yl)methanol Chemical compound CC(C)(C)C1=CSC(CO)=N1 OQMKVPYMYZSPCO-UHFFFAOYSA-N 0.000 description 2
- SFTCLTQJCZJJMS-NVNXTCNLSA-N (5z)-5-[[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C/4C(NC(=O)S\4)=O)=CN=3)=O)C=C2)=N1 SFTCLTQJCZJJMS-NVNXTCNLSA-N 0.000 description 2
- LINOADUJDAMYAH-FOWTUZBSSA-N (e)-2-methyl-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C(/C)C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 LINOADUJDAMYAH-FOWTUZBSSA-N 0.000 description 2
- MZPHTNGICPFQQY-MDWZMJQESA-N (e)-2-methyl-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C(/C)C(O)=O)=CN=3)=O)C=C2)=N1 MZPHTNGICPFQQY-MDWZMJQESA-N 0.000 description 2
- LHKVPTYLATZKDE-KQQUZDAGSA-N (e)-3-[2-(3-carbamoyloxypiperidin-1-yl)-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CCC4)OC(N)=O)N=3)=O)C=C2)=N1 LHKVPTYLATZKDE-KQQUZDAGSA-N 0.000 description 2
- PCTCSMVAVFMWHE-AATRIKPKSA-N (e)-3-[2-(3-hydroxypiperidin-1-yl)-4-oxo-8-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(COC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(O)CCC4)N=3)=O)C=C2)=N1 PCTCSMVAVFMWHE-AATRIKPKSA-N 0.000 description 2
- KYQTVLKRKHWJNU-KQQUZDAGSA-N (e)-3-[2-(3-hydroxypiperidin-1-yl)-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(O)CCC4)N=3)=O)C=C2)=N1 KYQTVLKRKHWJNU-KQQUZDAGSA-N 0.000 description 2
- KQPBRVZXAWDYLE-GQCTYLIASA-N (e)-3-[2-(carboxymethylsulfanyl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(SCC(O)=O)N=3)=O)C=C2)=N1 KQPBRVZXAWDYLE-GQCTYLIASA-N 0.000 description 2
- KYQTVLKRKHWJNU-QGIGQLMMSA-N (e)-3-[2-[(3r)-3-hydroxypiperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@H](O)CCC4)N=3)=O)C=C2)=N1 KYQTVLKRKHWJNU-QGIGQLMMSA-N 0.000 description 2
- KYQTVLKRKHWJNU-KZQZIPNXSA-N (e)-3-[2-[(3s)-3-hydroxypiperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@@H](O)CCC4)N=3)=O)C=C2)=N1 KYQTVLKRKHWJNU-KZQZIPNXSA-N 0.000 description 2
- XOKICKDSDWWKFY-FIFLTTCUSA-N (e)-3-[2-[3-(dimethylcarbamoyl)piperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CCC4)C(=O)N(C)C)N=3)=O)C=C2)=N1 XOKICKDSDWWKFY-FIFLTTCUSA-N 0.000 description 2
- LRSJPZRTEYLYKE-CDJQDVQCSA-N (e)-3-[2-[3-(methylcarbamoyl)piperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1C(C(=O)NC)CCCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(\C=C\C=3SC=C(N=3)C(C)C)=CC2=N1 LRSJPZRTEYLYKE-CDJQDVQCSA-N 0.000 description 2
- FJBPYTSCOMVMCZ-GGWOSOGESA-N (e)-3-[4-oxo-2-(oxolan-3-ylmethoxy)-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(OCC4COCC4)N=3)=O)C=C2)=N1 FJBPYTSCOMVMCZ-GGWOSOGESA-N 0.000 description 2
- HNJYCJKSWGXPRE-GQCTYLIASA-N (e)-3-[4-oxo-2-(oxolan-3-ylmethoxy)-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(OCC4COCC4)N=3)=O)C=C2)=N1 HNJYCJKSWGXPRE-GQCTYLIASA-N 0.000 description 2
- DQZOSTLPVPPEKC-SOFGYWHQSA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-pyridin-3-ylpyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(C=4C=NC=CC=4)N=3)=O)C=C2)=N1 DQZOSTLPVPPEKC-SOFGYWHQSA-N 0.000 description 2
- JYKQQUFWIWJLKW-GQCTYLIASA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=CN=3)=O)C=C2)=N1 JYKQQUFWIWJLKW-GQCTYLIASA-N 0.000 description 2
- CDBLFMLGKAKRCZ-SOFGYWHQSA-N (e)-3-[7-fluoro-2-(3-hydroxypiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC=2C(=CN3C(=O)C(\C=C\C(O)=O)=C(N4CC(O)CCC4)N=C3C=2)F)=N1 CDBLFMLGKAKRCZ-SOFGYWHQSA-N 0.000 description 2
- MPVACCJBUFTGCL-VOTSOKGWSA-N (e)-3-[8-[(4-cyclobutyl-1,3-thiazol-2-yl)carbamoyl]-2-(3-hydroxypiperidin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1C(O)CCCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(C(=O)NC=3SC=C(N=3)C3CCC3)=CC2=N1 MPVACCJBUFTGCL-VOTSOKGWSA-N 0.000 description 2
- HPXXDHOVORKYLH-LQYUOIDQSA-N (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3r)-3-carbamoyloxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@@H](CCC4)OC(N)=O)N=3)=O)C=C2)=N1 HPXXDHOVORKYLH-LQYUOIDQSA-N 0.000 description 2
- DQKLLQBFKPFJQE-LQYUOIDQSA-N (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3r)-3-hydroxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@H](O)CCC4)N=3)=O)C=C2)=N1 DQKLLQBFKPFJQE-LQYUOIDQSA-N 0.000 description 2
- USVVSYJTWOHHBF-CMDGGOBGSA-N (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[3-(dimethylcarbamoyl)piperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1C(C(=O)N(C)C)CCCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(C(=O)NC=3SC=C(N=3)C(C)(C)C)=CC2=N1 USVVSYJTWOHHBF-CMDGGOBGSA-N 0.000 description 2
- WCQVXLFVRLIFQX-SNAWJCMRSA-N (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 WCQVXLFVRLIFQX-SNAWJCMRSA-N 0.000 description 2
- LPCAQQJWWMQTCB-VQHVLOKHSA-N (e)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1C(O)CCCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(CCC=3SC=C(N=3)C3CCC3)=CC2=N1 LPCAQQJWWMQTCB-VQHVLOKHSA-N 0.000 description 2
- OGHDQRFJBOXHNI-DTQAZKPQSA-N (e)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]-2-methylprop-2-enoic acid Chemical compound C1=CN2C(=O)C(\C=C(/C)C(O)=O)=C(N3CCOCC3)N=C2C=C1CCC(SC=1)=NC=1C1CCC1 OGHDQRFJBOXHNI-DTQAZKPQSA-N 0.000 description 2
- YOYQCGLYCCHTRH-FNORWQNLSA-N (e)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=CN2C(=O)C(/C=C/C(=O)O)=C(N3CCOCC3)N=C2C=C1CCC(SC=1)=NC=1C1CCC1 YOYQCGLYCCHTRH-FNORWQNLSA-N 0.000 description 2
- BTWRWCIGJFESMK-GQCTYLIASA-N (e)-3-[8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CCC1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 BTWRWCIGJFESMK-GQCTYLIASA-N 0.000 description 2
- HJTKJDKUFPTLPT-AATRIKPKSA-N (e)-3-[8-[2-(4-ethylthiophen-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CCC1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=C1 HJTKJDKUFPTLPT-AATRIKPKSA-N 0.000 description 2
- FYHVKTFVKQDIKN-FNORWQNLSA-N (e)-3-[9-methoxy-2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=CN(C(C(\C=C\C(O)=O)=C(N2CCOCC2)N=2)=O)C=2C(OC)=C1CCC1=NC(C(C)C)=CS1 FYHVKTFVKQDIKN-FNORWQNLSA-N 0.000 description 2
- FPUVRCFNBGAEFE-AATRIKPKSA-N (e)-n-(3-aminopropylsulfonyl)-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enamide Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)NS(=O)(=O)CCCN)=C(N4CCOCC4)N=3)=O)C=C2)=N1 FPUVRCFNBGAEFE-AATRIKPKSA-N 0.000 description 2
- DGTQHZWFBASRIN-ATVHPVEESA-N (z)-2-fluoro-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C(/F)C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 DGTQHZWFBASRIN-ATVHPVEESA-N 0.000 description 2
- AFCZMWYFRRCAMJ-UYRXBGFRSA-N (z)-2-methoxy-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=CN2C(=O)C(\C=C(/OC)C(O)=O)=C(N3CCOCC3)N=C2C=C1CCC1=NC(C(C)C)=CS1 AFCZMWYFRRCAMJ-UYRXBGFRSA-N 0.000 description 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- OHYIHSLXTCVGPB-GQCTYLIASA-N 1-(2-fluoroethyl)-4-oxo-7-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]quinoline-3-carbonitrile Chemical compound CC(C)C1=CSC(\C=C\C=2C=C3C(C(C(C#N)=CN3CCF)=O)=CC=2)=N1 OHYIHSLXTCVGPB-GQCTYLIASA-N 0.000 description 2
- SJOHFFUPXUUBAE-GQCTYLIASA-N 1-(2-fluoroethyl)-4-oxo-7-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]quinoline-3-carboxamide Chemical compound CC(C)C1=CSC(\C=C\C=2C=C3C(C(C(C(N)=O)=CN3CCF)=O)=CC=2)=N1 SJOHFFUPXUUBAE-GQCTYLIASA-N 0.000 description 2
- CKLYAJDUYLJXDQ-GQCTYLIASA-N 1-(2-fluoroethyl)-4-oxo-7-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]quinoline-3-carboxylic acid Chemical compound CC(C)C1=CSC(\C=C\C=2C=C3C(C(C(C(O)=O)=CN3CCF)=O)=CC=2)=N1 CKLYAJDUYLJXDQ-GQCTYLIASA-N 0.000 description 2
- JOPZZMHHLURHGK-GQCTYLIASA-N 1-(2-fluoroethyl)-7-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]-3-(2h-tetrazol-5-yl)quinolin-4-one Chemical compound CC(C)C1=CSC(\C=C\C=2C=C3C(C(C(C=4NN=NN=4)=CN3CCF)=O)=CC=2)=N1 JOPZZMHHLURHGK-GQCTYLIASA-N 0.000 description 2
- TYVFIXHWGZZHFM-UHFFFAOYSA-N 1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carbaldehyde Chemical compound C1=C(C=O)C(=O)C=2C=C(F)C(F)=CC=2N1C1CC1 TYVFIXHWGZZHFM-UHFFFAOYSA-N 0.000 description 2
- PMJPMARNTGVYNM-UHFFFAOYSA-N 1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carbonitrile Chemical compound C1=C(C#N)C(=O)C=2C=C(F)C(F)=CC=2N1C1CC1 PMJPMARNTGVYNM-UHFFFAOYSA-N 0.000 description 2
- YQZIWBUPWLNXGH-UHFFFAOYSA-N 1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carboxamide Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(C(=O)N)=CN1C1CC1 YQZIWBUPWLNXGH-UHFFFAOYSA-N 0.000 description 2
- HVDOTLMZXQQSTE-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-2-morpholin-4-yl-4-oxo-7-[(4-propan-2-yl-1,3-thiazol-2-yl)methyl]quinoline-3-carboxylic acid Chemical compound CC(C)C1=CSC(CC=2C(=CC=3C(=O)C(C(O)=O)=C(N4CCOCC4)N(C4CC4)C=3C=2)F)=N1 HVDOTLMZXQQSTE-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- AZVGUUNVDZYTRM-ZCOYIIAOSA-N 2-(3-hydroxypiperidin-1-yl)-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]-3-[(e)-2-(2h-tetrazol-5-yl)ethenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C=4NN=NN=4)=C(N4CC(O)CCC4)N=3)=O)C=C2)=N1 AZVGUUNVDZYTRM-ZCOYIIAOSA-N 0.000 description 2
- UKLYKIOAFVLGEQ-AATRIKPKSA-N 2-(3-hydroxypiperidin-1-yl)-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C=C(N=3)N3CC(O)CCC3)=O)C=C2)=N1 UKLYKIOAFVLGEQ-AATRIKPKSA-N 0.000 description 2
- VCMVMMBPKAHJHO-UHFFFAOYSA-N 2-(bromomethyl)-4-propan-2-yl-1,3-thiazole Chemical compound CC(C)C1=CSC(CBr)=N1 VCMVMMBPKAHJHO-UHFFFAOYSA-N 0.000 description 2
- TYAQAJHTSFPCCD-UHFFFAOYSA-N 2-(chloromethyl)-4-propan-2-yl-1,3-thiazole Chemical compound CC(C)C1=CSC(CCl)=N1 TYAQAJHTSFPCCD-UHFFFAOYSA-N 0.000 description 2
- FBISFNRXZQNWKW-ONEGZZNKSA-N 2-(oxolan-3-ylmethoxy)-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C=C(OCC4COCC4)N=3)=O)C=C2)=N1 FBISFNRXZQNWKW-ONEGZZNKSA-N 0.000 description 2
- MQEKVNWXLOZKLL-SNAWJCMRSA-N 2-(oxolan-3-ylmethoxy)-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-3-[(e)-2-(2h-tetrazol-5-yl)ethenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C=4NN=NN=4)=C(OCC4COCC4)N=3)=O)C=C2)=N1 MQEKVNWXLOZKLL-SNAWJCMRSA-N 0.000 description 2
- WGEKKWNVNULNAW-UHFFFAOYSA-N 2-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1CN1N=C(CC(O)=O)N=N1 WGEKKWNVNULNAW-UHFFFAOYSA-N 0.000 description 2
- MLPOIOBDCZLJDC-UHFFFAOYSA-N 2-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]oxyacetic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(OCC(O)=O)=CN=3)=O)C=C2)=N1 MLPOIOBDCZLJDC-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- KBHIUXMALLGWCC-UHFFFAOYSA-N 2-acetamido-n-(4-cyclobutyl-1,3-thiazol-2-yl)pyridine-4-carboxamide Chemical compound C1=NC(NC(=O)C)=CC(C(=O)NC=2SC=C(N=2)C2CCC2)=C1 KBHIUXMALLGWCC-UHFFFAOYSA-N 0.000 description 2
- QOOQOYQRZMDXCK-UHFFFAOYSA-N 2-acetamido-n-(4-tert-butyl-1,3-thiazol-2-yl)pyridine-4-carboxamide Chemical compound C1=NC(NC(=O)C)=CC(C(=O)NC=2SC=C(N=2)C(C)(C)C)=C1 QOOQOYQRZMDXCK-UHFFFAOYSA-N 0.000 description 2
- DMDMVFLFRZTYPW-UHFFFAOYSA-N 2-amino-n-(4-cyclobutyl-1,3-thiazol-2-yl)pyridine-4-carboxamide Chemical compound C1=NC(N)=CC(C(=O)NC=2SC=C(N=2)C2CCC2)=C1 DMDMVFLFRZTYPW-UHFFFAOYSA-N 0.000 description 2
- OIGSNOFKOVJZTJ-UHFFFAOYSA-N 2-amino-n-(4-tert-butyl-1,3-thiazol-2-yl)pyridine-4-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C=2C=C(N)N=CC=2)=N1 OIGSNOFKOVJZTJ-UHFFFAOYSA-N 0.000 description 2
- NAFCUKZZHZYPKB-UHFFFAOYSA-N 2-bromo-1-pyridin-4-ylethanone Chemical compound BrCC(=O)C1=CC=NC=C1 NAFCUKZZHZYPKB-UHFFFAOYSA-N 0.000 description 2
- KVPPKLSMFYZNJZ-UHFFFAOYSA-N 2-hydroxy-3-[1-[(4-methoxyphenyl)methyl]tetrazol-5-yl]-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound COc1ccc(Cn2nnnc2-c2c(O)nc3cc(CCc4nc(cs4)C(C)C)ccn3c2=O)cc1 KVPPKLSMFYZNJZ-UHFFFAOYSA-N 0.000 description 2
- GEIQNDLQIWIVMN-UHFFFAOYSA-N 2-hydroxy-3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1CN1N=C(C=2C(N3C=CC(CCC=4SC=C(N=4)C(C)C)=CC3=NC=2O)=O)N=N1 GEIQNDLQIWIVMN-UHFFFAOYSA-N 0.000 description 2
- NSMIQZMYFCESAE-UHFFFAOYSA-N 2-hydroxy-4-oxo-8-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound CC(C)C1=CSC(COC2=CC=3N(C(C(C=O)=C(O)N=3)=O)C=C2)=N1 NSMIQZMYFCESAE-UHFFFAOYSA-N 0.000 description 2
- CTSKAQJASSVIMP-UHFFFAOYSA-N 2-hydroxy-8-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(COC2=CC=3N(C(C=C(O)N=3)=O)C=C2)=N1 CTSKAQJASSVIMP-UHFFFAOYSA-N 0.000 description 2
- KXYSZMPZCVWXJX-UHFFFAOYSA-N 2-hydroxy-9-methoxy-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CN(C(C=C(O)N=2)=O)C=2C(OC)=C1CCC1=NC(C(C)C)=CS1 KXYSZMPZCVWXJX-UHFFFAOYSA-N 0.000 description 2
- ZAMQSAIYUIEYHR-UHFFFAOYSA-N 2-methoxy-3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1CN1N=C(C=2C(N3C=CC(CCC=4SC=C(N=4)C(C)C)=CC3=NC=2OC)=O)N=N1 ZAMQSAIYUIEYHR-UHFFFAOYSA-N 0.000 description 2
- LFMZWGRRLZYVMG-UHFFFAOYSA-N 2-methoxy-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CN2C(=O)C(C=3NN=NN=3)=C(OC)N=C2C=C1CCC1=NC(C(C)C)=CS1 LFMZWGRRLZYVMG-UHFFFAOYSA-N 0.000 description 2
- GKHVQHCDFVYFQU-UHFFFAOYSA-N 2-morpholin-4-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=4NN=NN=4)=C(N4CCOCC4)N=3)=O)C=C2)=N1 GKHVQHCDFVYFQU-UHFFFAOYSA-N 0.000 description 2
- DETIDDJFCMUPPO-UHFFFAOYSA-N 2-morpholin-4-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-3-[2-(2h-tetrazol-5-yl)acetyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C(=O)CC4=NNN=N4)=C(N4CCOCC4)N=3)=O)C=C2)=N1 DETIDDJFCMUPPO-UHFFFAOYSA-N 0.000 description 2
- OEVPNPUIOVTBFR-UHFFFAOYSA-N 2-phenyl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C=C(N=3)C=3C=CC=CC=3)=O)C=C2)=N1 OEVPNPUIOVTBFR-UHFFFAOYSA-N 0.000 description 2
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 2
- XFVVSKOZOICORG-UHFFFAOYSA-N 3-[1-[(4-methoxyphenyl)methyl]tetrazol-5-yl]-2-morpholin-4-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1CN1C(C=2C(N3C=CC(CCC=4SC=C(N=4)C(C)C)=CC3=NC=2N2CCOCC2)=O)=NN=N1 XFVVSKOZOICORG-UHFFFAOYSA-N 0.000 description 2
- VLCSQZWXDZLHCK-UHFFFAOYSA-N 3-[2-(3-formylpiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]propanoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(CCC(O)=O)=C(N4CC(CCC4)C=O)N=3)=O)C=C2)=N1 VLCSQZWXDZLHCK-UHFFFAOYSA-N 0.000 description 2
- YYMAVZDLZBPOGH-UHFFFAOYSA-N 3-[2-(hydroxymethyl)cyclopropyl]-2-morpholin-4-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C4C(C4)CO)=C(N4CCOCC4)N=3)=O)C=C2)=N1 YYMAVZDLZBPOGH-UHFFFAOYSA-N 0.000 description 2
- CVNQQJVMGSKUCQ-UHFFFAOYSA-N 3-[2-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-4-yl]propanoic acid Chemical compound CC(C)(C)OC(=O)NC1=CC(CCC(O)=O)=CC=N1 CVNQQJVMGSKUCQ-UHFFFAOYSA-N 0.000 description 2
- JALYQJSKFTZSJY-UHFFFAOYSA-N 3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]-4-oxo-n-(4-propan-2-yl-1,3-thiazol-2-yl)pyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1N=C(C=2C(N3C=CC(=CC3=NC=2)C(=O)NC=2SC=C(N=2)C(C)C)=O)N=N1 JALYQJSKFTZSJY-UHFFFAOYSA-N 0.000 description 2
- IQOQIYILRIKBDP-UHFFFAOYSA-N 3-[2-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]acetyl]-2-morpholin-4-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(OC)=CC=C1CN1N=C(CC(=O)C=2C(N3C=CC(CCC=4SC=C(N=4)C(C)C)=CC3=NC=2N2CCOCC2)=O)N=N1 IQOQIYILRIKBDP-UHFFFAOYSA-N 0.000 description 2
- DRNFPBJYMNJKKB-UHFFFAOYSA-N 3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=4NC(=O)ON=4)=CN=3)=O)C=C2)=N1 DRNFPBJYMNJKKB-UHFFFAOYSA-N 0.000 description 2
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 2
- KZZIPBWYKRDJKM-UHFFFAOYSA-N 3-amino-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(N)=CN=3)=O)C=C2)=N1 KZZIPBWYKRDJKM-UHFFFAOYSA-N 0.000 description 2
- ZMWPHCDGLMOBQM-UHFFFAOYSA-N 3-methoxy-4-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyridin-2-amine Chemical compound C1=CN=C(N)C(OC)=C1CCC1=NC(C(C)C)=CS1 ZMWPHCDGLMOBQM-UHFFFAOYSA-N 0.000 description 2
- LNAFAKGSYGVWPV-UHFFFAOYSA-N 3-methoxy-4-methyl-2-nitropyridine Chemical compound COC1=C(C)C=CN=C1[N+]([O-])=O LNAFAKGSYGVWPV-UHFFFAOYSA-N 0.000 description 2
- BTPPPWUPZHJUTG-UHFFFAOYSA-N 3-methoxy-4-methylpyridin-2-amine Chemical compound COC1=C(C)C=CN=C1N BTPPPWUPZHJUTG-UHFFFAOYSA-N 0.000 description 2
- BCUJZXPQOJHSSM-UHFFFAOYSA-N 4-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyridin-2-amine Chemical compound CC(C)C1=CSC(COC=2C=C(N)N=CC=2)=N1 BCUJZXPQOJHSSM-UHFFFAOYSA-N 0.000 description 2
- PCCOZJIXRKUZLK-UHFFFAOYSA-N 4-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyridine-2-carboxylic acid Chemical compound CC(C)C1=CSC(COC=2C=C(N=CC=2)C(O)=O)=N1 PCCOZJIXRKUZLK-UHFFFAOYSA-N 0.000 description 2
- XFNINWMVRWSDSA-UHFFFAOYSA-N 4-[2-(3-bromo-4-ethylthiophen-2-yl)ethyl]pyridin-2-amine Chemical compound CCC1=CSC(CCC=2C=C(N)N=CC=2)=C1Br XFNINWMVRWSDSA-UHFFFAOYSA-N 0.000 description 2
- YMHOVKRGUHZEDL-UHFFFAOYSA-N 4-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]pyridin-2-amine Chemical compound CCC1=CSC(CCC=2C=C(N)N=CC=2)=N1 YMHOVKRGUHZEDL-UHFFFAOYSA-N 0.000 description 2
- QCOWZNYRWUSFPN-UHFFFAOYSA-N 4-cyclobutyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C2CCC2)=C1 QCOWZNYRWUSFPN-UHFFFAOYSA-N 0.000 description 2
- ABPKANCPBHXONL-UHFFFAOYSA-N 4-ethylthiophene-2-carbaldehyde Chemical compound CCC1=CSC(C=O)=C1 ABPKANCPBHXONL-UHFFFAOYSA-N 0.000 description 2
- PWGGPHUKKQTXAY-UHFFFAOYSA-N 4-methoxypyridine-2-carbonitrile Chemical compound COC1=CC=NC(C#N)=C1 PWGGPHUKKQTXAY-UHFFFAOYSA-N 0.000 description 2
- ICOWSSBPPBHNCA-UHFFFAOYSA-N 4-oxo-1h-pyridine-2-carbonitrile Chemical compound OC1=CC=NC(C#N)=C1 ICOWSSBPPBHNCA-UHFFFAOYSA-N 0.000 description 2
- IXQHPHKMXROABQ-UHFFFAOYSA-N 4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidine-3-carbonitrile Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C#N)=CN=3)=O)C=C2)=N1 IXQHPHKMXROABQ-UHFFFAOYSA-N 0.000 description 2
- LINACMPZWUSHDC-UHFFFAOYSA-N 4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidine-3-carboxamide Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C(N)=O)=CN=3)=O)C=C2)=N1 LINACMPZWUSHDC-UHFFFAOYSA-N 0.000 description 2
- GIPAIAWBTRQEEL-UHFFFAOYSA-N 4-oxo-n-(4-propan-2-yl-1,3-thiazol-2-yl)-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound CC(C)C1=CSC(NC(=O)C2=CC=3N(C(C(C4=NNN=N4)=CN=3)=O)C=C2)=N1 GIPAIAWBTRQEEL-UHFFFAOYSA-N 0.000 description 2
- VPRBHHGJZJNQIX-UHFFFAOYSA-N 4-oxo-n-(4-pyridin-4-yl-1,3-thiazol-2-yl)-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound C1=CN(C(C(C2=NNN=N2)=CN=2)=O)C=2C=C1C(=O)NC(SC=1)=NC=1C1=CC=NC=C1 VPRBHHGJZJNQIX-UHFFFAOYSA-N 0.000 description 2
- MKNPOHDDKJGVDY-UHFFFAOYSA-N 4-propan-2-yl-1,3-thiazole-2-carbaldehyde Chemical compound CC(C)C1=CSC(C=O)=N1 MKNPOHDDKJGVDY-UHFFFAOYSA-N 0.000 description 2
- CUSJGENRTWNHPV-UHFFFAOYSA-N 4-pyridin-4-yl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CN=CC=2)=C1 CUSJGENRTWNHPV-UHFFFAOYSA-N 0.000 description 2
- CUWZBHVYLVGOAB-UHFFFAOYSA-N 4-tert-butyl-1,3-thiazol-2-amine Chemical compound CC(C)(C)C1=CSC(N)=N1 CUWZBHVYLVGOAB-UHFFFAOYSA-N 0.000 description 2
- ZSICFKHOZSNTLK-UHFFFAOYSA-N 4-tert-butyl-1,3-thiazole-2-carbaldehyde Chemical compound CC(C)(C)C1=CSC(C=O)=N1 ZSICFKHOZSNTLK-UHFFFAOYSA-N 0.000 description 2
- MESLFDCEAHZLBZ-UHFFFAOYSA-N 5-fluoro-4-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyridin-2-amine Chemical compound CC(C)C1=CSC(CCC=2C(=CN=C(N)C=2)F)=N1 MESLFDCEAHZLBZ-UHFFFAOYSA-N 0.000 description 2
- RKMOPXJNMQWPLH-UHFFFAOYSA-N 5-fluoro-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC=C1F RKMOPXJNMQWPLH-UHFFFAOYSA-N 0.000 description 2
- ONGKUDFWIJCIGM-UHFFFAOYSA-N 8-[2-(3-bromo-4-ethylthiophen-2-yl)ethyl]-2-hydroxypyrido[1,2-a]pyrimidin-4-one Chemical compound CCC1=CSC(CCC2=CC=3N(C(C=C(O)N=3)=O)C=C2)=C1Br ONGKUDFWIJCIGM-UHFFFAOYSA-N 0.000 description 2
- FKGYNCJDDAZEDB-UHFFFAOYSA-N 8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidin-1-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound C1C(O)CCCN1C1=CC(=O)N(C=CC(CCC=2SC=C(N=2)C2CCC2)=C2)C2=N1 FKGYNCJDDAZEDB-UHFFFAOYSA-N 0.000 description 2
- MTGJSTIKKPCXKS-UHFFFAOYSA-N 8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CN2C(=O)C=C(N3CCOCC3)N=C2C=C1CCC(SC=1)=NC=1C1CCC1 MTGJSTIKKPCXKS-UHFFFAOYSA-N 0.000 description 2
- KKGYYZGRLBUYNG-UHFFFAOYSA-N 8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-hydroxypyrido[1,2-a]pyrimidin-4-one Chemical compound CCC1=CSC(CCC2=CC=3N(C(C=C(O)N=3)=O)C=C2)=N1 KKGYYZGRLBUYNG-UHFFFAOYSA-N 0.000 description 2
- ULIXWCNJXDABMT-UHFFFAOYSA-N 8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound CCC1=CSC(CCC2=CC=3N(C(C(C=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 ULIXWCNJXDABMT-UHFFFAOYSA-N 0.000 description 2
- XPGOFAFZPNEEGG-UHFFFAOYSA-N 8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound CCC1=CSC(CCC2=CC=3N(C(C=C(N=3)N3CCOCC3)=O)C=C2)=N1 XPGOFAFZPNEEGG-UHFFFAOYSA-N 0.000 description 2
- LCKGNRUKXLTOOX-UHFFFAOYSA-N 8-[2-(4-ethylthiophen-2-yl)ethyl]-2-hydroxypyrido[1,2-a]pyrimidin-4-one Chemical compound CCC1=CSC(CCC2=CC=3N(C(C=C(O)N=3)=O)C=C2)=C1 LCKGNRUKXLTOOX-UHFFFAOYSA-N 0.000 description 2
- RNUSFQNZRLRTIJ-UHFFFAOYSA-N 8-[2-(4-ethylthiophen-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound CCC1=CSC(CCC2=CC=3N(C(C(C=O)=C(N4CCOCC4)N=3)=O)C=C2)=C1 RNUSFQNZRLRTIJ-UHFFFAOYSA-N 0.000 description 2
- XJYOLXFIAPGKHA-UHFFFAOYSA-N 8-[2-(4-ethylthiophen-2-yl)ethyl]-2-morpholin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound CCC1=CSC(CCC2=CC=3N(C(C=C(N=3)N3CCOCC3)=O)C=C2)=C1 XJYOLXFIAPGKHA-UHFFFAOYSA-N 0.000 description 2
- PQVFOTAFFWEDJJ-UHFFFAOYSA-N 8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-pyridin-3-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C=C(N=3)C=3C=NC=CC=3)=O)C=C2)=N1 PQVFOTAFFWEDJJ-UHFFFAOYSA-N 0.000 description 2
- XDILWANHGMRJCT-UHFFFAOYSA-N 9-methoxy-2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound C1=CN(C(C(C=O)=C(N2CCOCC2)N=2)=O)C=2C(OC)=C1CCC1=NC(C(C)C)=CS1 XDILWANHGMRJCT-UHFFFAOYSA-N 0.000 description 2
- BWGZPJPLBOBAAJ-UHFFFAOYSA-N 9-methoxy-2-morpholin-4-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C(OC)=C1CCC1=NC(C(C)C)=CS1 BWGZPJPLBOBAAJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- IEEOKIIWXRFAHT-QNGOZBTKSA-N C1=CN2C(=O)C(/C=C(\OC)C(=O)OCC)=C(N3CCOCC3)N=C2C=C1CCC1=NC(C(C)C)=CS1 Chemical compound C1=CN2C(=O)C(/C=C(\OC)C(=O)OCC)=C(N3CCOCC3)N=C2C=C1CCC1=NC(C(C)C)=CS1 IEEOKIIWXRFAHT-QNGOZBTKSA-N 0.000 description 2
- HMEPGMQXEIXPQN-VQHVLOKHSA-N C1=CN2C(=O)C(/C=C/C(=O)OC)=C(C=3C=NC=CC=3)N=C2C=C1CCC1=NC(C(C)C)=CS1 Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC)=C(C=3C=NC=CC=3)N=C2C=C1CCC1=NC(C(C)C)=CS1 HMEPGMQXEIXPQN-VQHVLOKHSA-N 0.000 description 2
- FFYWKUSTWQERRB-BQYQJAHWSA-N C1=CN2C(=O)C(/C=C/C(=O)OC)=C(N3CC(O)CCC3)N=C2C=C1C(=O)NC(SC=1)=NC=1C1CCC1 Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC)=C(N3CC(O)CCC3)N=C2C=C1C(=O)NC(SC=1)=NC=1C1CCC1 FFYWKUSTWQERRB-BQYQJAHWSA-N 0.000 description 2
- RTSAEEHOVXQBBM-GQCTYLIASA-N CC(C)C1=CSC(CCC(C=CN23)=CC2=NC(N(CC2)CCN2C(C[N+]2(CC4)CCN4CC2)=O)=C(/C=C/C([O-])=O)C3=O)=N1 Chemical compound CC(C)C1=CSC(CCC(C=CN23)=CC2=NC(N(CC2)CCN2C(C[N+]2(CC4)CCN4CC2)=O)=C(/C=C/C([O-])=O)C3=O)=N1 RTSAEEHOVXQBBM-GQCTYLIASA-N 0.000 description 2
- PHJPGIHVDWQAAV-VQHVLOKHSA-N CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCN(CC4)C(=O)CCl)N=3)=O)C=C2)=N1 Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCN(CC4)C(=O)CCl)N=3)=O)C=C2)=N1 PHJPGIHVDWQAAV-VQHVLOKHSA-N 0.000 description 2
- AGLNBCGIHCURJM-VQHVLOKHSA-N CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCN(CC4)C(=O)CI)N=3)=O)C=C2)=N1 Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCN(CC4)C(=O)CI)N=3)=O)C=C2)=N1 AGLNBCGIHCURJM-VQHVLOKHSA-N 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- PCGSKWWAYGGFOQ-OAHLLOKOSA-N [(3r)-1-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-3-formyl-4-oxopyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl] formate Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(C=O)=C(N4C[C@@H](CCC4)OC=O)N=3)=O)C=C2)=N1 PCGSKWWAYGGFOQ-OAHLLOKOSA-N 0.000 description 2
- PCGSKWWAYGGFOQ-HNNXBMFYSA-N [(3s)-1-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-3-formyl-4-oxopyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl] formate Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(C=O)=C(N4C[C@H](CCC4)OC=O)N=3)=O)C=C2)=N1 PCGSKWWAYGGFOQ-HNNXBMFYSA-N 0.000 description 2
- MOOOFXJDYIHSMA-DGLUDJRXSA-N [1-[3-[(e)-2-[1-(2-cyanoethyl)tetrazol-5-yl]ethenyl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl] acetate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C=4N(N=NN=4)CCC#N)=C(N4CC(CCC4)OC(C)=O)N=3)=O)C=C2)=N1 MOOOFXJDYIHSMA-DGLUDJRXSA-N 0.000 description 2
- MVRUACHTVCXXKK-DGLUDJRXSA-N [1-[3-[(e)-3-(2-cyanoethylamino)-3-oxoprop-1-enyl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl] acetate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)NCCC#N)=C(N4CC(CCC4)OC(C)=O)N=3)=O)C=C2)=N1 MVRUACHTVCXXKK-DGLUDJRXSA-N 0.000 description 2
- AZUPWICFTGYDPA-UHFFFAOYSA-N [1-[7-fluoro-3-formyl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl] formate Chemical compound CC(C)C1=CSC(CCC=2C(=CN3C(=O)C(C=O)=C(N4CC(CCC4)OC=O)N=C3C=2)F)=N1 AZUPWICFTGYDPA-UHFFFAOYSA-N 0.000 description 2
- NUQFIEIMFLXGJA-UHFFFAOYSA-N [1-[8-[(4-cyclobutyl-1,3-thiazol-2-yl)carbamoyl]-3-formyl-4-oxopyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl] formate Chemical compound C1C(OC=O)CCCN1C1=C(C=O)C(=O)N2C=CC(C(=O)NC=3SC=C(N=3)C3CCC3)=CC2=N1 NUQFIEIMFLXGJA-UHFFFAOYSA-N 0.000 description 2
- FWAJBGXWBYYQFL-UHFFFAOYSA-N [3-[1-[(4-methoxyphenyl)methyl]tetrazol-5-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(OC)=CC=C1CN1C(C=2C(N3C=CC(CCC=4SC=C(N=4)C(C)C)=CC3=NC=2OS(=O)(=O)C=2C=CC(C)=CC=2)=O)=NN=N1 FWAJBGXWBYYQFL-UHFFFAOYSA-N 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 150000001782 cephems Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- XFQORBLOZMRTQZ-NBVRZTHBSA-N ethyl (e)-2-methyl-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C(\C)C(=O)OCC)=C(N3CCOCC3)N=C2C=C1CCC1=NC(C(C)C)=CS1 XFQORBLOZMRTQZ-NBVRZTHBSA-N 0.000 description 2
- RJEMCJSWIZBRQE-SOFGYWHQSA-N ethyl (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OCC)=CN=C2C=C1CCC1=NC(C(C)C)=CS1 RJEMCJSWIZBRQE-SOFGYWHQSA-N 0.000 description 2
- XAEWDPSGEBVNBL-OBGWFSINSA-N ethyl (e)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]-2-methylprop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C(\C)C(=O)OCC)=C(N3CCOCC3)N=C2C=C1CCC(SC=1)=NC=1C1CCC1 XAEWDPSGEBVNBL-OBGWFSINSA-N 0.000 description 2
- OLKHPNWQJPYZCB-RGEXLXHISA-N ethyl (z)-2-fluoro-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C(\F)C(=O)OCC)=C(N3CCOCC3)N=C2C=C1CCC1=NC(C(C)C)=CS1 OLKHPNWQJPYZCB-RGEXLXHISA-N 0.000 description 2
- QNBDQHZQLXNZLG-SOFGYWHQSA-N ethyl 1-(2-fluoroethyl)-4-oxo-7-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]quinoline-3-carboxylate Chemical compound C=1C=C2C(=O)C(C(=O)OCC)=CN(CCF)C2=CC=1\C=C\C1=NC(C(C)C)=CS1 QNBDQHZQLXNZLG-SOFGYWHQSA-N 0.000 description 2
- PBFKGEHWSKNZJC-UHFFFAOYSA-N ethyl 1-cyclopropyl-6,7-difluoro-2-methylsulfonyl-4-oxoquinoline-3-carboxylate Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(C(=O)OCC)=C(S(C)(=O)=O)N1C1CC1 PBFKGEHWSKNZJC-UHFFFAOYSA-N 0.000 description 2
- KQVKJJVXHAVVIM-UHFFFAOYSA-N ethyl 1-cyclopropyl-6,7-difluoro-2-morpholin-4-yl-4-oxoquinoline-3-carboxylate Chemical compound C1CC1N1C2=CC(F)=C(F)C=C2C(=O)C(C(=O)OCC)=C1N1CCOCC1 KQVKJJVXHAVVIM-UHFFFAOYSA-N 0.000 description 2
- KTNYJRYXIFCQIH-UHFFFAOYSA-N ethyl 1-cyclopropyl-6-fluoro-2-morpholin-4-yl-4-oxo-7-[(4-propan-2-yl-1,3-thiazol-2-yl)methyl]quinoline-3-carboxylate Chemical compound C1CC1N1C2=CC(CC=3SC=C(N=3)C(C)C)=C(F)C=C2C(=O)C(C(=O)OCC)=C1N1CCOCC1 KTNYJRYXIFCQIH-UHFFFAOYSA-N 0.000 description 2
- NAOHMNNTUFFTBF-UHFFFAOYSA-N ethyl 2-(2h-tetrazol-5-yl)acetate Chemical compound CCOC(=O)CC=1N=NNN=1 NAOHMNNTUFFTBF-UHFFFAOYSA-N 0.000 description 2
- TWPLGWQSPRBYPG-UHFFFAOYSA-N ethyl 2-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]oxyacetate Chemical compound C1=CN2C(=O)C(OCC(=O)OCC)=CN=C2C=C1CCC1=NC(C(C)C)=CS1 TWPLGWQSPRBYPG-UHFFFAOYSA-N 0.000 description 2
- XVBZFXZNJAFCHL-UHFFFAOYSA-N ethyl 2-aminopyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(N)=C1 XVBZFXZNJAFCHL-UHFFFAOYSA-N 0.000 description 2
- CWXZCMKOCAXEBM-UHFFFAOYSA-N ethyl 3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]-4-oxopyrido[1,2-a]pyrimidine-8-carboxylate Chemical compound C1=C(C(=O)OCC)C=CN(C2=O)C1=NC=C2C(=N1)N=NN1CC1=CC=C(OC)C=C1 CWXZCMKOCAXEBM-UHFFFAOYSA-N 0.000 description 2
- WRJJRJNLIWBMTN-UHFFFAOYSA-N ethyl 4-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OCC)=CC(OCC=2SC=C(N=2)C(C)C)=C1 WRJJRJNLIWBMTN-UHFFFAOYSA-N 0.000 description 2
- NXYYJUMPOIFBFP-UHFFFAOYSA-N ethyl 4-oxo-1h-pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC(O)=CC=N1 NXYYJUMPOIFBFP-UHFFFAOYSA-N 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BBVQXBIZQMQDPI-VQHVLOKHSA-N methyl (e)-3-[2-(3-formylpiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC)=C(N3CC(CCC3)C=O)N=C2C=C1CCC1=NC(C(C)C)=CS1 BBVQXBIZQMQDPI-VQHVLOKHSA-N 0.000 description 2
- INAFXTOBXKYBOF-VOTSOKGWSA-N methyl (e)-3-[8-[(4-cyclobutyl-1,3-thiazol-2-yl)carbamoyl]-2-(4-methylpiperazin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC)=C(N3CCN(C)CC3)N=C2C=C1C(=O)NC(SC=1)=NC=1C1CCC1 INAFXTOBXKYBOF-VOTSOKGWSA-N 0.000 description 2
- QIKPEPFSNMNLTJ-MDZDMXLPSA-N methyl (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[3-(dimethylcarbamoyl)piperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC)=C(N3CC(CCC3)C(=O)N(C)C)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 QIKPEPFSNMNLTJ-MDZDMXLPSA-N 0.000 description 2
- XPADEAYCESKPGF-AATRIKPKSA-N methyl (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC)=C(N3CCOCC3)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 XPADEAYCESKPGF-AATRIKPKSA-N 0.000 description 2
- WCXIMTPKJGOFAX-UHFFFAOYSA-N methyl 3-[2-(3-formylpiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]propanoate Chemical compound C1=CN2C(=O)C(CCC(=O)OC)=C(N3CC(CCC3)C=O)N=C2C=C1CCC1=NC(C(C)C)=CS1 WCXIMTPKJGOFAX-UHFFFAOYSA-N 0.000 description 2
- YRILZOGOLQYVGG-UHFFFAOYSA-N methyl 3-[2-[(2-methylpropan-2-yl)oxycarbonylamino]pyridin-4-yl]propanoate Chemical compound COC(=O)CCC1=CC=NC(NC(=O)OC(C)(C)C)=C1 YRILZOGOLQYVGG-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- WTZHHXXFVMZUSQ-BQYQJAHWSA-N n,n-dimethyl-1-[4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-2-yl]piperidine-3-carboxamide Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C=C(N=3)N3CC(CCC3)C(=O)N(C)C)=O)C=C2)=N1 WTZHHXXFVMZUSQ-BQYQJAHWSA-N 0.000 description 2
- CWZPIIBODZZQLX-UHFFFAOYSA-N n-(4-cyclobutyl-1,3-thiazol-2-yl)-3-formyl-2-(3-hydroxypiperidin-1-yl)-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound C1C(O)CCCN1C1=C(C=O)C(=O)N2C=CC(C(=O)NC=3SC=C(N=3)C3CCC3)=CC2=N1 CWZPIIBODZZQLX-UHFFFAOYSA-N 0.000 description 2
- RXLYNDDWAMZCDD-UHFFFAOYSA-N n-(4-methyl-5-nitropyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC(C)=C([N+]([O-])=O)C=N1 RXLYNDDWAMZCDD-UHFFFAOYSA-N 0.000 description 2
- SCAITYHQAUUNMI-CQSZACIVSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-2-[(3r)-3-hydroxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C=C(N=3)N3C[C@H](O)CCC3)=O)C=C2)=N1 SCAITYHQAUUNMI-CQSZACIVSA-N 0.000 description 2
- SCAITYHQAUUNMI-AWEZNQCLSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-2-[(3s)-3-hydroxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C=C(N=3)N3C[C@@H](O)CCC3)=O)C=C2)=N1 SCAITYHQAUUNMI-AWEZNQCLSA-N 0.000 description 2
- YUAINGJXHKGWOX-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-2-[3-(dimethylcarbamoyl)piperidin-1-yl]-3-formyl-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound C1C(C(=O)N(C)C)CCCN1C1=C(C=O)C(=O)N2C=CC(C(=O)NC=3SC=C(N=3)C(C)(C)C)=CC2=N1 YUAINGJXHKGWOX-UHFFFAOYSA-N 0.000 description 2
- WPHMFQQZMMNZTO-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-2-[3-(dimethylcarbamoyl)piperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound C1C(C(=O)N(C)C)CCCN1C1=CC(=O)N(C=CC(=C2)C(=O)NC=3SC=C(N=3)C(C)(C)C)C2=N1 WPHMFQQZMMNZTO-UHFFFAOYSA-N 0.000 description 2
- ZEGSUYZBEHTSAT-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C=C(N=3)N3CCOCC3)=O)C=C2)=N1 ZEGSUYZBEHTSAT-UHFFFAOYSA-N 0.000 description 2
- BTJXRBZBCYWGSF-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-3-formyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(C=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 BTJXRBZBCYWGSF-UHFFFAOYSA-N 0.000 description 2
- CUZMHRNZROKDNM-UHFFFAOYSA-N n-(4-tert-butyl-1,3-thiazol-2-yl)-4-oxo-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(C4=NNN=N4)=CN=3)=O)C=C2)=N1 CUZMHRNZROKDNM-UHFFFAOYSA-N 0.000 description 2
- IHZJIMFVFYNPMM-UHFFFAOYSA-N n-(5-amino-4-methylpyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC(C)=C(N)C=N1 IHZJIMFVFYNPMM-UHFFFAOYSA-N 0.000 description 2
- FNHPTZIEXVBRFX-UHFFFAOYSA-N n-(5-fluoro-4-methylpyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC(C)=C(F)C=N1 FNHPTZIEXVBRFX-UHFFFAOYSA-N 0.000 description 2
- KPDWVFSXTQKIJV-VOTSOKGWSA-N n-methyl-1-[4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-2-yl]piperidine-3-carboxamide Chemical compound C1C(C(=O)NC)CCCN1C1=CC(=O)N(C=CC(\C=C\C=2SC=C(N=2)C(C)C)=C2)C2=N1 KPDWVFSXTQKIJV-VOTSOKGWSA-N 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical group C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- AYKMWTOAGNRIIM-HTXNQAPBSA-N tert-butyl (E)-3-[2-diphenoxyphosphoryloxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(OP(=O)(OC=4C=CC=CC=4)OC=4C=CC=CC=4)N=3)=O)C=C2)=N1 AYKMWTOAGNRIIM-HTXNQAPBSA-N 0.000 description 2
- QVRKXYNRPWRMCH-VOTSOKGWSA-N tert-butyl (E)-3-[2-hydroxy-4-oxo-8-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(COC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(O)N=3)=O)C=C2)=N1 QVRKXYNRPWRMCH-VOTSOKGWSA-N 0.000 description 2
- KQAXPAFGWXXABX-LFIBNONCSA-N tert-butyl (e)-2-methyl-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C(/C)C(=O)OC(C)(C)C)=CN=3)=O)C=C2)=N1 KQAXPAFGWXXABX-LFIBNONCSA-N 0.000 description 2
- XECFBGADOXVJLE-GFULKKFKSA-N tert-butyl (e)-3-[2-(3-carbamoyloxypiperidin-1-yl)-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CC(CCC4)OC(N)=O)N=3)=O)C=C2)=N1 XECFBGADOXVJLE-GFULKKFKSA-N 0.000 description 2
- YKBRYBYDYPEXEY-PKNBQFBNSA-N tert-butyl (e)-3-[2-(3-carbamoyloxypiperidin-1-yl)-7-fluoro-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC=2C(=CN3C(=O)C(\C=C\C(=O)OC(C)(C)C)=C(N4CC(CCC4)OC(N)=O)N=C3C=2)F)=N1 YKBRYBYDYPEXEY-PKNBQFBNSA-N 0.000 description 2
- MEGXLLWYJQCFGC-MDZDMXLPSA-N tert-butyl (e)-3-[2-(3-carbamoyloxypiperidin-1-yl)-8-[(4-cyclobutyl-1,3-thiazol-2-yl)carbamoyl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3CC(CCC3)OC(N)=O)N=C2C=C1C(=O)NC(SC=1)=NC=1C1CCC1 MEGXLLWYJQCFGC-MDZDMXLPSA-N 0.000 description 2
- HROBMRXMIKEXLJ-CMDGGOBGSA-N tert-butyl (e)-3-[2-(3-hydroxypiperidin-1-yl)-4-oxo-8-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(COC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CC(O)CCC4)N=3)=O)C=C2)=N1 HROBMRXMIKEXLJ-CMDGGOBGSA-N 0.000 description 2
- QFKJNSYTSDGMRL-IHJNGOQESA-N tert-butyl (e)-3-[2-(4-methylphenyl)sulfonyloxy-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(OS(=O)(=O)C=4C=CC(C)=CC=4)N=3)=O)C=C2)=N1 QFKJNSYTSDGMRL-IHJNGOQESA-N 0.000 description 2
- MDZIAJUGTHULKN-JAWUIPDLSA-N tert-butyl (e)-3-[2-[(3r)-3-formyloxypiperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4C[C@@H](CCC4)OC=O)N=3)=O)C=C2)=N1 MDZIAJUGTHULKN-JAWUIPDLSA-N 0.000 description 2
- BXUKNRZSLSAYLO-WAEYIKQSSA-N tert-butyl (e)-3-[2-[(3r)-3-hydroxypiperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4C[C@H](O)CCC4)N=3)=O)C=C2)=N1 BXUKNRZSLSAYLO-WAEYIKQSSA-N 0.000 description 2
- MDZIAJUGTHULKN-ZURJXIQKSA-N tert-butyl (e)-3-[2-[(3s)-3-formyloxypiperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4C[C@H](CCC4)OC=O)N=3)=O)C=C2)=N1 MDZIAJUGTHULKN-ZURJXIQKSA-N 0.000 description 2
- LIKJILQKPQPCFZ-ZRDIBKRKSA-N tert-butyl (e)-3-[2-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]sulfanyl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(SCC(=O)OC(C)(C)C)N=3)=O)C=C2)=N1 LIKJILQKPQPCFZ-ZRDIBKRKSA-N 0.000 description 2
- QACIPMUVRXTDKM-DCIPZJNNSA-N tert-butyl (e)-3-[2-[3-(dimethylcarbamoyl)piperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CC(CCC4)C(=O)N(C)C)N=3)=O)C=C2)=N1 QACIPMUVRXTDKM-DCIPZJNNSA-N 0.000 description 2
- UMRPQDGUPMJZNV-WGDLNXRISA-N tert-butyl (e)-3-[2-[3-(methylcarbamoyl)piperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1C(C(=O)NC)CCCN1C1=C(\C=C\C(=O)OC(C)(C)C)C(=O)N2C=CC(\C=C\C=3SC=C(N=3)C(C)C)=CC2=N1 UMRPQDGUPMJZNV-WGDLNXRISA-N 0.000 description 2
- XBDFCOWRTOSHSK-CSKARUKUSA-N tert-butyl (e)-3-[2-methoxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(\C=C\C(=O)OC(C)(C)C)=C(OC)N=C2C=C1CCC1=NC(C(C)C)=CS1 XBDFCOWRTOSHSK-CSKARUKUSA-N 0.000 description 2
- WLYVQSMUSPGDTP-CDJQDVQCSA-N tert-butyl (e)-3-[2-morpholin-4-yl-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCOCC4)N=3)=O)C=C2)=N1 WLYVQSMUSPGDTP-CDJQDVQCSA-N 0.000 description 2
- XRGRBLZQWOZJPB-VQHVLOKHSA-N tert-butyl (e)-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCOCC4)N=3)=O)C=C2)=N1 XRGRBLZQWOZJPB-VQHVLOKHSA-N 0.000 description 2
- QYLFZFOCTPHQTF-CDJQDVQCSA-N tert-butyl (e)-3-[4-oxo-2-(oxolan-3-ylmethoxy)-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(OCC4COCC4)N=3)=O)C=C2)=N1 QYLFZFOCTPHQTF-CDJQDVQCSA-N 0.000 description 2
- USXMQJNWPUGTNA-VQHVLOKHSA-N tert-butyl (e)-3-[4-oxo-2-(oxolan-3-ylmethoxy)-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(OCC4COCC4)N=3)=O)C=C2)=N1 USXMQJNWPUGTNA-VQHVLOKHSA-N 0.000 description 2
- LJKJTQJBBUBTSL-PKNBQFBNSA-N tert-butyl (e)-3-[7-fluoro-2-(3-formylpiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CCC=2C(=CN3C(=O)C(\C=C\C(=O)OC(C)(C)C)=C(N4CC(CCC4)C=O)N=C3C=2)F)=N1 LJKJTQJBBUBTSL-PKNBQFBNSA-N 0.000 description 2
- SLWHNGWFKSIEPS-MDZDMXLPSA-N tert-butyl (e)-3-[8-[(4-cyclobutyl-1,3-thiazol-2-yl)carbamoyl]-2-(3-formyloxypiperidin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3CC(CCC3)OC=O)N=C2C=C1C(=O)NC(SC=1)=NC=1C1CCC1 SLWHNGWFKSIEPS-MDZDMXLPSA-N 0.000 description 2
- USQQGMNFQSAHMH-JBVUFVISSA-N tert-butyl (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3r)-3-formyloxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3C[C@@H](CCC3)OC=O)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 USQQGMNFQSAHMH-JBVUFVISSA-N 0.000 description 2
- USQQGMNFQSAHMH-YXBWYFRISA-N tert-butyl (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3s)-3-formyloxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3C[C@H](CCC3)OC=O)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 USQQGMNFQSAHMH-YXBWYFRISA-N 0.000 description 2
- YPBARZSTVYKASV-ZRDIBKRKSA-N tert-butyl (e)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-formyloxypiperidin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3CC(CCC3)OC=O)N=C2C=C1CCC(SC=1)=NC=1C1CCC1 YPBARZSTVYKASV-ZRDIBKRKSA-N 0.000 description 2
- BUYLTEGBZHONEX-ZRDIBKRKSA-N tert-butyl (e)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3CC(O)CCC3)N=C2C=C1CCC(SC=1)=NC=1C1CCC1 BUYLTEGBZHONEX-ZRDIBKRKSA-N 0.000 description 2
- XKKPMPVFXSXNFF-CSKARUKUSA-N tert-butyl (e)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3CCOCC3)N=C2C=C1CCC(SC=1)=NC=1C1CCC1 XKKPMPVFXSXNFF-CSKARUKUSA-N 0.000 description 2
- CEZOYOUKSQCXNO-VQHVLOKHSA-N tert-butyl (e)-3-[8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CCC1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCOCC4)N=3)=O)C=C2)=N1 CEZOYOUKSQCXNO-VQHVLOKHSA-N 0.000 description 2
- OBBLGGSEWILJRY-CMDGGOBGSA-N tert-butyl (e)-3-[8-[2-(4-ethylthiophen-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound CCC1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCOCC4)N=3)=O)C=C2)=C1 OBBLGGSEWILJRY-CMDGGOBGSA-N 0.000 description 2
- RTBKYJPRDDXPFF-CSKARUKUSA-N tert-butyl (e)-3-[9-methoxy-2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN(C(C(\C=C\C(=O)OC(C)(C)C)=C(N2CCOCC2)N=2)=O)C=2C(OC)=C1CCC1=NC(C(C)C)=CS1 RTBKYJPRDDXPFF-CSKARUKUSA-N 0.000 description 2
- KQVZAGYPFXWRQC-UHFFFAOYSA-N tert-butyl n-(3-methoxy-4-methylpyridin-2-yl)carbamate Chemical compound COC1=C(C)C=CN=C1NC(=O)OC(C)(C)C KQVZAGYPFXWRQC-UHFFFAOYSA-N 0.000 description 2
- XDTVJOMRLQQOHP-UHFFFAOYSA-N tert-butyl n-(5-fluoro-4-methylpyridin-2-yl)carbamate Chemical compound CC1=CC(NC(=O)OC(C)(C)C)=NC=C1F XDTVJOMRLQQOHP-UHFFFAOYSA-N 0.000 description 2
- ALIGAGKOMZGVKH-UHFFFAOYSA-N tert-butyl n-[4-(3-amino-3-oxopropyl)pyridin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC(CCC(N)=O)=CC=N1 ALIGAGKOMZGVKH-UHFFFAOYSA-N 0.000 description 2
- ORFSFKQDGHOIJA-UHFFFAOYSA-N tert-butyl n-[4-[(4-propan-2-yl-1,3-thiazol-2-yl)methoxy]pyridin-2-yl]carbamate Chemical compound CC(C)C1=CSC(COC=2C=C(NC(=O)OC(C)(C)C)N=CC=2)=N1 ORFSFKQDGHOIJA-UHFFFAOYSA-N 0.000 description 2
- QBIWNKWRQIOXOW-UHFFFAOYSA-N tert-butyl n-[4-[2-(3-bromo-4-ethylthiophen-2-yl)ethyl]pyridin-2-yl]carbamate Chemical compound CCC1=CSC(CCC=2C=C(NC(=O)OC(C)(C)C)N=CC=2)=C1Br QBIWNKWRQIOXOW-UHFFFAOYSA-N 0.000 description 2
- AUUZNTNVKIRLNM-UHFFFAOYSA-N tert-butyl n-[4-[2-(4-tert-butyl-1,3-thiazol-2-yl)-2-hydroxyethyl]pyridin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC(C)(C)C)=CC(CC(O)C=2SC=C(N=2)C(C)(C)C)=C1 AUUZNTNVKIRLNM-UHFFFAOYSA-N 0.000 description 2
- APKDRLJEZMSGHM-UHFFFAOYSA-N tert-butyl n-[5-fluoro-4-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyridin-2-yl]carbamate Chemical compound CC(C)C1=CSC(CCC=2C(=CN=C(NC(=O)OC(C)(C)C)C=2)F)=N1 APKDRLJEZMSGHM-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- HSQIYOPBCOPMSS-ZETCQYMHSA-N (2s)-5-(diaminomethylideneamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCN=C(N)N HSQIYOPBCOPMSS-ZETCQYMHSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- AVAWMINJNRAQFS-ZCFIWIBFSA-N (3r)-n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)[C@@H]1CCNC1 AVAWMINJNRAQFS-ZCFIWIBFSA-N 0.000 description 1
- BIWOSRSKDCZIFM-RXMQYKEDSA-N (3r)-piperidin-3-ol Chemical compound O[C@@H]1CCCNC1 BIWOSRSKDCZIFM-RXMQYKEDSA-N 0.000 description 1
- VLECDMDGMKPUSK-NUBCRITNSA-N (3r)-piperidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCCNC1 VLECDMDGMKPUSK-NUBCRITNSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- VLECDMDGMKPUSK-JEDNCBNOSA-N (3s)-piperidin-3-ol;hydrochloride Chemical compound Cl.O[C@H]1CCCNC1 VLECDMDGMKPUSK-JEDNCBNOSA-N 0.000 description 1
- QXNSHVVNEOAAOF-RXMQYKEDSA-N (6R)-4-oxa-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical compound S1OC=CN2[C@H]1CC2=O QXNSHVVNEOAAOF-RXMQYKEDSA-N 0.000 description 1
- NAGXUBPPMNFIGA-ONEGZZNKSA-N (E)-3-[2-hydroxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enenitrile Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C#N)=C(O)N=3)=O)C=C2)=N1 NAGXUBPPMNFIGA-ONEGZZNKSA-N 0.000 description 1
- JVHPUGNMNZAHET-RJRFIUFISA-N (Z)-3-(1-cyclopropyl-6,7-difluoro-4-oxoquinolin-3-yl)prop-2-enoic acid Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(\C=C/C(=O)O)=CN1C1CC1 JVHPUGNMNZAHET-RJRFIUFISA-N 0.000 description 1
- MGIQIOIWMJEZDT-UTCJRWHESA-N (Z)-3-[1-cyclopropyl-6-fluoro-4-oxo-7-[(4-propan-2-yl-1,3-thiazol-2-yl)methyl]quinolin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CC=2C(=CC=3C(=O)C(\C=C/C(O)=O)=CN(C=3C=2)C2CC2)F)=N1 MGIQIOIWMJEZDT-UTCJRWHESA-N 0.000 description 1
- IVSUXRRMGJJUAP-DTQAZKPQSA-N (e)-2-methyl-3-[8-[2-[4-(1-methylcyclopropyl)-1,3-thiazol-2-yl]ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=CN2C(=O)C(\C=C(/C)C(O)=O)=C(N3CCOCC3)N=C2C=C1CCC(SC=1)=NC=1C1(C)CC1 IVSUXRRMGJJUAP-DTQAZKPQSA-N 0.000 description 1
- KXPGNUWGXFRQEM-GQCTYLIASA-N (e)-3-[2-(2-amino-2-oxoethyl)sulfanyl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(SCC(N)=O)N=3)=O)C=C2)=N1 KXPGNUWGXFRQEM-GQCTYLIASA-N 0.000 description 1
- RSTRJFPTFQAKIG-CSKARUKUSA-N (e)-3-[2-(3,4-dihydro-1h-isoquinolin-2-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC5=CC=CC=C5CC4)N=3)=O)C=C2)=N1 RSTRJFPTFQAKIG-CSKARUKUSA-N 0.000 description 1
- LHMALOHJZWAWFM-GQCTYLIASA-N (e)-3-[2-(3-aminoazetidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(N)C4)N=3)=O)C=C2)=N1 LHMALOHJZWAWFM-GQCTYLIASA-N 0.000 description 1
- XZQHMSLRROWPRF-SOFGYWHQSA-N (e)-3-[2-(3-aminopiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(N)CCC4)N=3)=O)C=C2)=N1 XZQHMSLRROWPRF-SOFGYWHQSA-N 0.000 description 1
- MEGDTTHCFKZHNB-GQCTYLIASA-N (e)-3-[2-(3-carbamoylmorpholin-4-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C(COCC4)C(N)=O)N=3)=O)C=C2)=N1 MEGDTTHCFKZHNB-GQCTYLIASA-N 0.000 description 1
- CUIHNOFLTHBFIA-SOFGYWHQSA-N (e)-3-[2-(3-carbamoyloxypiperidin-1-yl)-7-fluoro-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC=2C(=CN3C(=O)C(\C=C\C(O)=O)=C(N4CC(CCC4)OC(N)=O)N=C3C=2)F)=N1 CUIHNOFLTHBFIA-SOFGYWHQSA-N 0.000 description 1
- OARZCCFTDMZAGJ-VOTSOKGWSA-N (e)-3-[2-(3-carbamoyloxypiperidin-1-yl)-8-[(4-cyclobutyl-1,3-thiazol-2-yl)carbamoyl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1C(OC(=O)N)CCCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(C(=O)NC=3SC=C(N=3)C3CCC3)=CC2=N1 OARZCCFTDMZAGJ-VOTSOKGWSA-N 0.000 description 1
- OYLNAXDFDINPLA-GQCTYLIASA-N (e)-3-[2-(3-carbamoylpiperazin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(NCC4)C(N)=O)N=3)=O)C=C2)=N1 OYLNAXDFDINPLA-GQCTYLIASA-N 0.000 description 1
- CTZJFABYXGSYAC-SOFGYWHQSA-N (e)-3-[2-(3-carbamoylpiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CCC4)C(N)=O)N=3)=O)C=C2)=N1 CTZJFABYXGSYAC-SOFGYWHQSA-N 0.000 description 1
- WROFJRSGXBUADP-GQCTYLIASA-N (e)-3-[2-(3-cyanomorpholin-4-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C(COCC4)C#N)N=3)=O)C=C2)=N1 WROFJRSGXBUADP-GQCTYLIASA-N 0.000 description 1
- ZPFZZHGJHWCODA-GQCTYLIASA-N (e)-3-[2-(3-cyanopiperazin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(NCC4)C#N)N=3)=O)C=C2)=N1 ZPFZZHGJHWCODA-GQCTYLIASA-N 0.000 description 1
- JDMJHGPHORQHTG-SOFGYWHQSA-N (e)-3-[2-(3-cyanopiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CCC4)C#N)N=3)=O)C=C2)=N1 JDMJHGPHORQHTG-SOFGYWHQSA-N 0.000 description 1
- VKDITIUOUFOKGX-SOFGYWHQSA-N (e)-3-[2-(3-hydroxy-3-methylpiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(C)(O)CCC4)N=3)=O)C=C2)=N1 VKDITIUOUFOKGX-SOFGYWHQSA-N 0.000 description 1
- KQIRCFYMOINYJB-SOFGYWHQSA-N (e)-3-[2-(3-hydroxypiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(O)CCC4)N=3)=O)C=C2)=N1 KQIRCFYMOINYJB-SOFGYWHQSA-N 0.000 description 1
- LERCYFHMEQLWJJ-GQCTYLIASA-N (e)-3-[2-(3-hydroxypyrrolidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(O)CC4)N=3)=O)C=C2)=N1 LERCYFHMEQLWJJ-GQCTYLIASA-N 0.000 description 1
- DQQWGDAIXDQGQN-GQCTYLIASA-N (e)-3-[2-(4-aminopiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCC(N)CC4)N=3)=O)C=C2)=N1 DQQWGDAIXDQGQN-GQCTYLIASA-N 0.000 description 1
- OOFSYTNCPPKSGG-GQCTYLIASA-N (e)-3-[2-(4-carbamoylpiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCC(CC4)C(N)=O)N=3)=O)C=C2)=N1 OOFSYTNCPPKSGG-GQCTYLIASA-N 0.000 description 1
- ZBVSNASMKBDYCM-GQCTYLIASA-N (e)-3-[2-(4-cyanopiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCC(CC4)C#N)N=3)=O)C=C2)=N1 ZBVSNASMKBDYCM-GQCTYLIASA-N 0.000 description 1
- YZBRCTUNFKYDCK-GQCTYLIASA-N (e)-3-[2-(4-fluoropiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCC(F)CC4)N=3)=O)C=C2)=N1 YZBRCTUNFKYDCK-GQCTYLIASA-N 0.000 description 1
- ZSJAQQUKKYZESF-SOFGYWHQSA-N (e)-3-[2-(4-methyl-1,4-diazepan-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCN(C)CCC4)N=3)=O)C=C2)=N1 ZSJAQQUKKYZESF-SOFGYWHQSA-N 0.000 description 1
- MZRDVQIKQLTLHV-JHTBKMLMSA-N (e)-3-[2-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@@H](CC4)N(C)C)N=3)=O)C=C2)=N1 MZRDVQIKQLTLHV-JHTBKMLMSA-N 0.000 description 1
- LYFQFJFRHDYQTH-QQOXCAACSA-N (e)-3-[2-[(3r)-3-(methylamino)pyrrolidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1[C@H](NC)CCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(CCC=3SC=C(N=3)C(C)C)=CC2=N1 LYFQFJFRHDYQTH-QQOXCAACSA-N 0.000 description 1
- PBKZWZLBYAEPMR-MQDFFIGUSA-N (e)-3-[2-[(3r)-3-aminopyrrolidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@H](N)CC4)N=3)=O)C=C2)=N1 PBKZWZLBYAEPMR-MQDFFIGUSA-N 0.000 description 1
- LHKVPTYLATZKDE-QGIGQLMMSA-N (e)-3-[2-[(3r)-3-carbamoyloxypiperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@@H](CCC4)OC(N)=O)N=3)=O)C=C2)=N1 LHKVPTYLATZKDE-QGIGQLMMSA-N 0.000 description 1
- KWNTWERKUNZRRK-DPCDFWGDSA-N (e)-3-[2-[(3r,4s)-3,4-dihydroxypiperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@@H](O)[C@@H](O)CC4)N=3)=O)C=C2)=N1 KWNTWERKUNZRRK-DPCDFWGDSA-N 0.000 description 1
- MZRDVQIKQLTLHV-IWHGQQBYSA-N (e)-3-[2-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@H](CC4)N(C)C)N=3)=O)C=C2)=N1 MZRDVQIKQLTLHV-IWHGQQBYSA-N 0.000 description 1
- LHKVPTYLATZKDE-KZQZIPNXSA-N (e)-3-[2-[(3s)-3-carbamoyloxypiperidin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@H](CCC4)OC(N)=O)N=3)=O)C=C2)=N1 LHKVPTYLATZKDE-KZQZIPNXSA-N 0.000 description 1
- QMCIEVALOKERBU-JKNJVXJCSA-N (e)-3-[2-[(3s)-3-carbamoyloxypiperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@H](CCC4)OC(N)=O)N=3)=O)C=C2)=N1 QMCIEVALOKERBU-JKNJVXJCSA-N 0.000 description 1
- KQIRCFYMOINYJB-JKNJVXJCSA-N (e)-3-[2-[(3s)-3-hydroxypiperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@@H](O)CCC4)N=3)=O)C=C2)=N1 KQIRCFYMOINYJB-JKNJVXJCSA-N 0.000 description 1
- XSTGDBVAMQIKKQ-VFQYTZJCSA-N (e)-3-[2-[(3s,4s)-3-amino-4-(fluoromethyl)pyrrolidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@H](CF)[C@H](N)C4)N=3)=O)C=C2)=N1 XSTGDBVAMQIKKQ-VFQYTZJCSA-N 0.000 description 1
- FTOODIKBUIJEDP-RGBLOPSHSA-N (e)-3-[2-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@@H](C)N[C@@H](C)C4)N=3)=O)C=C2)=N1 FTOODIKBUIJEDP-RGBLOPSHSA-N 0.000 description 1
- YMZDNCDAZDWWHP-FHHGHWCOSA-N (e)-3-[2-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC5(CC5)[C@H](N)C4)N=3)=O)C=C2)=N1 YMZDNCDAZDWWHP-FHHGHWCOSA-N 0.000 description 1
- FPQQHSOOJMEGHL-SOFGYWHQSA-N (e)-3-[2-[2-(2-aminoethylsulfanylmethyl)pyridin-3-yl]sulfanyl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(SC=4C(=NC=CC=4)CSCCN)N=3)=O)C=C2)=N1 FPQQHSOOJMEGHL-SOFGYWHQSA-N 0.000 description 1
- LVBYFIONGLYQNL-VQHVLOKHSA-N (e)-3-[2-[2-(3-aminopropyl)-2-carbamoylpiperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C(CCCC4)(CCCN)C(N)=O)N=3)=O)C=C2)=N1 LVBYFIONGLYQNL-VQHVLOKHSA-N 0.000 description 1
- CDPHTQHNDZWMQY-GQCTYLIASA-N (e)-3-[2-[2-(aminomethyl)morpholin-4-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CN)OCC4)N=3)=O)C=C2)=N1 CDPHTQHNDZWMQY-GQCTYLIASA-N 0.000 description 1
- AWVOQPZZZQKCEY-GQCTYLIASA-N (e)-3-[2-[2-(hydroxymethyl)morpholin-4-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CO)OCC4)N=3)=O)C=C2)=N1 AWVOQPZZZQKCEY-GQCTYLIASA-N 0.000 description 1
- IPPCJFIBUUKICS-VQHVLOKHSA-N (e)-3-[2-[2-acetyl-4-(dimethylamino)piperazin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C(CN(CC4)N(C)C)C(C)=O)N=3)=O)C=C2)=N1 IPPCJFIBUUKICS-VQHVLOKHSA-N 0.000 description 1
- SYDVQMCXCLAGML-SOFGYWHQSA-N (e)-3-[2-[3-(2-aminoethyl)-2-carbamoylpiperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C(C(CCN)CCC4)C(N)=O)N=3)=O)C=C2)=N1 SYDVQMCXCLAGML-SOFGYWHQSA-N 0.000 description 1
- BAPORSUAEIHBKD-ZRDIBKRKSA-N (e)-3-[2-[3-(dimethylamino)-2-(ethylcarbamoyl)piperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CCNC(=O)C1C(N(C)C)CCCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(CCC=3SC=C(N=3)C(C)C)=CC2=N1 BAPORSUAEIHBKD-ZRDIBKRKSA-N 0.000 description 1
- RGVZJIADHIMQML-CSKARUKUSA-N (e)-3-[2-[3-(dimethylamino)piperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CCC4)N(C)C)N=3)=O)C=C2)=N1 RGVZJIADHIMQML-CSKARUKUSA-N 0.000 description 1
- FJIFHQHDAWFMSS-VQHVLOKHSA-N (e)-3-[2-[3-(methylamino)piperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1C(NC)CCCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(CCC=3SC=C(N=3)C(C)C)=CC2=N1 FJIFHQHDAWFMSS-VQHVLOKHSA-N 0.000 description 1
- GMHFCZNQDNVIDS-CSKARUKUSA-N (e)-3-[2-[4-(dimethylamino)-2-(ethylcarbamoyl)piperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CCNC(=O)C1CC(N(C)C)CCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(CCC=3SC=C(N=3)C(C)C)=CC2=N1 GMHFCZNQDNVIDS-CSKARUKUSA-N 0.000 description 1
- OQLIUFRGSJSMLG-SOFGYWHQSA-N (e)-3-[2-[4-(dimethylamino)piperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCC(CC4)N(C)C)N=3)=O)C=C2)=N1 OQLIUFRGSJSMLG-SOFGYWHQSA-N 0.000 description 1
- VKMOGNPQHSWHPT-GQCTYLIASA-N (e)-3-[2-[4-(hydroxymethyl)piperidin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCC(CO)CC4)N=3)=O)C=C2)=N1 VKMOGNPQHSWHPT-GQCTYLIASA-N 0.000 description 1
- YSOPBVJOWLNXMC-PVHVJQTOSA-N (e)-3-[2-[4-[(2s)-2,5-diaminopentanoyl]piperazin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCN(CC4)C(=O)[C@@H](N)CCCN)N=3)=O)C=C2)=N1 YSOPBVJOWLNXMC-PVHVJQTOSA-N 0.000 description 1
- BGMZTVPCPHCGEC-GLJAUCNMSA-N (e)-3-[2-[4-[(2s)-2,6-diaminohexanoyl]piperazin-1-yl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCN(CC4)C(=O)[C@@H](N)CCCCN)N=3)=O)C=C2)=N1 BGMZTVPCPHCGEC-GLJAUCNMSA-N 0.000 description 1
- SHZJVUWVAQPOOA-FQQXRIEFSA-N (e)-3-[2-[4-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]piperazin-1-yl]-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCN(CC4)C(=O)[C@@H](N)CCCNC(N)=N)N=3)=O)C=C2)=N1 SHZJVUWVAQPOOA-FQQXRIEFSA-N 0.000 description 1
- ZCQIBQHTFSYQTK-FNORWQNLSA-N (e)-3-[2-methylsulfanyl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=CN2C(=O)C(\C=C\C(O)=O)=C(SC)N=C2C=C1CCC1=NC(C(C)C)=CS1 ZCQIBQHTFSYQTK-FNORWQNLSA-N 0.000 description 1
- HMFCKOVWBWGXKG-GGWOSOGESA-N (e)-3-[2-morpholin-4-yl-4-oxo-8-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 HMFCKOVWBWGXKG-GGWOSOGESA-N 0.000 description 1
- QTVMIVPLMQEVLQ-DUXPYHPUSA-N (e)-3-[2-morpholin-4-yl-4-oxo-8-[2-[4-(trifluoromethyl)-1,3-thiazol-2-yl]ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=CN2C(=O)C(/C=C/C(=O)O)=C(N3CCOCC3)N=C2C=C1CCC1=NC(C(F)(F)F)=CS1 QTVMIVPLMQEVLQ-DUXPYHPUSA-N 0.000 description 1
- NVZNBGVRTZIHAO-GQCTYLIASA-N (e)-3-[4-oxo-2-(4-oxopiperidin-1-yl)-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCC(=O)CC4)N=3)=O)C=C2)=N1 NVZNBGVRTZIHAO-GQCTYLIASA-N 0.000 description 1
- BCKMVAIXBDJPHH-ONEGZZNKSA-N (e)-3-[4-oxo-2-(oxolan-3-ylmethoxy)-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enenitrile Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C#N)=C(OCC4COCC4)N=3)=O)C=C2)=N1 BCKMVAIXBDJPHH-ONEGZZNKSA-N 0.000 description 1
- VPTQIVDNKKSLBK-GQCTYLIASA-N (e)-3-[4-oxo-2-piperazin-1-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCNCC4)N=3)=O)C=C2)=N1 VPTQIVDNKKSLBK-GQCTYLIASA-N 0.000 description 1
- MIMVODHFVQLJKD-VQHVLOKHSA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-(pyridin-2-ylmethoxy)pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(OCC=4N=CC=CC=4)N=3)=O)C=C2)=N1 MIMVODHFVQLJKD-VQHVLOKHSA-N 0.000 description 1
- ASRBPYRFGKNPBK-SOFGYWHQSA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-(pyridin-3-ylmethylamino)pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(NCC=4C=NC=CC=4)N=3)=O)C=C2)=N1 ASRBPYRFGKNPBK-SOFGYWHQSA-N 0.000 description 1
- FREQYVPZEWKCJN-GQCTYLIASA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-(pyridin-4-ylmethoxy)pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(OCC=4C=CN=CC=4)N=3)=O)C=C2)=N1 FREQYVPZEWKCJN-GQCTYLIASA-N 0.000 description 1
- VHJWMUQUMQRSCZ-CSKARUKUSA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-[3-(pyrrolidin-2-ylmethylcarbamoyl)piperidin-1-yl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CCC4)C(=O)NCC4NCCC4)N=3)=O)C=C2)=N1 VHJWMUQUMQRSCZ-CSKARUKUSA-N 0.000 description 1
- XMSWTHBRCGQYPR-HLKVNRHESA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-[4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]piperazin-1-yl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCN(CC4)[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)N=3)=O)C=C2)=N1 XMSWTHBRCGQYPR-HLKVNRHESA-N 0.000 description 1
- UFXXDOFWNDALQX-PVHVJQTOSA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-[4-[(2s)-pyrrolidine-2-carbonyl]piperazin-1-yl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCN(CC4)C(=O)[C@H]4NCCC4)N=3)=O)C=C2)=N1 UFXXDOFWNDALQX-PVHVJQTOSA-N 0.000 description 1
- DGSHQPAJENHDDX-GQCTYLIASA-N (e)-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-pyridin-4-ylpyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(C=4C=CN=CC=4)N=3)=O)C=C2)=N1 DGSHQPAJENHDDX-GQCTYLIASA-N 0.000 description 1
- NOTSHROOKWSDFT-AATRIKPKSA-N (e)-3-[8-[(4-cyclobutyl-1,3-thiazol-2-yl)carbamoyl]-2-(4-methylpiperazin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1CN(C)CCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(C(=O)NC=3SC=C(N=3)C3CCC3)=CC2=N1 NOTSHROOKWSDFT-AATRIKPKSA-N 0.000 description 1
- HPXXDHOVORKYLH-LFAOLKIESA-N (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3s)-3-carbamoyloxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@H](CCC4)OC(N)=O)N=3)=O)C=C2)=N1 HPXXDHOVORKYLH-LFAOLKIESA-N 0.000 description 1
- DQKLLQBFKPFJQE-LFAOLKIESA-N (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3s)-3-hydroxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C[C@@H](O)CCC4)N=3)=O)C=C2)=N1 DQKLLQBFKPFJQE-LFAOLKIESA-N 0.000 description 1
- LXRHPRCZAKREDT-BQYQJAHWSA-N (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[3-(methylcarbamoyl)piperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1C(C(=O)NC)CCCN1C1=C(\C=C\C(O)=O)C(=O)N2C=CC(C(=O)NC=3SC=C(N=3)C(C)(C)C)=CC2=N1 LXRHPRCZAKREDT-BQYQJAHWSA-N 0.000 description 1
- SFMDKJYWYKNHKR-BQYQJAHWSA-N (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-4-oxo-2-piperidin-1-ylpyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)(C)C1=CSC(NC(=O)C2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCCCC4)N=3)=O)C=C2)=N1 SFMDKJYWYKNHKR-BQYQJAHWSA-N 0.000 description 1
- OOBGCSHBZGUNMY-DTQAZKPQSA-N (e)-3-[8-[2-(4-tert-butyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]-2-methylprop-2-enoic acid Chemical compound C1=CN2C(=O)C(\C=C(/C)C(O)=O)=C(N3CCOCC3)N=C2C=C1CCC1=NC(C(C)(C)C)=CS1 OOBGCSHBZGUNMY-DTQAZKPQSA-N 0.000 description 1
- KQVRGLIQAWTREJ-FNORWQNLSA-N (e)-3-[8-[2-(4-tert-butyl-1,3-thiazol-2-yl)ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 KQVRGLIQAWTREJ-FNORWQNLSA-N 0.000 description 1
- NRGNRHOOUFZUKV-HWKANZROSA-N (e)-3-[8-[2-[4-(1-methylcyclopropyl)-1,3-thiazol-2-yl]ethyl]-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C=1SC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=NC=1C1(C)CC1 NRGNRHOOUFZUKV-HWKANZROSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- HMEUSWKXYHBYKT-AATRIKPKSA-N (e)-n-methylsulfonyl-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enamide Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)NS(C)(=O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 HMEUSWKXYHBYKT-AATRIKPKSA-N 0.000 description 1
- HTNWSNGMHLBYNY-AATRIKPKSA-N (e)-n-methylsulfonyl-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enamide Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)NS(C)(=O)=O)=CN=3)=O)C=C2)=N1 HTNWSNGMHLBYNY-AATRIKPKSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- FGODERGVNHDAMT-WQRHYEAKSA-N (z)-2-fluoro-3-[2-(3-hydroxypiperidin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C(/F)C(O)=O)=C(N4CC(O)CCC4)N=3)=O)C=C2)=N1 FGODERGVNHDAMT-WQRHYEAKSA-N 0.000 description 1
- XHLACBLIPMYPCA-WQRHYEAKSA-N (z)-3-[2-(2-acetyl-4-aminopiperazin-1-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]-2-fluoroprop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C(/F)C(O)=O)=C(N4C(CN(N)CC4)C(C)=O)N=3)=O)C=C2)=N1 XHLACBLIPMYPCA-WQRHYEAKSA-N 0.000 description 1
- HFNUKVRWYDEFMJ-YBEGLDIGSA-N (z)-3-[2-(3-carbamoylmorpholin-4-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]-2-fluoroprop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C(/F)C(O)=O)=C(N4C(COCC4)C(N)=O)N=3)=O)C=C2)=N1 HFNUKVRWYDEFMJ-YBEGLDIGSA-N 0.000 description 1
- MMVXOHVHSWRXBO-ZDLGFXPLSA-N (z)-3-[2-(3-cyanomorpholin-4-yl)-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]-2-fluoroprop-2-enoic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C(/F)C(O)=O)=C(N4C(COCC4)C#N)N=3)=O)C=C2)=N1 MMVXOHVHSWRXBO-ZDLGFXPLSA-N 0.000 description 1
- HCTHZZSYUGOKAD-ALCCZGGFSA-N (z)-3-[2-methoxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoic acid Chemical compound C1=CN2C(=O)C(\C=C/C(O)=O)=C(OC)N=C2C=C1CCC1=NC(C(C)C)=CS1 HCTHZZSYUGOKAD-ALCCZGGFSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- SEJPAVHHMCUTPS-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-3-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]urea Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(NC(=O)NS(=O)(=O)C=4C=CC(C)=CC=4)=CN=3)=O)C=C2)=N1 SEJPAVHHMCUTPS-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- GZHHPYMRGKDCQH-SOFGYWHQSA-N 1-[3-[(e)-2-carboxyethenyl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-2-yl]piperidine-3-carboxylic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(CCC4)C(O)=O)N=3)=O)C=C2)=N1 GZHHPYMRGKDCQH-SOFGYWHQSA-N 0.000 description 1
- XOVQZALLIVPJIZ-GQCTYLIASA-N 1-[3-[(e)-2-carboxyethenyl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-2-yl]piperidine-4-carboxylic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CCC(CC4)C(O)=O)N=3)=O)C=C2)=N1 XOVQZALLIVPJIZ-GQCTYLIASA-N 0.000 description 1
- KPUMHBMHJIQMBI-UHFFFAOYSA-N 1-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-2-yl]piperidine-4-carbonitrile Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=4NN=NN=4)=C(N4CCC(CC4)C#N)N=3)=O)C=C2)=N1 KPUMHBMHJIQMBI-UHFFFAOYSA-N 0.000 description 1
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 1
- SAIRZMWXVJEBMO-UHFFFAOYSA-N 1-bromo-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CBr SAIRZMWXVJEBMO-UHFFFAOYSA-N 0.000 description 1
- CCXQVBSQUQCEEO-UHFFFAOYSA-N 1-bromobutan-2-one Chemical compound CCC(=O)CBr CCXQVBSQUQCEEO-UHFFFAOYSA-N 0.000 description 1
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 1
- JPJOOTWNILDNAW-UHFFFAOYSA-N 1-cyclobutylethanone Chemical compound CC(=O)C1CCC1 JPJOOTWNILDNAW-UHFFFAOYSA-N 0.000 description 1
- KNEXGVPHPGXAGF-UHFFFAOYSA-N 1-cyclopropyl-6,7-difluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 KNEXGVPHPGXAGF-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WMQUKDQWMMOHSA-UHFFFAOYSA-N 1-pyridin-4-ylethanone Chemical compound CC(=O)C1=CC=NC=C1 WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 1
- FNGLVNXJDZMKIL-UHFFFAOYSA-N 2,2-bis(2,4,6-trichlorophenyl)propanedioic acid Chemical compound ClC=1C=C(Cl)C=C(Cl)C=1C(C(O)=O)(C(=O)O)C1=C(Cl)C=C(Cl)C=C1Cl FNGLVNXJDZMKIL-UHFFFAOYSA-N 0.000 description 1
- BDHFOMVLOGNDKV-UHFFFAOYSA-N 2-(dimethylamino)-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=4NN=NN=4)=C(N(C)C)N=3)=O)C=C2)=N1 BDHFOMVLOGNDKV-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-L 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfonatoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoate Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C([O-])=O)\C1=CSC(N)=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-L 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- CPWQJVMLLMUUND-UHFFFAOYSA-N 2-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]cyclopropane-1-carboxylic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C4C(C4)C(O)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 CPWQJVMLLMUUND-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
- HYZXDNKDMWICDW-UHFFFAOYSA-N 2-aminopyridine-4-carbaldehyde Chemical class NC1=CC(C=O)=CC=N1 HYZXDNKDMWICDW-UHFFFAOYSA-N 0.000 description 1
- QMKZZQPPJRWDED-UHFFFAOYSA-N 2-aminopyridine-4-carboxylic acid Chemical class NC1=CC(C(O)=O)=CC=N1 QMKZZQPPJRWDED-UHFFFAOYSA-N 0.000 description 1
- PBQUIUOUHCUOKC-UHFFFAOYSA-N 2-hydroxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidine-3-carbaldehyde Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=O)=C(O)N=3)=O)C=C2)=N1 PBQUIUOUHCUOKC-UHFFFAOYSA-N 0.000 description 1
- MVUXZCRKJCFIGN-UHFFFAOYSA-N 2-hydroxy-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-3-(2H-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=4NN=NN=4)=C(O)N=3)=O)C=C2)=N1 MVUXZCRKJCFIGN-UHFFFAOYSA-N 0.000 description 1
- RSLPCYAVRWFFLB-UHFFFAOYSA-N 2-methoxy-2-phosphonoacetic acid Chemical compound COC(C(O)=O)P(O)(O)=O RSLPCYAVRWFFLB-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical class CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- ZUUZNOFTKGDLLN-UHFFFAOYSA-N 3-(1,3,2-dioxaborinan-2-yl)pyridine Chemical compound O1CCCOB1C1=CC=CN=C1 ZUUZNOFTKGDLLN-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- LAMYCGIJDRDOOP-ONEGZZNKSA-N 3-[(e)-3-hydroxyprop-1-enyl]-2-morpholin-4-yl-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\CO)=C(N4CCOCC4)N=3)=O)C=C2)=N1 LAMYCGIJDRDOOP-ONEGZZNKSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- RAYKBFYRNXOESN-UHFFFAOYSA-N 3-bromo-2-(bromomethyl)-4-ethylthiophene Chemical compound CCC1=CSC(CBr)=C1Br RAYKBFYRNXOESN-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- SLDBAXYJAIRQMX-UHFFFAOYSA-N 3-ethylthiophene Chemical compound CCC=1C=CSC=1 SLDBAXYJAIRQMX-UHFFFAOYSA-N 0.000 description 1
- TYBVEGWFIZWFNZ-GQCTYLIASA-N 4-[3-[(e)-2-carboxyethenyl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-2-yl]morpholine-3-carboxylic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4C(COCC4)C(O)=O)N=3)=O)C=C2)=N1 TYBVEGWFIZWFNZ-GQCTYLIASA-N 0.000 description 1
- OAZDOEQYFXPSLO-GQCTYLIASA-N 4-[3-[(e)-2-carboxyethenyl]-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-2-yl]piperazine-2-carboxylic acid Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(O)=O)=C(N4CC(NCC4)C(O)=O)N=3)=O)C=C2)=N1 OAZDOEQYFXPSLO-GQCTYLIASA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- ABJMARLKAXBQBC-UHFFFAOYSA-N 4-methoxy-1-oxidopyridin-1-ium;hydrate Chemical compound O.COC1=CC=[N+]([O-])C=C1 ABJMARLKAXBQBC-UHFFFAOYSA-N 0.000 description 1
- COIBQJMOZNXKIB-UHFFFAOYSA-N 4-methyl-2-nitropyridin-3-ol Chemical compound CC1=CC=NC([N+]([O-])=O)=C1O COIBQJMOZNXKIB-UHFFFAOYSA-N 0.000 description 1
- GRBBNZYMXKTQAI-UHFFFAOYSA-N 4-methyl-5-nitropyridin-2-amine Chemical compound CC1=CC(N)=NC=C1[N+]([O-])=O GRBBNZYMXKTQAI-UHFFFAOYSA-N 0.000 description 1
- VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 1
- MXXLHBCSVDDTIX-UHFFFAOYSA-N 4-oxo-1h-pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(O)=CC=N1 MXXLHBCSVDDTIX-UHFFFAOYSA-N 0.000 description 1
- GBIUCCNVPYLHJG-UHFFFAOYSA-N 4-oxo-3h-cinnoline-3-carboxylic acid Chemical compound C1=CC=C2C(=O)C(C(=O)O)N=NC2=C1 GBIUCCNVPYLHJG-UHFFFAOYSA-N 0.000 description 1
- JTJGLQLRUUWMOZ-UHFFFAOYSA-N 4-propan-2-yl-1,3-thiazol-2-amine;hydrobromide Chemical compound Br.CC(C)C1=CSC(N)=N1 JTJGLQLRUUWMOZ-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- BPXSLLRPRFTCEO-UHFFFAOYSA-N 5-[4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=4OC(=O)NN=4)=CN=3)=O)C=C2)=N1 BPXSLLRPRFTCEO-UHFFFAOYSA-N 0.000 description 1
- JAOUODJPHOTWFF-UHFFFAOYSA-N 5-[[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=C4C(NC(=O)S4)=O)=C(N4CCOCC4)N=3)=O)C=C2)=N1 JAOUODJPHOTWFF-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- FMXSYRBHGUMFBA-UHFFFAOYSA-N 6-amino-3-azaniumylidene-9-[2-carboxy-4-[6-[4-[4-[4-[4-[3-carboxy-6-[4-(trifluoromethyl)phenyl]naphthalen-1-yl]phenyl]piperidin-1-yl]butyl]triazol-1-yl]hexylcarbamoyl]phenyl]-5-sulfoxanthene-4-sulfonate Chemical compound Nc1ccc2c(-c3ccc(cc3C(O)=O)C(=O)NCCCCCCn3cc(CCCCN4CCC(CC4)c4ccc(cc4)-c4cc(cc5cc(ccc45)-c4ccc(cc4)C(F)(F)F)C(O)=O)nn3)c3ccc(=[NH2+])c(c3oc2c1S(O)(=O)=O)S([O-])(=O)=O FMXSYRBHGUMFBA-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- LZDHHALOFCXHAT-UHFFFAOYSA-N 8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]-2-(pyridin-3-ylmethoxy)-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(C=4NN=NN=4)=C(OCC=4C=NC=CC=4)N=3)=O)C=C2)=N1 LZDHHALOFCXHAT-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- JOIUCOQHSVWSMT-DAXSKMNVSA-N C12=CC(F)=C(F)C=C2C(=O)C(\C=C/C(=O)OC(C)(C)C)=CN1C1CC1 Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(\C=C/C(=O)OC(C)(C)C)=CN1C1CC1 JOIUCOQHSVWSMT-DAXSKMNVSA-N 0.000 description 1
- NFHAYXLKZOFNEF-BBVFFXRHSA-N C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3C[C@H](CCC3)OC(N)=O)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3C[C@H](CCC3)OC(N)=O)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 NFHAYXLKZOFNEF-BBVFFXRHSA-N 0.000 description 1
- AVJSJLIWRHLNAW-FNORWQNLSA-N CC(C)C1=CSC(CCC(C=CN23)=CC2=NC(N(CC2)CCN2C(C[N+]2=CN(C)C=C2)=O)=C(/C=C/C([O-])=O)C3=O)=N1 Chemical compound CC(C)C1=CSC(CCC(C=CN23)=CC2=NC(N(CC2)CCN2C(C[N+]2=CN(C)C=C2)=O)=C(/C=C/C([O-])=O)C3=O)=N1 AVJSJLIWRHLNAW-FNORWQNLSA-N 0.000 description 1
- RBKDKOBFQDQWHX-SOFGYWHQSA-N CC(C)C1=CSC(CCC(C=CN23)=CC2=NC(N2CC[N+](C)(C)CC2)=C(/C=C/C([O-])=O)C3=O)=N1 Chemical compound CC(C)C1=CSC(CCC(C=CN23)=CC2=NC(N2CC[N+](C)(C)CC2)=C(/C=C/C([O-])=O)C3=O)=N1 RBKDKOBFQDQWHX-SOFGYWHQSA-N 0.000 description 1
- KURDFPHCHFLQIQ-WYMLVPIESA-N CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(C=4C=CC=CC=4)N=3)=O)C=C2)=N1 Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(C=4C=CC=CC=4)N=3)=O)C=C2)=N1 KURDFPHCHFLQIQ-WYMLVPIESA-N 0.000 description 1
- SWCGWNHDBMTXEY-WYMLVPIESA-N CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(OS(=O)(=O)C=4C=CC(C)=CC=4)N=3)=O)C=C2)=N1 Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(OS(=O)(=O)C=4C=CC(C)=CC=4)N=3)=O)C=C2)=N1 SWCGWNHDBMTXEY-WYMLVPIESA-N 0.000 description 1
- VDQPLHXVVMHCNC-CDJQDVQCSA-N CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCNCC4)N=3)=O)C=C2)=N1 Chemical compound CC(C)C1=CSC(\C=C\C2=CC=3N(C(C(\C=C\C(=O)OC(C)(C)C)=C(N4CCNCC4)N=3)=O)C=C2)=N1 VDQPLHXVVMHCNC-CDJQDVQCSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical class ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- MDOHMABLVGWDTH-UHFFFAOYSA-N [1-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-3-formyl-4-oxopyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl] formate Chemical compound C1C(OC=O)CCCN1C1=C(C=O)C(=O)N2C=CC(CCC=3SC=C(N=3)C3CCC3)=CC2=N1 MDOHMABLVGWDTH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-aminopropionic acid Natural products NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- WYPCGKBOSFOHGU-UHFFFAOYSA-N bis(2,4,6-trichlorophenyl) propanedioate Chemical compound ClC1=CC(Cl)=CC(Cl)=C1OC(=O)CC(=O)OC1=C(Cl)C=C(Cl)C=C1Cl WYPCGKBOSFOHGU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- CDHICTNQMQYRSM-UHFFFAOYSA-N di(propan-2-yl)alumane Chemical compound CC(C)[AlH]C(C)C CDHICTNQMQYRSM-UHFFFAOYSA-N 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SCXMWKHAWMEEHS-UHFFFAOYSA-N diethyl 2-[1-[(4-methoxyphenyl)methyl]tetrazol-5-yl]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)C1=NN=NN1CC1=CC=C(OC)C=C1 SCXMWKHAWMEEHS-UHFFFAOYSA-N 0.000 description 1
- UQEHYJSUZFEFMS-UHFFFAOYSA-N diethyl 4-(dimethylaminomethylidene)pent-2-enedioate Chemical compound CCOC(=O)C=CC(=CN(C)C)C(=O)OCC UQEHYJSUZFEFMS-UHFFFAOYSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- RHFZTBSULNJWEI-UHFFFAOYSA-N dimethyl 2-(methoxymethylidene)propanedioate Chemical compound COC=C(C(=O)OC)C(=O)OC RHFZTBSULNJWEI-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- IWZBWQJQJHSTIZ-GDNBJRDFSA-N ethyl (Z)-2-fluoro-3-[2-hydroxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C(\F)C(=O)OCC)=C(O)N=C2C=C1CCC1=NC(C(C)C)=CS1 IWZBWQJQJHSTIZ-GDNBJRDFSA-N 0.000 description 1
- VIGAKXNALDHSCN-UHFFFAOYSA-N ethyl 1-cyclopropyl-6,7-difluoro-2-methylsulfanyl-4-oxoquinoline-3-carboxylate Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(C(=O)OCC)=C(SC)N1C1CC1 VIGAKXNALDHSCN-UHFFFAOYSA-N 0.000 description 1
- LVSYULZEUZGHFX-UHFFFAOYSA-N ethyl 1-cyclopropyl-6,7-difluoro-2-methylsulfinyl-4-oxoquinoline-3-carboxylate Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(C(=O)OCC)=C(S(C)=O)N1C1CC1 LVSYULZEUZGHFX-UHFFFAOYSA-N 0.000 description 1
- FVPISMANESAJQZ-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-2-fluoroacetate Chemical compound CCOC(=O)C(F)P(=O)(OCC)OCC FVPISMANESAJQZ-UHFFFAOYSA-N 0.000 description 1
- BVSRWCMAJISCTD-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpropanoate Chemical compound CCOC(=O)C(C)P(=O)(OCC)OCC BVSRWCMAJISCTD-UHFFFAOYSA-N 0.000 description 1
- IWZBWQJQJHSTIZ-UHFFFAOYSA-N ethyl 2-fluoro-3-[2-hydroxy-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(C=C(F)C(=O)OCC)=C(O)N=C2C=C1CCC1=NC(C(C)C)=CS1 IWZBWQJQJHSTIZ-UHFFFAOYSA-N 0.000 description 1
- FDXHIEMXNXKRAJ-UHFFFAOYSA-N ethyl 3-(dimethylamino)-2-(2-ethoxy-2-oxoethoxy)-3-methoxyprop-2-enoate Chemical compound CCOC(=O)COC(=C(OC)N(C)C)C(=O)OCC FDXHIEMXNXKRAJ-UHFFFAOYSA-N 0.000 description 1
- JSEMUSFPVZYRSG-UHFFFAOYSA-N ethyl 3-(triphenyl-$l^{5}-phosphanylidene)propanoate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CCC(=O)OCC)C1=CC=CC=C1 JSEMUSFPVZYRSG-UHFFFAOYSA-N 0.000 description 1
- YIDSWRWEIYEKGF-SOFGYWHQSA-N ethyl 4-oxo-7-[(e)-2-(4-propan-2-yl-1,3-thiazol-2-yl)ethenyl]-1h-quinoline-3-carboxylate Chemical compound C=1C=C2C(=O)C(C(=O)OCC)=CNC2=CC=1\C=C\C1=NC(C(C)C)=CS1 YIDSWRWEIYEKGF-SOFGYWHQSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLNWILHOFOBOFD-UHFFFAOYSA-N lithium sulfide Chemical compound [Li+].[Li+].[S-2] GLNWILHOFOBOFD-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- JGZKUKYUQJUUNE-UHFFFAOYSA-L magnesium;ethoxyethane;dibromide Chemical compound [Mg+2].[Br-].[Br-].CCOCC JGZKUKYUQJUUNE-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- SARVTQFJJABHLS-UHFFFAOYSA-N methyl 3-(dimethylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]prop-2-enoate Chemical compound COC(=O)C(=CN(C)C)NC(=O)OC(C)(C)C SARVTQFJJABHLS-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- DRGBMMYONIQOHI-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-4-oxo-3-(2h-tetrazol-5-yl)pyrido[1,2-a]pyrimidine-8-carboxamide Chemical compound N=1C2=CC=CC=C2SC=1NC(=O)C(=C1)C=CN(C2=O)C1=NC=C2C=1N=NNN=1 DRGBMMYONIQOHI-UHFFFAOYSA-N 0.000 description 1
- QGZHGSGLCZEGHA-UHFFFAOYSA-N n-(4-methylpyridin-2-yl)acetamide Chemical compound CC(=O)NC1=CC(C)=CC=N1 QGZHGSGLCZEGHA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GJIWAHKHYCEKFG-UHFFFAOYSA-N n-methylpiperidine-3-carboxamide;hydrochloride Chemical compound Cl.CNC(=O)C1CCCNC1 GJIWAHKHYCEKFG-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FVYATPQQFYZEHN-TWGQIWQCSA-N n1c(C(C)C)csc1Cc1cc2n(C3CC3)cc(\C=C/C(=O)OC(C)(C)C)c(=O)c2cc1F Chemical compound n1c(C(C)C)csc1Cc1cc2n(C3CC3)cc(\C=C/C(=O)OC(C)(C)C)c(=O)c2cc1F FVYATPQQFYZEHN-TWGQIWQCSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- ZEJPMRKECMRICL-UHFFFAOYSA-N o-ethyl 2-amino-2-oxoethanethioate Chemical compound CCOC(=S)C(N)=O ZEJPMRKECMRICL-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000006772 olefination reaction Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 1
- WSHJJCPTKWSMRR-RXMQYKEDSA-N penam Chemical compound S1CCN2C(=O)C[C@H]21 WSHJJCPTKWSMRR-RXMQYKEDSA-N 0.000 description 1
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- KOUDKOMXLMXFKX-UHFFFAOYSA-N sodium oxido(oxo)phosphanium hydrate Chemical compound O.[Na+].[O-][PH+]=O KOUDKOMXLMXFKX-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- JOIUCOQHSVWSMT-QPJJXVBHSA-N tert-butyl (e)-3-(1-cyclopropyl-6,7-difluoro-4-oxoquinolin-3-yl)prop-2-enoate Chemical compound C12=CC(F)=C(F)C=C2C(=O)C(/C=C/C(=O)OC(C)(C)C)=CN1C1CC1 JOIUCOQHSVWSMT-QPJJXVBHSA-N 0.000 description 1
- FVYATPQQFYZEHN-RMKNXTFCSA-N tert-butyl (e)-3-[1-cyclopropyl-6-fluoro-4-oxo-7-[(4-propan-2-yl-1,3-thiazol-2-yl)methyl]quinolin-3-yl]prop-2-enoate Chemical compound CC(C)C1=CSC(CC=2C(=CC=3C(=O)C(\C=C\C(=O)OC(C)(C)C)=CN(C=3C=2)C2CC2)F)=N1 FVYATPQQFYZEHN-RMKNXTFCSA-N 0.000 description 1
- AUUMKKUYVIVWJJ-MDZDMXLPSA-N tert-butyl (e)-3-[8-[(4-cyclobutyl-1,3-thiazol-2-yl)carbamoyl]-2-(3-hydroxypiperidin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3CC(O)CCC3)N=C2C=C1C(=O)NC(SC=1)=NC=1C1CCC1 AUUMKKUYVIVWJJ-MDZDMXLPSA-N 0.000 description 1
- NFHAYXLKZOFNEF-QZEKMECESA-N tert-butyl (e)-3-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-2-[(3r)-3-carbamoyloxypiperidin-1-yl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]prop-2-enoate Chemical compound C1=CN2C(=O)C(/C=C/C(=O)OC(C)(C)C)=C(N3C[C@@H](CCC3)OC(N)=O)N=C2C=C1C(=O)NC1=NC(C(C)(C)C)=CS1 NFHAYXLKZOFNEF-QZEKMECESA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- YMMCNZHNCAARBJ-UHFFFAOYSA-N tert-butyl 2-diethoxyphosphorylpropanoate Chemical compound CCOP(=O)(OCC)C(C)C(=O)OC(C)(C)C YMMCNZHNCAARBJ-UHFFFAOYSA-N 0.000 description 1
- UFORZZXGNFYDKG-UHFFFAOYSA-N tert-butyl n-(3-sulfamoylpropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCS(N)(=O)=O UFORZZXGNFYDKG-UHFFFAOYSA-N 0.000 description 1
- YBHQCFHDGZBQRO-CMDGGOBGSA-N tert-butyl n-[3-[[(e)-3-[2-morpholin-4-yl-4-oxo-8-[2-(4-propan-2-yl-1,3-thiazol-2-yl)ethyl]pyrido[1,2-a]pyrimidin-3-yl]prop-2-enoyl]sulfamoyl]propyl]carbamate Chemical compound CC(C)C1=CSC(CCC2=CC=3N(C(C(\C=C\C(=O)NS(=O)(=O)CCCNC(=O)OC(C)(C)C)=C(N4CCOCC4)N=3)=O)C=C2)=N1 YBHQCFHDGZBQRO-CMDGGOBGSA-N 0.000 description 1
- NRFQVIHDDIFXRG-BQYQJAHWSA-N tert-butyl n-[4-[(e)-2-(4-tert-butyl-1,3-thiazol-2-yl)ethenyl]pyridin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC(C)(C)C)=CC(\C=C\C=2SC=C(N=2)C(C)(C)C)=C1 NRFQVIHDDIFXRG-BQYQJAHWSA-N 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- KIAOHNBKFRHHKE-UHFFFAOYSA-M triphenyl-[(4-propan-2-yl-1,3-thiazol-2-yl)methyl]phosphanium;bromide Chemical compound [Br-].CC(C)C1=CSC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 KIAOHNBKFRHHKE-UHFFFAOYSA-M 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
Definitions
- the present invention relates to a medicament useful for preventive and therapeutic treatment of microbial infectious diseases.
- antibacterial agents For preventive or therapeutic treatment of infectious diseases caused by microorganisms, various antibacterial agents have so far been developed, and drugs such as ⁇ -lactam antibiotics (penicillins, cephems, monobactams, carbapenems, and penems), aminoglycosides, quinolones, macrolides, tetracyclines, rifamycins, chloramphenicols, and phosphomycins have been practically used.
- ⁇ -lactam antibiotics penicillins, cephems, monobactams, carbapenems, and penems
- aminoglycosides aminoglycosides
- quinolones macrolides
- tetracyclines tetracyclines
- rifamycins chloramphenicols
- phosphomycins phosphomycins
- problematic bacteria which cause particularly intractable or serious infectious diseases among those caused by resistant bacteria, include Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).
- MRSA methicillin-resistant Staphylococcus aureus
- Antibacterial agents effective against these bacteria have been limited so far, and it is not certain whether or not therapeutic efficacy of the currently available drugs will be expected in the future. In particular, no drug is available at present by which specifically high efficacy against resistant Pseudomonas aeruginosa can be achieved.
- the drug efflux pumps of Pseudomonas aeruginosa excrete various drugs including ⁇ -lactams, tetracyclines, chloramphenicols, and quinolones, to which the drug resistance of Pseudomonas aeruginosa is attributable.
- an antibacterial agent that has a novel structure, by which resistance acquisition due to a drug efflux pump, one of factors of resistance acquisition, can be avoided, or develop an agent for a combinational use with currently available antibacterial agents that can restore their efficacy by inhibiting functions of drug efflux pumps.
- an object of the present invention is to provide a novel medicament for the treatment of infectious diseases that improves therapeutic efficacy of an agent against pathogenic microorganisms, in particular, a medicament that acts on a microorganism with acquired resistance to an antimicrobial agent, and eliminates the resistance of the bacteria by inhibiting a drug efflux pump so as to improve preventive and/or therapeutic effect of the antimicrobial agent.
- the inventors of the present invention conducted various researches to search for compounds that eliminate resistance to an antimicrobial drug of Pseudomonas aeruginosa that has acquired the resistance. As a result, they found that the compounds represented by the following general formula (I) or (II) had the desired activity, and thus achieved the present invention.
- the present invention thus provides a medicament for preventive and/or therapeutic treatment of microbial infections, which comprises as an active ingredient a compound represented by the following general formula (I) or a physiologically acceptable salt thereof, or a hydrate thereof: wherein, R 1 and R 2 each independently represent hydrogen atom, a halogen atom, hydroxyl group, a group of OZ 1-6 (the group of OZ 1-6 represents an alkyl group having 1-6 carbon atoms or a fluoroalkyl group having 1-6 carbon atoms, which bonds via the oxygen atom), a group of S(O) n Z 1-4 (Z 1-4 represents an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms or an alkylene group derived therefrom), a group of N(R 12 )(R 13 ) (R 12 and R 13 each independently represent hydrogen atom, an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms
- a medicament for eliminating resistance of a microorganism with acquired drug resistance which comprises a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof as an active ingredient
- a medicament for enhancing effect of an antimicrobial agent which comprises a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof as an active ingredient.
- the aforementioned medicaments wherein the microorganism is Pseudomonas aeruginosa are preferred embodiments of the present invention.
- the present invention also provides a pharmaceutical composition for preventive and/or therapeutic treatment of microbial infections, which comprises a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof together with an antimicrobial agent.
- a method for preventive and/or therapeutic treatment of microbial infections which comprises the step of administering to a mammal including human a preventively and/or therapeutically effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof; a method for eliminating resistance of a microorganism with acquired resistance to an antimicrobial agent, which comprises the step of contacting with the microorganism an effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof; a method for inhibiting acquisition of resistance to an antimicrobial agent by a microorganism, which comprises the step of contacting with a microorganism an effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof; a method for enhancing sensitivity of a microorganism to an antimicrobial agent, which comprises the step of contacting with a microorganism an effective amount of a compound represented by the aforementioned general formula
- the compounds represented by the aforementioned general formula (I) or physiologically acceptable salts thereof are usually administered with one or more of antimicrobial agents simultaneously or separately, or successively.
- the present invention also provides a use of the compounds represented by the aforementioned general formula (I) or physiologically acceptable salts thereof for the manufacture of the aforementioned medicaments.
- the present invention also provides a medicament for preventive and/or therapeutic treatment of microbial infections, which comprises as an active ingredient a compound represented by the following general formula (I), a physiologically acceptable salt thereof, or hydrates thereof
- R 1 , R 2 , R 3 , R 4 , W 1 , W 2 and Q have the same meanings as those defined above;
- R 14 represents hydrogen atom, Z 1-4 , Z 1-4 R 5 or Z 1-4 OR 5 ;
- X and Y each independently represent C—H or nitrogen atom.
- alkyl group means a linear, branched or cyclic alkyl group or an alkyl group consisting of a combination thereof. The same is applied to an alkyl moiety of a substituent having the alkyl moiety (for example, fluoroalkyl group).
- R 1 is preferably an alkyl group.
- the alkyl group include a linear or branched alkyl group having 1-8 carbon atoms (for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group and the like), and a cyclic alkyl group having 3-8 carbon atoms, preferably 3-6 carbon atoms (for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group and the like).
- the cyclic alkyl group may have another alkyl group or a halogen atom, hydroxyl group or the like on the ring.
- R 1 is also preferably an aryl group, a heteroaryl group or a heterocyclic group.
- the aryl group may preferably has a 5- or 6-membered ring.
- the heterocyclic group a heterocyclic group having 3-8, preferably 3-6, of ring constituting atoms can be used, and the ring may be saturated or partially saturated.
- a substituent that binds to the heterocyclic group for example, an alkyl group or a halogen atom is preferred.
- R 2 is preferably hydrogen atom or a halogen atom.
- W 1 is preferably a linking group having a length of two atoms, and —CH ⁇ CH—, —N(R 12 )CO—, —CON(R 12 )—, —CH 2 O— and —CH 2 CH 2 — are more preferred.
- R 3 is preferably hydrogen atom, a halogen atom, amino group or hydroxyl group.
- R 4 is preferably hydrogen atom, —OZ 0-4 R 5 or —N(R 6 )(R 7 ).
- R 5 is preferably a 5- or 6-membered aryl group, 5- to 7-membered alicyclic group, 4- to 7-membered saturated heterocyclic group, or 5- or 6-membered unsaturated heterocyclic group, which may be substituted, and more preferably a 4- to 7-membered saturated heterocyclic group or a 5- or 6-membered unsaturated heterocyclic group.
- R 6 and R 7 represent hydrogen atom, an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms, or they bind to each other to form a saturated or unsaturated 5- to 7-membered ring.
- the ring may contain one or two hetero atoms as atoms constituting the ring.
- R 6 and R 7 may have one to three substituents selected from the group shown as follows: a halogen atom, hydroxyl group, a group of OCON(R 12 )(R 13 ), a group of CON(R 12 )(R 13 ), a group of N(R 12 )CON(R 12 )(R 13 ), a group of Z 1-4 , a group of OZ 1-4 , a group S(O) n Z 1-4 , a group of CH 2 OH, a group of (CH 2 ) m N(R 12 )(R 13 ), carboxyl group, cyano group, a group of CO-Z 1-4 (R 10 )—N(R 12 )(R 13 ) and a group of wherein R 10 is a substituent on ⁇ -carbon atom of an amino acid, or a group comprising an alkyl group or a fluoroalkyl group having 1-4 carbon atoms and a quaternary salt such as substituted at the
- R 6 and R 7 form a piperidine ring or the like and said ring has a substituent such as fluorine atom, hydroxyl group, a group of OCON(R 12 )(R 13 ) and a group of CON(R 12 )(R 13 ) on the ring.
- the ring formed by R 6 and R 7 bound to each other is preferably a piperazine ring, and preferred examples include a piperazine ring of which 4-position (nitrogen atom not bound to the pyridopyrimidine ring) is substituted with an alkyl group or a fluoroalkyl group having 1-4 carbon atoms, or with other substituent such as CO-Z 1-4 (R 10 )—N(R 12 )(R 13 ) and
- W 2 is preferably a single bond or a group represented by —C(R 8 ) ⁇ C(R 9 )—.
- R 8 and R 9 each independently represent hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, cyano group, carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group or a group of N(R 12 )(R 13 ), more preferably hydrogen atom, a halogen atom or a lower alkyl group.
- Q represents an acidic group, preferably an acidic group which is carboxyl group, 1,2,3,4-tetrazol-5-yl group or an equivalent thereof.
- type of the acidic group is not particularly limited, and said group may be any one of cyclic or non-cyclic, or a combination thereof.
- Examples include a lower alkoxy group, hydroxyl group, carboxyl group, N-cyanocarboxamido group, a methanesulfonylamido group having 1-3 fluorine atoms, —CONH-(5-tetrazolyl) group, 5-tetrazolyl group which may be substituted, 1,2,3-triazolyl group which may be substituted, 2,4-dioxothiazolidin-5-ylidenyl group which may be substituted, 4-oxo-2-thioxothiazolidin-5-ylidenyl group which may be substituted, 5-oxo-4-tetrazolyl group which may be substituted, 3-(5-oxo)-[1.2.4]oxadiazolidinyl group which may be substituted, 2-(3,5-dioxo)-[1.2.4]oxadiazolidinyl group which may be substituted, 5-(3-oxo)-[1.2.4]oxadiazolidinyl
- More preferred examples include carboxyl group, 5-tetrazolyl group which may be substituted, N-cyanocarboxamido group, a methanesulfonylamido group that has 1-3 fluorine atoms, —CONH-(5-tetrazolyl) group or the like.
- R 1 , R 2 , R 3 , R 4 , W 1 , W 2 and Q of the compounds represented by the general formula (II) those explained as for R 1 , R 2 , R 3 , R 4 , W 1 , W 2 and Q in the aforementioned general formula (I) can be preferably used, respectively.
- R 14 is preferably an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms.
- the compounds represented by the aforementioned general formula (I) can be produced by the following methods.
- Compound 3 can be obtained by heating Aminopyridine derivative 1 and malonic acid or an ester of malonic acid in a solvent such as toluene and xylene.
- ester of malonic acid Ester 2 as a phenol ester substituted with an electron-withdrawing group such as a halogen atom can be used.
- An alkyl ester can also be used.
- Aldehyde 4 By formylating Compound 3 with Vilsmeier's reagent prepared from phosphorus oxychloride or oxalyl chloride and dimethylformamide (DMF), Aldehyde 4 can be obtained.
- By subjecting Compound 4 to the Wittig reaction or Horner-Emons reaction Acrylic acid derivative 5 can be synthesized.
- Compound 5 can be obtained by reacting an alkyloxycarbomethylene-triphenylphosphorane which may be substituted with the aldehyde compound in an inert solvent such as tetrahydrofuran, DMF or methylene chloride.
- an inert solvent such as tetrahydrofuran, DMF or methylene chloride.
- the target compound can be synthesized by reacting the aldehyde compound with a dialkylphosphonoacetic acid ester which may be substituted at the 2-position in the presence of a base in an inert solvent such as THF and DMF.
- Compound 7 having amino group at the 2-position as a linker can be obtained by converting the hydroxyl group at the 2-position of Compound 5 into tosyl group, mesyl group, diphenylphosphoric acid ester or the like, and then replacing the resulting group with an amine.
- the ester group of the acrylic acid moiety can be hydrolyzed in the final step to obtain Compound I-A.
- ester group a lower alkyl ester such as those of methyl group and ethyl group, tert-butyl ester, benzyl ester, allyl ester and so forth can be used, and they can be hydrolyzed by hydrolysis under an alkaline or acidic condition, catalytic reduction or a method by using a metal catalyst such as palladium.
- Compound I-A can also be synthesized by the method shown in Scheme 2.
- Compound 9 can be obtained by converting the hydroxyl group at the 2-position of Compound 3 into tosyl group, mesyl group, diphenylphosphoric acid ester or the like and then replacing the resulting group with an amine.
- the resulting product can be formylated with Vilsmeier's reagent prepared from phosphorus oxychloride or oxalyl chloride and dimethylformamide to obtain Aldehyde 10.
- Vilsmeier's reagent prepared from phosphorus oxychloride or oxalyl chloride and dimethylformamide to obtain Aldehyde 10.
- Acrylic acid derivative 7 can be synthesized.
- Compound 7 can be obtained by reacting an alkyloxycarbomethylenetriphenylphosphorane which may be substituted with the aldehyde compound in an inert solvent such as THF, DMF, toluene or methylene chloride.
- an inert solvent such as THF, DMF, toluene or methylene chloride.
- the target compound can be synthesized by reacting the aldehyde compound with a dialkylphosphonoacetic acid ester which may be substituted at the 2-position in the presence of a base in an inert solvent such as THF and DMF.
- a compound in which a substituent is introduced at the 2-position of the pyridopyrimidine ring as a linker can be synthesized by the method shown in Scheme 3.
- Compound 11 can be synthesized by reacting Compound 5 with an alkylating agent in the presence of a base.
- the ester portion of the resulting Compound 11 can be hydrolyzed to obtain Compound I-B in a manner similar to that for the aforementioned compound having a nitrogen atom as a linker.
- Compound I-B can also be synthesized by the method shown in Scheme 4, i.e., by alkylation of Compound 3 with an alkylating agent and subsequent formylation, olefination and deprotection of the ester portion.
- Compound 1-A of which W portion is an amide bond can be synthesized by condensing an aminothiazole derivative, which is a known compound or can be synthesized by a known method, and a 2-aminopyridine-4-carboxylic acid derivative of which amino group is protected by a usual method used for a reaction of forming a peptide bond, and deprotecting the protective group of the amino group.
- Compound 1-B of which W portion is a double bond can be synthesized by condensing 2-Methylthiazole derivative 17, which is a known compound or can be synthesized by a known method, and 2-Aminopyridine-4-carbaldehyde derivative 18 of which amino group is protected under a condition for the Knoevenagel reaction, and removing the protective group of the amino group.
- the condition of the Knoevenagel reaction the reaction can also be performed by heating in acetic anhydride or in the presence of a base such as piperidine and piperazine and in the co-presence of an acid such as acetic acid.
- Compound 1-D of which W portion is an ether bond can be synthesized by condensing Thiazolemethyl halide 24, which is a known compound or can be synthesized by a known method, and 4-Hydroxypyridine-2-carboxylic acid ester 25 in the presence of a base, hydrolyzing the ester portion of the resulting Compound 26, and then converting the produced carboxylic acid into Amine derivative 28 by employing the Curtius rearrangement or the like.
- Amino compound 1-D can also be obtained by first converting the carboxylic acid into a condensation product with hydrazine, then converting the resulting product into an acid azide with a nitrous acid salt or a derivative thereof, further subjecting the resulting product to a rearrangement reaction and, if required, removing the protective group of the amino group.
- Compound 1-E where W portion is ethylene, can be synthesized by reacting an anion, obtained by treating 2-Amino-4-methylpyridine derivative 20 of which amino group is protected with a strong base such as n-BuLi, with Thiazolemethyl halide 24 to obtain a condensation product and then removing the protective group of the amino group.
- a strong base such as n-BuLi
- Compound 1-E can also be synthesized by reacting an anion, obtained by treating 2-Amino-4-methylpyridine derivative 20 of which amino group is protected with a strong base such as n-BuLi, with Halogenoacetic acid derivative 30 to obtain a condensation product, converting the ester portion into an amide, then converting the resulting product into a thioamide compound by using Lawesson's reagent, diphosphorous pentasulfide or the like and condensing the product with a haloketone compound.
- a strong base such as n-BuLi
- a compound of which W portion is a triple bond can be synthesized by the synthetic methods described in WO9633181 published Oct. 24, 1996.
- Amide derivative 35 can be obtained by converting N-Alkyl-quinolone-carboxylic acid derivative 34 described in PCT/JP00/07565 into a mixed acid anhydride, and then reacting the resulting product with ammonia or an ethylamine having an electron-withdrawing group (EWG) such as cyanoethylamine and 3-aminopropanoic acid ester.
- EWG electron-withdrawing group
- the alkylamide derivative can be converted into Compound 36 by treatment with sodium azide and trifluoromethanesulfonic acid anhydride in an acetonitrile solvent to form a tetrazole ring.
- the product can be converted into Tetrazole compound II-A by treatment with DUB in an inert solvent such as methylene chloride or treatment with a base such as sodium methoxide in an alcohol.
- Tetrazole compound II-A can similarly be obtained by subjecting Carbamoyl derivative 35 to dehydration reaction to obtain Cyano derivative 37 and treating the resulting compound with sodium azide and aluminum chloride in dimethylformamide.
- Tetrazole compound II-A can be produced by subjecting Carboxylic acid 34 having a cinnolin-4-one or naphthylidin-4-one structure to the same treatment.
- Compound 38 which is a known compound or can be easily derived from a known compound, can be converted into a diazo compound by treating the amino group with sodium nitrite, and the resulting product can be reacted with a malonic acid ester to obtain Compound 39 (R 5 ⁇ H).
- An electrophilic regent such as an alkyl halide can be reacted with the nitrogen atom of the resulting Compound 39 (R 5 ⁇ H) by using a base such as sodium hydride and potassium carbonate in a solvent such as DMF and THF, and then the product can be heated in a solvent such as Dowtherm A and PPA and treated under an ordinary hydrolysis condition to obtain Carboxylic acid 41.
- the Carboxylic acid 41 obtained can be subjected to a treatment similar to the aforementioned treatment (Scheme 11) to produce Tetrazole compound II-B.
- Compound 42 when W portion is —CH 2 O—, Compound 42 can be converted into an alkoxide by treatment with a strong base such as sodium hydride in DMF or THF, and the alkoxide can be reacted with Compound 43, which is a known compound or can be synthesized by a known method (Japanese Patent Un-examined Publication (Kokai) No. 57-144264 or 60-197686), to obtain Compound 44. Subsequently, Compound 44 can be converted into a carboxylic acid by hydrolysis and subjected to a treatment similar to the aforementioned treatment (Scheme 11) to produce Tetrazole compound II-C.
- a strong base such as sodium hydride in DMF or THF
- Compound 45 which is a known compound or can be synthesized by a known method, can be esterified and then subjected to treatment with an oxidizing agent such as selenium dioxide, and the resulting Aldehyde derivative 46 and Compound 47 can be subjected to the Wittig reaction and further subjecting the adduct to addition of ammonia to obtain Carbamoyl compound 49.
- the resulting Carbamoyl derivative 49 can be converted into Tetrazole compound II-D by using the same method as in Scheme 11.
- the synthetic intermediates and the target compounds in the aforementioned preparations can be isolated and purified by using methods for isolation and purification ordinarily used in the field of organic synthetic chemistry, for example, neutralization, filtration, extraction, drying, concentration, recrystallization, various chromatographic techniques and the like.
- the synthetic intermediates may be used in subsequent reactions without purification.
- a salt of compound of the general formula (I) or (II) is desired, a product obtained in the form of a salt may be purified without any treatment.
- a salt can be formed by dissolving or suspending the product in a suitable organic solvent, and then adding an acid or base. It is also possible to convert a compound represented by the general formula (I) or (II) obtained in the form of a salt into a compound in a free form, and then convert the result into an appropriate salt.
- the compounds represented by the general formula (I) have an activity for inhibiting drug efflux pumps of microorganisms. More specifically, the compounds represented by the general formula (I) can act on a microorganism with acquired resistance to an antimicrobial agent to inhibit its drug efflux pump, and eliminate the resistance of the microorganism. In addition, the compounds represented by the general formula (I) can act on a microorganism to inhibit a drug efflux pump, thereby suppress the acquisition of resistance to an antimicrobial agent by a microorganism.
- the medicament of the present invention that comprises a compound represented by the general formula (I) as an active ingredient is useful for preventive and/or therapeutic treatment of microbial infections, generally by a combinational administration with an antimicrobial agent.
- the medicament of the present invention is extremely useful as a medicament for preventive and/or therapeutic treatment of, in particular, infectious diseases caused by a microorganism with acquired resistance to one or more antimicrobial agents.
- Methods for using the medicament of the present invention are not particularly limited. Examples include a method of administering one or more antimicrobial agents, and also administering the medicament of the present invention simultaneously, separately, or successively to enhance the activity of the antimicrobial agent(s); and a method of preparing a pharmaceutical composition comprising one or more antimicrobial agents and the medicament of the present invention (so-called a compound drug) and the administering the composition.
- the medicament of the present invention can be used for various infections by microorganisms including Gram-positive or Gram-negative bacteria, aerobic or anaerobic bacteria and the like.
- the medicament of the present invention can most suitably be used for infections by Pseudomonas aeruginosa with acquired resistance to one or more antimicrobial agents, or infections by Pseudomonas aeruginosa with low sensitivity to antimicrobial agents.
- the medicament of the present invention can be used for microbial infections of mammals including human.
- antimicrobial agents Drugs having variety of structures have been known as antimicrobial agents, and various drugs are clinically used.
- kinds of antimicrobial agents that can be administered in combination with the medicament of the present invention are not particularly limited, and examples include, for example, penicillin (penam) antibiotics, cephalosporin (cephem) antibiotics, oxacephem antibiotics, penem antibiotics, carbapenem antibiotics, monobactam antibiotics, aminoglycoside antibiotics, macrolide antibiotics, chloramphenicol antibiotics, tetracycline antibiotics, glycopeptide antibiotics, phosphomycin antibiotics, lincomycin antibiotics, sulfonamide preparations, p-aminosalicylic acid preparations, isonicotinic acid hydrazide preparations, quinolone synthetic antimicrobial agents and the like.
- antimicrobial agents are not limited to these examples. When a pharmaceutical composition comprising one or more antimicrobial agents together with the medicament of the present invention is manufactured, the antimicrobial agents
- a substance selected from the group consisting of the compounds represented by the formula (I) and pharmaceutically acceptable salts thereof, and hydrates thereof and solvates thereof can be used as the active ingredient of the medicament of the present invention.
- Two or more of the substances may be used in combination.
- the aforementioned substance, per se, may be administered as the medicament of the present invention.
- the substance is administered in the form of a pharmaceutical composition comprising one or more of the aforementioned substances as the active ingredient together with one or more pharmaceutical additives.
- the pharmaceutical composition may optionally be added with one or more of other pharmaceutically active ingredients such as the aforementioned antimicrobial agents and ⁇ -lactamase inhibitors.
- a pharmaceutical composition for the use of administration in vivo can be readily prepared by mixing one or more of the aforementioned substances as the active ingredient and one or more pharmaceutically acceptable additives for pharmaceutical preparations according to methods for formulation ordinarily used in the field of manufacturing pharmacy.
- the route of administration of the medicament of the present invention is not particularly limited; however, it is desirable to appropriately chose the most effective administration route for preventive and/or therapeutic treatment of a target infectious disease.
- Examples of pharmaceutical compositions suitable for oral administration include, for example, capsules, powders, tablets, granules, subtilized granules, emulsions, syrups, solutions, suspensions and the like.
- compositions suitable for parenteral administration include, for example, inhalants, sprays, intrarectal preparations, injections, drip infusions, ointments, creams, transdermal preparations, transmucosal preparations, eye drops, nasal drops, ear drops, tape preparations, patches and the like.
- inhalants sprays, intrarectal preparations, injections, drip infusions, ointments, creams, transdermal preparations, transmucosal preparations, eye drops, nasal drops, ear drops, tape preparations, patches and the like.
- sprays for example, inhalants, sprays, intrarectal preparations, injections, drip infusions, ointments, creams, transdermal preparations, transmucosal preparations, eye drops, nasal drops, ear drops, tape preparations, patches and the like.
- the forms of the medicament of the present invention are not limited to these examples.
- liquid preparations such as emulsions and syrups can be prepared by using pharmaceutical additives including water; saccharides such as sucrose, sorbitol, fructose; glycols such as polyethylene glycol and propylene glycol; oils such as sesame oil, olive oil and soybean oil; antiseptics such as p-hydroxybenzoic acid esters; flavors such as strawberry flavor and peppermint and the like.
- pharmaceutical additives including water; saccharides such as sucrose, sorbitol, fructose; glycols such as polyethylene glycol and propylene glycol; oils such as sesame oil, olive oil and soybean oil; antiseptics such as p-hydroxybenzoic acid esters; flavors such as strawberry flavor and peppermint and the like.
- Solid preparations such as capsules, tablets, powders and granules can be prepared by using excipients such as lactose, glucose, sucrose and mannitol; disintegrating agents such as starch and sodium alginate; lubricants such as magnesium stearate and talc; binders such as polyvinyl alcohol, hydroxypropylcellulose and gelatin; surfactants such as fatty acid esters; plasticizers such as glycerin and the like.
- excipients such as lactose, glucose, sucrose and mannitol
- disintegrating agents such as starch and sodium alginate
- lubricants such as magnesium stearate and talc
- binders such as polyvinyl alcohol, hydroxypropylcellulose and gelatin
- surfactants such as fatty acid esters
- plasticizers such as glycerin and the like.
- liquid preparations such as injections, drip infusions and eye drops can preferably be prepared as sterilized isotonic liquid preparations.
- injections can be prepared by using an aqueous medium such as a solution of sodium chloride, a solution of glucose, or a mixture of saline and glucose solution.
- the intrarectal preparations can be prepared generally in the form of suppositories by using carriers such as cacao butter, hydrogenated fat and hydrogenated carboxylic acid.
- a non-irritable carrier can be used that enables fine dispersion and enhances absorption of the aforementioned substances as the active ingredient. Examples of such a carrier include lactose, glycerin and the like. Aerosols, dry powders or the like can also be chosen as the form of preparation.
- pharmaceutical additives used for the manufacture of the medicament of the present invention are not limited to those mentioned above, and any additives available for those skilled in the art can be used.
- a dose and frequency of administration of the medicament of the present invention are not particularly limited, and a suitable dose can be chosen depending on the type and severity of a microbial infection, the presence or absence of an underlying disease, the age and body weight of a patient and the like.
- tert-Butyl N-(4-methyl-2-pyridyl)carbamate (5 g, 24.0 mmol) was dissolved in tetrahydrofuran (120 ml), cooled to ⁇ 78° C., and then added dropwise with n-butyl lithium (40 ml, 60 mmol). Then, the reaction solution was warmed and stirred at room temperature. The reaction mixture was stirred for 1 hour, then again cooled to ⁇ 78° C., and added dropwise with methyl bromoacetate (3.4 ml) dissolved in tetrahydrofuran (10 ml).
- the resulting oily compound was added with dichloromethane (50 ml) and slowly added dropwise with trifluoroacetic acid (50 ml) under ice cooling. Then, the reaction solution was warmed to room temperature and stirred 1 hour. The resulting solution was neutralized with saturated sodium hydrogencarbonate and extracted with chloroform. The organic layer was washed with saturated brine, and the resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
- reaction solution was diluted with chloroform, washed with water, dried over magnesium sulfate and then concentrated under reduced pressure.
- reaction solution was further added with phosphorus oxychloride (34 ⁇ l) at room temperature and stirred at room temperature for 20 minutes.
- the solvent was evaporated under reduced pressure, and the resulting residue was neutralized by adding saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate and chloroform.
- the organic layer collected was washed with saturated brine, dried over magnesium sulfate and concentrated under reduced pressure.
- E Ethyl (E)-3- ⁇ 8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl ⁇ -2-methyl-2-propenoate (120 mg, 0.236 mmol) dissolved in methanol (5 ml) was added dropwise with 1 N aqueous sodium hydroxide (2 ml) under ice cooling. The reaction solution was stirred for 10 minutes and then warmed to room temperature because the reaction did not progress.
- reaction solution was stirred for 45 minutes, then further added with 1 N aqueous sodium hydroxide (2 ml), and after 1 hour, further added with 1 N aqueous sodium hydroxide (2 ml).
- the solvent was evaporated under reduced pressure, and the resulting sodium salt of the title compound was dissolved in 1,4-dioxane, added with 4 N hydrochloric acid (6 ml) and stirred.
- the reaction solution was concentrated under reduced pressure, and the residue was neutralized with saturated aqueous sodium hydrogencarbonate and extracted with chloroform and methanol.
- the organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
- tert-Butyl N-[4-(3-amino-3-thioxopropyl)-2-pyridyl]carbamate (590 mg, 2.10 mmol) dissolved in ethanol (20 ml) was added with 1-bromo-2-butanone (0.23 ml, 2.10 mmol) and refluxed by heating at 100° C. The reaction solution was stirred for 1 hour and then returned to room temperature. The solvent was evaporated under reduced pressure, and the residue was diluted with chloroform. The mixture was washed with saturated aqueous sodium hydrogencarbonate and dried over sodium sulfate, and concentrated under reduced pressure.
- tert-Butyl N-(4-methyl-2-pyridyl)carbamate 800 mg, 3.84 mmol dissolved in tetrahydrofuran (15 ml) was cooled to ⁇ 78° C. and then added dropwise with a solution of n-butyl lithium in hexane (1.5 M, 6.4 ml, 9.6 mmol). The reaction solution was stirred at room temperature for 1 hour, then cooled to ⁇ 78° C. again and added dropwise with a solution of the above obtained 3-bromo-2-(bromomethyl)-4-ethylthiophene in tetrahydrofuran (14 ml). After the reaction solution was stirred at ⁇ 78° C.
- N1-(4-Methyl-2-pyridyl)acetamide (25 g, 0.168 mol) suspended in water (250 ml) was added with potassium permanganate (76.1 g, 0.50 mol) at 100° C. over 1 hour and then stirred for 40 minutes.
- the reaction solution was returned to room temperature, and black crystals were removed by filtration.
- the resulting filtrate was added with 12 N hydrochloric acid until pH of the solution became 3 to 4. After the reaction solution was stirred for about 15 minutes, the deposited white crystals were collected by filtration, washed with water, and dried by using a vacuum pump to obtain 7.65 g (25%) of the title compound without purification.
- N4-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-(acetylamino)isonicotinamide (546 mg) dissolved in ethanol (12 ml) was added dropwise with concentrated hydrochloric acid (1.2 ml) at room temperature and stirred at 80-90° C. for 1 hour. The reaction solution was returned to room temperature, concentrated under reduced pressure, neutralized with 1 N sodium hydroxide and extracted with chloroform.
- N4-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-aminoisonicotinamide 200 mg, 0.724 mmol was added with xylene (20 ml) and trichlorophenyl malonate (370 mg, 0.796 mmol) and refluxed by heating at 130° C. The reaction solution was stirred for 1 hour, then returned to room temperature and concentrated under reduced pressure. The resulting orange crystals was taken by filtration, washed with chloroform, dried under reduced pressure to obtain 209 mg (84%) of the title compound as orange crystals without purification.
- reaction solution was neutralized with saturated aqueous sodium hydrogencarbonate and concentrated under reduced pressure.
- the resulting residue was added with chloroform for extraction, and the organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
- reaction solution was further stirred at room temperature for 30 minutes and concentrated under reduced pressure.
- reaction solution was added with 1 N hydrochloric acid until pH of the solution became 4 and extracted with chloroform.
- the organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
- the title compound was obtained as the residue without purification as a brown oily substance (5.4 g, 100%).
- N8-(4-Cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]-pyrimidine-8-carboxamide (100 mg, 0.29 mmol) was added with acetonitrile (2 ml) and dimethylformamide (1 ml), cooled to ⁇ 10° C. with ice, then added with diphenyl chlorophosphate (0.2 ml, 0.96 mmol), and further added dropwise with diisopropylethylamine (0.3 ml, 1.74 mmol). The reaction solution was stirred at ⁇ 10° C.
- Ethyl 2-aminoisonicotinate (6.5 g, 39.23 mmol) was added with acetic acid (500 ml) and ethyl 3-(dimethylamino)-2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-2-propenoate (13 g, 39.23 mmol) and refluxed by heating at 130° C. for 5 hours. The reaction solution was returned to room temperature and poured into water, and this was extracted with chloroform. The resulting organic layer was washed with saturated brine, and the collected organic layer was dried over magnesium sulfate.
- the reaction solution was added dropwise with 1 N hydrochloric acid (3 ml) at room temperature, and the deposited yellow crystals were taken by filtration and washed with water.
- the crystals were dissolved in chloroform and ethanol, concentrated under reduced pressure, and dried to obtain the title compound as yellow crystals without purification.
- the product was dissolved in anisole (0.2 ml) and trifluoroacetic acid (5 ml), stirred at room temperature for 5 hours, and added with water.
- the deposited yellow crystals were collected by filtration and washed with water, and the resulting crystals were dissolved in chloroform and ethanol and concentrated under reduced pressure.
- the crude crystals was added with ethanol, taken by filtration and washed with diethyl ether to obtain 28 mg (67% for the two steps) of the title compound as yellow crystals.
- reaction solution was stirred further 2 hours, then returned to room temperature, added with 4-isopropyl-1,3-thiazol-2-amine hydrobromide (1.32 mmol) and stirred at room temperature for 2 hours and 30 minutes.
- the reaction solution was added with 2 N hydrochloric acid (7 ml), and the deposited crystals were collected by filtration and washed with water. The resulting yellow crystals were dissolved in chloroform and washed with saturated brine, and the collected organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain the title compound as yellow crystals without purification.
- N8-(4-Isopropyl-1,3-thiazol-2-yl)-3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (330 mg, 0.66 mmol) was added with trifluoroacetic acid (10 ml) at room temperature and stirred for 3 days.
- the reaction solution was poured into ice water, and the deposited yellow crystals were collected by filtration, washed with water, then dissolved in chloroform and ethanol, and concentrated under reduced pressure.
- the resulting yellow crystals were suspended in a small amount of ethanol, and the crystals were taken by filtration and washed with diethyl ether to obtain 54 mg (21% for the two steps) of the title compound as yellow crystals.
- reaction solution was concentrated under reduced pressure, and the resulting residue was added with methanol (2 ml), water (0.2 ml) and sodium formate (12 mg) at room temperature and stirred at room temperature for 7 hours.
- the reaction solution was further added with trichloroacetyl isocyanate (9.7 ⁇ l, 0.082 mmol), stirred at the same temperature for further 1 hour, and added with chloroform/methanol (10:1, v/v, 6 ml), and the solvent was evaporated.
- the residue was dissolved in methanol (1.5 ml), added with water (0.2 ml) and sodium formate (9.6 mg, 0.14 mmol) stirred at room temperature for 2 hours and 30 minutes.
- the mixture was further added with sodium formate (9.6 mg, 0.14 mmol), and stirred at room temperature for further 20 hours.
- reaction solution was stirred at room temperature for 23 hours, then further added with a solution of 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]ethanoyl chloride (0.27 g, 1.05 mmol) in methylene chloride (2 ml) and pyridine (170.2 ⁇ l, 2.10 mmol) under ice cooling. Further, the reaction solution was added with the same amounts of the acid chloride and pyridine twice every 24 hours, and stirred at room temperature. The solvent was evaporated, and the residue was added with saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate.
- N 8 -[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]-pyrimidine-8-carboxamide (301.9 mg, 0.88 mmol) was suspended in dimethylformamide (6 ml) and acetonitrile (12 ml), added dropwise with diisopropylethylamine (1.83 ml, 10.5 mmol) and diphenyl chlorophosphate (545.1 ⁇ l, 2.63 mmol) at ⁇ 10° C. under an argon flow, and stirred at the same temperature for 5 minutes and at room temperature for 15 minutes.
- reaction solution was cooled to ⁇ 10° C. again, added dropwise with a solution of 3-[(dimethylamino)carbonyl]piperidine trifluoroacetic acid salt (1.18 g, 4.38 mmol) in dimethylformamide (5 ml), and stirred at room temperature for 1 hour and at about 80° C. for 2 hours.
- the reaction solution was heated to about 100° C., heated for 30 minutes with stirring, then added with diisopropylethylamine (1.83 ml, 10.5 mmol), and further heated at 100° C. for 3 hours and 30 minutes with stirring. After cooling, the solution was added with saturated aqueous sodium hydrogencarbonate and extracted with chloroform.
- reaction solution was added with saturated aqueous sodium hydrogencarbonate and extracted with chloroform.
- organic layer was washed with saturated brine and dried over anhydrous sodium sulfate, and the solvent was evaporated to obtain the title compound (84.2 mg, quantitative) as yellow oil.
- reaction solution was further added with 1 N aqueous sodium hydroxide (5.62 ml, 5.62 mmol), stirred at room temperature for 2 hours, further added with 1 N aqueous sodium hydroxide (2.81 ml, 2.81 mmol), and stirred at room temperature for 3 hours.
- reaction solution was diluted with methylene chloride, washed with water, 5% aqueous citric acid, saturated aqueous sodium hydrogencarbonate and then with saturated brine, and the solution was dried over magnesium sulfate. Then, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (260 mg).
- reaction solution was added with ethyl acetate and hexane, washed with 0.2 M hydrochloric acid, and dried over sodium over sodium sulfate, and the solvent was evaporated under reduced pressure.
- the residue was purified by silica gel column chromatography to obtain the title compound (14 mg) as yellow powder.
- reaction solution was added with ethyl acetate and hexane, washed with 0.2 M hydrochloric acid, and dried over sodium sulfate, and the solvent was evaporated under reduced pressure.
- the residue was purified by silica gel column chromatography to obtain the title compound (32 mg) as yellow powder.
- the resulting compound was dissolved in anhydrous tetrahydrofuran (600 ⁇ l) and dimethylformamide (600 ⁇ l), added with 4-dimethylaminopyridine (10.2 mg, 0.0831 mmol) and p-toluenesulfonyl chloride (13.4 mg, 0.0703 mmol), and stirred at room temperature for 2 hours.
- the reaction mixture was added with water and extracted with chloroform.
- tert-Butyl N-(4-methyl-2-pyridyl)carbamate (6.24 g, 30.0 mmol) was dissolved in anhydrous tetrahydrofuran (100 ml), added with n-butyl lithium (1.59 M in n-hexane, 47.1 ml, 74.9 mmol) at ⁇ 78° C. under argon atmosphere, and then stirred at room temperature for 1.5 hours. The reaction solution was cooled to ⁇ 78° C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I):
wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH═CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)═C(R9)−(R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.
wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH═CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)═C(R9)−(R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.
Description
- This application is a continuation of application Ser. No. 09/842,234, filed Apr. 26, 2001, the disclosure of which is incorporated by reference herein in its entirety.
- The present invention relates to a medicament useful for preventive and therapeutic treatment of microbial infectious diseases.
- For preventive or therapeutic treatment of infectious diseases caused by microorganisms, various antibacterial agents have so far been developed, and drugs such as β-lactam antibiotics (penicillins, cephems, monobactams, carbapenems, and penems), aminoglycosides, quinolones, macrolides, tetracyclines, rifamycins, chloramphenicols, and phosphomycins have been practically used. However, with the increase of clinically used amount of antibacterial agents, remarkable numbers of resistant bacterial strains to these antibacterial agents have emerged, which becomes a serious problem in the treatment of infectious diseases.
- Examples of problematic bacteria, which cause particularly intractable or serious infectious diseases among those caused by resistant bacteria, include Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agents effective against these bacteria have been limited so far, and it is not certain whether or not therapeutic efficacy of the currently available drugs will be expected in the future. In particular, no drug is available at present by which specifically high efficacy against resistant Pseudomonas aeruginosa can be achieved. With the increase of aged population and the popularization of sophisticated medical technologies including human organ transplantation and anti-cancer treatments, infections frequently occurring particularly in patients with reduced immunity, i.e., so-called opportunistic infections, have become an extremely serious problem in the clinical field, and under the circumstances, early developments of measures against the resistant bacteria are desired.
- Recently, the presence of drug efflux pumps has recognized as a bacterial excretion mechanism of drugs through researches on resistance acquiring mechanisms of resistant bacteria. In earlier researches, a pump that specifically excretes a tetracycline antibacterial agent from bacterial cells was identified in 1980 by the group of Levy, and the discovery was noted as a major factor of the resistance to tetracycline (L. McMurry, Proc. Natl. Acad. Sci. U.S.A., 77, 3974, 1980). Furthermore, based on recent researches, the presence of multidrug-excreting drug efflux pumps was reported in Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, Staphylococcus bacteria, Diplococcus pneumoniae, and Neisseria gonorrhoeae. Four multidrug efflux pumps have so far been reported as homological drug efflux pumps deriving from Pseudomonas aeruginosa, and they have been considered as a cause of low drug sensitivity inherent to Pseudomonas aeruginosa (K. Poole et al., J. Bacteriol., 175, 7363, 1993; K. Poole et al., M. Microbiol., 21, 713, 1996; T. Kohler et al., M. Microbiol., 23, 345, 1997; T. Mine et al., Antimicrob. Agents Chemother., 43, 415, 1999).
- The drug efflux pumps of Pseudomonas aeruginosa excrete various drugs including β-lactams, tetracyclines, chloramphenicols, and quinolones, to which the drug resistance of Pseudomonas aeruginosa is attributable.
- In order to overcome the problem, it will be effective to invent an antibacterial agent that has a novel structure, by which resistance acquisition due to a drug efflux pump, one of factors of resistance acquisition, can be avoided, or develop an agent for a combinational use with currently available antibacterial agents that can restore their efficacy by inhibiting functions of drug efflux pumps.
- Therefore, an object of the present invention is to provide a novel medicament for the treatment of infectious diseases that improves therapeutic efficacy of an agent against pathogenic microorganisms, in particular, a medicament that acts on a microorganism with acquired resistance to an antimicrobial agent, and eliminates the resistance of the bacteria by inhibiting a drug efflux pump so as to improve preventive and/or therapeutic effect of the antimicrobial agent.
- In order to achieve the aforementioned object, the inventors of the present invention conducted various researches to search for compounds that eliminate resistance to an antimicrobial drug of Pseudomonas aeruginosa that has acquired the resistance. As a result, they found that the compounds represented by the following general formula (I) or (II) had the desired activity, and thus achieved the present invention.
- The present invention thus provides a medicament for preventive and/or therapeutic treatment of microbial infections, which comprises as an active ingredient a compound represented by the following general formula (I) or a physiologically acceptable salt thereof, or a hydrate thereof:
wherein, R1 and R2 each independently represent hydrogen atom, a halogen atom, hydroxyl group, a group of OZ1-6 (the group of OZ1-6 represents an alkyl group having 1-6 carbon atoms or a fluoroalkyl group having 1-6 carbon atoms, which bonds via the oxygen atom), a group of S(O)nZ1-4 (Z1-4 represents an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms or an alkylene group derived therefrom), a group of N(R12)(R13) (R12 and R13 each independently represent hydrogen atom, an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms), a group of Z1-8 which may be substituted (Z1-8 represents an alkyl group having 1-8 carbon atoms or a fluoroalkyl group having 1-8 carbon atoms), a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group, or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4)); W1 represents a group selected from the group consisting of —CH═CH—, —N(R12)CO—, —CON(R12)—, —CH2O— and —CH2CH2— (each of the aforementioned groups binds to the thiazole ring at the left end);
R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group;
R4 represents a group selected from the group consisting of hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group having 1-4 carbon atoms, a fluorine-substituted alkylene group having 1-4 carbon atoms or a single bond, and R5 represents a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4)), a group of —S(O)nZ0-4R5, a group of —N(R6)(R7) (R6 and R7 each independently represent hydrogen atom or Z1-4, or they may bind to each other to form a saturated or unsaturated 5- to 7-membered ring (the ring may contain one or two hetero atoms as ring constituting atoms), and R6 and R7 may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OCON(R12)(R13), a group of CON(R12)(R13), a group of N(R12)CON(R12)(R13), a group of Z1-4, a group of OZ1-4, a group S(O)nZ1-4, group of CH2OH, a group of (CH2)mN(R12)(R13), carboxyl group, cyano group, a group of CO-Z1-4(R10)—N(R12)(R13) (R10 is a substituent corresponding to a side chain on an amino acid carbon or a group of -Z1-4-R11 (R11 represents a substituent which forms a quaternary salt) and a group of
a 5- or 6-membered aryl group which may be substituted and a 5- or 6-membered unsaturated heterocyclic group which may be substituted; W2 represents a single bond or —C(R8)═C(R9)— (R8 and R9 each independently represent hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, cyano group, carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group or a group of N(R12)(R13)), Q represents an acidic group, and W2 and Q may bind together to form vinylidenethiazolidinedione in E- or Z-configuration or an equivalent heterocyclic ring; m and n each independently represent an integer of 0 to 2, and q represents an integer of 0 to 3. - As other aspects of the present invention, provided are a medicament for eliminating resistance of a microorganism with acquired drug resistance, which comprises a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof as an active ingredient; and a medicament for enhancing effect of an antimicrobial agent, which comprises a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof as an active ingredient. The aforementioned medicaments wherein the microorganism is Pseudomonas aeruginosa are preferred embodiments of the present invention. The present invention also provides a pharmaceutical composition for preventive and/or therapeutic treatment of microbial infections, which comprises a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof together with an antimicrobial agent.
- As further aspects of the present invention, provided are a method for preventive and/or therapeutic treatment of microbial infections, which comprises the step of administering to a mammal including human a preventively and/or therapeutically effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof; a method for eliminating resistance of a microorganism with acquired resistance to an antimicrobial agent, which comprises the step of contacting with the microorganism an effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof; a method for inhibiting acquisition of resistance to an antimicrobial agent by a microorganism, which comprises the step of contacting with a microorganism an effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof; a method for enhancing sensitivity of a microorganism to an antimicrobial agent, which comprises the step of contacting with a microorganism an effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof; and a method for improving effect of an antimicrobial agent, which comprises the step of administering to a mammal including human an effective amount of a compound represented by the aforementioned general formula (I) or a physiologically acceptable salt thereof. The compounds represented by the aforementioned general formula (I) or physiologically acceptable salts thereof are usually administered with one or more of antimicrobial agents simultaneously or separately, or successively. The present invention also provides a use of the compounds represented by the aforementioned general formula (I) or physiologically acceptable salts thereof for the manufacture of the aforementioned medicaments.
- In addition to the aforementioned inventions, the present invention also provides a medicament for preventive and/or therapeutic treatment of microbial infections, which comprises as an active ingredient a compound represented by the following general formula (I), a physiologically acceptable salt thereof, or hydrates thereof
- In the formula, R1, R2, R3, R4, W1, W2 and Q have the same meanings as those defined above; R14 represents hydrogen atom, Z1-4, Z1-4R5 or Z1-4OR5; and X and Y each independently represent C—H or nitrogen atom.
- In the specification, the “alkyl group” means a linear, branched or cyclic alkyl group or an alkyl group consisting of a combination thereof. The same is applied to an alkyl moiety of a substituent having the alkyl moiety (for example, fluoroalkyl group).
- In the general formula (I), R1 is preferably an alkyl group. Examples of the alkyl group include a linear or branched alkyl group having 1-8 carbon atoms (for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group and the like), and a cyclic alkyl group having 3-8 carbon atoms, preferably 3-6 carbon atoms (for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group and the like). The cyclic alkyl group may have another alkyl group or a halogen atom, hydroxyl group or the like on the ring. R1 is also preferably an aryl group, a heteroaryl group or a heterocyclic group. The aryl group may preferably has a 5- or 6-membered ring. As the heterocyclic group, a heterocyclic group having 3-8, preferably 3-6, of ring constituting atoms can be used, and the ring may be saturated or partially saturated. As a substituent that binds to the heterocyclic group, for example, an alkyl group or a halogen atom is preferred.
- R2 is preferably hydrogen atom or a halogen atom.
- W1 is preferably a linking group having a length of two atoms, and —CH═CH—, —N(R12)CO—, —CON(R12)—, —CH2O— and —CH2CH2— are more preferred.
- R3 is preferably hydrogen atom, a halogen atom, amino group or hydroxyl group.
- R4 is preferably hydrogen atom, —OZ0-4R5 or —N(R6)(R7).
- R5 is preferably a 5- or 6-membered aryl group, 5- to 7-membered alicyclic group, 4- to 7-membered saturated heterocyclic group, or 5- or 6-membered unsaturated heterocyclic group, which may be substituted, and more preferably a 4- to 7-membered saturated heterocyclic group or a 5- or 6-membered unsaturated heterocyclic group.
- R6 and R7 represent hydrogen atom, an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms, or they bind to each other to form a saturated or unsaturated 5- to 7-membered ring. The ring may contain one or two hetero atoms as atoms constituting the ring. R6 and R7 may have one to three substituents selected from the group shown as follows: a halogen atom, hydroxyl group, a group of OCON(R12)(R13), a group of CON(R12)(R13), a group of N(R12)CON(R12)(R13), a group of Z1-4, a group of OZ1-4, a group S(O)nZ1-4, a group of CH2OH, a group of (CH2)mN(R12)(R13), carboxyl group, cyano group, a group of CO-Z1-4(R10)—N(R12)(R13) and a group of
wherein R10 is a substituent on α-carbon atom of an amino acid, or a group comprising an alkyl group or a fluoroalkyl group having 1-4 carbon atoms and a quaternary salt such as
substituted at the terminal of said alkyl or fluoroalkyl group (in the definitions of the aforementioned substituents, R12 and R13 represent hydrogen atom, an alkyl group or a fluoroalkyl group having 1-4 carbon atoms, n independently represents an integer of 0 to 2, and q represents an integer of 0 to 3). - More preferably, R6 and R7 form a piperidine ring or the like and said ring has a substituent such as fluorine atom, hydroxyl group, a group of OCON(R12)(R13) and a group of CON(R12)(R13) on the ring. The ring formed by R6 and R7 bound to each other is preferably a piperazine ring, and preferred examples include a piperazine ring of which 4-position (nitrogen atom not bound to the pyridopyrimidine ring) is substituted with an alkyl group or a fluoroalkyl group having 1-4 carbon atoms, or with other substituent such as CO-Z1-4(R10)—N(R12)(R13) and
- W2 is preferably a single bond or a group represented by —C(R8)═C(R9)—. R8 and R9 each independently represent hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, cyano group, carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group or a group of N(R12)(R13), more preferably hydrogen atom, a halogen atom or a lower alkyl group.
- Q represents an acidic group, preferably an acidic group which is carboxyl group, 1,2,3,4-tetrazol-5-yl group or an equivalent thereof. However, type of the acidic group is not particularly limited, and said group may be any one of cyclic or non-cyclic, or a combination thereof. Examples include a lower alkoxy group, hydroxyl group, carboxyl group, N-cyanocarboxamido group, a methanesulfonylamido group having 1-3 fluorine atoms, —CONH-(5-tetrazolyl) group, 5-tetrazolyl group which may be substituted, 1,2,3-triazolyl group which may be substituted, 2,4-dioxothiazolidin-5-ylidenyl group which may be substituted, 4-oxo-2-thioxothiazolidin-5-ylidenyl group which may be substituted, 5-oxo-4-tetrazolyl group which may be substituted, 3-(5-oxo)-[1.2.4]oxadiazolidinyl group which may be substituted, 2-(3,5-dioxo)-[1.2.4]oxadiazolidinyl group which may be substituted, 5-(3-oxo)-[1.2.4]oxadiazolidinyl group which may be substituted, 3-(5-oxo)-[1.2.4]isoxazolidyl group which may be substituted or the like. More preferred examples include carboxyl group, 5-tetrazolyl group which may be substituted, N-cyanocarboxamido group, a methanesulfonylamido group that has 1-3 fluorine atoms, —CONH-(5-tetrazolyl) group or the like.
- For R1, R2, R3, R4, W1, W2 and Q of the compounds represented by the general formula (II), those explained as for R1, R2, R3, R4, W1, W2 and Q in the aforementioned general formula (I) can be preferably used, respectively.
- R14 is preferably an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms.
-
- As shown in Scheme 1, Compound 3 can be obtained by heating Aminopyridine derivative 1 and malonic acid or an ester of malonic acid in a solvent such as toluene and xylene. As the ester of malonic acid, Ester 2 as a phenol ester substituted with an electron-withdrawing group such as a halogen atom can be used. An alkyl ester can also be used. By formylating Compound 3 with Vilsmeier's reagent prepared from phosphorus oxychloride or oxalyl chloride and dimethylformamide (DMF), Aldehyde 4 can be obtained. By subjecting Compound 4 to the Wittig reaction or Horner-Emons reaction, Acrylic acid derivative 5 can be synthesized. Where the Wittig reaction is employed, Compound 5 can be obtained by reacting an alkyloxycarbomethylene-triphenylphosphorane which may be substituted with the aldehyde compound in an inert solvent such as tetrahydrofuran, DMF or methylene chloride. Where the Horner-Emons reaction is employed, the target compound can be synthesized by reacting the aldehyde compound with a dialkylphosphonoacetic acid ester which may be substituted at the 2-position in the presence of a base in an inert solvent such as THF and DMF. Compound 7 having amino group at the 2-position as a linker can be obtained by converting the hydroxyl group at the 2-position of Compound 5 into tosyl group, mesyl group, diphenylphosphoric acid ester or the like, and then replacing the resulting group with an amine. The ester group of the acrylic acid moiety can be hydrolyzed in the final step to obtain Compound I-A. As the ester group, a lower alkyl ester such as those of methyl group and ethyl group, tert-butyl ester, benzyl ester, allyl ester and so forth can be used, and they can be hydrolyzed by hydrolysis under an alkaline or acidic condition, catalytic reduction or a method by using a metal catalyst such as palladium.
- Further, Compound I-A can also be synthesized by the method shown in Scheme 2. Compound 9 can be obtained by converting the hydroxyl group at the 2-position of Compound 3 into tosyl group, mesyl group, diphenylphosphoric acid ester or the like and then replacing the resulting group with an amine. The resulting product can be formylated with Vilsmeier's reagent prepared from phosphorus oxychloride or oxalyl chloride and dimethylformamide to obtain Aldehyde 10. By subjecting Compound 10 to the Wittig reaction or Horner-Emons reaction, Acrylic acid derivative 7 can be synthesized. Where the Wittig reaction is employed, Compound 7 can be obtained by reacting an alkyloxycarbomethylenetriphenylphosphorane which may be substituted with the aldehyde compound in an inert solvent such as THF, DMF, toluene or methylene chloride. Where the Horner-Emons reaction is employed, the target compound can be synthesized by reacting the aldehyde compound with a dialkylphosphonoacetic acid ester which may be substituted at the 2-position in the presence of a base in an inert solvent such as THF and DMF.
-
- A compound in which a substituent is introduced at the 2-position of the pyridopyrimidine ring as a linker can be synthesized by the method shown in Scheme 3.
-
-
- Compound 1 used for the aforementioned synthesis can be synthesized as follows.
- For example, Compound 1-A of which W portion is an amide bond can be synthesized by condensing an aminothiazole derivative, which is a known compound or can be synthesized by a known method, and a 2-aminopyridine-4-carboxylic acid derivative of which amino group is protected by a usual method used for a reaction of forming a peptide bond, and deprotecting the protective group of the amino group.
- Compound 1-B of which W portion is a double bond can be synthesized by condensing 2-Methylthiazole derivative 17, which is a known compound or can be synthesized by a known method, and 2-Aminopyridine-4-carbaldehyde derivative 18 of which amino group is protected under a condition for the Knoevenagel reaction, and removing the protective group of the amino group. As for the condition of the Knoevenagel reaction, the reaction can also be performed by heating in acetic anhydride or in the presence of a base such as piperidine and piperazine and in the co-presence of an acid such as acetic acid.
- An anion that can be obtained by treating 2-Amino-4-methylpyridine derivative 20 of which amino group is protected with a strong base such as n-BuLi and an aldehyde are reacted, and then the resulting hydroxyl group can be subjected to tosylation, mesylation or the like, or the resulting product is converted into a halogenated compound such as by chlorination or bromination. The resulting product is then subjected to elimination reaction using a base such as DBU to obtain Double bond-containing derivative 23. By removing its amino protective group, Compound 1-C can be synthesized.
- Compound 1-D of which W portion is an ether bond can be synthesized by condensing Thiazolemethyl halide 24, which is a known compound or can be synthesized by a known method, and 4-Hydroxypyridine-2-carboxylic acid ester 25 in the presence of a base, hydrolyzing the ester portion of the resulting Compound 26, and then converting the produced carboxylic acid into Amine derivative 28 by employing the Curtius rearrangement or the like. Amino compound 1-D can also be obtained by first converting the carboxylic acid into a condensation product with hydrazine, then converting the resulting product into an acid azide with a nitrous acid salt or a derivative thereof, further subjecting the resulting product to a rearrangement reaction and, if required, removing the protective group of the amino group.
- Compound 1-E, where W portion is ethylene, can be synthesized by reacting an anion, obtained by treating 2-Amino-4-methylpyridine derivative 20 of which amino group is protected with a strong base such as n-BuLi, with Thiazolemethyl halide 24 to obtain a condensation product and then removing the protective group of the amino group.
- As shown in Scheme 10, Compound 1-E can also be synthesized by reacting an anion, obtained by treating 2-Amino-4-methylpyridine derivative 20 of which amino group is protected with a strong base such as n-BuLi, with Halogenoacetic acid derivative 30 to obtain a condensation product, converting the ester portion into an amide, then converting the resulting product into a thioamide compound by using Lawesson's reagent, diphosphorous pentasulfide or the like and condensing the product with a haloketone compound.
- A compound of which W portion is a triple bond can be synthesized by the synthetic methods described in WO9633181 published Oct. 24, 1996.
-
- Amide derivative 35 can be obtained by converting N-Alkyl-quinolone-carboxylic acid derivative 34 described in PCT/JP00/07565 into a mixed acid anhydride, and then reacting the resulting product with ammonia or an ethylamine having an electron-withdrawing group (EWG) such as cyanoethylamine and 3-aminopropanoic acid ester. The alkylamide derivative can be converted into Compound 36 by treatment with sodium azide and trifluoromethanesulfonic acid anhydride in an acetonitrile solvent to form a tetrazole ring. Then, the product can be converted into Tetrazole compound II-A by treatment with DUB in an inert solvent such as methylene chloride or treatment with a base such as sodium methoxide in an alcohol.
- Further, Tetrazole compound II-A can similarly be obtained by subjecting Carbamoyl derivative 35 to dehydration reaction to obtain Cyano derivative 37 and treating the resulting compound with sodium azide and aluminum chloride in dimethylformamide. Similarly, Tetrazole compound II-A can be produced by subjecting Carboxylic acid 34 having a cinnolin-4-one or naphthylidin-4-one structure to the same treatment.
- As shown in Scheme 12, where a derivative having a cinnolin-4-one structure is desired, Compound 38, which is a known compound or can be easily derived from a known compound, can be converted into a diazo compound by treating the amino group with sodium nitrite, and the resulting product can be reacted with a malonic acid ester to obtain Compound 39 (R5═H). An electrophilic regent such as an alkyl halide can be reacted with the nitrogen atom of the resulting Compound 39 (R5═H) by using a base such as sodium hydride and potassium carbonate in a solvent such as DMF and THF, and then the product can be heated in a solvent such as Dowtherm A and PPA and treated under an ordinary hydrolysis condition to obtain Carboxylic acid 41. The Carboxylic acid 41 obtained can be subjected to a treatment similar to the aforementioned treatment (Scheme 11) to produce Tetrazole compound II-B.
- As shown in Scheme 13, when W portion is —CH2O—, Compound 42 can be converted into an alkoxide by treatment with a strong base such as sodium hydride in DMF or THF, and the alkoxide can be reacted with Compound 43, which is a known compound or can be synthesized by a known method (Japanese Patent Un-examined Publication (Kokai) No. 57-144264 or 60-197686), to obtain Compound 44. Subsequently, Compound 44 can be converted into a carboxylic acid by hydrolysis and subjected to a treatment similar to the aforementioned treatment (Scheme 11) to produce Tetrazole compound II-C.
- As for the aforementioned production of cinnolin-4-one derivative, a method wherein 3-chloro-4-fluoroaniline is used as a starting material is compared with a method wherein 3,4-difluoroaniline is used, 3,4-difluoroaniline will give much higher yield of cinnolin-4-one-3-carboxylic acid as for the thermal cyclization reaction performed in a solvent such as Dowtherm A and PPA in the production of the known Compound 43 and selectivity of the substitution of the alkoxide shown in Scheme 13.
- As shown in Scheme 14, where the compound in which W is an olefin is desired, Compound 45, which is a known compound or can be synthesized by a known method, can be esterified and then subjected to treatment with an oxidizing agent such as selenium dioxide, and the resulting Aldehyde derivative 46 and Compound 47 can be subjected to the Wittig reaction and further subjecting the adduct to addition of ammonia to obtain Carbamoyl compound 49. The resulting Carbamoyl derivative 49 can be converted into Tetrazole compound II-D by using the same method as in Scheme 11.
- The synthetic intermediates and the target compounds in the aforementioned preparations can be isolated and purified by using methods for isolation and purification ordinarily used in the field of organic synthetic chemistry, for example, neutralization, filtration, extraction, drying, concentration, recrystallization, various chromatographic techniques and the like. The synthetic intermediates may be used in subsequent reactions without purification. When a salt of compound of the general formula (I) or (II) is desired, a product obtained in the form of a salt may be purified without any treatment. When a product is obtained in a free form, a salt can be formed by dissolving or suspending the product in a suitable organic solvent, and then adding an acid or base. It is also possible to convert a compound represented by the general formula (I) or (II) obtained in the form of a salt into a compound in a free form, and then convert the result into an appropriate salt.
- Although it is not intended to be bound by any specific theory, the compounds represented by the general formula (I) have an activity for inhibiting drug efflux pumps of microorganisms. More specifically, the compounds represented by the general formula (I) can act on a microorganism with acquired resistance to an antimicrobial agent to inhibit its drug efflux pump, and eliminate the resistance of the microorganism. In addition, the compounds represented by the general formula (I) can act on a microorganism to inhibit a drug efflux pump, thereby suppress the acquisition of resistance to an antimicrobial agent by a microorganism. Therefore, the medicament of the present invention that comprises a compound represented by the general formula (I) as an active ingredient is useful for preventive and/or therapeutic treatment of microbial infections, generally by a combinational administration with an antimicrobial agent. The medicament of the present invention is extremely useful as a medicament for preventive and/or therapeutic treatment of, in particular, infectious diseases caused by a microorganism with acquired resistance to one or more antimicrobial agents.
- Methods for using the medicament of the present invention are not particularly limited. Examples include a method of administering one or more antimicrobial agents, and also administering the medicament of the present invention simultaneously, separately, or successively to enhance the activity of the antimicrobial agent(s); and a method of preparing a pharmaceutical composition comprising one or more antimicrobial agents and the medicament of the present invention (so-called a compound drug) and the administering the composition.
- Kinds of microbial infections that are applicable by the medicament of the present invention are not particularly limited. Bacteria are suitable as target microorganisms. The medicament of the present invention can be used for various infections by microorganisms including Gram-positive or Gram-negative bacteria, aerobic or anaerobic bacteria and the like. The medicament of the present invention can most suitably be used for infections by Pseudomonas aeruginosa with acquired resistance to one or more antimicrobial agents, or infections by Pseudomonas aeruginosa with low sensitivity to antimicrobial agents. The medicament of the present invention can be used for microbial infections of mammals including human.
- Drugs having variety of structures have been known as antimicrobial agents, and various drugs are clinically used. Kinds of antimicrobial agents that can be administered in combination with the medicament of the present invention are not particularly limited, and examples include, for example, penicillin (penam) antibiotics, cephalosporin (cephem) antibiotics, oxacephem antibiotics, penem antibiotics, carbapenem antibiotics, monobactam antibiotics, aminoglycoside antibiotics, macrolide antibiotics, chloramphenicol antibiotics, tetracycline antibiotics, glycopeptide antibiotics, phosphomycin antibiotics, lincomycin antibiotics, sulfonamide preparations, p-aminosalicylic acid preparations, isonicotinic acid hydrazide preparations, quinolone synthetic antimicrobial agents and the like. However, antimicrobial agents are not limited to these examples. When a pharmaceutical composition comprising one or more antimicrobial agents together with the medicament of the present invention is manufactured, the antimicrobial agents exemplified above can also be used.
- As the active ingredient of the medicament of the present invention, a substance selected from the group consisting of the compounds represented by the formula (I) and pharmaceutically acceptable salts thereof, and hydrates thereof and solvates thereof can be used. Two or more of the substances may be used in combination. The aforementioned substance, per se, may be administered as the medicament of the present invention. Generally, however, it is desirable that the substance is administered in the form of a pharmaceutical composition comprising one or more of the aforementioned substances as the active ingredient together with one or more pharmaceutical additives. The pharmaceutical composition may optionally be added with one or more of other pharmaceutically active ingredients such as the aforementioned antimicrobial agents and β-lactamase inhibitors.
- A pharmaceutical composition for the use of administration in vivo can be readily prepared by mixing one or more of the aforementioned substances as the active ingredient and one or more pharmaceutically acceptable additives for pharmaceutical preparations according to methods for formulation ordinarily used in the field of manufacturing pharmacy. The route of administration of the medicament of the present invention is not particularly limited; however, it is desirable to appropriately chose the most effective administration route for preventive and/or therapeutic treatment of a target infectious disease. Examples of pharmaceutical compositions suitable for oral administration include, for example, capsules, powders, tablets, granules, subtilized granules, emulsions, syrups, solutions, suspensions and the like. Examples of pharmaceutical compositions suitable for parenteral administration include, for example, inhalants, sprays, intrarectal preparations, injections, drip infusions, ointments, creams, transdermal preparations, transmucosal preparations, eye drops, nasal drops, ear drops, tape preparations, patches and the like. However, the forms of the medicament of the present invention are not limited to these examples.
- Among the pharmaceutical compositions suitable for oral administration, liquid preparations such as emulsions and syrups can be prepared by using pharmaceutical additives including water; saccharides such as sucrose, sorbitol, fructose; glycols such as polyethylene glycol and propylene glycol; oils such as sesame oil, olive oil and soybean oil; antiseptics such as p-hydroxybenzoic acid esters; flavors such as strawberry flavor and peppermint and the like. Solid preparations such as capsules, tablets, powders and granules can be prepared by using excipients such as lactose, glucose, sucrose and mannitol; disintegrating agents such as starch and sodium alginate; lubricants such as magnesium stearate and talc; binders such as polyvinyl alcohol, hydroxypropylcellulose and gelatin; surfactants such as fatty acid esters; plasticizers such as glycerin and the like.
- Among the pharmaceutical compositions suitable for parenteral administration, liquid preparations such as injections, drip infusions and eye drops can preferably be prepared as sterilized isotonic liquid preparations. For example, injections can be prepared by using an aqueous medium such as a solution of sodium chloride, a solution of glucose, or a mixture of saline and glucose solution. The intrarectal preparations can be prepared generally in the form of suppositories by using carriers such as cacao butter, hydrogenated fat and hydrogenated carboxylic acid. For the preparation of sprays, a non-irritable carrier can be used that enables fine dispersion and enhances absorption of the aforementioned substances as the active ingredient. Examples of such a carrier include lactose, glycerin and the like. Aerosols, dry powders or the like can also be chosen as the form of preparation. However, pharmaceutical additives used for the manufacture of the medicament of the present invention are not limited to those mentioned above, and any additives available for those skilled in the art can be used.
- A dose and frequency of administration of the medicament of the present invention are not particularly limited, and a suitable dose can be chosen depending on the type and severity of a microbial infection, the presence or absence of an underlying disease, the age and body weight of a patient and the like.
- The present invention will be explained more specifically with reference to the examples. However, the scope of the present invention is not limited to the following examples.
- tert-Butyl N-(4-methyl-2-pyridyl)carbamate (5 g, 24.0 mmol) was dissolved in tetrahydrofuran (120 ml), cooled to −78° C., and then added dropwise with n-butyl lithium (40 ml, 60 mmol). Then, the reaction solution was warmed and stirred at room temperature. The reaction mixture was stirred for 1 hour, then again cooled to −78° C., and added dropwise with methyl bromoacetate (3.4 ml) dissolved in tetrahydrofuran (10 ml). After the reaction mixture was stirred for 30 minutes, the reaction was stopped with saturated brine and the reaction mixture was extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform:ethyl acetate=3:1→5:1) to obtain 3.95 g (59%) of the title compound as pale yellow crystals.
- 1H-NMR (CDCl3) δ: 1.53 (9H, s), 2.67 (2H, t, J=7.81 Hz), 2.95 (2H, t, J=7.81 Hz), 3.68 (3H, s), 6.82 (1H, dd, J=1.22, 5.13 Hz), 7.84 (1H, s), 8.13 (1H, d, J=5.13 Hz)
- Methyl 3-{2-[(tert-butoxycarbonyl)amino]-4-pyridyl}propanoate (30.65 g, 0.11 mol) dissolved in methanol (200 ml) was added with 1 N aqueous sodium hydroxide (164 ml) and stirred at room temperature for 21 hours. After the solvent was evaporated under reduced pressure and the residue was washed with diethyl ether, the resulting aqueous layer was added with concentrated hydrochloric acid until pH of the layer became 1. The solution was washed with ethyl acetate, and the resulting aqueous layer was neutralized by further adding sodium hydroxide. The solution was extracted with chloroform:methanol=10:1, and the resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure to obtain 11.16 g (38%) of the title compound as yellow crystals without purification.
- 1H-NMR (CD3OD)δ: 1.54 (9H, s), 2.67 (2H, t, J=7.59 Hz), 2.95 (2H, t, J=7.59 Hz), 6.90 (1H, d, J=5.14 Hz), 7.80 (1H, s), 8.08 (1H, d, J=5.14 Hz)
- EI/MS; m/z: 267 (M++1)
- 3-{2-[(tert-Butoxycarbonyl)amino]-4-pyridyl}propanoic acid (11.16 g, 41.92 mmol) dissolved in tetrahydrofuran (200 ml) was added with triethylamine (9 ml, 62.89 mmol), cooled with ice, and then added dropwise with ethyl chloroformate (6 ml, 62.89 mmol). The reaction mixture was stirred for 10 minutes, and then added with aqueous ammonia (50 ml) dissolved in tetrahydrofuran (50 ml) at 0° C. The reaction mixture was stirred for 20 minutes under ice cooling, and then the solvent was evaporated under reduced pressure. The resulting residue was washed with water and extracted with chloroform. The resulting organic layer was washed with saturated brine, and the organic layer was dried over sodium sulfate and concentrated under reduced pressure to obtain 11.794 g (100%) of the title compound as brown crystals without purification.
- 1H-NMR (CD3OD) δ: 1.53 (9H, s), 2.57 (2H, t, J=8.05 Hz), 2.97 (2H, t, J=8.05 Hz), 5.40 (2H, br), 6.84 (1H, dd, J=1.46, 5.13 Hz), 7.83 (1H, s), 8.13 (1H, d, J=5.13 Hz)
- EI/MS; m/z: 266 (M++1)
- Under argon atmosphere, tert-butyl N-[4-(3-amino-3-oxopropyl)-2-pyridyl]-carbamate (11.79 g, 44.44 mmol) dissolved in tetrahydrofuran (100 ml) was added with Lawesson's reagent (9 g, 22.22 mmol) and stirred at 70-80° C. for 30 minutes. After the reaction mixture was returned to room temperature, the solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=20:1) to obtain 9.544 g (76%) of the title compound as pale yellow crystals.
- 1H-NMR (CD3OD) δ: 1.53 (9H, s), 2.89 (2H, t, J=8.30 Hz), 3.09 (2H, t, J=8.30 Hz), 6.94 (1H, d, J=5.13 Hz), 7.75 (1H, s), 8.08 (1H, d, J=5.13 Hz)
- EI/MS; m/z: 282 (M++1)
- 1-Cyclobutyl-1-ethanone (500 mg, 5.1 mmol) dissolved in methanol (5 ml) was added with bromine (0.3 ml, 5.6 mmol) and stirred at room temperature for 1 hour. The resulting ocher reaction mixture was added with water (3 ml) under ice cooling, and then gradually added with potassium carbonate (350 mg). The mixture was extracted with dichloromethane, and the resulting organic layer was neutralized with saturated aqueous sodium hydrogencarbonate and washed with saturated brine. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain 867 mg (96%) of the title compound without purification.
- 1H-NMR (CDCl3) δ:1.88 (1H,m), 2.00 (1H,m), 2.20-2.37 (4H,m), 3.60 (1H, qu, J=8.53 Hz), 3.88 (2H, s)
- tert-Butyl N-[4-(3-amino-3-thioxopropyl)-2-pyridyl]carbamate (1.38 g, 4.9 mmol) dissolved in ethanol was added with 2-bromo-1-cyclobutyl-1-ethanone (867 mg, 4.9 mmol) and refluxed at 100° C. for 1 hour. The resulting reaction solution was cooled to room temperature, then neutralized with saturated aqueous sodium hydrogencarbonate and extracted with chloroform. The resulting organic layer was washed with saturated brine, dried over magnesium sulfate and concentrated under reduced pressure.
- The resulting oily compound was added with dichloromethane (50 ml) and slowly added dropwise with trifluoroacetic acid (50 ml) under ice cooling. Then, the reaction solution was warmed to room temperature and stirred 1 hour. The resulting solution was neutralized with saturated sodium hydrogencarbonate and extracted with chloroform. The organic layer was washed with saturated brine, and the resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
- The brown oily residue (1.37 g) was added with xylene (7 ml) and trichlorophenyl malonate (2.7 g, 5.83 mmol) and refluxed by heating at 140° C. for 1 hour, and the solvent was evaporated under reduced pressure. The resulting oily compound was purified by silica gel chromatography (ethyl acetate chloroform:methanol=30:1→10:1→5:1) to obtain 657 mg (41% for the three steps) of the title compound as pale yellow crystals.
- 1H-NMR (CDCl3) δ: 1.91 (1H,m), 2.01 (1H, qu, J=8.79 Hz), 2.22 (2H, d qu, J=2.44, 8.79 Hz), 2.34 (2H, tq, J=2.44, 8.79 Hz), 3.39 (4H, dd, J=6.84, 20.75 Hz), 3.63 (1H, qu, J=8.79 Hz), 5.33 (1H, s), 6.76 (1H, s), 7.11 (1H, dd, J=1.71, 7.08 Hz), 7.40 (1H, s), 9.02 (1H, d, J=7.08 Hz)
- 8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (120 mg, 0.366 mmol) dissolved in tetrahydrofuran (4 ml) and dimethylformamide (1 ml) was added with 4-dimethylaminopyridine (60 mg, 0.475 mmol) and p-tolunenesulfonyl chloride (77 mg, 0.402 mmol) at room temperature and stirred for 30 minutes. The solvent was evaporated under reduced pressure, and the residue was washed with water and extracted with chloroform. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
- The resulting oily compound was added with dimethylformamide (3 ml) and 3-hydroxypiperidine (45 mg, 0.44 mmol), and stirred at 60° C. for 40 hours. The solvent was evaporated under reduced pressure, and then the residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=20:1) to obtain 103 mg (68% for the two steps) of the title compound as oil.
- 1H-NMR (CDCl3) δ: 1.56 (1H, m), 1.66 (1H, m), 1.62-2.09 (4H, m), 2.23 (2H, d qu, J=2.20, 9.03 Hz), 2.35 (2H, m), 3.15 (2H, t, J=7.32 Hz), 3.35 (2H, t, J=7.32 Hz), 3.37 (1H, m), 3.48 (1H, m), 3.63 (1H, qu, J=9.03 Hz), 3.68 (1H, m), 3.84 (1H, m), 3.99 (1H, dd, J=2.93, 13.18 Hz), 5.64 (1H, s), 6.71 (1H, dd, J=1.71, 7.32 Hz), 6.76 (1H, s), 7.10 (1H, s), 8.76 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 411 (M++1)
- 8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxypiperidino)-4H-pyrido[1, 2-a]pyrimidin-4-one (103 mg, 0.251 mmol) dissolved in dichloromethane (3 ml) was added with imidazole (51 mg, 0.753 mmol) and tert-butyldimethylsilyl chloride (57 mg, 0.376 mmol) under ice cooling and stirred for 1 hour. Then, as the reaction did not progress, the reaction mixture was warmed to room temperature and further added with imidazole and tert-butyldimethylsilyl chloride so that the reaction was completed. The reaction solution was diluted with chloroform, washed with water, dried over magnesium sulfate and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=20:1) to obtain 128 mg (97%) of the title compound as an orange oily substance.
- 1H-NMR (CDCl3) δ: 0.87 (9H, s), 0.92 (6H, s), 1.53 (2H, m), 1.80-2.09 (4H, m), 2.23 (2H, m), 2.34 (2H, m), 3.02 (2H, m), 3.14 (2H, t, J=8.04 Hz), 3.35 (2H, t, J=8.04 Hz), 3.64 (2H, m), 4.00 (1H, brd), 4.20 (1H, brd), 5.59 (1H, s), 6.69 (1H, dd, J=1.95, 7.31 Hz), 6.75 (1H, s), 7.06 (1H, s), 8.76 (1H, d, J=7.31 Hz)
- EI/MS; m/z: 525 (M++1)
- Under ice cooling, dimethylformamide (2 ml) was added with phosphorus oxychloride (34 μl, 0.366 mmol), and then the reaction solution was added dropwise with 2-(3-{[1-(tert-butyl)-1,1-dimethylsilyl]oxy}piperidino)-8-[2-(4-cyclobutyl1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one (128 mg, 0.244 mmol) dissolved in dimethylformamide under ice cooling. Then the reaction solution was warmed to room temperature. After 2 hours, the reaction solution was further added with phosphorus oxychloride (34 μl) at room temperature and stirred at room temperature for 20 minutes. The solvent was evaporated under reduced pressure, and the resulting residue was neutralized by adding saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate and chloroform. The organic layer collected was washed with saturated brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=20:1) to obtain 69 mg (61%) of the title compound as a yellow oily substance.
- 1H-NMR (CDCl3) δ: 1.25-2.09 (6H, m), 2.22 (2H, dqu, J=2.45, 9.06 Hz), 2.34 (2H, m), 3.18 (2H, t, J=7.83 Hz), 3.36 (2H, t, J=7.83 Hz), 3.65 (3H, m), 3.82 (1H, dd, J=6.37, 13.47 Hz), 3.91 (1H, dd, J=3.18, 13.47 Hz), 5.07 (1H, m), 6.77 (1H, dd, J=1.71, 7.34 Hz), 6.77 (1H, s), 7.07 (1H, s), 7.98 (1H, s), 8.72 (1H, d, J=7.34 Hz), 10.08 (1H, s)
- EI/MS; m/z: 467 (M++1)
- 1-{8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-3-formyl-4-oxo-4H-pyrido[1,2-a]py rimidin-2-yl}-3-piperidylformate (69 mg, 0.148 mmol) dissolved in tetrahydrofuran (3 ml) was added with (tert-butoxycarbonylmethylene)triphenylphosphorane (84 mg, 0.222 mmol) and refluxed at 100° C. After 7 hours, the reaction solution was further added with the phosphorane (90 mg) and further refluxed for 11 hours. Then the phosphorane (90 mg) was further added, and after 5 hours, the phosphorane (89 mg) was further added. The reaction solution was refluxed for 10 hours, then added with the phosphorane (90 mg) and refluxed for 5 hours. The reaction solution was returned to room temperature, and the solvent was evaporated under reduced pressure. The residue was purified by thin layer silica gel chromatography (chloroform:methanol=30:1) to obtain 94 mg of the title compound as yellow crystals in a mixture with triphenylphosphine oxide.
- 1H-NMR (CDCl3) δ: 1.51 (9H, s), 1.89-2.04 (6H, m), 2.22 (2H, m), 2.34 (2H, m), 3.19 (2H, t, J=7.81 Hz), 3.36 (2H, t, J=7.81 Hz), 3.53-3.68 (4H, m), 3.79 (1H, dd, J=3.42, 13.67 Hz), 5.13 (1H, m), 6.76 (1H, s), 6.84 (1H, dd, J=1.95, 7.32 Hz), 7.06 (1H, d, J=15.63 Hz), 7.20 (1H, s), 7.65 (1H, d, J=15.63 Hz), 8.08 (1H, s), 8.85 (1H, d, J=7.32 Hz)
- tert-Butyl (E)-3-[8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-formyloxy-piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (95 mg, 0.168 mmol) dissolved in methanol (4 ml) was added with sodium methoxide (4 mg, 0.074 mmol) under ice cooling and stirred for 45 minutes under ice cooling. Then the reaction solution was further added with sodium methoxide (4 mg), and after 5 minutes, further added with sodium methoxide (10 mg). After the reaction solution was stirred for 15 minutes, the reaction was stopped with saturated brine and added with chloroform for extraction. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure, and the residue was purified by thin layer silica gel chromatography (chloroform:methanol=20:1) to obtain 76 mg (84%) of the title compound as yellow crystals in a mixture with triphenylphosphine oxide.
- 1H-NMR (CDCl3) δ: 1.51 (9H, s), 1.82-2.08 (6H, m), 2.17-2.25 (2H, m), 2.32-2.36 (2H, m), 3.19 (2H, t, J=7.32 Hz), 3.36 (2H, t, J=7.32 Hz), 3.53-3.65 (4H, m), 3.92 (1H, d, J=13.92 Hz), 4.01 (1H, s), 6.77 (1H, s), 6.86 (1H, dd, J=1.95, 7.32 Hz), 7.03 (1H, d, J=15.63 Hz), 7.19 (1H, s), 7.62 (1H, d, J=15.63 Hz), 8.85 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 537 (M++1)
- tert-Butyl (E)-3-[8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-(3-hydroxy-piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (76 mg, 0.142 mmol) was added with formic acid (3 ml) and stirred at room temperature for 2 hours and 30 minutes. After the formic acid was evaporated under reduced pressure, the residue was purified by thin layer silica gel chromatography (chloroform:methanol=15:1) to obtain 39 mg (55% for the three steps) of the title compound as yellow crystals.
- 1H-NMR (CDCl3) δ: 1.25 (1H, m), 1.52 (1H, m), 1.83-2.08 (4H, m), 2.21 (2H, d qu, J=2.44, 8.30 Hz), 2.36 (2H, tq, J=2.93, 8.30 Hz), 3.19 (2H, t, J=7.32 Hz), 3.36 (2H, t, J=7.32 Hz), 3.63 (4H, m), 3.88 (1H, d, J=13.43 Hz), 4.02 (1H, brd), 6.76 (1H, s), 6.86 (1H, dd, J=2.71, 7.32 Hz), 7.06 (1H, d, J=15.63 Hz), 7.19 (1H, s), 7.65 (1H, d, J=15.63 Hz), 8.84 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 481 (M++1)
- 8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]-pyrimidin-4-one (302 mg, 0.925 mmol) dissolved in tetrahydrofuran (14 ml) and dimethylformamide (6 ml) was added with 4-dimethylaminopyridine (150 mg, 1.20 mmol) and p-tolunenesulfonyl chloride (194 mg, 1.02 mmol) and stirred at room temperature for 20 minutes.
- After the solvent was evaporated under reduced pressure, the residue was diluted with chloroform and washed with water. The resulting organic layer was dried over magnesium sulfate and concentrated under reduced pressure.
- The residue was dissolved in dimethylformamide (2 ml), added with morpholine (1 ml, 11.5 mmol) and stirred at 70° C. for 3 hours. After the reaction solution was returned to room temperature, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=20:1) to obtain 351 mg of the title compound as pale yellow crystals as a substance containing dimethylformamide.
- 1H-NMR (CDCl3) δ: 1.92 (1H, m), 2.02 (1H, m), 2.23 (2H, m), 2.35 (2H, m), 3.16 (2H, t, J=8.32 Hz), 3.35 (2H, t, J=8.32 Hz), 3.66 (4H, t, J=5.38 Hz), 3.70 (1H, m), 3.78 (4H, t, J=5.38 Hz), 5.57 (1H, s), 6.74 (1H, dd, J=2.94, 7.09 Hz), 6.76 (1H, s), 7.13 (1H, s), 8.78 (1H, d, J=7.09 Hz)
- EI/MS; m/z: 397 (M++1)
- Reactions were performed in the same manner as in Example 1, (I) by using 8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (346 mg, 0.8726 mmol) to obtain 305 mg (82%) of the title compound as ocher solid.
- 1H-NMR (CDCl3) δ: 1.92-2.96 (6H, m), 3.19 (2H, t, J=7.34 Hz), 3.36 (2H, t, J=7.34 Hz), 3.68 (1H, m)3.73 (4H, t, J=5.14 Hz), 3.82 (4H, t, J=5.14 Hz), 6.77 (1H, s), 6.78 (1H, dd, J=1.96, 7.34 Hz), 7.08 (1H, s), 8.74 (1H, d, J=7.34 Hz), 10.01 (1H, s)
- EI/MS; m/z: 425 (M++1)
- Reactions were performed in the same manner as in Example 1, (J) by using 8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]-pyrimidin-3-carbaldehyde (100 mg, 0.2356 mmol) to obtain 127 mg (100%) of the title compound as a yellow oily substance in a mixture with triphenylphosphine oxide.
- 1H-NMR (CDCl3) δ: 2.02 (1H, m), 2.20 (1H, m), 2.23 (2H, m), 2.34 (2H, m), 3.20 (2H, t, J=7.08 Hz), 3.37 (2H, t, J=7.08 Hz), 3.60 (4H, t, J=4.39 Hz), 3.63 (1H, m), 3.83 (4H, t, J=4.39 Hz), 6.76 (1H, s), 6.85 (1H, dd, J=1.71, 7.32 Hz), 7.05 (1H, d, J=15.63 Hz), 7.21 (1H, s), 7.64 (1H, d, J=15.63 Hz), 8.86 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 523 (M++1)
- Reactions were performed in the same manner as in Example 1, (L) by using tert-butyl (E)-3-{8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (127 mg, 0.2430 mmol) to obtain 82.7 mg (73%) of the title compound as yellow crystals.
- 1H-NMR (CDCl3) δ: 1.92 (1H, m), 2.01 (1H, m), 2.22 (2H, m), 2.34 (2H, m), 3.19 (2H, t, J=8.06 Hz), 3.37 (2H, t, J=8.06 Hz), 3.61 (4H, s), 3.64 (1H, m), 3.81 (4H, s), 6.76 (1H, s), 6.86 (1H, dd, J=1.47, 7.32 Hz), 7.08 (1H, d, J=15.63 Hz), 7.19 (1H, s), 7.64 (1H, d, J=15.63 Hz), 8.87 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 467 (M++1).
- IR (cm−1): 2962, 2850, 1680, 1647, 1516, 1444
- 8-[2-(4-Cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-carbaldehyde (100 mg, 0.236 mmol) dissolved in toluene (2 ml) was added with (carbethoxyethylidene)triphenylphosphorane (102 mg, 0.283 mmol) and refluxed by heating at 130° C. Then the regent was added until the reaction was completed, and 7 equivalents of the regent was finally added. After the reaction mixture was stirred for 4 days, the solvent was evaporated under reduced pressure, and the resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=40:1) to obtain 443 mg of yellow crystals in a mixture with triphenylphosphine oxide.
- 1H-NMR (CDCl3) δ: 1.33 (3H, t, J=7.08 Hz), 1.88 (3H, s), 1.90 (1H, m), 2.05 (1H, m), 2.23 (2H, m), 2.35 (2H, m), 3.20 (2H, t, J=7.81 Hz), 3.37 (2H, t, J=7.81 Hz), 3.57 (4H, t, J=4.88 Hz), 3.64 (1H, m), 3.73 (4H, t, J=4.88 Hz), 4.25 (2H, q, J=7.08 Hz), 6.77 (1H, s), 6.82 (1H, d, J=7.33 Hz), 7.21 (1H, s), 7.57 (1H, s), 8.84 (1H, d, J=7.33 Hz)
- Ethyl (E)-3-{8-[2-(4-cyclobutyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoate (120 mg, 0.236 mmol) dissolved in methanol (5 ml) was added dropwise with 1 N aqueous sodium hydroxide (2 ml) under ice cooling. The reaction solution was stirred for 10 minutes and then warmed to room temperature because the reaction did not progress. The reaction solution was stirred for 45 minutes, then further added with 1 N aqueous sodium hydroxide (2 ml), and after 1 hour, further added with 1 N aqueous sodium hydroxide (2 ml). The solvent was evaporated under reduced pressure, and the resulting sodium salt of the title compound was dissolved in 1,4-dioxane, added with 4 N hydrochloric acid (6 ml) and stirred. Then the reaction solution was concentrated under reduced pressure, and the residue was neutralized with saturated aqueous sodium hydrogencarbonate and extracted with chloroform and methanol. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=30:1) to obtain 75 mg (66%) of the title compound as yellow crystals.
- 1H-NMR (CDCl3) δ: 1.84 (3H, s), 1.91 (1H, m), 2.02 (1H, hex, J=9.06 Hz), 2.22 (2H, d qu, J=2.21, 9.06 Hz), 2.34 (2H, q, J=8.57 Hz), 3.16 (2H, t, J=8.08 Hz), 3.36 (2H, t, J=8.08 Hz), 3.56 (4H, s), 3.64 (1H, qu, J=8.57 Hz), 3.70 (4H, s), 6.76 (1H, s), 6.80 (1H, dd, J=1.22, 7.10 Hz), 7.16 (1H, s), 7.57 (1H, s), 8.83 (1H, d, J=7.10 Hz)
- EI/MS; m/z: 481 (M++1)
- IR (cm−1): 2958, 2919, 2850, 1666, 1641, 1440, 1251, 1115
- tert-Butyl N-[4-(3-amino-3-thioxopropyl)-2-pyridyl]carbamate (590 mg, 2.10 mmol) dissolved in ethanol (20 ml) was added with 1-bromo-2-butanone (0.23 ml, 2.10 mmol) and refluxed by heating at 100° C. The reaction solution was stirred for 1 hour and then returned to room temperature. The solvent was evaporated under reduced pressure, and the residue was diluted with chloroform. The mixture was washed with saturated aqueous sodium hydrogencarbonate and dried over sodium sulfate, and concentrated under reduced pressure.
- The resulting residue was added with dichloromethane (20 ml) and added dropwise with trifluoroacetic acid (20 ml) under ice cooling. Then the reaction solution was warmed to room temperature and stirred for 15 hours. The trifluoroacetic acid was evaporated under reduced pressure, and the residue was neutralized with saturated sodium hydrogencarbonate and extracted with chloroform. The organic layer was washed with saturated brine and the collected organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue without purification gave 477 mg (98%) of the title compound as an orange oily substance.
- 1H-NMR (CDCl3) δ: 1.29 (3H, t, J=7.59 Hz), 2.78 (2H, dq, J=0.98, 7.59 Hz), 2.98 (2H, t, J=8.33 Hz), 3.25 (2H, t, J=8.33 Hz), 6.37 (1H, s), 6.52 (1H, dd, J=1.23, 5.39 Hz), 6.72 (1H, s), 7.93 (1H, d, J=5.39 Hz)
- 4-[2-(4-Ethyl-1,3-thiazol-2-yl)ethyl]-2-pyridinamine (480 mg, 2.044 mmol) dissolved in xylene (10 ml) was added with trichlorophenyl malonate (1 g, 2.160 mmol) and refluxed by heating at 140° C. The reaction solution was stirred for 3 hours and returned to room temperature. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=80:1→50:1→5:1) to obtain 135 mg (22%) of orange crystals.
- 1H-NMR (CDCl3) δ: 1.28 (3H, t, J=7.57 Hz), 2.78 (2H, q, J=7.57 Hz), 3.36 (4H, dd, J=6.35, 17.82 Hz), 5.33 (1H, s), 6.76 (1H, s), 7.09 (1H, d, J=7.08 Hz), 7.39 (1H, s), 9.02 (1H, d, J=7.08 Hz)
- EI/MS; m/z: 302 (M++1)
- Reactions were performed in the same manner as in Example 2, (A) by using 8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (135 mg, 0.4480 mmol) as a starting material to obtain 120 mg (72%) of the title compound as pale yellow crystals.
- 1H-NMR(CDCl3) δ: 1.29 (3H, t, J=7.57 Hz), 2.78 (2H, dq, J=0.977, 7.57 Hz), 3.16 (2H, t, J=8.06 Hz), 3.34 (2H, t, J=8.06 Hz), 3.64 (4H, t, J=5.13 Hz), 3.77 (4H, t, J=5.13 Hz), 5.57 (1H, s), 6.74 (1H, d, J=0.977 Hz), 6.74 (1H, dd, J=1.953, 7.08 Hz), 7.12 (1H, d, J=1.953 Hz), 8.79 (1H, d, J=7.08 Hz)
- EI/MS; m/z: 371 (M++1)
- Reactions were performed in the same manner as in Example 1, (I) by using 8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (120 mg, 0.324 mmol) to obtain 116 mg (90%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.29 (3H, t, J=7.57 Hz), 2.78 (2H, q, J=7.57 Hz), 3.19 (2H, t, J=7.08 Hz), 3.35 (2H, t, J=7.08 Hz), 3.73 (4H, t, J=4.15 Hz), 3.82 (4H, t, J=4.15 Hz), 6.76 (1H, s), 6.78 (1H, dd, J=1.71, 7.32 Hz), 7.07 (1H, d, J=1.71 Hz), 8.74 (1H, d, J=7.32 Hz), 10.11 (1H, s)
- EI/MS; m/z: 399 (M++1)
- Reactions were performed in the same manner as in Example 1, (J) by using 8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde (116 mg, 0.2911 mmol) to obtain the title compound as yellow crystals in a mixture with triphenylphosphine oxide.
- 1H-NMR (CDCl3) δ: 1.28 (3H, t, J=7.57 Hz), 1.51 (9H, s), 2.78 (2H, q, J=7.57 Hz), 3.20 (2H, t, J=7.08 Hz), 3.36 (2H, t, J=7.08 Hz), 3.60 (4H, t, J=4.88 Hz), 3.83 (4H, t, J=4.88 Hz), 6.74 (1H, s), 6.85 (1H, dd, J=1.71, 7.32 Hz), 7.05 (1H, d, J=15.87 Hz), 7.20 (1H, s), 7.68 (1H, d, J=15.87 Hz), 8.87 (1H, d, J=7.32 Hz)
- Reactions were performed in the same manner as in Example 1, (L) by using tert-butyl (E)-3-{8-[2-(4-ethyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoate (144 mg, 0.290 mmol) to obtain 93 mg (73%) of the title compound as yellow crystals.
- 1H-NMR (CDCl3) δ: 1.29 (3H, t, J=7.57 Hz), 2.79 (2H, q, J=7.57 Hz), 3.21 (2H, t, J=7.08 Hz), 3.38 (2H, t, J=7.08 Hz), 3.63 (4H, t, J=6.15 Hz), 3.83 (4H, t, J=6.15 Hz), 6.75 (1H, s), 6.87 (1H, dd, J=1.47, 7.32 Hz), 7.09 (1H, d, J=15.63 Hz), 7.21 (1H, s), 7.68 (1H, d, J=15.63 Hz), 8.87 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 441 (M++1)
- IR (cm−1): 2964, 2919, 2850, 1681, 1517, 1444
- 4-Methoxypyridine-N-oxide hydrate (1 g, 6.99 mmol) dissolved in dichloromethane (4 ml) was added with trimethylsilyl cyanide (1 ml, 7.69 mmol) and subsequently added dropwise with N,N-dimethylcarbamoyl chloride (0.8 ml, 9.09 mmol) under ice cooling. The reaction solution was warmed to room temperature, stirred for 1 hour, and then added further with trimethylsilyl cyanide (0.2 ml, 1.40 mmol). The reaction solution was stirred for 19 hours, then added with 10% potassium carbonate (2 ml). The mixture was diluted with ethyl acetate, washed with saturated brine and dried over magnesium sulfate, and then concentrated under reduced pressure. The resulting crystals were washed with hexane to obtain 560 mg (60%) of the title compound as pink crystals without purification.
- 1H-NMR (CDCl3) δ: 3.92 (3H, s), 7.02 (1H, dd, J=2.44, 5.86 Hz), 7.22 (1H, d, J=2.44 Hz), 8.51 (1H, d, J=5.86 Hz)
- 4-Methoxy-2-pyridinecarbonitrile (544 mg, 4.055 mmol) was added with 47% hydrobromic acid (6 ml) and refluxed by heating at 130° C. The reaction solution was stirred for 22 hours, returned to room temperature, and then concentrated under reduced pressure. The residue was subjected to azeotropy with toluene and diethyl ether to remove excessive hydrobromic acid. The resulting white crystals were washed with diethyl ether to obtain 1.47 g of the title compound containing hydrogen bromide without purification.
- 1H-NMR (CD3OD) δ:7.48 (1H, dd, J=2.44, 6.83 Hz), 7.81 (1H, d, J=2.44 Hz), 8.63 (1H, d, J=6.83 Hz)
- 4-Hydroxy-2-pyridinecarbonitrile (25.48 g, 0.2121 mol) dissolved in ethanol (400 ml) was added with concentrated hydrochloric acid (40 ml) and refluxed by heating at 110° C. for 6 days. The reaction solution was returned to room temperature, evaporated under reduced pressure and added with chloroform:methanol=20:1. After insoluble crystals were removed by filtration, the resulting filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform:methanol=20:1→10:1) to obtain 22.4 g (63% for the two steps) of the title compound as yellow crystals.
- 1H-NMR (CD3OD) δ: 1.32 (3H, t, J=7.32 Hz), 4.52 (2H, q, J=7.32 Hz), 7.18 (1H, dd, J=2.69, 6.84 Hz), 7.58 (1H, d, J=2.69 Hz), 8.36 (1H, d, J=6.84 Hz)
- EI/MS; m/z: 168 (M++1)
- (4-Isopropyl-1,3-thiazol-2-yl)methanol (10 g, 63.6011 mmol) dissolved in dichloromethane (60 ml) was added with thionyl chloride (7 ml, 95.40 mmol) under ice cooling, and then the reaction solution was returned to room temperature and stirred for 20 minutes. The reaction solution was concentrated under reduced pressure, and the residue was subjected to azeotropy with toluene and then diluted with diethyl ether, and further neutralized with saturated aqueous sodium hydrogencarbonate. The organic layer was washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure. The title compound was obtained as the residue without purification (11 g, 100%).
- 1H-NMR (CDCl3) δ: 1.30 (6H, d, J=7.08 Hz), 3.09 (1H, qu, J=7.08 Hz), 4.83 (2H, s), 6.91 (1H, s)
- EI/MS; m/z: 176 (M++1)
- Ethyl 4-hydroxy-2-pyridinecarboxylate (19.5 g, 0.057 mol) dissolved in dimethylformamide (200 ml) was added with a solution of 2-(chloromethyl)-4-isopropyl-1,3-thiazole (11 g, 0.063 mol) in dimethylformamide (150 ml). The mixture was added with potassium iodide (9.5 g) and potassium carbonate (12 g) at room temperature, then heated to 110° C. and stirred for 1 hour. The reaction solution was returned to room temperature, and the solvent was evaporated under reduced pressure. The residue was diluted with chloroform and washed with water. The resulting organic layer was washed with saturated brine, and the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (chloroform) to obtain 8.049 g (46%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.32 (6H, d, J=6.86 Hz), 1.44 (3H, t, J=7.10 Hz), 3.12 (1H, qu, J=6.86 Hz), 4.47 (2H, q, J=7.10 Hz), 5.44 (2H, s), 6.94 (1H, s), 7.09 (1H, dd, J=2.694, 5.63 Hz), 7.80 (1H, d, J=2.694 Hz), 8.58 (1H, d, J=5.63 Hz)
- EI/MS; m/z: 307 (M++1)
- Ethyl 4-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinecarboxylate (7.44 g, 24.28 mmol) dissolved in ethanol (50 ml) was added dropwise with 1 N sodium hydroxide (27 ml, 26.70 mmol) at room temperature, and stirred at room temperature for 1 hour and 30 minutes. The solvent was evaporated under reduced pressure, and the resulting Na salt crystals were washed with ethyl acetate.
- The crystals were added with 4 N hydrochloric acid (27 ml) and 1,4-dioxane (40 ml), stirred and concentrated under reduced pressure. The residue was subjected to azeotropy with toluene, and the solvent was completely evaporated. The resulting crystals were filtered with chloroform:methanol=10:1, and the filtrate was concentrated under reduced pressure. The resulting pale yellow crystals were purified by silica gel column chromatography (chloroform:methanol=20:1→10:1→5:1) to obtain 6.7 g (100%) of the title compound as white crystals.
- 1H-NMR (CD3OD) δ: 1.37 (6H, d, J=6.83 Hz), 3.22 (1H, qu, J=6.83 Hz), 5.96 (2H, s), 7.54 (1H, s), 7.92 (1H, dd, J=2.68, 6.83 Hz), 8.22 (1H, d, J=2.68 Hz), 8.80 (1H, d, J=6.83 Hz)
- EI/MS; m/z: 279 (M++1).
- 4-[(4-Isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinecarboxylic acid (50 mg, 0.18 mmol) was added with toluene (12 ml), triethylamine (63 μl, 0.45 mmol) and diphenyl phosphorylazide (78 μl, 0.36 mmol) and refluxed by heating at 140° C. for 7 hours. The reaction solution was returned to room temperature, added with tert-butanol (12 ml) and refluxed again by heating at 140° C. The reaction solution was stirred for 18 hours and then returned to room temperature, and the solvent was evaporated under reduced pressure. The residue was purified by thin layer silica gel chromatography (chloroform:methanol=40:1) to obtain 33 mg (53%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.32 (6H, d, J=6.86 Hz), 1.53 (9H, s), 3.11 (1H, qu, J=6.86 Hz), 5.40 (2H, s), 6.60 (1H, dd, J=2.45, 5.88 Hz), 6.91 (1H, s), 7.73 (1H, s), 8.15 (1H, dd, J=2.45, 5.88 Hz)
- EI/MS; m/z: 350 (M++1)
- tert-Butyl N-{4-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridyl}carbamate (706 mg, 2.202 mmol) dissolved in dichloromethane (20 ml) was added dropwise with trifluoroacetic acid (20 ml) under ice cooling, then warmed to room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure, diluted with chloroform, then neutralized with saturated aqueous sodium hydrogencarbonate and extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=50:1→30:1→20:1) to obtain 331 mg (66%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.32 (6H, d, J=6.83 Hz), 3.11 (1H, qu, J=6.83 Hz), 5.31 (2H, s), 6.08 (1H, d, J=1.95 Hz), 6.35 (1H, dd, J=1.95, 5.85 Hz), 6.91 (1H, s), 7.91 (1H, d, J=5.85 Hz)
- 4-[(4-Isopropyl-1,3-thiazol-2-yl)methoxy]-2-pyridinamine (378 mg, 1.52 mmol) dissolved in xylene (15 ml) was added with trichlorophenyl malonate (750 mg, 1.62 mmol) and refluxed by heating at 140° C. for 1 hour and 30 minutes. The reaction solution was returned to room temperature and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=100:1→80:1→50:1) to obtain 307 mg (64%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.33 (6H, d, J=6.84 Hz), 3.15 (1H, qu, J=6.84 Hz), 5.23 (1H, s), 5.60 (2H, s), 6.95 (1H, dd, J=2.44, 7.57 Hz), 7.01 (1H, s), 7.06 (1H, d, J=2.44 Hz), 8.99 (1H, d, J=7.57 Hz)
- EI/MS; m/z: 318 (M++1)
- Dimethylformamide (3 ml) was added with phosphorus oxychloride (130 μl, 1.42 mmol) under ice cooling, and further added dropwise with 2-hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4H-pyrido[1,2-a]pyrimidin-4-one (300 mg, 0.945 mmol) dissolved in dimethylformamide (6 ml) under ice cooling. Then, the reaction solution was returned to room temperature and stirred for 1 hour. The reaction was stopped with saturated aqueous sodium hydrogencarbonate, and the reaction solution was extracted with chloroform. The resulting organic layer was washed with saturated brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=50:1→30:1→10:1) to obtain 45 mg (14%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.32 (6H, d, J=6.84 Hz), 3.13 (1H, qu, J=6.84 Hz), 5.50 (2H, s), 6.94 (1H, d, J=6.85 Hz), 6.99 (2H, s), 8.92 (1H, d, J=6.85 Hz), 10.13 (1H, s)
- EI/MS; m/z: 346 (M++1)
- 2-Hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4-oxo-4H-pyrido[1,2-a]pyr imidin-3-carbaldehyde (45 mg, 0.13 mmol) dissolved in tetrahydrofuran (2 ml) and dimethylformamide (1 ml) was added with (tert-butoxycarbonylmethylene)triphenyl-phosphorane (60 mg, 0.16 mmol) and refluxed by heating at 100° C. for 2 hours. The reaction solution was returned to room temperature and concentrated under reduced pressure, and the residue was purified by thin layer silica gel chromatography (chloroform:methanol=20:1) to obtain 36 mg (62%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.26 (6H, d, J=6.86 Hz), 1.44 (9H, s), 3.08 (1H, qu, J=6.86 Hz), 5.57 (2H, s), 6.82 (1H, d, J=15.92 Hz), 6.90 (1H, d, J=7.83 Hz), 6.96 (1H, s), 7.01 (1H, s), 7.69 (1H, d, J=15.92 Hz), 8.95 (1H, d, J=7.83 Hz)
- EI/MS; m/z: 444 (M++1)
- Reactions were performed in the same manner as in Example 1, (G) by using tert-butyl (E)-3-{2-hydroxy-8-[(4-isopropyl-1,3-thiazol-2-yl)methoxy]-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoate (26 mg, 0.059 mmol) to obtain 24 mg (78%) of the title compound as yellow oily compound.
- 1H-NMR (CDCl3) δ: 1.33 (6H, d, J=7.08 Hz), 1.51 (9H, s), 1.60 (2H, m), 1.83 (2H, m), 3.14 (1H, qu, J=7.08 Hz), 3.56 (3H, m), 3.92 (1H, dd, J=3.91,13.67 Hz), 4.02 (1H, m), 5.44 (2H, s), 6.75 (1H, dd, J=2.68, 7.32 Hz), 6.76 (1H, s), 6.97 (1H, s), 6.98 (1H, d, J=15.62 Hz), 7.48 (1H, d, J=15.62 Hz), 8.86 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 527 (M++1)
- tert-Butyl (E)-3-{2-(3-hydroxypiperidino)-8-[(4-isopropyl-1,3-thiazol-2-yl)-methoxy]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (24 mg, 0.046 mmol) was added with a mixture of 4 N hydrochloric acid and dioxane (1 ml) and stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by thin layer silica gel chromatography (chloroform:methanol=15:1) to obtain 24 mg (100%) of the title compound as yellow crystals.
- 1H-NMR (CD3OD) δ: 1.33 (6H, d, J=7.08 Hz), 1.57 (1H, m), 1.69 (1H, m), 1.89 (1H, m), 2.07 (1H, m), 3.14 (1H, qu, J=7.08 Hz), 3.16 (1H, m), 3.17 (1H, m), 3.82 (2H, m), 4.04 (1H, d, J=9.52 Hz), 5.54 (2H, s), 6.87 (1H, d, J=7.81 Hz), 6.92 (1H, d, J=15.38 Hz), 6.95 (1H, s), 7.18 (1H, s), 7.61 (1H, d, J=15.38 Hz), 8.81 (1H, d, J=7.81 Hz)
- EI/MS; m/z: 471 (M++1)
- 3-Ethylthiophene (2 g, 17.8 mmol) dissolved in diethyl ether (18 ml) was added with a solution of n-butyl lithium in hexane (1.5 M, 14 ml, 21.4 mmol) at room temperature and refluxed by heating at 60° C. for 15 minutes. The reaction solution was returned to room temperature and added dropwise with dimethylformamide (2 ml, 23.2 mmol) dissolved in diethyl ether. After the reaction solution was stirred for 2 hours at room temperature, the reaction was stopped with saturated aqueous ammonium chloride, and the reaction solution was extracted with chloroform. The collected organic layer was washed with saturated brine, then dried over magnesium sulfate and concentrated under reduced pressure.
- The residue was purified by silica gel column chromatography (hexane:ethyl acetate=20:1→10:1) to obtain 2 g (80%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.27 (3H, t, J=7.59 Hz), 2.68 (2H, q, J=7.59 Hz), 7.39 (1H, s), 7.63 (1H, s), 9.87 (1H, s)
- 4-Ethyl-2-thiophenecarbaldehyde (1 g, 7.13 mmol) dissolved in methanol (7 ml) was added with sodium borohydride (135 mg, 3.57 mmol) under ice cooling, stirred for 10 minutes and then further added with sodium borohydride (150 mg, 3.96 mmol) at 0° C. After the reaction solution was stirred under ice cooling for 30 minutes, the reaction was stopped with saturated aqueous ammonium chloride and the reaction solution was extracted with chloroform. The organic layer collected was dried over magnesium sulfate and concentrated under reduced pressure to obtain 1 g (100%) of the title compound without purification.
- 1H-NMR (CDCl3) δ: 1.22 (3H, t, J=7.56 Hz), 2.59 (2H, q, J=7.56 Hz), 4.75 (2H, s), 6.86 (2H, s)
- (4-Ethyl-2-thienyl)methanol (1 g, 7.03 mmol) dissolved in dichloromethane (7 ml) was added with thionyl bromide (0.8 ml, 10.55 mmol) under ice cooling and then warmed to room temperature. The reaction solution was stirred for 20 minutes and then concentrated under reduced pressure, and the residue was neutralized by adding saturated aqueous sodium hydrogencarbonate and extracted with diethyl ether. The organic layer was washed with saturated brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was used in the subsequent reaction without purification.
- tert-Butyl N-(4-methyl-2-pyridyl)carbamate (800 mg, 3.84 mmol) dissolved in tetrahydrofuran (15 ml) was cooled to −78° C. and then added dropwise with a solution of n-butyl lithium in hexane (1.5 M, 6.4 ml, 9.6 mmol). The reaction solution was stirred at room temperature for 1 hour, then cooled to −78° C. again and added dropwise with a solution of the above obtained 3-bromo-2-(bromomethyl)-4-ethylthiophene in tetrahydrofuran (14 ml). After the reaction solution was stirred at −78° C. for 1 hour and the reaction was stopped with saturated brine, the reaction solution was extracted with ethyl acetate. The organic layer collected was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform) to obtain 1.3 g (85%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.15 (3H, t, J=7.57 Hz), 1.55 (9H, s), 2.52 (2H, q, J=7.57 Hz), 2.92 (2H, t, J=8.55 Hz), 3.04 (2H, t, J=8.55 Hz), 6.50 (1H, s), 6.77 (1H, d, J=5.13 Hz), 7.87 (1H, s), 8.18 (1H, d, J=5.13 Hz)
- EI/MS; m/z: 411 (M+)
- tert-Butyl N-{4-[2-(3-bromo-4-ethyl-2-thienyl)ethyl]-2-pyridyl}carbamate (1.34 g, 4.04 mmol) dissolved in dichloromethane (40 ml) was added with trifluoroacetic acid (40 ml) at 0° C. and stirred at 0° C. for 3 hours. The reaction solution was concentrated under reduced pressure, neutralized with saturated sodium hydrogencarbonate and extracted with chloroform, and then the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:ethyl acetate=3:1→1:1 ethyl acetate only) to obtain 524 mg (56%) of the title compound.
- 1H-NMR (CD3OD) δ: 1.12 (3H, t, J=7.56 Hz), 2.48 (2H, q, J=7.56 Hz), 2.79 (2H, t, J=7.56 Hz), 3.01 (2H, t, J=7.56 Hz), 6.40 (1H, s), 6.46 (1H, d, J=5.36 Hz), 6.53 (1H, s), 7.76 (1H, d, J=5.36 Hz)
- EI/MS; m/z: 310 (M+−1)
- Reactions were performed in the same manner as in Example 4, (B) by using 4-[2-(3-bromo-4-ethyl-2-thienyl)ethyl]-2-pyridylamine as a starting material. After the reaction was completed, the reaction solution was concentrated under reduced pressure and the crystals in the resulting turbid solution was removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform→chloroform:ethyl acetate=1:1→ethyl acetate→ethyl acetate:methanol=50:1→30:1 →10:1) to obtain 180 mg (38%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.14 (3H, t, J=7.56 Hz), 2.49 (2H, q, J=7.56 Hz), 3.15 (4H, s), 5.31 (1H, s), 6.53 (1H, s), 7.12 (1H, d, J=7.07 Hz), 7.24 (1H, s), 8.98 (1H, d, J=7.07 Hz)
- 8-[2-(3-Bromo-4-ethyl-2-thienyl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (96 mg, 0.25 mmol) dissolved in toluene (6 ml) was added with tributyltin hydride (75 μl 1) and 2,2-azobisisobutyronitrile (4 mg, 0.025 mmol) and refluxed by heating at 140° C. Then 2,2-azobisisobutyronitrile and tributyltin hydride were further added until the reaction was completed while the progress of the reaction was monitored by LC-MS. 34 mg (0.22 mmol) of 2,2-azobisisobutyronitrile and 350 μl (1.30 mmol) of tributyltin hydride were used. The reaction solution was returned to room temperature and the reaction was stopped with an aqueous solution of potassium fluoride. The reaction solution was extracted with ethyl acetate, and the organic layer was washed with saturated brine. Then, the aqueous layer was extracted with ethyl acetate. The organic layer collected was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by thin layer silica gel chromatography (chloroform:methanol=20:1) to obtain 119 mg of the title compound with contained impurities.
- 1H-NMR (CDCl3) δ: 1.28 (3H, t, J=7.32 Hz), 2.56 (2H, q, J=7.32 Hz), 3.04 (2H, t, J=8.06 Hz), 3.17 (2H, t, J=8.06 Hz), 5.34 (1H, s), 5.63 (1H, s), 6.74 (1H, d, J=4.88 Hz), 7.04 (1H, d, J=7.08 Hz), 7.35 (1H, s), 9.02 (1H, d, J=7.08 Hz)
- ES-MS: 301 (M++1)
- Reactions were performed in the same manner as in Example 2, (A) by using 8-[2-(4-ethyl-2-thienyl)ethyl]-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one (122 mg, 0.406 mmol) as a starting material. As a result, 122 mg of the title compound was obtained as a yellow oily substance in a mixture with impurities.
- 1H-NMR (CDCl3) δ: 1.20 (3H, t, J=7.57 Hz), 2.56 (2H, q, J=7.57 Hz), 3.01 (2H, t, J=7.32 Hz), 3.16 (2H, t, J-7.32 Hz), 3.66 (4H, t, J=4.88 Hz), 3.78 (4H, t, J=4.88 Hz), 5.62 (1H, s), 6.64 (1H, s), 6.73 (2H, m), 7.11 (1H, s), 8.79 (1H, d, J=7.08 Hz)
- ES-MS; m/z: 370 (M++1)
- Reactions were performed in the same manner as in Example 1, (I) by using 8-[2-(4-ethyl-2-thienyl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (122 mg, 0.33 mmol) as a starting material. As a result, 52 mg (40% for the three steps) of the title compound in orange color was obtained.
- 1H-NMR (CDCl3) δ: 1.20 (3H, t, J=7.56 Hz), 2.56 (2H, q, J=7.56 Hz), 3.02 (2H, t, J=8.04 Hz), 3.17 (2H, t, J=8.04 Hz), 3.73 (4H, d, J=4.88 Hz), 3.82 (4H, d, J=4.88 Hz), 6.64 (1H, s), 6.74 (1H, s), 6.76 (1H, dd, J=1.95, 7.07 Hz), 7.03 (1H, s), 8.74 (1H, d, J=7.07 Hz), 10.11 (1H, s)
- EI/MS; m/z: 398 (M++1)
- Reactions were performed in the same manner as in Example 1, (J) by using 8-[2-(4-ethyl-2-thienyl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde (52 mg, 0.13 mmol) as a starting material. As a result, 65 mg of the title compound was obtained as an orange oily substance in a mixture with triphenylphosphine oxide.
- 1H-NMR (CDCl3) δ: 1.20 (3H, t, J=7.59 Hz), 1.51 (9H, s), 2.56 (2H, q, J=7.59 Hz), 3.04 (2H, t, J=8.08 Hz), 3.17 (2H, t, J=8.08 Hz), 3.60 (4H, t, J=4.41 Hz), 3.83 (4H, t, J=4.41 Hz), 6.63 (1H, s), 6.73 (1H, s), 6.82 (1H, dd, J=1.96, 7.35 Hz), 7.05 (1H, d, J=15.68 Hz), 7.17 (1H, s), 7.69 (1H, d, J=15.68 Hz), 8.87 (1H, d, J=7.35 Hz)
- EI/MS; m/z: 496 (M++1)
- Reactions were performed in the same manner as in Example 1, (L) by using tert-butyl (E)-3-{8-[2-(4-ethyl-2-thienyl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]-pyrimidin-3-yl}-2-propenoate (65 mg, 0.13 mmol) as a starting material. As a result, 32 mg (56%) of yellow crystals were obtained.
- 1H-NMR (CDCl3) δ: 1.20 (3H, t, J=7.57 Hz), 2.56 (2H, q, J=7.57 Hz), 3.05 (2H, t, J=7.81 Hz), 3.18 (2H, t, J=7.81 Hz), 3.63 (4H, t, J=4.40 Hz), 3.84 (4H, t, J=4.40 Hz), 6.63 (1H, s), 6.74 (1H, s), 6.84 (1H, dd, J=1.95, 7.32 Hz), 7.11 (1H, d, J=15.38 Hz), 7.18 (1H, s), 7.69 (1H, d, J=15.38 Hz), 8.88 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 440 (M++1)
- N1-(4-Methyl-2-pyridyl)acetamide (25 g, 0.168 mol) suspended in water (250 ml) was added with potassium permanganate (76.1 g, 0.50 mol) at 100° C. over 1 hour and then stirred for 40 minutes. The reaction solution was returned to room temperature, and black crystals were removed by filtration. The resulting filtrate was added with 12 N hydrochloric acid until pH of the solution became 3 to 4. After the reaction solution was stirred for about 15 minutes, the deposited white crystals were collected by filtration, washed with water, and dried by using a vacuum pump to obtain 7.65 g (25%) of the title compound without purification.
- 1H-NMR (CD3OD) δ: 2.20 (3H, s), 7.59 (1H, dd, J=1.47, 5.13 Hz), 8.42 (1H, dd, J=0.73, 5.13 Hz), 8.63 (1H, s)
- EI/MS; m/z: 179 (M+)
- 2-(Acetylamino)isonicotinic acid (500 mg, 2.8 mmol) was added dropwise with thionyl chloride (15 ml, 68.5 mmol) at room temperature, warmed to 80° C. and stirred for 30 minutes. The reaction solution was returned to room temperature, concentrated under reduced pressure, and the residue was subjected to azeotropy with toluene to evaporate excessive thionyl chloride. The resulting yellow crystals was added to a mixed solution of pyridine (0.25 ml), dichloromethane (5 ml) and 4-(tert-butyl)-1,3-thiazol-2-amine (525 mg, 3.35 mmol) under ice cooling. The mixture was stirred at 0° C. for 30 minutes, then warmed to room temperature, and further stirred for 2 hours and 30 minutes. The reaction solution was added with water and extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=80:1→50:1) to obtain 545.8 mg (61%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.31 (9H, s), 2.26 (3H, s), 6.61 (1H, s), 7.63 (1H, dd, J=0.49, 5.14 Hz), 8.44 (1H, d, J=5.14 Hz), 8.51 (1H, brd), 8.72 (1H, s)
- EI/MS; m/z: 319 (M++1)
- N4-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-(acetylamino)isonicotinamide (546 mg) dissolved in ethanol (12 ml) was added dropwise with concentrated hydrochloric acid (1.2 ml) at room temperature and stirred at 80-90° C. for 1 hour. The reaction solution was returned to room temperature, concentrated under reduced pressure, neutralized with 1 N sodium hydroxide and extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=60:1→20:1) to obtain 247.2 mg (52%) of the title compound as white crystals.
- 1H-NMR (CD3OD) δ: 1.33 (9H, s), 6.63 (1H, d, J=0.73 Hz), 7.05 (1H, t, J=0.73 Hz), 7.09 (1H, ddd, J=0.73, 1.46, 5.36 Hz), 8.13 (1H, dd, J=0.73, 5.36 Hz)
- EI/MS; m/z: 275 (M+−1)
- N4-[4-(tert-Butyl)-1,3-thiazol-2-yl]-2-aminoisonicotinamide (200 mg, 0.724 mmol) was added with xylene (20 ml) and trichlorophenyl malonate (370 mg, 0.796 mmol) and refluxed by heating at 130° C. The reaction solution was stirred for 1 hour, then returned to room temperature and concentrated under reduced pressure. The resulting orange crystals was taken by filtration, washed with chloroform, dried under reduced pressure to obtain 209 mg (84%) of the title compound as orange crystals without purification.
- 1H-NMR (DMSO-d6) δ: 1.31 (9H, s),3.45 (2H, m), 6.88 (1H, s), 7.77 (1H, d, J=7.08 Hz), 8.02 (1H, s), 8.99 (1H, d, J=7.08 Hz)
- EI/MS; m/z: 345 (M++1)
- Reactions were performed in the same manner as in Example 2, (A) by using N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]pyrimidine-8-carboxamide (209 mg, 0.607 mmol). The resulting crude product was purified by silica gel column chromatography (chloroform:methanol=50:1→30:1) to obtain 147 mg of the title compound in a mixture with byproducts.
- 1H-NMR (CD3OD) δ: 1.36 (9H, s), 3.46 (4H, t, J=4.64 Hz), 3.58 (4H, t, J=4.64 Hz), 5.71 (1H, s), 6.64 (1H, s), 7.51 (1H, d, J=7.57 Hz), 7.99 (1H, s), 8.89 (1H, d, J=7.57 Hz)
- EI/MS; m/z: 414 (M++1)
- Dimethylformamide (1 ml) was added dropwise with phosphorus oxychloride (66 μl, 0.712 mmol) under ice cooling, then warmed to room temperature, and stirred for 15 minutes. The reaction solution was cooled to 0° C. with ice, added with N8-[4-(tertbutyl)-1,3-thiazol-2-yl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-c arboxamide (147 mg, 0.356 mmol) dissolved in dimethylformamide (4 ml) under ice cooling, and stirred at 0° C. for 2 hours and 30 minutes. The reaction solution was neutralized with saturated aqueous sodium hydrogencarbonate and concentrated under reduced pressure. The resulting residue was added with chloroform for extraction, and the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=40:1) to obtain 98.2 mg of the title compound as yellow crystals in a mixture with dimethylformamide.
- 1H-NMR (CDCl3) δ: 1.34 (9H, s), 3.78 (4H, d, J=4.88 Hz), 3.82 (4H, d, J=4.88 Hz), 6.59 (1H, s), 7.44 (1H, dd, J=1.71, 7.32 Hz), 7.86 (1H, s), 8.87 (1H, d, J=7.32 Hz), 10.16 (1H, s)
- EI/MS; m/z: 442 (M++1)
- N8-[4-(tert-Butyl)-1,3-thiazol-2-yl]-3-formyl-2-morpholino-4-oxo-4H-pyrido-[1,2-a]pyrimidine-8-carboxamide (98.2 mg, 0.223 mmol) was added with tetrahydrofuran (6 ml), lithium chloride (30 mg, 0.669 mmol) and bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)-phosphonate (142 μl, 0.669 mmol), then added dropwise with 1,8-diazabicyclo[5.4.0]undec-7-ene (92 μg 1,0.669 mmol) at room temperature, stirred at room temperature for 1 hour, and further added with bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)-phosphonate (75 μl) and 1,8-diaza-bicyclo[5.4.0]undec-7-ene (45 μl). The reaction solution was further stirred at room temperature for 30 minutes and concentrated under reduced pressure. The resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=40:1) to obtain 145.8 mg of the title compound in a mixture with 1,8-diazabicyclo[5.4.0]undec-7-ene.
- 1H-NMR (CD3OD) δ: 1.35 (9H, s), 3.70 (4H, m), 3.78 (4H, m), 3.86 (3H, s), 6.62 (1H, s), 7.12 (1H, d, J=15.63 Hz), 7.41 (1H, s), 7.58 (1H, d, J=7.57 Hz), 7.59 (1H, d, J=15.63 Hz), 8.98 (1H, d, J=7.57 Hz)
- EI/MS; m/z: 498 (M++1)
- Methyl (E)-3-[8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (145.8 mg, 0.293 mmol) was added with methanol (2 ml), tetrahydrofuran (5 ml) and water (1 ml), and then added dropwise with 1 N sodium hydroxide (1 ml) at room temperature. After the reaction solution was stirred at room temperature for 1 hour, the solution was further added with 1 N sodium hydroxide (2 ml) and further stirred at room temperature for 15 hours. The reaction solution was added with 1 N hydrochloric acid until pH of the solution became 4 and extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=20:1) to obtain 15.4 mg (5% for the four steps) of the title compound as yellow crystals.
- 1H-NMR (DMSO-d6) δ: 1.27 (9H, s), 3.70 (4H, m), 3.78 (4H, m), 6.54 (1H, brd), 6.93 (1H, d, J=15.38 Hz), 7.48 (1H, d, J=15.38 Hz), 7.78 (1H, d, J=7.08 Hz), 8.05 (1H, s), 8.88 (1H, d, J=7.08 Hz)
- ES-MS: 484 (M++1), 482 (M+−1)
- Thiourea (2.3 g, 30.0 mmol) was dissolved in ethanol (100 ml), added with 2-bromo-1-cyclobutyl-1-ethanone synthesized in the same manner as in Example 1, (E), and then heated to 100° C. The reaction solution was stirred for 1 hour, then returned to room temperature, neutralized with saturated sodium hydrogencarbonate and extracted with chloroform. The collected organic layer was washed with saturated brine, dried over magnesium sulfate and then concentrated under reduced pressure.
- The title compound was obtained as the residue without purification as a brown oily substance (5.4 g, 100%).
- 1H-NMR (CDCl3) δ 1.86 (1H, m), 1.98 (1H, qu, J=9.31 Hz), 2.12-2.37 (4H, m), 3.38 (1H, qu, J=8.08 Hz), 5.36 (2H, brd), 6.07 (1H, s)
- Reactions were performed in the same manner as in Example 7, (B) by using 2-(acetylamino)isonicotinic acid (3.3 g, 18.42 mmol) as the starting material and 4-cyclobutyl-1,3-thiazol-2-amine (3 g, 18.42 mmol) to obtain 3.76 g (65%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.91 (1H, m), 2.03 (1H, qu, J=9.03 Hz),2.15-2.42 (4H, m), 2.23 (3H, s), 3.55 (1H, qu, J=8.55 Hz), 6.63 (1H, s), 7.56 (1H, d, J=5.13 Hz), 8.37 (1H, s), 8.66 (1H, s)
- EI/MS; m/z: 317 (M++1)
- Reactions were performed in the same manner as in Example 7, (C) by using N4-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(acetylamino)isonicotinamide (3.76 g, 11.9 mmol) to obtain 1.73 g (53%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.94-2.37 (6H, m), 3.58 (1H, qu, J=8.57 Hz), 6.67 (1H, s), 7.07 (1H, s), 7.09 (1H, d, J=5.14 Hz), 8.10 (1H, d, J=5.14 Hz)
- EI/MS; m/z: 273 (M+−1)
- Reactions were performed in the same manner as in Example 7, (D) by using N4-(4-cyclobutyl-1,3-thiazol-2-yl)-2-aminoisonicotinamide (1.73 g, 6.3 mmol) to obtain 1.85 g (86%) of the title compound as brown solid.
- 1H-NMR (DMSO-d6) δ: 1.85-1.98 (2H, m), 2.16-2.27 (4H, m), 3.47 (2H, m), 3.57 (1H, m), 6.91 (1H, s), 7.74 (1H, d, J=7.35 Hz), 8.27 (1H, s), 8.97 (1H, d, J=7.35 Hz)
- EI/MS; m/z: 343 (M++1)
- N8-(4-Cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]-pyrimidine-8-carboxamide (100 mg, 0.29 mmol) was added with acetonitrile (2 ml) and dimethylformamide (1 ml), cooled to −10° C. with ice, then added with diphenyl chlorophosphate (0.2 ml, 0.96 mmol), and further added dropwise with diisopropylethylamine (0.3 ml, 1.74 mmol). The reaction solution was stirred at −10° C. for 30 minutes, then added with 3-hydroxypiperidine (90 mg, 0.89 mmol), warmed to room temperature, and then further warmed to 80° C. As the reaction was not completed, the reaction solution was further added with 3-hydroxypiperidine (60 mg), stirred for 1 hour, and further added with 3-hydroxypiperidine (70 mg). After the disappear of the starting material was observed, the reaction was stopped with saturated aqueous sodium hydrogencarbonate, and the reaction solution was extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=15:1) to obtain 85.2 mg (69%) of the title compound as yellow crystals.
- 1H-NMR (CDCl3) δ: 1.60-2.06 (6H, m), 2.21-2.35 (4H, m), 3.57 (4H, m), 3.95 (2H, m), 5.75 (1H, s), 6.62 (1H, s), 7.28 (1H, dd, J=1.71, 7.56 Hz), 7.74 (1H, s), 8.87 (1H, d, J=7.56 Hz)
- EI/MS; m/z: 426 (M++1)
- Reactions were performed in the same manner as in Example 7, (F) by using N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(3-hydroxypiperidino)-4-oxo-4H-pyrido[1,2-a]-pyrimidine-8-carboxamide (85.2 mg, 0.20 mmol) to obtain 27.5 mg (30%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.84-2.38 (10H, m), 3.43-3.63 (4H, m), 3.90 (1H, m), 4.08 (1H, m), 6.61 (1H, s), 7.39 (1H, d, J=7.07 Hz), 7.82 (1H, s), 8.87 (1H, d.J=7.07 Hz), 10.09 (1H, s)
- EI/MS; m/z: 454 (M++1)
- Reactions were performed in the same manner as in Example 7, (G) by using N8-(4-cyclobutyl-1,3-thiazol-2-yl)-3-formyl-2-(3-hydroxypiperidino)-4-oxo-4H-pyrido-[1,2-a]pyrimidine-8-carboxamide (27.5 mg, 0.061 mmol) to obtain 16.3 mg (53%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.91 (5H, m), 2.06 (1H, m), 2.20 (2H, m), 2.38 (2H, m), 3.61 (4H, m), 3.68 (3H, s), 3.88 (1H, m), 4.04 (1H, m), 6.60 (1H, s), 7.14 (1H, d, J=15.63 Hz), 7.47 (1H.dd, J=1.95, 7.57 Hz), 7.57 (1H, d, J=15.63 Hz), 7.94 (1H, s), 8.99 (1H, d, J=7.57 Hz)
- EI/MS; m/z: 610 (M++1)
- Reactions were performed in the same manner as in Example 7, (H) by using methyl (E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-hydroxy-piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (16.3 mg, 0.032 mmol) to obtain 11 mg (69%) of the title compound as orange crystals.
- 1H-NMR (CD3OD) δ: 1.59-2.08 (6H, m), 2.27-2.37 (4H, m), 3.62 (3H, s), 3.87 (2H, m), 4.08 (1H, d, J=12.21 Hz), 6.69 (1H, s), 7.09 (1H, d, J=15.87 Hz), 7.48 (1H, d, J=15.87 Hz), 7.60 (1H, dd, J=1.95, 7.32 Hz), 8.07 (1H, s), 8.94 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 496 (M++1)
- Reactions were performed in the same manner as in Example 8, (E) by using N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]pyrimidine-* 8-carboxamide (60 mg, 0.174 mmol) and N-methylpiperazine (60 μl, 0.52 mmol) as regents to obtain 51.2 mg (69%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.94 (1H, m), 2.04 (1H, m), 2.23 (2H, m), 2.34 (2H, m), 2.35 (3H, s), 2.50 (4H, t, J=5.13 Hz), 3.57 (1H, qu, J=8.30 Hz), 3.72 (4H, brd), 5.68 (1H, s), 6.63 (1H, s), 7.30 (1H.dd, J=1.95, 7.32 Hz), 7.80 (1H, s), 8.95 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 425 (M++1)
- Reactions were performed in the same manner as in Example 7, (F) by using N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(4-methylpiperazino)-4-oxo-4H-pyrido[1,2-a]-pyrimidine-8-carboxamide (51.2 mg, 0.1206 mmol), and the product was used without purification to perform reactions in the same manner as in Example 7,(d) to obtain 24.7 mg (40% for the two steps) of the title compound.
- 1H-NMR (CDCl3) δ 1.94 (1H, m), 2.05 (1H, m), 2.23 (2H, m), 2.34 (3H, s), 2.35 (2H, m), 2.54 (4H, m), 3.58 (1H, qu, J=8.54 Hz), 3.68 (4H, m), 3.81 (3H, s), 6.62 (1H, s), 7.16 (1H, d, J=15.63 Hz), 7.43 (1H, dd, J=1.95, 7.57 Hz), 7.57 (1H, d, J=15.63 Hz), 7.88 (1H, s), 8.99 (1H, d, J=7.57 Hz)
- EI/MS; m/z: 509 (M++1)
- Reactions were performed in the same manner as in Example 7, (H) by using methyl (E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(4-methyl-piperazino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (24.7 mg, 0.049 mmol) to obtain 14.1 mg (59%) of the title compound in yellow color.
- 1H-NMR (CD3OD) δ: 1.96-2.38 (6H, m), 2.37 (3H, s), 2.61 (4H, m), 3.59 (1H, m), 3.67 (4H, m), 6.66 (1H, s), 7.08 (1H, d, J=15.63 Hz), 7.48 (1H, d, J=15.63 Hz), 7.61 (1H.dd, J=1.71, 7.57 Hz), 8.09 (1H, s), 8.96 (1H, d, J=7.57 Hz)
- EI/MS; m/z: 495 (M++1)
- Ethyl 1H-tetrazole-5-acetate (30 g, 0.192 mol) was dissolved in dimethylformamide (100 ml), cooled with ice, and added with potassium carbonate (32 g, 0.231 mol). The mixture was added dropwise with 4-methoxybenzochloride (31 ml, 0.231 mol) and stirred at room temperature for 21 hours. The reaction solution was concentrated under reduced pressure and subjected to azeotropy with toluene. The resulting residue was diluted with ethyl acetate and washed with water, and the compound dissolved in the aqueous layer was extracted with ethyl acetate. The organic layer collected was dried over magnesium sulfate. The organic layer was concentrated under reduced pressure, and then the residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1) to obtain 24 g (46%) of the title compound as a colorless transparent substance.
- 1H-NMR (CDCl3) δ: 1.25 (3H, t, J=7.07 Hz), 3.79 (3H, s), 3.93 (2H, s), 4.18 (2H, qu, J=7.07 Hz), 5.68 (2H, s), 6.88 (2H, d, J=8.78 Hz), 7.31 (2H, d, J=8.78 Hz)
- EI/MS; m/z: 275 (M+−1)
- Dimethylformamide dimethylacetal (13 ml, 97.3 mmol) was dissolved in ethyl 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetate (24 g, 88.4 mmol) and heated to 100° C. for 3 hours with stirring. The reaction solution was purified by silica gel column chromatography (hexane:ethyl acetate=3:1→1:1→1:3) to obtain 14 g (48%) of yellow crystals.
- 1H-NMR (CDCl3) δ: 1.26 (3H, t, J=7.07 Hz), 2.04 (6H, s), 3.79 (3H, s), 4.11 (2H, qu, J=7.07 Hz), 5.70 (2H, s), 6.86 (2H, d, J=9.02 Hz), 7.30 (2H, d, J=9.02 Hz), 7.73 (1H, s)
- EI/MS; m/z: 332 (M++1)
- 2-(Acetylamino)isonicotinic acid (13 g, 73.60 mmol) synthesized by the method of Example 7, (A) was added with ethanol (50 ml) and toluene (150 ml) and heated to 100-110° C. The mixture was added dropwise with concentrated sulfuric acid (7 ml) and heated for 11 hour with stirring. The reaction solution was returned to room temperature and poured into saturated aqueous sodium hydrogencarbonate cooled with ice. The mixture was extracted with chloroform and the collected organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain 7.6 g (23% for the two steps) of the title compound as pale yellow crystals without purification.
- 1H-NMR (CDCl3) δ: 1.39 (3H, t, J=7.07 Hz), 4.37 (2H, qu, J=7.07 Hz), 4.63 (2H, brd), 7.07 (1H, s), 7.17 (1H, dd, J=0.98, 5.12 Hz), 8.18 (1H, d, J=5.12 Hz)
- EI/MS; m/z: 165 (M+−1)
- Ethyl 2-aminoisonicotinate (6.5 g, 39.23 mmol) was added with acetic acid (500 ml) and ethyl 3-(dimethylamino)-2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-2-propenoate (13 g, 39.23 mmol) and refluxed by heating at 130° C. for 5 hours. The reaction solution was returned to room temperature and poured into water, and this was extracted with chloroform. The resulting organic layer was washed with saturated brine, and the collected organic layer was dried over magnesium sulfate. The organic layer was concentrated under reduced pressure and subjected to azeotropy with toluene, and the resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=80:1→50:1→30:1) to obtain 8.6 g of the title compound.
- 1H-NMR (CDCl3) δ: 1.45 (3H, t, J=7.08 Hz), 3.79 (3H, s), 4.49 (2H,q, J=7.08 Hz), 5.82 (2H, s)6.89 (2H, d, J=8.54 Hz), 7.30 (2H, d, J=8.54 Hz), 7.74 (1H, d, J=6.59 Hz), 8.39 (1H, s), 9.28 (1H, s), 9.29 (1H, d, J=6.59 Hz)
- EI/MS; m/z: 407 (M++1)
- Ethyl 3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]-pyrimidine-8-carboxylate (8.6 g, 21.1 mmol) was dissolved in tetrahydrofuran (170 ml) and added dropwise with 0.5 N aqueous sodium hydroxide (65 ml) at room temperature. The reaction solution was stirred for 1 hour and 30 minutes, then added with 1 N hydrochloric acid (55 ml) and water (250 ml) under ice cooling and warmed to room temperature with stirring. The deposited yellow crystals were taken by filtration, washed with water, dissolved in ethanol and concentrated under reduced pressure. The resulting crystals were dried under reduced pressure to obtain 4 g (27% for the two steps) of the title compound without purification.
- 1H-NMR (CDCl3) δ: 3.81 (3H, s), 5.83 (2H, s), 6.92 (2H, d, J=8.55 Hz), 7.43 (2H, d, J=8.55 Hz), 7.83 (1H, dd, J=1.22, 7.32 Hz), 8.40 (1H, s), 9.23 (1H, s), 9.31 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 379 (M++1)
- 3-[2-(4-Methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]-pyrimidine-8-carboxylic acid (40 mg, 0.114 mmol) was added with dimethylformamide (2 ml), 4-(tert-butyl)-1,3-thiazol-2-amine (20 mg, 0.125 mmol), 1-hydroxybenzotriazole (20 mg, 0.136 mmol) and 4-dimethylaminopyridine (21 mg, 0.170 mmol) at room temperature, then added with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (35 mg, 0.170 mmol) at room temperature, and stirred at room temperature for 24 hours. The reaction solution was added dropwise with 1 N hydrochloric acid (3 ml) at room temperature, and the deposited yellow crystals were taken by filtration and washed with water. The crystals were dissolved in chloroform and ethanol, concentrated under reduced pressure, and dried to obtain the title compound as yellow crystals without purification. The product was dissolved in anisole (0.2 ml) and trifluoroacetic acid (5 ml), stirred at room temperature for 5 hours, and added with water. The deposited yellow crystals were collected by filtration and washed with water, and the resulting crystals were dissolved in chloroform and ethanol and concentrated under reduced pressure. The crude crystals was added with ethanol, taken by filtration and washed with diethyl ether to obtain 28 mg (67% for the two steps) of the title compound as yellow crystals.
- 1H-NMR (CD3OD) δ 1.38 (9H, s), 6.66 (1H, s), 8.10 (1H, d, J=8.30 Hz), 8.57 (1H, s), 9.38 (1H, d, J=8.30 Hz), 9.39 (1H, s)
- EI/MS; m/z: 397 (M++1)
- 4-Acetylpyridine (3.62 g, 29.9 mmol) was added with acetic acid (30 ml) and 47% hydrobromic acid (5.3 ml) at room temperature, subsequently added dropwise with bromine (1.6 ml in total) four times at an interval of 5 minutes, stirred at room temperature for 2 hours and 30 minutes. The mixture was further added with bromine (1.6 ml), and stirred at room temperature for 20 hours. The reaction solution was filtered, and the resulting crystals were washed with diethyl ether and dried to obtain 12.43 g of the title compound as a salt of hydrogen bromide in the form of orange crystals without purification.
- 1H-NMR (CD3OD) δ: 3.73 (2H, dd, J=1.21,28.76 Hz), 8.26 (2H, d, J=6.83 Hz), 8.89 (2H, d, J=6.83 Hz)
- EI/MS; m/z: 279 (M+−1)
- Reactions were performed in the same manner as in Example 8, (A) by using 2-bromo-1-(4-pyridyl)-1-ethanone (1 g, 3.56 mmol) to obtain 410 mg (65%) of the title compound.
- 1H-NMR (CD3OD) δ: 7.26 (1H, s), 7.80 (2H, d, J=6.35 Hz), 8.50 (2H, d, J=6.35 Hz)
- EI/MS; m/z: 176 (M+−1)
- Reactions were performed in the same manner as in Example 10, (F) by using 3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-c arboxylic acid (120 mg, 0.32 mmol) and 4-(4-pyridyl)-1,3-thiazol-2-amine (62 mg, 0.35 mmol) to obtain 35.7 mg (27% for the two steps) of the title compound as orange crystals.
- 1H-NMR (DMSO-d6) δ: 8.03 (3H, m), 8.29 (1H, s), 8.66 (1H, d, J=0.977 Hz), 8.73 (2H, d, J=5.62 Hz), 9.29 (1H, s), 9.32 (1H, d, J=6.54 Hz)
- ES-MS; m/z: 418 (M++1)
- IR (cm−1): 1668, 1633, 1567, 1492, 1288
- Reactions were performed in the same manner as in Example 10, (F) by using 3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-c arboxylic acid (60 mg, 0.16 mmol) and 2-aminobenzothiazole (30 mg, 0.17 mmol) to obtain 2 mg (3% for the two steps) of an orange compound.
- 1H-NMR (DMSO-d6) δ: 7.39 (1H, t, J=7.57 Hz), 7.52 (1H, t, J=7.57 Hz), 7.78 (1H, d, J=7.57 Hz), 8.05 (2H, d, J=7.57 Hz), 8.61 (1H, s), 9.28 (1H, s), 9.31 (1H, d, J=7.57 Hz)
- ES-MS; m/z: 391 (M++1)
- Reactions were performed in the same manner as in Example 9, (A) by using N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]pyrimidine-8-carboxamide (40 mg, 0.12 mmol), and the resulting compound was added with 4 N hydrochloric acid solution in dioxane (2 ml) and stirred to obtain 12 mg (24%) of the title compound as hydrochloride. NMR for free form and Mass:
- 1H-NMR (CDCl3) δ: 1.94 (1H, m), 2.04 (1H, m), 2.23 (2H, m), 2.34 (2H, m), 2.35 (3H, s), 2.50 (4H, t, J=5.13 Hz), 3.57 (1H, qu, J=8.30 Hz), 3.72 (4H, brd), 5.68 (1H, s), 6.63 (1H, s), 7.30 (1H.dd, J=1.95, 7.32 Hz), 7.80 (1H, s), 8.95 (1H, d, J=7.32 Hz)
- EI/MS; m/z: 425 (M++1)
- (A) N8-(4-Isopropyl-1,3-thiazol-2-yl)-3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide
- 3-[2-(4-Methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]-pyrimidine-8-carboxylic acid (250 mg, 0.66 mmol) was dissolved in dimethylformamide (6 ml), added with N,N-carbonylbis-1H-imidazole (abbreviated as “CDI” hereinafter, 160 mg, 0.991 mmol) and heated to 90° C. with stirring. After 1 hour and 30 minutes, the reaction solution was further added with CDI (170 mg), further stirred for 1 hour, and then further added with CDI (170 mg). The reaction solution was stirred further 2 hours, then returned to room temperature, added with 4-isopropyl-1,3-thiazol-2-amine hydrobromide (1.32 mmol) and stirred at room temperature for 2 hours and 30 minutes. The reaction solution was added with 2 N hydrochloric acid (7 ml), and the deposited crystals were collected by filtration and washed with water. The resulting yellow crystals were dissolved in chloroform and washed with saturated brine, and the collected organic layer was dried over magnesium sulfate and concentrated under reduced pressure to obtain the title compound as yellow crystals without purification.
- 1H-NMR (CD3OD) δ: 1.34 (6H, d, J=6.83 Hz), 3.00 (1H, qu, J=6.83 Hz), 3.80 (3H, s), 5.85 (2H, s), 6.63 (1H, s), 6.92 (2H, d, J=8.78 Hz), 7.44 (2H, d, J=8.78 Hz), 8.04 (1H, dd, J=1.46, 7.56 Hz), 8.50 (1H, s), 9.20 (1H, s), 9.34 (1H, d, J=7.56 Hz)
- EI/MS; m/z: 503 (M++1)
- N8-(4-Isopropyl-1,3-thiazol-2-yl)-3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (330 mg, 0.66 mmol) was added with trifluoroacetic acid (10 ml) at room temperature and stirred for 3 days. The reaction solution was poured into ice water, and the deposited yellow crystals were collected by filtration, washed with water, then dissolved in chloroform and ethanol, and concentrated under reduced pressure. The resulting yellow crystals were suspended in a small amount of ethanol, and the crystals were taken by filtration and washed with diethyl ether to obtain 54 mg (21% for the two steps) of the title compound as yellow crystals.
- 1H-NMR (DMSO-d6) δ: 1.27 (6H, d, J=6.84 Hz), 2.93 (1H, m), 6.90 (1H, s), 8.02 (1H, d, J=7.08 Hz), 8.55 (1H, s), 9.26 (1H, s), 9.29 (1H, d, J=7.08 Hz)
- ES-MS; m/z: 383 (M++1)
- Reactions were performed in the same manner as in Example 7, (F) by using N8-(4-cyclobutyl-1,3-thiazol-2-yl)-2-(3-hydroxypiperidino)-4-oxo-4H-pyrido[1,2-a]-pyrimidine-8-carboxamide (85 mg, 0.20 mmol) to obtain 21 mg (22%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.92-2.41 (10H, m), 3.58-3.68 (3H, m), 3.93 (2H, m), 5.10 (1H, m), 6.61 (1H, s), 7.39 (1H, dd, J=1.95, 7.31 Hz), 7.79 (1H, d, J=1.95 Hz), 8.01 (1H, s), 8.89 (1H, d, J=7.31 Hz), 10.14 (1H, s)
- EI/MS; m/z: 482 (M++1)
- Reactions were performed in the same manner as in Example 1, (J) by using 1-(8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-3-formyl-4-oxo-4H-pyrido[1,2-a]-pyrimidin-2-yl)-3-piperidyl formate (36 mg, 0.075 mmol), and the resulting reaction solution was purified by thin layer silica gel chromatography (chloroform:methanol=30:1) to obtain 35 mg of the title compound as orange crystals in a mixture with triphenylphosphine oxide.
- 1H-NMR (CDCl3) δ: 1.52 (9H, s), 1.94-2.00 (6H, m), 2.23-2.34 (4H, m), 3.57-3.83 (5H, m), 5.15 (1H, m), 6.62 (1H, s), 7.09 (1H, d, J=15.63 Hz), 7.48 (1H, dd, J=1.71, 7.32 Hz), 7.49 (1H, d, J=15.63 Hz), 7.91 (1H, s), 8.09 (1H, s), 8.98 (1H, d, J=7.32 Hz)
- Reactions were performed in the same manner as in Example 1, (K) by using tert-butyl (E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-formyloxy-piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (35 mg, 0.060 mmol), and the resulting crude crystals were purified by thin layer silica gel chromatography (chloroform:methanol=40:1) to obtain 16 mg (40% for the two steps) of the title compound as yellow crystals.
- 1H-NMR (CDCl3) δ: 1.52 (9H, s), 1.72-2.07 (6H, m), 2.17-2.38 (4H, m), 3.60 (4H, m), 3.80 (1H, m), 4.02 (1H, m), 6.61 (1H, s), 7.10 (1H, d, J=15.60 Hz), 7.48 (1H, dd, J=1.71, 7.31 Hz), 7.49 (1H, d, J=15.60 Hz), 7.97 (1H, s), 9.00 (1H, d, J=7.31 Hz)
- EI/MS; m/z: 552 (M++1)
- tert-Butyl (E)-3-[8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-2-(3-hydroxypiperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (16 mg, 0.029 mmol) was dissolved in ethyl acetate (3 ml), added with trichloroacetyl isocyanate (10 μl) under ice cooling, stirred at 0° C. for 1 hour, then further added with trichloroacetyl isocyanate (10 μl), and further stirred for 30 minutes. Then, the reaction solution was concentrated under reduced pressure, and the resulting residue was added with methanol (2 ml), water (0.2 ml) and sodium formate (12 mg) at room temperature and stirred at room temperature for 7 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by thin layer silica gel chromatography (chloroform:methanol=30:1) to obtain 20 mg of the title compound.
- 1H-NMR (CDCl3) δ: 1.51 (9H, s), 1.90-2.36 (10H, m), 3.36-3.77 (4H, m), 4.04 (1H, m), 4.92 (1H, m), 6.62 (1H, s), 7.10 (1H, d, J=15.38 Hz), 7.54 (1H, d, J=7.57 Hz), 7.60 (1H, d, J=15.38 Hz), 8.07 (1H, s), 9.00 (1H, d, J=7.57 Hz)
- EI/MS; m/z: 595 (M++1)
- tert-Butyl (E)-3-(2-{3-[(aminocarbonyl)oxy]piperidino}-8-{[(4-cyclobutyl-1,3-thiazol-2-yl)amino]carbonyl}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (20 mg, 0.034 mmol) was added with a mixed solution of 4 N hydrochloric acid and dioxane (1.5 ml) at room temperature and stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=10:1) to obtain 9 mg (58% for the two steps) of the title compound as yellow crystals.
- 1H-NMR (CD3OD) δ: 1.68 (2H, m), 1.94-2.10 (4H, m), 2.23 (2H, m), 2.38 (2H, m), 3.39-3.72 (4H, m), 3.98 (1H, dd, J=5.86, 11.70 Hz), 4.86 (1H, m), 6.64 (1H, s), 7.10 (1H, d, J=15.63 Hz), 7.56 (1H, d, J=7.32 Hz), 7.68 (1H, d, J=15.63 Hz), 8.07 (1H, s), 8.96 (1H, d, J=7.32 Hz)
- ES-MS; m/z: 539 (M++1)
- (E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid (222.7 mg, 0.49 mmol) dissolved in tetrahydrofuran (8 ml) was added with triethylamine (342 μl) and ethyl chloroformate (141 μl 1) at −20° C., then stirred at room temperature for 1 hour, and subsequently added with aqueous sodium borohydride (0.8 M, 4 ml) at room temperature. The aqueous sodium borohydride was occasionally added until the reaction was completed, and the completion of the reaction was confirmed by TLC. Then, the reaction solution was added with water and extracted with chloroform and chloroform:methanol=10:1, and the organic layer collected was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=100:1→60:1→30:1) to recover 81 mg (37%) of the title compound and 82 mg of the starting material.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.83 Hz), 3.07 (1H, qu, J=6.83 Hz), 3.19 (2H, t, J=7.80 Hz), 3.36 (2H, t, J=7.80 Hz), 3.53 (4H, t, J=4.88 Hz), 3.80 (4H, t, J=4.88 Hz), 4.35 (2H, d, J=5.85 Hz), 6.44 (1H, d, J=15.60 Hz), 6.72 (1H, s), 6.83 (1H, dd, J=1.95, 7.31 Hz), 7.00 (1H, dt, J=5.85, 15.60 Hz) 7.21 (1H, s), 8.87 (1H, d, J=7.31 Hz)
- EI/MS; m/s: 441 (M++1)
- 3-[(E)-3-Hydroxy-1′-propenyl]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (81 mg, 0.18 mmol) was added with dichloromethane (3 ml) and a solution of diethyl zinc in hexane (1.02 M, 270 μl, 0.275 mmol) and subsequently added dropwise with iodomethane (30 μl, 0.366 mmol) at room temperature. After the reaction solution was stirred for 2 hours, the reaction was stopped with saturated aqueous ammonium chloride, and the reaction solution was extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=15:1) to obtain 61 mg (73%) of the title compound.
- 1H-NMR (CDCl3) δ: 0.90 (1H, m), 1.04 (2H, m), 1.29 (6H, d, J=6.84 Hz), 1.52 (1H, dt, J=5.62, 7.57 Hz), 3.07 (1H, qu, J=6.84 Hz), 3.17 (2H, t, J=7.32 Hz), 3.35 (2H, t, J=7.32 Hz), 3.56 (2H, m), 3.84 (6H, m), 4.12 (1H, d, J=9.52 Hz), 4.68 (1H, brd), 6.73 (1H, s), 6.78 (1H, dd, J=1.71, 7.32 Hz), 7.16 (1H, s), 8.80 (1H, d, J=7.32 Hz)
- EI/MS; m/s: 455 (M++1)
- 3-[2-(Hydroxymethyl)cyclopropyl]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (55 mg, 0.121 mmol) dissolved in acetone (10 ml) was added dropwise with Jones' reagent (130 μl, 0.363 mmol) under ice cooling with and stirred for 2 hours. Then, the reaction solution was further added with Jones' reagent (165 μl) and stirred for 2 hours. Then, the reaction was stopped with saturated sodium thiosulfate, and the reaction solution was extracted with chloroform. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue was purified by thin layer silica gel chromatography (chloroform:methanol=10:1) to obtain 2.2 mg (4%) of the title compound as yellow crystals.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=7.07 Hz), 1.35 (1H, dt, J=4.39, 7.80 Hz), 1.63 (1H, dt, J=4.39, 8.53 Hz), 1.85 (1H, dt, J=3.90, 8.53 Hz), 2.34 (1H, dt, J=3.90, 7.80 Hz), 3.07 (1H, qu, J=7.07 Hz), 3.18 (2H, t, J=7.07 Hz), 3.35 (2H, t, J=7.07 Hz), 3.58 (2H, m), 3.77 (6H, m), 6.72 (1H, s), 6.80 (1H, dd, J=1.46, 7.31 Hz), 7.17 (1H, s), 8.81 (1H, d, J=7.31 Hz)
- EI/MS; m/s: 469 (M++1)
- Reactions were performed in the same manner as in Example 8, (E) by using N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]pyrimidine-8-carboxamide (300 mg, 0.871 mmol) and (R)-(+)-3-hydroxypiperidine (530 mg, 5.226 mmol) to obtain 241.8 mg (65%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.34 (9H, s), 1.57 (1H, m), 1.76 (1H, m), 1.96 (2H, m), 3.61 (3H, m), 3.90 (2H, m), 5.69 (1H, s), 6.60 (1H, s), 7.31 (1H, dd, J=1.71, 7.32 Hz), 7.76 (1H, s), 8.86 (1H, d, J=7.32 Hz)
- EI/MS; m/s: 428 (M++1)
- Reactions were performed in the same manner as in Example 7, (F) by using N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-[(3R)-3-hydroxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (295 mg, 0.690 mmol) and phosphorus oxychloride (130 μl, 1.38 mmol) to obtain 277 mg (68%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.34 (9H, s), 1.70 (1H, m), 1.87-2.03 (3H, m), 3.66 (2H, m), 3.91 (2H, m), 5.09 (1H, brd), 6.58 (1H, s), 7.52 (1H, dd, J=1.71, 7.32 Hz), 7.96 (1H, s), 8.01 (1H, s), 8.87 (1H, d, J=7.32 Hz), 10.14 (1H, s)
- EI/MS; m/s: 484 (M++1)
- Reactions were performed in the same manner as in Example 1, (J) by using (3R)-1-[8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino]carbonyl}-3-formyl-4-oxo-4H-pyrido-[1,2-a]pyrimidin-2-yl]hexahydro-3-pyridinyl formate (277 mg, 0.5723 mmol), and the resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=100:1→70:1→50:1) to obtain 559 mg (100% or more) of the title compound as a brown oily substance in a mixture with byproducts.
- 1H-NMR (CDCl3) δ: 1.28 (9H, s), 1.53 (9H, s), 1.71-1.97 (4H, m), 3.46-3.73 (4H, m), 5.09 (1H, brd), 6.56 (1H, s), 7.09 (1H, d, J=15.60 Hz), 7.64 (1H, dd, J=1.95, 7.31 Hz), 7.65 (1H, d, J=15.60 Hz), 8.01 (1H, s), 8.05 (1H, s), 8.82 (1H, d, J=7.31 Hz)
- EI/MS; m/s: 580 (M+−1)
- Reactions were performed in the same manner as in Example 1, (K) by using tert-butyl (E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3R)-3-formyloxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (559 mg, 0.961 mmol) to obtain 368 mg (69%) of the title compound as an orange oily substance.
- 1H-NMR (CDCl3) δ: 1.32 (9H, s), 1.52 (9H, s), 1.77-1.90 (4H, m), 3.54-3.73 (4H, m), 4.01 (1H, brd), 6.54 (1H, s), 7.04 (1H, d, J=15.63 Hz), 7.64 (1H, dd, J=1.95, 7.32 Hz), 7.65 (1H, d, J=15.63 Hz), 8.00 (1H, s), 8.84 (1H, d, J=7.32 Hz)
- Reactions were performed in the same manner as in Example 15, (E) by using tert-butyl (E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3R)-3-hydroxy-hexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (140 mg, 0.253 mmol) as a mixture containing triphenylphosphine oxide to obtain 42 mg (33%) of the title compound as orange crystals.
- 1H-NMR (CD3OD) δ: 1.36 (9H, s), 1.61 (2H, m), 1.92 (1H, m), 2.06 (1H, m), 3.21 (1H, dd, J=8.55, 12.94 Hz), 3.36 (1H, m), 3.86 (2H, m), 4.10 (1H, d, J=12.94 Hz), 6.68 (1H, s), 7.05 (1H, d, J=15.63 Hz), 7.60 (1H, dd, J=1.95, 7.32 Hz), 7.61 (1H, d, J=15.63 Hz), 8.05 (1H, s), 8.95 (1H, d, J=7.32 Hz) ES-MS; m/s: 498 (M++1)
- Reactions were performed in the same manner as in Example 15, (D) by using tert-butyl (E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino) carbonyl)-2-[(3R)-3-hydroxy-hexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (240 mg, 0.436 mmol) to obtain 254 mg (98%) of an orange oily compound.
- 1H-NMR (CDCl3) δ: 1.30 (9H, s), 1.49 (9H, s), 1.69-2.17 (4H, m), 3.34 (1H, m), 3.54 (1H, m), 3.65 (1H, m), 3.87 (1H, m), 4.93 (1H, brd), 6.60 (1H, s), 7.07 (1H, d, J=15.63 Hz), 7.56 (1H, dd, J=1.95, 7.33 Hz), 7.68 (1H, d, J=15.63 Hz), 8.06 (1H, s), 8.96 (1H, d, J=7.33 Hz)
- Reactions were performed in the same manner as in Example 15, (E) by using tert-butyl (E)-3-[2-{(3R)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(tert-butyl)-1,3-thiazol-2-yl]aminocarbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (254 mg, 0.426 mmol) containing byproducts to obtain 51 mg (22%) of the title compound as orange crystals.
- 1H-NMR (CD3OD) δ: 1.35 (9H, s), 1.68 (1H, m), 1.94 (3H, m), 3.46 (1H, m), 3.66 (3H, m), 3.98 (1H, dd, J=4.88, 13.43 Hz), 4.87 (1H, s), 6.63 (1H, s), 7.10 (1H, d, J=15.63 Hz), 7.56 (1H, dd, J=1.95, 7.33 Hz), 7.68 (1H, d, J=15.63 Hz), 8.06 (1H, s), 8.96 (1H, d, J=7.33 Hz)
- EI/MS; m/s: 541 (M++1)
- Reactions were performed in the same manner as in Example 8, (E) by using N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]pyrimidine-8-carboxamide (600 mg, 1.74 mmol) and (S)-(−)-3-hydroxypiperidine hydrochloride (360 mg, 2.61 mmol) to obtain 463 mg (62%) of the title compound.
- 1H-NMR (CDCl3) δ: 1.35 (9H, s), 1.59 (1H, brd), 1.73-1.99 (3H, m), 3.61 (3H, m), 3.93 (2H, m), 5.71 (1H, s), 6.61 (1H, s), 7.31 (1H, d, J=7.32 Hz), 7.77 (1H, s), 8.89 (1H, d, J=7.32 Hz)
- EI/MS; m/s: 428 (M++1)
- Reactions were performed in the same manner as in Example 7, (F) by using N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-[(3S)-3-hydroxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (463 mg, 1.08 mmol) and phosphorus oxychloride (0.3 ml, 3.25 mmol) to obtain 600 mg (100%) of the title compound as a substance containing dimethylformamide without purification.
- 1H-NMR (CDCl3) δ: 1.32 (9H, s), 1.72 (1H, m), 1.89-2.04 (3H, m), 3.68 (2H, m), 3.92 (2H, d, J=3.90 Hz), 5.09 (1H, brd), 6.59 (1H, s), 7.47 (1H, dd, J=1.95, 7.31 Hz), 7.89 (1H, s), 8.01 (1H, s), 8.88 (1H, d, J=7.31 Hz), 10.14 (1H, s)
- Reactions were performed in the same manner as in Example 1, (J) by using (3S)-1-[8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-3-formyl-4-oxo-4H-pyrido-[1,2-a]pyrimidin-2-yl]hexahydro-3-pyridinyl formate (524 mg, 1.083 mmol), and the resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=100:1→70:1→50:1) to obtain 742 mg (100% or more) of the title compound as a brown oily substance in a mixture containing byproducts.
- 1H-NMR (CDCl3) δ: 1.28 (9H, s), 1.53 (9H, s), 1.68-2.03 (4H, m), 3.48-3.71 (4H, m), 5.10 (1H, m), 6.57 (1H, s), 7.09 (1H, d, J=15.63 Hz), 7.64 (1H, dd, J=1.95, 7.32 Hz), 7.65 (1H, d, J=15.63 Hz), 7.99 (1H, s), 8.06 (1H, s), 8.85 (1H, d, J=7.32 Hz)
- EI/MS; m/s: 580 (M+−1)
- Reactions were performed in the same manner as in Example 1, (K) by using tert-butyl (E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3S)-3-formyloxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (630 mg, 1.083 mmol) to obtain 439 mg (73%) of the title compound as an orange oily substance.
- 1H-NMR (CDCl3) δ: 1.34 (9H, s), 1.52 (9H, s), 1.78-1.90 (4H, m), 3.54 (2H, brd), 3.65-3.74 (2H, m), 4.02 (1H, brd), 6.53 (1H, s), 7.03 (1H, d, J=15.60 Hz), 7.56 (1H, d, J=7.31 Hz), 7.60 (1H, d, J=15.60 Hz), 7.99 (1H, s), 8.84 (1H, d, J=7.31 Hz)
- EI/MS; m/s: 554 (M++1)
- Reactions were performed in the same manner as in Example 15, (D) by using tert-butyl (E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino]carbonyl}-2-[(3S)-3-hydroxy-hexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (140 mg, 0.2529 mmol) to obtain 131 mg (87%) of an orange oily compound.
- 1H-NMR (CDCl3) δ: 1.30 (9H, s), 1.49 (9H, s), 1.70-2.00 (4H, m), 3.35 (1H, m), 3.54 (1H, d, J=12.43 Hz), 3.67 (1H, m), 3.88 (1H, m), 4.92 (1H, brd), 6.60 (1H, s), 7.05 (1H, d, J=15.60 Hz), 7.55 (1H, dd, J=1.95, 7.31 Hz), 7.68 (1H, d, J=15.60 Hz), 8.05 (1H, s), 8.97 (1H, d, J=7.31 Hz)
- EI/MS; m/s: 597 (M++1)
- Reactions were performed in the same manner as in Example 15, (E) by using tert-butyl (E)-3-{2-{(3S)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl}-8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (131 mg, 0.219 mmol) containing by products to obtain 40 mg (3.4%) of the title compound as orange crystals.
- 1H-NMR (CD3OD) δ: 1.35 (9H, s), 1.68 (1H, m), 1.93 (3H, m), 3.49 (1H, m), 3.69 (2H, m), 3.96 (1H, dd, J=5.36, 12.92 Hz), 4.86 (1H, brd), 6.62 (1H, s), 7.11 (1H, d, J=15.60 Hz), 7.55 (1H, dd, J=1.95, 7.56 Hz), 7.68 (1H, d, J=15.60 Hz), 8.06 (1H, s), 8.96 (1H, d, J=7.56 Hz)
- EI/MS; m/s: 541 (M++1)
- Reactions were performed in the same manner as in Example 15, (E) by using tert-butyl(E)-3-{8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-[(3S)-3-hydroxyhexahydro-1-pyridinyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (50 mg, 0.090 mmol) containing triphenylphosphine oxide as a mixture to obtain 17 mg (38%) of the title compound as orange crystals.
- 1H-NMR (CD3OD) δ: 1.39 (9H, s), 1.65 (2H, m), 1.92 (1H, m), 2.04 (1H, m), 3.82-4.03 (5H, m), 6.62 (1H, s), 7.07 (1H, d, J=15.43 Hz), 7.56 (1H, d, J=7.35 Hz), 7.60 (1H, d, J=15.43 Hz), 8.03 (1H, s), 8.95 (1H, d, J=7.35 Hz)
- ES-MS; m/s: 498 (M++1)
- tert-Butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-[(4-methylphenyl)-sulfonyl]oxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenate (31.4 mg, 0.053 mmol) was dissolved in dimethylformamide (1 ml), added with (3R)-(+)-3-(dimethylamino)-pyrrolidine (30.1 mg, 0.26 mmol), and stirred at room temperature for 4 hours. The solvent was evaporated, and the residue was purified by preparative TLC (chloroform:methanol=10:1, v/v) to obtain 16.8 mg of yellow oil.
- The product was added with 4 N hydrochloric acid solution in dioxane (2 ml), and stirred at room temperature for 4 hours. The solvent was evaporated, and the residue was purified by preparative TLC (chloroform:methanol=10:1, v/v). The residue was lyophilized to obtain 11.3 mg (44.5% for the two steps) of the title compound as yellow powder.
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.8 Hz), 1.68-1.80 (1H, m), 2.03-2.15 (1H, m), 2.19 (6H, s), 2.62-2.75 (1H, m), 2.92-3.01 (1H, m), 3.14 (2H, t, J=7.7 Hz), 3.49-3.58 (1H, m), 3.62-3.78 (3H, m), 6.79 (1H, d, J=15.1 Hz), 7.07 (1H, s), 7.08 (1H, dd, J=7.3, 1.7 Hz), 7.22 (1H, s), 7.68 (1H, d, J=15.1 Hz), 8.72 (1H, d, J=7.3 Hz)
- ESI/MS; m/z: 482 (MH+)
- EI/MS; m/z: 481 (M+)
- FAB/MS; m/z: 482 (MH+)
- H-R FAB/MS: Calcd. for C25H31N5O3S: 482.2226, Found: 482.2230
- In a similar manner, the following compounds were synthesized in which the substituent at the 2-position was converted.
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.15-1.32 (2H, m), 1.52-1.83 (5H, m), 2.85 (1H, t, J=11.4 Hz), 2.90-3.10 (2H, m), 3.16 (2H, t, J=7.3 Hz), 3.85 (1H, brd, J=11.8 Hz), 4.01 (1H, brd, J=12.0 Hz), 4.56 (1H, brs), 6.85 (1H, d, J=15.4 Hz), 7.07 (1H, s), 7.15 (1H, dd, J=7.3 Hz), 7.28 (1H, s), 7.42 (1H, d, J=15.7 Hz), 8.75 (1H, d, J=7.1 Hz)
- ESI/MS; m/z: 483 (MH+)
- FAB/MS; m/z: 483 (MH+), 505 (M++Na)
- Anal. Calcd. for C25H30N4O4Si.5/4H2O: C, 50.45; H, 6.49; N, 11.09, Found: C, 50.35; H, 6.16; N, 10.68
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=7.1 Hz), 2.91-3.02 (2H, m), 3.12-3.22 (4H, m), 3.42-3.67 (2H, m), 3.75-3.82 (1H, m), 3.87-3.97 (2H, m), 4.77-4.82 (1H, m), 6.87 (1H, d, J=15.5 Hz), 7.07 (1H, s), 7.20 (1H, dd, J=7.3, 2.0 Hz), 7.34 (1H, s), 7.46 (1H, d, J=15.5 Hz), 8.79 (1H, d, J=7.3 Hz), 11.88 (1H, brs)
- ESI/MS; m/z: 485 (MH+)
- FAB/MS; m/z: 485 (MH+)
- H-RFAB/MS: Calcd. for C24H28N4O5S: 485.1859, Found: 485.1862
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.78-2.00 (2H, m), 2.92-3.02 (1H, m), 3.10-3.18 (3H, m), 3.55-3.64 (1H, m), 3.78-2.92 (2H, m), 4.39-4.46 (1H, m), 5.00 (1H, brd, J=3.4 Hz), 6.79 (1H, d, J=15.2 Hz), 7.06 (1H, d, J=1.7 Hz), 7.07 (1H, dd, J=7.3, 0.7 Hz), 7.18 (1H, d, J=1.7 Hz), 7.68 (1H, d, J=15.2 Hz), 8.70 (1H, d, J=7.3 Hz)
- EI/MS; m/z: 436 (M+−H2O)
- FAB/MS; m/z: 455 (MH+), 477 (M++Na)
- H-R FAB/MS: Calcd. for C23H26N4O4S: 455.1753, Found: 455.1753
- 1H-NMR (DMSO-d6) δ: 1.19 (6H, d, J=6.8 Hz), 2.90-3.10 (1H, m), 3.13 (2H, t, J=7.5 Hz), 4.69 (2H, d, J=5.9 Hz), 7.06 (1H, s), 7.10 (1H, dd, J=7.3, 2.0 Hz), 7.13 (1H, d, J=14.9 Hz), 7.21 (1H, s), 7.32 (1H, dd, J=7.8, 4.9 Hz), 7.74 (1H, d, J=14.9 Hz), 7.75 (1H, brs), 8.32-8.39 (1H, m), 8.40-8.47 (1H, m), 8.58-8.62 (1H, m), 8.73 (1H, d, J=7.3 Hz), 11.82 (1H, brs)
- EI/MS; m/z: 431 (M+−CO2)
- FAB/MS; m/z: 476 (MH+)
- H-R FAB/MS: Calcd. for C25H25N5O3S: 476.1756, Found: 476.1757
- 1H-NMR (DMSO-d6) δ: 1.19 (6H, d, J=6.8 Hz), 1.30-1.48 (1H, m), 1.48-1.62 (1H, m), 1.73-1.88 (1H, m), 1.88-1.98 (1H, m), 2.92-3.01 (2H, m), 3.10-3.21 (3H, m), 3.37 (2H, t, J=7.6 Hz), 3.54-3.65 (1H, m), 3.65-3.75 (1H, m), 3.84-3.92 (1H, m), 3.85-3.63 (1H, m), 6.85 (1H, d, J=15.5 Hz), 7.07 (1H, s), 7.15 (1H, dd, J=7.4, 1.7 Hz), 7.28 (1H, brs), 7.42 (1H, d, J=15.5 Hz), 8.75 (1H, d, J=7.4 Hz)
- FAB/MS; m/z: 469 (MH+)
- H-R FAB/MS: Calcd. for C24H28N4O4S: 469.1910, Found: 469.1927
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.8 Hz), 2.00-2.10 (1H, m), 2.17-2.27 (1H, m), 2.93-3.03 (1H, m), 3.16 (2H, t, J=7.2 Hz), 3.65-3.75 (2H, m), 3.84-3.98 (3H, m), 6.86 (1H, d, J=15.2 Hz), 7.09 (1H, s), 7.13 (1H, d, J=7.3 Hz), 7.25 (1H, s), 7.70 (1H, d, J=15.2 Hz), 8.13-7.28 (2H, br), 8.75 (1H, d, J=7.3 Hz)
- LC/MS; m/z: 454 (MH+)
- FAB/MS; m/z: 454 (MH+)
- H-R FAB/MS: Calcd. for C23H27N5O3S: 454.1913, Found: 454.1920
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.8 Hz), 2.92-3.02 (1H, m), 3.13-3.27 (6H, m), 3.21 (2H, t, J=7.2 Hz), 6.92 (1H, d, J=15.6 Hz), 7.10 (1H, s), 7.27 (1H, d, J=7.1 Hz), 7.40 (1H, s), 7.43 (1H, d, J=15.6 Hz), 8.85 (1H, d, J=7.3 Hz), 9.17 (1H, br)
- LC/MS; m/z: 454 (MH+)
- EI/MS; m/z: 453 (M+)
- FAB/MS; m/z: 454 (MH+), 476 (M++Na)
- H-R FAB/MS: Calcd. for C23H27N5O3S: 454.1913, Found: 454.1912
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.9 Hz), 1.26 (3H, s), 1.27 (3H, s), 2.92-3.02 (1H, m), 3.12-3.25 (4H, m), 3.90-3.98 (2H, m), 6.90 (1H, d, J=15.7 Hz), 7.09 (1H, s), 7.26 (1H, dd, J=7.3, 1.7 Hz), 7.42 (1H, d, J=15.7 Hz), 7.41 (1H, s), 8.83 (1H, d, J=7.3 Hz), 9.03 (1H, d, J=9.6 Hz), 9.50 (1H, br)
- EI/MS; m/z: 481 (M+)
- H-R EI/MS: Calcd. for C25H31N5O3S: 481.2148, Found: 481.2150
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.8 Hz), 1.64-1.78 (2H, m), 2.10-2.19 (2H, m), 2.73 (3H, s), 2.75 (3H, s), 2.93-3.02 (1H, m), 3.03-3.14 (2H, m), 3.19 (2H, t, J=7.2 Hz), 3.38 (2H, t, J=7.2 Hz), 4.02-4.11 (1H, m), 6.91 (1H, d, J=15.5 Hz), 7.09 (1H, s), 7.22 (1H, dd, J=7.3, 1.7 Hz), 7.34 (1H, s), 7.43 (1H, d, J=15.5 Hz), 8.81 (1H, d, J=7.3 Hz), 10.19-10.27 (1H, m)
- FAB/MS; m/z: 496 (MH+)
- H-R FAB/MS: Calcd. for C26H33N5O3S: 496.2382, Found: 496.2386
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 2.84-3.14 (5H, m), 3.20 (2H, t, J=7.1 Hz), 3.63-3.85 (3H, m), 3.85-3.92 (1H, m), 3.97-4.03 (1H, m), 6.90 (1H, d, J=15.5 Hz), 7.08 (1H, s), 7.25 (1H, d, J=7.3 Hz), 7.33 (1H, s), 7.45 (1H, d, J=15.5 Hz), 7.92 (2H, br), 8.82 (1H, d, J=7.6 Hz)
- FAB/MS; m/z: 484 (MH+)
- H-R EI/MS: Calcd. for C24H29N5O4S: 484.2019, Found: 484.1999
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.8 Hz), 2.11-2.31 (2H, m), 2.58-2.64 (3H, m), 2.92-3.02 (1H, m), 3.13-3.21 (2H, m), 3.35-3.42 (2H, m), 3.44-3.52 (1H, m), 3.65-3.75 (1H, m), 3.80-4.05 (3H, m), 6.86 (1H, d, J=15.2 Hz), 7.11 (1H, s), 7.14 (1H, dd, J=7.3, 1.7 Hz), 7.26 (1H, s), 7.68 (1H, d, J=15.2 Hz), 8.76 (1H, d, J=7.3 Hz), 9.05-9.30 (1H, br)
- FAB/MS; m/z: 468 (MH+)
- H-R FAB/MS: Calcd. for C24H29N5O3S: 468.2069, Found: 468.2085
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.8 Hz), 1.68-1.80 (1H, m), 2.03-2.12 (1H, m), 2.18 (6H, s), 2.64-2.73 (1H, m), 2.92-3.03 (1H, m), 3.10-3.18 (2H, m), 2.49-2.58 (1H, m), 2.62-2.79 (3H, m), 6.78 (1H, d, J=15.1 Hz), 7.05-7.08 (2H, m), 7.22 (1H, s), 7.68 (1H, d, J=15.1 Hz), 8.71 (1H, d, J=7.3 Hz)
- FAB/MS; m/z: 482 (MH+), 504 (M++Na).
- H-R FAB/MS: Calcd. for C25H31N5O3S: 482.2226, Found: 482.2231
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.8 Hz), 2.08-2.10 (1H, m), 2.12-2.37 (1H, m), 2.77 (3H, s), 2.92-3.03 (1H, m), 3.12-3.20 (2H, m), 3.50-3.72 (5H, m), 3.75-3.87 (2H, m), 4.08-4.17 (1H, m), 6.80 (1H, d, J=15.4 Hz), 7.10 (1H, s), 7.16 (1H, dd, J=7.3, 1.2 Hz), 7.28 (1H, s), 7.48 (1H, d, J=15.4 Hz), 8.77 (1H, d, J=7.3 Hz), 10.38 (1H, br)
- FAB/MS; m/z: 482 (MH+), 504 (M++Na)
- H-R FAB/MS: Calcd. for C25H31N5O3S: 482.2226, Found: 482.2234
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=7.1 Hz), 1.58-1.72 (2H, m), 1.97-2.08 (2H, m), 2.93-3.03 (1H, m), 3.06-3.17 (2H, m), 3.17-3.23 (2H, m), 3.23-3.55 (3H, m), 3.60-3.75 (2H, m), 6.91 (1H, d, J=15.5 Hz), 7.15 (1H, s), 7.21 (1H, d, J=7.1 Hz), 7.34 (1H, s), 7.42 (1H, d, J=15.5 Hz), 8.19 (2H, br), 8.80 (1H, d, J=7.3 Hz)
- FAB/MS; m/z: 468 (MH+)
- H-R FAB/MS: Calcd. for C24H29N5O3S: 468.2069, Found: 468.2069
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.12-1.35 (2H, m), 1.68-1.82 (3H, m), 2.92-3.07 (3H, m), 3.12-3.21 (2H, m), 3.95-4.03 (2H, m), 4.52-4.57 (1H, m), 6.87 (1H, d, J=15.5 Hz), 7.07 (1H, s), 7.16 (1H, d, J=6.6 Hz), 7.28 (1H, s), 7.41 (1H, d, J=15.5 Hz), 8.75 (1H, d, J=7.1 Hz)
- FAB/MS; m/z: 483 (MH+), 505 (M++Na)
- H-R FAB/MS: Calcd. for C25H30N4O4S: 483.2066, Found: 483.2064
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.8 Hz), 1.58-1.72 (2H, m), 1.77-1.88 (1H, m), 2.00-2.14 (1H, m), 2.92-3.05 (1H, m), 3.03-3.55 (8H, m), 6.91 (1H, d, J=15.5 Hz), 7.13 (1H, s), 7.24 (1H, d, J=6.8 Hz), 7.37 (1H, s), 7.45 (1H, d, J=15.5 Hz), 8.25 (3H, br), 8.82 (1H, d, J=6.8 Hz)
- FAB/MS; m/z: 468 (MH+)
- H-R FAB/MS: Calcd. for C24H29N5O3S: 468.2069, Found: 468.2073
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.8 Hz), 1.55-1.78 (2H, m), 1.78-1.89 (1H, m), 2.05-2.20 (1H, m), 2.62 (3H, s), 2.92-3.03 (1H, m), 3.05-3.55 (8H, m), 3.98-4.07 (1H, m), 6.91 (1H, d, J=15.5 Hz), 7.11 (1H, s), 7.24 (1H, d, J=7.3 Hz), 7.38 (1H, s), 7.44 (1H, d, J=15.5 Hz), 8.82 (1H, d, J=7.3 Hz), 8.90 (1H, br), 9.07 (1H, br)
- EI/MS; m/z: 481 (M+)
- FAB/MS; m/z: 482 (MH+)
- H-R FAB/MS: Calcd. for C25H31N5O3S: 482.2226, Found: 482.2244
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 1.52-1.80 (2H, m), 1.82-1.93 (1H, m), 2.14-2.23 (1H, m), 2.49 (6H, s), 2.80-2.90 (1H, m), 2.90-3.01 (2H, m), 3.01-3.12 (1H, m), 3.17-3.24 (2H, m), 3.32-3.40 (2H, m), 4.02-4.12 (1H, m), 4.27-4.36 (1H, m), 6.74 (1H, s), 6.83 (1H, dd, J=7.3, 1.7 Hz), 7.08 (1H, d, J=15.6 Hz), 7.19 (1H, s), 7.56 (1H, d, J=15.6 Hz), 8.85 (1H, d, J=7.3 Hz)
- EI/MS; m/z: 495 (M+)
- FAB/MS; m/z: 496 (MH+)
- H-R FAB/MS: Calcd. for C26H33N5O3S: 496.2382, Found: 496.2383
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.55-1.67 (2H, m), 1.67-1.84 (1H, m), 1.88-2.00 (1H, m), 2.40-2.50 (1H, m), 2.90-3.12 (3H, m), 3.12-3.22 (2H, m), 3.81-3.91 (1H, m), 4.00-4.12 (1H, m), 6.86 (1H, d, J=15.5 Hz), 6.89 (1H, s), 7.07 (1H, s), 7.17 (1H, d, J=7.1 Hz), 7.29 (1H, br), 7.34 (1H, s), 7.41 (1H, d, J=15.5 Hz), 8.76 (1H, d, J=7.1 Hz), 11.89 (1H, br)
- FAB/MS; m/z: 496 (MH+)
- H-R FAB/MS: Calcd. for C25H29N5O4S: 496.2019, Found: 496.2018
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.60-1.76 (2H, m), 1.76-1.85 (2H, m), 2.35-2.46 (1H, m), 2.92-3.09 (3H, m), 3.12-3.20 (2H, m), 3.92-4.00 (2H, m), 6.82 (1H, s), 6.87 (1H, d, J=15.5 Hz), 7.07 (1H, s), 7.17 (1H, dd, J=7.3, 1.7 Hz), 7.22-7.33 (2H, m), 7.42 (1H, d, J=15.5 Hz), 8.77 (1H, d, J=15.5 Hz), 11.88 (1H, br)
- FAB/MS; m/z: 496 (MH+)
- H-R FAB/MS: Calcd. for C25H29N5O4S: 496.2019, Found: 496.2015
- 1H-NMR (DMSO-d6) δ: 1.70-1.90 (3H, m), 1.00-1.09 (1H, m), 1.20 (6H, d, J=6.9 Hz), 2.91-3.02 (1H, m), 3.13-3.22 (2H, m), 3.22-3.28 (1H, m), 3.62-3.75 (1H, m), 3.77-3.85 (1H, m), 4.19-4.32 (2H, m), 6.87 (1H, d, J=15.2 Hz), 7.08 (1H, s), 7.14 (1H, d, J=6.9, 2.2 Hz), 7.25 (1H, s), 7.68 (1H, d, J=15.2 Hz), 8.16 (2H, br), 8.75 (1H, d, J=6.9 Hz)
- FAB/MS; m/z: 480 (MH+)
- H-R FAB/MS: Calcd. for C25H29N5O3S: 480.2069, Found: 480.2062
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.9 Hz), 2.83-3.07 (2H, m), 3.12-3.20 (2H, m), 3.34-3.42 (2H, m), 3.65-3.83 (2H, m), 3.87-4.10 (3H, m), 4.62-4.70 (1H, m), 4.72-4.81 (1H, m), 6.88 (1H, d, J=15.3 Hz), 7.09 (1H, s), 7.14 (1H, dd, J=7.3, 1.7 Hz), 7.27 (1H, s), 7.68 (1H, d, J=15.3 Hz), 8.29 (2H, br), 8.75 (1H, d, J=7.3 Hz)
- FAB/MS; m/z: 486 (MH+)
- H-R FAB/MS: Calcd. for C24H28FN5O3S: 486.1975, Found: 486.1974
- 1H-NMR (DMSO-d6) δ: 1.19 (6H, d, J=6.9 Hz), 1.30-1.60 (2H, m), 1.73-1.83 (1H, m), 1.83-1.96 (1H, m), 2.90-3.00 (2H, m), 3.08-3.21 (3H, m), 3.52-3.61 (1H, m), 3.63-3.72 (1H, m), 3.82-3.91 (1H, m), 4.85-4.93 (1H, m), 6.84 (1H, d, J=15.4 Hz), 7.07 (1H, s), 7.14 (1H, d, J=6.9 Hz), 7.27 (1H, s), 7.41 (1H, d, J=15.4 Hz), 8.74 (1H, d, J=7.8 Hz), 11.85 (1H, br).
- FAB/MS; m/z: 469 (MH+)
- H-R FAB/MS: Calcd. for C24H28N4O4S: 469.1910, Found: 469.1901
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.31-1.61 (2H, m), 1.74-1.85 (1H, m), 1.85-1.98 (1H, m), 2.90-3.00 (2H, m), 3.08-3.21 (3H, m), 3.53-3.63 (1H, m), 3.63-3.75 (1H, m), 3.83-3.92 (1H, m), 4.86-4.95 (1H, m), 6.85 (1H, d, J=15:7 Hz), 7.07 (1H, s), 7.15 (1H, d, J=6.6 Hz), 7.28 (1H, s), 7.42 (1H, d, J=15.7 Hz), 8.75 (1H, d, J=7.3 Hz), 11.88 (1H, br)
- FAB/MS; m/z: 469 (MH+)
- H-R FAB/MS: Calcd. for C24H28N4O4S: 469.1910, Found: 469.1921
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.8 Hz), 2.93-3.03 (1H, m), 3.13-3.23 (2H, m), 3.43-3.53 (2H, m), 3.65-3.85 (2H, m), 4.25-4.35 (2H, m), 4.50-4.58 (1H, m), 6.92 (1H, d, J=15.2 Hz), 7.10 (1H, s), 7.16 (1H, d, J=7.6 Hz), 7.28 (1H, s), 7.50 (1H, d, J=15.2 Hz), 8.49 (1H, br), 8.77 (1H, d, J=7.1 Hz)
- FAB/MS; m/z: 440 (MH+)
- H-R FAB/MS: Calcd. for C22H25N5O3S: 440.1756, Found: 440.1768
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.8 Hz), 1.75-1.88 (2H, m), 1.93-2.10 (2H, m), 2.91-3.01 (1H, m), 3.14-3.21 (2H, m), 3.32-3.40 (2H, m), 3.40-3.52 (2H, m), 3.52-3.68 (2H, m), 4.83-4.92 (0.5H, m), 4.95-5.04 (0.5H, m), 6.88 (1H, d, J=15.6 Hz), 7.07 (1H, s), 7.19 (1H, dd, J=7.1, 1.5 Hz), 7.33 (1H, s), 7.44 (1H, d, J=15.6 Hz), 8.79 (1H, d, J=7.1 Hz), 11.91 (1H, br)
- FAB/MS; m/z: 470 (MH+)
- H-R FAB/MS: Calcd. for C24H27FN4O3S: 470.1788, Found: 470.1779
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.8 Hz), 2.91-3.01 (1H, m), 3.15-3.22 (2H, m), 3.30-3.41 (6H, m), 3.79-3.87 (4H, m), 6.91 (1H, d, J=15.4 Hz), 7.07 (1H, s), 7.22 (1H, dd, J=7.3, 1.8 Hz), 7.37 (1H, s), 7.52 (1H, d, J=15.4 Hz), 8.81 (1H, d, J=7.3 Hz), 11.94 (1H, br)
- FAB/MS; m/z: 467 (MH+)
- H-R FAB/MS: Calcd. for C24H26N4O4S: 467.1753, Found: 467.1765
- 1H-NMR (CD3OD) δ: 1.35 (6H, d, J=6.8 Hz), 3.12-3.23 (2H, m), 3.25-3.43 (4H, m), 3.53-3.90 (18H, m), 7.10 (1H, d, J=15.7 Hz), 7.18 (1H, s), 7.35 (1H, dd, J=7.1,2.4 Hz), 7.42 (1H, s), 7.57 (1H, d, J=15.7 Hz), 8.94 (1H, d, J=7.1 Hz)
- LC-MS; m/z: 616 (MH+)
- 1H-NMR (CD3OD) δ: 1.26 (6H, d, J=6.8 Hz), 1.70-1.92 (2H, m), 1.92-2.10 (2H, m), 2.98-3.10 (1H, m), 3.17-3.25 (2H, m), 3.36-3.58 (7H, m), 3.68-3.78 (2H, m), 3.82-3.98 (3H, m), 4.00-4.12 (1H, m), 4.39 (1H, d, J=7.3 Hz), 6.95 (1H, d, J=15.6 Hz), 6.96 (1H, s), 7.04 (1H, dd, J=7.3, 1.7 Hz), 7.21 (1H, s), 7.60 (1H, d, J=15.6 Hz), 8.79 (1H, d, J=7.3 Hz)
- FAB/MS; m/z: 631 (MH+)
- H-R FAB/MS: Calcd. for C30H38N4O9S: 631.2438, Found: 631.2485
- 1H-NMR (DMSO-d6) δ: 1.19 (6H, d, J=7.1 Hz), 1.60-1.72 (1H, m), 1.77-1.88 (1H, m), 2.90-3.01 (1H, m), 3.12-3.20 (2H, m), 3.35-3.42 (2H, m), 3.45-3.66 (3H, m), 3.72-3.80 (1H, m), 4.57-4.60 (1H, m), 4.60-4.70 (1H, m), 6.83 (1H, d, J=15.5 Hz), 7.06 (1H, s), 7.13 (1H, d, J=7.6 Hz), 7.26 (1H, s), 7.42 (1H, d, J=15.5 Hz), 8.73 (1H, d, J=7.1 Hz)
- FAB/MS; m/z: 485 (MH+)
- H-R FAB/MS: Calcd. for C24H28N4O5S: 485.1859, Found: 485.1882
- tert-Butyl (E)-3-{8-[2-(4-isoprolyl-1,3-thiazol-2-yl)ethyl]-2-m orpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenate (29.8 mg, 0.058 mmol) was dissolved in methanol (20 ml), added with 10% palladium/carbon (6.0 mg) and stirred at room temperature under hydrogen flow for 4 hours and 30 minutes. After the catalyst was removed by filtration, the solvent was evaporated and the residue was purified by preparative TLC (chloroform:methanol=30:1, v/v) to obtain the title compound (8.0 mg, 26.7%) as a pale yellow oily substance.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 1.43 (9H, s), 2.62-2.70 (2H, m), 2.87-2.93 (2H, m), 3.02-3.12 (1H, m), 3.16-3.23 (2H, m), 3.32-3.47 (6H, m), 3.80-3.86 (4H, m), 6.73 (1H, s), 6.82 (1H, dd, J=7.3, 1.7 Hz), 7.22 (1H, s), 8.81 (1H, d, J=7.3 Hz)
- The tert-Butyl 3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propanoate (8.0 mg, 0.016 mmol) obtained in (A) was added with 4 N hydrochloric acid in dioxane (1 ml), stirred at room temperature for 3 hours, further added with 4 N hydrochloric acid in dioxane (1 ml), and stirred for further 4 hours. The solvent was evaporated, and the residue was purified by preparative TLC (chloroform:methanol=10:1, v/v) and lyophilized from dioxane to obtain the title compound (4.3 mg, 60.4%) as pale yellow powder.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.9 Hz), 2.76 (2H, t, J=6.9 Hz), 2.92 (2H, t, J=6.9 Hz), 3.02-3.12 (1H, m), 3.18-3.25 (2H, m), 3.3.4-3.56 (6H, m), 3.78-3.86 (4H, m), 6.73 (1H, s), 6.88 (1H, dd, J=7.3, 1.7 Hz), 7.26 (1H, s), 8.82 (1H, d, J=7.1 Hz)
- LC/MS; m/z: 457 (MH+), 455 (M+−1)
- EI/MS; m/z: 456 (MH+)
- H-R EI/MS: Calcd. for C23H28N4O4S: 456.1831, Found: 456.1848
- (E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-(4-methyl)piperazino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoic acid (19.9 mg, 0.043 mmol) was dissolved in dimethylformamide (1 ml), added dropwise with methyl iodide (0.1 ml, 1.61 mmol), sealed with a stopper and left in a refrigerator for 14 hours. The solvent and excessive reagents were evaporated, and the residue was lyophilized from dioxane/water to obtain the title compound (29.7 mg, quantitative).
- 1H-NMR (DMSO-d6) δ: 1.21 (6H, d, J=6.9 Hz), 2.55 (6H, s), 2.91-3.02 (1H, m), 3.15-3.26 (2H, m), 3.45-3.55 (4H, m), 3.82-3.92 (4H, m), 6.93 (1H, d, J=15.5 Hz), 7.09 (1H, s), 7.29 (1H, d, J=7.1 Hz), 7.41 (1H, s), 7.45 (1H, d, J=15.5 Hz), 8.14 (1H, br), 8.85 (1H, d, J=7.3 Hz)
- FAB/MS; m/z: 482 (M+)
- H-R FAB/MS: Calcd. for C25H32N5O3S: 482.2226, Found: 482.2216
- tert-Butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-[(4-methylphenyl)-sulfonyl]oxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenate (111.4 mg, 0.19 mmol) was dissolved in dimethylformamide (3 ml), added dropwise with triethylamine (130.4 μl, 0.93 mmol), added with R-(+)-3-hydroxypiperidine hydrochloride (128.7 mg, 0.93 mmol), and stirred at room temperature for 17 hours. The solvent was evaporated, and then the residue was purified by preparative TLC (chloroform:methanol=30:1, v/v) to obtain the title compound (91.4 mg, 93.2%) as yellow oil.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 1.51 (9H, s), 1.72-1.95 (4H, m), 3.01-3.11 (1H, m), 3.16-3.23 (2H, m), 3.32-3.40 (2H, m), 3.49-3.68 (3H, m), 3.88-3.97 (1H, m), 3.97-4.07 (1H, m), 6.74 (1H, s), 6.86 (1H, d, J=7.3 Hz), 7.03 (1H, d, J=15.6 Hz), 7.19 (1H, s), 7.49 (1H, d, J=15.6 Hz), 8.85 (1H, d, J=7.3 Hz)
- The tert-Butyl (E)-3-{2-[(3R)-3-hydroxyhexahydro-1-pyridinyl]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenate (38.9 mg, 0.074 mmol) obtained in (A) was dissolved in ethyl acetate (3 ml), added with trichloroacetyl isocyanate (9.7 μl, 0.082 mmol) under ice cooling, and stirred at the same temperature for 1 hour. The reaction solution was further added with trichloroacetyl isocyanate (9.7 μl, 0.082 mmol), stirred at the same temperature for further 1 hour, and added with chloroform/methanol (10:1, v/v, 6 ml), and the solvent was evaporated. The residue was dissolved in methanol (1.5 ml), added with water (0.2 ml) and sodium formate (9.6 mg, 0.14 mmol) stirred at room temperature for 2 hours and 30 minutes. The mixture was further added with sodium formate (9.6 mg, 0.14 mmol), and stirred at room temperature for further 20 hours. The solvent was evaporated, and the residue was purified by preparative TLC (chloroform:methanol=30:1, v/v) to obtain the title compound (74.9 mg, quantitative) as yellow solid.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.9 Hz), 1.50 (9H, s), 1.80-2.10 (4H, m), 3.02-3.12 (1H, m), 3.15-3.23 (2H, m), 3.23-3.40 (3H, m), 3.45-3.63 (1H, m), 3.65-3.77 (2H, m), 4.75-4.85 (1H, m), 6.73 (1H, s), 6.85 (1H, dd, J=7.3, 1.7 Hz), 7.08 (1H, d, J=15.7 Hz), 7.22 (1H, s), 7.73 (1H, d, J=15.7 Hz), 8.86 (1H, d, J=7.1 Hz)
- The tert-Butyl (E)-3-{2-(3R)-3-[(aminocarbonyl)oxy]hexahydro-1-pyridinyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenate (74.9 mg, 0.074 mmol) obtained in (B) was dissolved in 4 N hydrochloric acid solution in dioxane and stirred at room temperature for 5 hours. After the solvent was evaporated, the residue was purified by preparative TLC (chloroform:methanol=10:1, v/v) and lyophilized from dioxane to obtain the title compound (17.6 mg, 67.5%) as yellow powder.
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.55-1.70 (2H, m), 1.80-1.90 (1H, m), 1.90-2.02 (1H, m), 2.90-3.01 (1H, m), 3.13-3.20 (2H, m), 3.30-3.42 (3H, m), 3.45-3.60 (2H, m), 3.80-3.88 (1H, m), 4.54-4.62 (1H, m), 6.49 (2H, br), 6.87 (1H, d, J=15.4 Hz), 7.07 (1H, s,), 7.17 (1H, dd, J=7.3, 1.7 Hz), 7.32 (1H, s), 7.44 (1H, d, J=15.4 Hz), 8.76 (1H, d, J=7.3 Hz), 11.89 (1H, br)
- FAB/MS; m/z: 512 (MH+)
- H-R FAB/MS: Calcd. for C25H29N5O5S: 512.1968, Found: 512.1970
- The title compound was synthesized in the same manner as in Example 54.
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.53-1.70 (2H, m), 1.80-1.90 (1H, m), 1.90-2.02 (1H, m), 2.91-3.01 (1H, m), 3.13-3.20 (2H, m), 3.30-3.42 (3H, m), 3.45-3.62 (2H, m), 3.80-3.88 (1H, m), 4.53-4.63 (1H, m), 6.49 (2H, br), 6.87 (1H, d, J=15.4 Hz), 7.07 (1H, s,), 7.17 (1H, dd, J=7.3, 1.7 Hz), 7.32 (1H, s), 7.44 (1H, d, J=15.4 Hz), 8.76 (1H, d, J=7.3 Hz), 11.89 (1H, br)
- FAB/MS; m/z: 512 (MH+)
- H-R FAB/MS: Calcd. for C25H29N5O5S: 512.1968, Found: 512.1968
- The title compound was synthesized in the same manner as in Example 54.
- 1H-NMR (DMSO-d6) δ: 1.20 (6H, d, J=6.9 Hz), 1.57-1.70 (2H, m), 1.91-2.01 (2H, m), 2.91-3.01 (1H, m), 3.13-3.20 (2H, m), 3.27-3.40 (4H, m), 3.72-3.82 (2H, m), 4.69-4.78 (1H, m), 6.50 (2H, br), 6.86 (1H, d, J=15.4 Hz), 7.07 (1H, s), 7.18 (1H, dd, J=7.3, 2.0 Hz), 7.32 (1H, s), 7.44 (1H, d, J=15.4 Hz), 8.77 (1H.d, J=7.3 Hz), 11.90 (1H, br)
- FAB/MS; m/z: 512 (MH+)
- H-R FAB/MS: Calcd. for C25H29N5O5S: 512.1968, Found: 512.1964
- Ethyl 2-(1H-1,2,3,4-tetrazol-5-yl)acetate (5.0 g, 32.0 mmol) was dissolved in dimethylformamide (20 ml), added with potassium carbonate (5.75 g, 41.6 mmol). The mixture was further added dropwise with 4-methoxybenzyl chloride (5.21 ml, 38.4 mmol) under ice cooling and stirred at the same temperature for 1 hour and 30 minutes and at room temperature for 15 hours. The solvent was evaporated, and the residue was diluted with toluene, washed with water and saturated brine, and dried over anhydrous sodium sulfate. Then, the solvent was evaporated and the residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1, v/v) to obtain the title compound (3.78 g, 42.7%) as colorless oil.
- 1H-NMR (CDCl3) δ: 1.25 (3H, t, J=7.1 Hz), 3.79 (3H, s), 3.94 (2H, s), 4.19 (2H,q, J=7.1 Hz), 5.68 (2H, s), 6.82-6.92 (2H, m), 7.28-7.38 (2H, m)
- The ethyl 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetate (2.15 g, 7.78 mmol) obtained in (A) was dissolved in tetrahydrofuran/methanol (3:1, v/v, 60 ml), added dropwise with a solution of lithium hydroxide (359.2 mg, 8.56 mmol) in water (15 ml) under ice cooling and then stirred at room temperature for 2 hours. The solvent was evaporated, and the residue was added with 1 N aqueous hydrochloric acid to obtain pH of about 1. The solution was extracted with ethyl acetate, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. Then, the solvent was evaporated to obtain the title compound (1.91 g, 98.8%).
- 1H-NMR (CDCl3): 3.79 (3H, s), 3.99 (2H, s), 5.68 (2H, s), 6.85-6.95 (2H, m), 7.29-7.39 (2H, m)
- The 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetic acid (262.0 mg, 1.05 mmol) obtained in (B) was added dropwise with thionyl chloride (615.9 v 1, 8.44 mmol) under ice cooling and stirred at room temperature for 30 minutes. Excessive regents were evaporated to obtain the title compound (0.27 g, quantitative) as pale yellow oil.
- The 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]ethanoyl chloride (0.27 g, 1.05 mmol) obtained in (C) was dissolved in methylene chloride (3 ml), added dropwise with pyridine (170.2 μl, 2.10 mmol) under ice cooling, and added dropwise with a solution of 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido-[1,2-a]pyrimidin-4-one (80.9 mg, 0.21 mmol) in methylene chloride (3 ml). The reaction solution was stirred at room temperature for 23 hours, then further added with a solution of 2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]ethanoyl chloride (0.27 g, 1.05 mmol) in methylene chloride (2 ml) and pyridine (170.2 μl, 2.10 mmol) under ice cooling. Further, the reaction solution was added with the same amounts of the acid chloride and pyridine twice every 24 hours, and stirred at room temperature. The solvent was evaporated, and the residue was added with saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated and the residue was purified by preparative TLC (hexane:ethyl acetate=1:1, v/v and chloroform:methanol=30:1, v/v) to obtain the title compound (10.1 mg, 7.8%) as yellow oil.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 3.02-3.12 (1H, m), 3.12-3.20 (2H, m), 3.31-3.38 (2H, m), 3.60-3.75 (8H, m), 3.79 (3H, s), 4.68 (2H, s), 5.66 (2H, s), 6.72 (1H, dd, J=7.3, 1.5 Hz), 6.73 (1H, s), 6.86 (2H, d, J=8.6 Hz), 7.03 (1H, s), 7.29 (2H, d, J=8.6 Hz), 8.71 (1H, d, J=7.3 Hz)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-{2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]acetyl}-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (8.9 mg, 0.014 mmol) obtained in (D) was dissolved in trifluoroacetic acid (5 ml) and stirred at room temperature for 18 hours. The solvent was evaporated, and the residue was purified by preparative TLC (chloroform:methanol=10:1, v/v) and lyophilized from dioxane to obtain the title compound (4.8 mg, 67.0%) as pale yellow powder.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.9 Hz), 3.01-3.12 (1H, m), 3.17-3.23 (2H, m), 3.32-3.40 (2H, m), 3.55-3.63 (4H, m), 3.67-3.76 (4H, m), 4.75 (2H, s), 6.74 (1H, s), 6.80 (1H, d, J=7.3 Hz), 7.07 (1H, s), 8.73 (1H, d, J=7.3 Hz)
- FAB/MS; m/z: 495 (MH+)
- H-R FAB/MS: Calcd. for C23H26N8O3S: 495.1927, Found: 495.1955
- N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2,4-dioxo-3,4-dihydro-2H-pyrido[1,2-a]-pyrimidine-8-carboxamide (301.9 mg, 0.88 mmol) was suspended in dimethylformamide (6 ml) and acetonitrile (12 ml), added dropwise with diisopropylethylamine (1.83 ml, 10.5 mmol) and diphenyl chlorophosphate (545.1 μl, 2.63 mmol) at −10° C. under an argon flow, and stirred at the same temperature for 5 minutes and at room temperature for 15 minutes. The reaction solution was cooled to −10° C. again, added dropwise with a solution of 3-[(dimethylamino)carbonyl]piperidine trifluoroacetic acid salt (1.18 g, 4.38 mmol) in dimethylformamide (5 ml), and stirred at room temperature for 1 hour and at about 80° C. for 2 hours. The reaction solution was heated to about 100° C., heated for 30 minutes with stirring, then added with diisopropylethylamine (1.83 ml, 10.5 mmol), and further heated at 100° C. for 3 hours and 30 minutes with stirring. After cooling, the solution was added with saturated aqueous sodium hydrogencarbonate and extracted with chloroform. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate and the solvent was evaporated. The residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=50:1→20:1, v/v) and preparative TLC (chloroform:methanol=20:1, v/v) to obtain the title compound (85.9 mg, 20.3%) as yellow orange oil.
- 1H-NMR (CDCl3) δ: 1.33 (9H, s), 1.42-1.62 (1H, m), 1.70-2.08 (3H, m), 2.57-3.20 (3H, m), 2.99 (3H, s), 3.12 (3H, s), 4.03-4.90 (2H, m), 5.69 (1H, s), 6.60 (1H, s), 7.36-7.22 (1H, m), 7.89 (1H, s), 8.97 (1H, d, J=7.3 Hz)
- LC-MS; m/z: 483 (MH+)
- Dimethylformamide (2 ml) was added dropwise with phosphorus oxychloride (24.9 μl, 0.27 mmol) under ice cooling, and stirred at room temperature for 30 minutes. The reaction solution was cooled with ice again, added dropwise with a solution of the N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-{3-[(dimethylamino)carbonyl]-piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (85.9 mg, 0.18 mmol) obtained in (A) in dimethylformamide (2 ml) and stirred at the same temperature for 2 hours. The reaction solution was added with saturated aqueous sodium hydrogencarbonate and extracted with chloroform. The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate, and the solvent was evaporated to obtain the title compound (84.2 mg, quantitative) as yellow oil.
- 1H-NMR (CDCl3) δ: 1.34 (9H, s), 1.57-2.10 (4H, m), 2.89 (3H, s), 2.97 (3H, s), 3.00-3.28 (3H, m), 4.10-4.45 (2H, m), 6.59 (1H, s), 7.35-7.45 (1H, m), 7.82 (1H, s), 8.95 (1H, s), 8.86 (1H, d, J=7.3 Hz), 10.12 (1H, s)
- ESI/MS; m/z: 511 (MH+)
- The N8-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-{3-[(dimethylamino)carbonyl]-piperidino}-3-formyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carboxamide (84.2 mg, 0.18 mmol) obtained in (B) was dissolved in tetrahydrofuran (10 ml), added with lithium chloride (45.3 mg, 1.07 mmol), and added dropwise with bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl)phosphonate (112.9 μl, 0.53 mmol) and 1,8-diazabicyclo-[5,4,0]undec-7-ene (73.4 μl, 0.53 mmol). After the reaction solution was stirred at room temperature for 2 hours, the solvent was evaporated, and the residue was purified by preparative TLC (chloroform:methanol=20:1, v/v) to obtain the title compound (63.7 mg, 68.2%) as a mixture of orange oil and solid.
- 1H-NMR (CDCl3) δ: 1.35 (9H, s), 1.56-1.70 (1H, m), 1.70-2.00 (3H, m), 2.92-3.20 (3H, m), 2.99 (3H, s), 3.19 (3H, s), 3.78 (3H, s), 3.97-4.03 (1H, m), 4.22-4.30 (1H, m), 6.60 (1H, s), 7.10 (1H, d, J=15.6 Hz), 7.45 (1H, dd, J=7.3, 1.7 Hz), 7.49 (1H, d, J=15.6 Hz), 7.85 (1H, d, J=1.7 Hz), 8.96 (1H, d, J=7.3 Hz)
- The methyl (E)-3-(8-({[4-(tert-butyl)-1,3-thiazol-2-yl]amino}carbonyl)-2-{3-[(dimethylamino)carbonyl]piperidino}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (63.7 mg, 0.11 mmol) obtained in (C) was dissolved in methanol (10 ml), added dropwise with 1 N aqueous sodium hydroxide (562.0 μl, 0.56 mmol), and stirred at room temperature for 1 hour. The reaction solution was further added with 1 N aqueous sodium hydroxide (5.62 ml, 5.62 mmol), stirred at room temperature for 2 hours, further added with 1 N aqueous sodium hydroxide (2.81 ml, 2.81 mmol), and stirred at room temperature for 3 hours. The reaction solution was adjusted to about pH 2 with 1 N hydrochloric acid aqueous solution and extracted with chloroform/methanol (10:1, v/v). The organic layer was washed with saturated brine and dried over anhydrous sodium sulfate, and the solvent was evaporated. The residue was purified by preparative TLC (chloroform:methanol=20:1, v/v) and lyophilized from dioxane to obtain the title compound (37.6 mg, 38.5%, for the three steps) as yellow orange powder.
- 1H-NMR (DMSO-d6) δ: 1.31 (9H, s), 1.60-1.80 (3H, m), 1.85-1.94 (1H, m), 2.84 (3H, s), 2.97-3.05 (1H, m), 3.12 (3H, s), 3.30-3.45 (2H, m), 3.95-4.03 (1H, m), 4.08-4.15 (1H, m), 6.82-6.95 (1H, m), 6.93 (1H, d, J=15.6 Hz), 7.44 (1H, d, J=15.6 Hz), 7.60-7.67 (1H, m), 8.12-8.18 (1H, m), 8.90 (1H, d, J=7.3 Hz)
- FAB/MS; m/z: 553 (MH+)
- H-R FAB/MS: Calcd. for C27H32N6O5S: 553.2233, Found: 553.2236
- The title compound was synthesized in the same manner as in Example 58.
- 1H-NMR (DMSO-d6) δ: 1.31 (9H, s), 1.62-1.72 (6H, m), 3.53-3.62 (4H, m), 6.82-6.92 (1H, m), 6.93 (1H, d, J=15.6 Hz), 7.45 (1H, d, J=15.6 Hz), 7.57-7.62 (1H, m), 8.14-8.20 (1H, m), 8.89 (1H, d, J=7.3 Hz)
- FAB/MS; m/z: 482 (MH+)
- H-R FAB/MS: Calcd. for C24H27N5O4S: 482.1862, Found: 482.1844
- The title compound was synthesized in the same manner as in Example 58.
- 1H-NMR (DMSO-d6) δ: 1.31 (9H, s), 1.58-1.80 (3H, m), 1.89-1.97 (1H, m), 2.59 (3H, d, J=4.4 Hz), 3.18-3.20 (2H, m), 3.30-3.42 (2H, m), 3.90-3.97 (1H, m), 4.11-4.18 (1H, m), 6.79-6.89 (1H, m), 6.93 (1H, d, J=15.6 Hz), 7.43 (1H, d, J=15.6 Hz), 7.60-7.66 (1H, m), 7.77-7.83 (1H, m), 8.19-8.26 (1H, m), 8.90 (1H, d, J=7.6 Hz)
- FAB/MS; m/z: 539 (MH+)
- H-R FAB/MS: Calcd. for C26H30N6O5S: 539.2077, Found: 539.2112
- 2-Amino-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridine (9.8 g) and bis(2,4,6-trichlorophenyl) malonate (18 g) were refluxed by heating in xylene for 30 minutes and left stand for cooling. The reaction mixture was added with ether, and the deposited crystals were collected by filtration, washed with ethyl acetate and dried to obtain the title compound (10.3 g). The reaction solution was combined and the solvent was evaporated. The residue was purified by silica gel column chromatography to further obtain the title compound (1.5 g).
- 1H-NMR (CDCl3): 1.29 (6H, d, J=6.8 Hz), 3.06 (1H, m), 3.34 (2H, m), 3.38 (2H, m), 5.34 (1H, s), 6.74 (1H, s), 7.10 (1H, dd, J=7.1,1.7 Hz), 7.37 (1H, s), 9.02 (1H, d, J=7.1 Hz)
- The 2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]-pyrimidin-4-one (500 mg) obtained in (A) was dissolved in methylene chloride (20 ml), added with triethylamine (0.26 ml) and p-toluenesulfonyl chloride (360 mg) and stirred for 24 hours under nitrogen atmosphere. The reaction solution was added with morpholine (0.83 ml) and stirred for 12 hours, and the solvent was evaporated. The residue was purified by silica gel column chromatography to obtain the title compound (273 mg).
- 1H-NMR (CDCl3): 1.30 (s, 3H), 1.33 (s, 3H), 3.07 (m, 1H), 3.18 (m, 2H), 3.48 (m, 2H), 3.67 (m, 4H), 3.79 (m, 4H), 5.59 (s, 1H), 6.77 (s, 1H), 6.78 (d, 1H), 7.11 (s, 1H), 8.80 (d, 1H)
- Dimethylformamide (10 ml) was added with phosphorus oxychloride (0.60 ml) under ice cooling, stirred for 30 minutes, then added with the 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (1.0 g) obtained in (B), stirred for 1 hour, and added with saturated aqueous sodium hydrogencarbonate to adjust the reaction solution to pH of about 8. The reaction solution was extracted with ethyl acetate, and the organic layer was washed with saturated brine and dried over sodium sulfate. The solvent was evaporated under reduced pressure to obtain the title compound (1.07 g).
- 1H-NMR (CDCl3): 1.31 (s, 3H), 1.33 (s, 3H), 3.10 (m, 1H), 3.22 (m, 2H), 3.42 (m, 2H), 3.73 (m, 4H), 3.81 (m, 4H), 6.80 (s, 1H), 6.82 (d, 1H), 7.09 (s, 1H), 8.75 (d, 1H), 10.11 (s, 1H)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde (110 mg) obtained in (C) and (tert-butoxy-carbonylmethylene)triphenylphosphorane (441 mg) were stirred in tetrahydrofuran (5 ml) at 80° C. for 15 hours. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound (150 mg) as yellow powder.
- 1H-NMR (CDCl3): 1.29 (6H, d, J=6.8 Hz), 1.51 (9H, s), 3.05 (1H, m), 3.20 (2H, m), 3.37 (2H, m), 3.60 (4H, m), 3.83 (4H, m), 6.73 (1H, s), 6.85 (1H, d, J=6.8 Hz), 7.05 (1H, d, J=15.4 Hz), 7.20 (1H, s), 7.50 (1H, d, J=15.4 Hz), 8.87 (1H, d, J=7.1 Hz)
- The tert-butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (39 mg) obtained in (D) was stirred in formic acid (1 ml) for 4.5 hours, and the solvent was evaporated under reduced pressure to obtain the title compound (30 mg).
- 1H-NMR (CD3OD): 1.26 (6H, d, J=6.8 Hz), 3.03 (1H, m), 3.20 (2H, m), 3.31 (2H, m), 3.56 (4H, m), 3.79 (4H, m), 6.94 (1H, d, J=15.6 Hz), 6.96 (1H, s), 7.05 (1H, d, J=6.6 Hz), 7.21 (1H, s), 7.55 (1H, d, J=15.6 Hz), 8.76 (1H, d, J=7.1 Hz)
- The compounds of Examples 62 to 77 mentioned below were synthesized in the same manner as in Example 61.
- 1H-NMR (CD3OD) δ: 3.26 (m, 2H), 3.50 (m, 2H), 3.61 (m, 4H), 3.81 (m, 4H), 6.68 (d, J=15.6 Hz, 1H), 7.12 (d, 1H), 7.32 (s, 1H), 7.62 (d, J=16 Hz, 1H), 8.03 (s, 1H), 8.84 (d, 1H)
- MS (ES+) m/z 481 (M++1)
- 1H-NMR (CDCl3) δ: 1.31 (s, 9H), 3.19 (t, 2H), 3.35 (t, 2H), 3.59 (m, 4H), 3.79 (m, 4H), 6.72 (s, 1H), 6.85 (d, 1H), 7.07 (d, J=16 Hz, 1H), 7.18 (s, 1H), 7.62 (d, J=16 Hz, 1H), 8.84 (d, 1H)
- MS (ES+) m/z 469 (M++1); MS (ES−) m/z 467 (M+−1)
- 1H-NMR (CD3OD) δ:0.70 (m, 2H), 1.03 (m, 2H), 1.41 (s, 3H), 3.18 (t, 2H), 3.37 (t, 2H), 3.59 (m, 4H), 3.80 (m, 4H), 6.92 (s, 1H), 6.98 (d, J=16 Hz, 1H), 7.08 (s, 1H), 7.25 (s, 1H), 7.60 (d, J=16 Hz, 1H), 8.82 (d, 1H)
- MS (ES+) m/z 467 (M++1); MS (ES−) m/z 465 (M+−1)
- 1H-NMR (CDCl3) δ: 1.26 (d, 6H), 2.38 (m, 1H), 2.55 (m, 1H), 2.67 (m, 1H), 2.82 (m, 1H), 3.08 (m, 1H), 3.12 (m, 2H), 3.39 (m, 3H), 3.56 (m, 2H), 3.82 (m, 2H), 3.92 (m, 1H), 6.75 (s, 1H), 6.84 (d, 1H), 7.07 (d, J=14 Hz, 1H), 7.21 (s, 1H), 7.33 (s, 1H), 7.20 (s, 1H), 7.65 (m, 2H), 8.82 (d, 1H)
- MS (ES+) m/z 497 (M++1); MS (ES−) m/z 495 (M+−1)
- 1H-NMR (CDCl3) δ: 1.29 (d, 6H), 2.00 (m, 2H), 2.13 (m, 2H), 2.62 (m, 1H), 3.10 (m, 3H), 3.20 (m, 2H), 3.39 (m, 2H), 4.08 (m, 2H), 6.75 (s, 1H), 6.83 (d, 1H), 7.08 (d, J=15.6 Hz, 1H), 7.22 (s, 1H), 7.69 (d, J=15.6 Hz, 1H), 8.86 (d, 1H)
- MS (ES+) m/z 497 (M++1); MS (ES−) m/z 495 (M+−1)
- 1H-NMR (CDCl3) δ: 1.33 (d, 6H), 2.95 (m, 1H), 3.12 (m, 2H), 3.23 (m, 2H), 3.56 (t, 2H), 3.88 (t, 2H), 4.81 (s, 2H), 6.88 (m, 2H), 7.11 (d, J=15 Hz, 1H), 7.19 (m, 6H), 7.79 (d, J=15 Hz, 1H), 8.86 (d, 1H)
- MS (ES+) m/z 501 (M++1)
- 1H-NMR (CD3OD) δ: 1.12 (s, 3H), 1.23 (d, 6H), 1.65 (m, 2H), 1.97 (m, 1H), 3.08 (m, 1H), 3.2 (m, 3H), 3.39 (m, 4H), 3.68 (m, 2H), 6.95 (d, J=14 Hz, 1H), 6.98 (s, 1H), 7.02 (d, 1H), 7.21 (s, 1H), 7.62 (d, J=14 Hz, 1H), 8.78 (d, 1H)
- MS (ES+) m/z 483 (M++1); MS (ES−) m/z 481 (M+−1)
- 1H-NMR (CDCl3) δ: 1.30 (d, 6H), 1.65 (m, 1H), 1.90 (m, 2H), 2.00 (m, 1H), 2.98 (m, 1H), 3.08 (m, 1H), 3.22 (m, 2H), 3.40 (m, 2H), 3.52 (m, 1H), 3.65 (m, 1H), 3.83 (m, 1H), 4.18 (m, 1H), 6.75 (s, 1H), 6.92 (d, 1H), 7.11 (d, J=15.6 Hz, 1H), 7.25 (s, with CDCl3, 1H), 7.63 (d, J=15.6 Hz, 1H), 8.88 (d, 1H)
- MS (ES+) m/z 478 (M++1); MS (ES−) m/z 476 (M+−1)
- 1H-NMR (CDCl3) δ: 1.33 (d, 6H), 2.04 (m, 4H), 2.95 (m, 1H), 3.21 (m, 3H), 3.55 (m, 4H), 3.79 (m, 2H), 6.92 (m, 2H), 7.08 (d, J=15.6 Hz, 1H), 7.26 (1Hs, with CHCl3, 1H), 7.62 (d, J=15.6 Hz, 1H), 8.89 (d, 1H)
- MS (ES+) m/z 478 (M++1)
- 1H-NMR (CDCl3) δ: 1.29 (d, 6H), 3.05 (m, 1H), 3.22 (t, 2H), 3.40 (t, 2H), 3.46 (m, 1H), 3.7-4.0 (m, 4H), 4.08 (m, 1H), 4.72 (m, 1H), 6.74 (s, 1H), 6.97 (d, 1H), 7.14 (d, J=15.6 Hz, 1H), 7.28 (s, 1H), 7.67 (d, J=15.6 Hz, 1H), 8.90 (d, 1H)
- MS (ES+) m/z 480 (M++1); MS (ES−) m/z 478 (M+−1)
- 1H-NMR (CD3OD) δ: 1.25 (d, 6H), 3.02 (m, 1H), 3.2-3.4 (m, with CHD2OD), 4.24 (m, 1H), 6.96 (s, 1H), 7.04 (d, J=16 Hz, 1H), 7.14 (m, 1H), 7.37 (s, 1H), 7.58 (d, J=16 Hz, 1H), 8.84 (d, 1H)
- MS (ES+) m/z 497 (M++1)
- 1H-NMR (CD3OD) δ: 1.23 (d, 6H), 3.02 (m, 1H), 3.15-3.42 (m, with CHD2OD), 3.62 (m, 1H), 3.95 (m, 1H), 4.75 (m, 1H), 6.96 (s, 1H), 7.05 (m, 2H), 7.37 (m, 2H), 8.82 (d, 1H)
- MS (ES+) m/z 520 (M++Na); MS (ES−) m/z 496 (M+−1)
- 1H-NMR (300 MHz, CD3OD) δ: 1.23 (d, 6H), 3.02 (m, 1H), 3.15-3.42 (m, with CHD2OD), 3.71 (m, 1H), 3.92 (m, 1H), 4.12 (m, 1H), 6.81 (s, 1H), 7.00 (m, 2H), 7.25 (m, 1H), 7.52 (d, J=16 Hz, 1H), 8.82 (d, 1H)
- 1H-NMR (CDCl3+CD3OD) δ: 1.22 (d, 6H), 3.0 (m, 1H), 3.14 (t, 2H), 3.31 (m, 4H), 3.73 (m, 2H), 4.02 (m, 1H), 4.12 (m, 2H), 6.70 (s, 1H), 6.88 (d, 1H), 6.97 (d, J=15.6 Hz, 1H), 7.21 (s, 1H), 7.53 (d, J=15.6 Hz, 1H), 8.78 (d, 1H).
- MS (ES+) m/z 499 (M++1)
- 1H-NMR (CDCl3) δ: 1.30 (d, 6H), 3.0-3.2 (m, 5H), 3.47 (m, 2H), 3.81 (m, 2H), 4.02 (m, 1H), 4.21 (m, 1H), 4.42 (m, 1H), 6.82 (s, 1H), 6.92 (d, 1H), 7.08 (d, J=15.6 Hz, 1H), 7.26 (s, with CHCl3, 1H), 7.64 (d, J=15.6 Hz, 1H), 8.87 (d, 1H)
- MS (ES+) m/z 498 (M++1); MS (ES−) m/z 496 (M+−1)
- 1H-NMR (CD3OD) δ: 1.23 (d, 6H), 3.02 (m, 1H), 3.18 (m, 2H), 3.4 (m, 3H), 3.75 (m, 1H), 3.98 (m, 1H), 4.5 & 5.12 (2 doublets, mixture of anomers, 1H), 6.98 (s, 1H), 7.02 (m, 2H), 7.18 (s, 1H), 7.73 (d, J=16 Hz, 1H), 8.75 (d, 1H)
- MS (ES+) m/z 547 (M++1); MS (ES−) m/z 545 (M+−1)
- tert-Butyl (E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-2-piperazino-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (10 mg, 0.0197 mmol) and N-α, ω-1, ω-2-tri-tert-butoxycarbonyl-L-arginine (BOC-Arg, (BOC)2OH, 14 mg, 0.0295 mmol) were added with methylene chloride (1 ml). The mixture was further added with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC HCl, 11 mg, 0.0591 mmol) and stirred at room temperature overnight. The reaction solution was diluted with methylene chloride, washed with 5% aqueous citric acid, saturated aqueous sodium hydrogencarbonate and saturated brine, and dried over sodium sulfate. The solvent was evaporated under reduced pressure, and then the residue was added with trifluoroacetic acid (1 ml) and stirred in the dark for 1 hour. The reaction solution was added with toluene, and the solvent was evaporated under reduced pressure. The residue was purified by medium pressure column chromatography (Amberkron column, gradient 100% 0.1% TFA in H2O to 100% CH3CN over 80 minutes, 3 ml/minute) to obtain the title compound (7.0 mg).
- 1H-NMR (CD3OD): 1.34 (d, 6H), 1.70 (m, 2H), 1.90 (m, 2H), 3.10 (m, 1H), 3.70 (m, 8H), 3.92 (m, 1H), 4.54 (t, 1H), 7.08 (d, 1H), 7.28 (s, 1H), 7.52 (d, 1H), 7.55 (m, 2H), 7.66 (d, 1H), 7.72 (d, 1H), 8.93 (d, 1H)
- MS (ES+): 631 (M+Na)
- The compounds of Examples 79 to 91 mentioned below were synthesized in the same manner as in Example 78.
- 1H-NMR (CD3OD): 1.26 (d, 6H), 1.70 (m, 2H), 1.90 (m, 2H), 3.03 (m, 1H), 3.20-3.42 (m, 7H), 3.50-3.80 (m, 8H), 3.90 (m, 1H), 4.53 (t, 1H), 6.98 (s, 1H), 7.05 (d, 1H), 7.15 (d, 1H), 7.30 (s, 1H), 7.64 (d, 1H), 8.87 (d, 1H)
- MS (ES+): 610
- 1H-NMR (CD3OD): 1.29 (s, 9H), 1.69 (m, 2H), 1.88 (m, 2H), 3.10-3.50 (m, 5H), 3.50-3.80 (m, 10H), 3.90 (m, 2H), 4.53 (m, 1H), 6.96 (s, 1H), 7.05 (d, 1H), 7.16 (d, 1H), 7.30 (s, 1H), 7.65 (d, 1H), 8.88 (d, 1H)
- MS (ES+): 624
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 1.80 (m, 4H), 2.05 (m, 1H), 2.65 (m, 1H), 2.94 (s, 6H), 3.05 (m, 2H), 3.15-3.25 (m, 4H), 3.42 (t, 2H), 3.58 (t, 2H), 4.10 (m, 2H), 6.98 (d, J=15.6 Hz, 1H), 7.03 (s, 1H), 7.06 (dd, 1H), 7.23 (s, 1H), 7.58 (d, J=15.6 Hz, 1H), 8.80 (d, 1H)
- MS (ES+) m/z 567 (M++1)
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 1.88 (m,4H), 2.53 (m, 1H), 2.94 (s,6H), 3.02 (m, 1H), 3.0-3.25 (m, 6H), 3.41 (t, 2H), 3.55 (t, 2H), 4.15 (m, 2H), 6.97 (m, 2H), 7.04 (dd, 1H), 7.22 (s, 1H), 7.60 (d, J=15.6 Hz, 1H), 8.80 (d, 1H)
- MS (ES+) m/z 567 (M++1)
- 1H-NMR (CD3OD) δ: 1.23 (d, 6H), 2.95 (s, 6H), 3.02 (m, 1H), 3.2-3.35 (m, with CHD2OD), 3.42 (m, 1H), 3.58 (m, 1H), 3.63 (m, 2H), 3.80 (m, 1H), 4.28 (s, 2H), 6.96 (s, 1H), 7.05 (d, J=13 Hz, 1H), 7.14 (d, 1H), 7.29 (s, 1H), 7.62 (d, J=13 Hz, 1H), 8.85 (d, 1H)
- 1H-NMR (CD3OD) δ: 1.26(d, J=7 Hz, 6H), 2.85 (m, 4H), 3.02 (m, 1H), 3.2 (m, 4H), 3.40 (t, 2H), 3.78 (t, 2H), 6.99 (m, 2H), 7.11 (d, J=15.6 Hz, 1H), 7.15 (s, 1H), 7.73 (d, J=15.6 Hz, 1H), 8.78 (d, 1H)
- MS (ES+) m/z 488 (M++1)
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 1.84 (m, 3H), 2.06 (m, 1H), 2.68 (m, 1H), 2.93 (m, 2H), 3.02 (m, 2H), 3.2-3.3 (m, with CD3OD), 3.42 (m, 3H), 4.08 (m, 2H), 6.9-7.02 (m, 2H), 7.07 (dd, 1H), 7.25 (s, 1H), 7.58 (d, J=15.6 Hz, 1H), 8.81 (d, 1H)
- MS (ES+) m/z 553 (M++1)
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 1.79 (m, 3H), 2.06 (m, 1H), 2.68 (m, 1H), 3.0-3.1 (m, 4H), 3.15-3.28 (m, 3H), 3.45 (m, 4H), 4.1 (m, 2H), 6.97 (d, J=15.6 Hz, 1H), 7.06 (m, 2H), 7.25 (s, 1H), 7.58 (d, J=15.6 Hz, 1H), 8.79 (d, 1H)
- MS (ES+) m/z 539 (M++1)
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 1.79 (m, 4H), 2.04 (m, 4H), 2.68 (m, 1H), 2.9-3.1 (m, 2H), 3.15-3.35 (m, with CD3OD), 3.35-3.55 (m, 4H), 3.68 (m, 1H), 4.1 (m, 2H), 6.99 (m, 2H), 7.08 (d, 1H), 7.25 (s, 1H), 7.59 (d, J=15.6 Hz, 1H), 8.81 (d, 1H)
- MS (ES+) m/z 579 (M++1)
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 3.02 (m, 1H), 3.23 (t, 2H), 3.42 (t, 2H), 3.62 (m, 6H), 3.78 (m, 2H), 3.99 (s, 2H), 6.98 (s, 1H), 7.02 (d, J=15.6 Hz, 1H), 7.13 (d, 1H), 7.27 (s, 1H), 7.63 (d, J=15.6 Hz, 1H), 8.84 (d, 1H)
- MS (ES+) m/z 511 (M++1)
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 1.9-2.1 (m, 3H), 2.52 (m, 1H), 3.02 (m, 1H), 3.25 (t, 2H), 3.42 (t, 2H), 3.5-3.9 (m, 10H), 4.68 (m, 1H), 6.97 (s, 1H), 7.03 (d, J=15.6 Hz, 1H), 7.14 (d, 1H), 7.28 (s, 1H), 7.63 (d, J=15.6 Hz, 1H), 8.83 (d, 1H, d)
- MS (ES+) m/z 551 (M++1)
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 1.51 (m, 2H), 1.72 (m, 2H), 1.90 (m, 2H), 2.95 (m, 2H), 3.02 (m, 1H), 3.25 (t, 2H), 3.42 (t, 2H), 3.5-3.8 (m, 7H), 3.95 (m, 1H), 4.50 (m, 1H), 6.98 (s, 1H), 7.04 (d, J=15.6 Hz, 1H), 7.14 (d, 1H), 7.28 (s, 1H), 7.64 (d, J=15.6 Hz, 1H), 8.85 (d, 1H)
- MS (ES+) m/z 582 (M++1)
- 1H-NMR (CD3OD) δ: 1.26 (d, J=7 Hz, 6H), 1.80 (m, 2H), 1.92 (m, 2H), 2.99 (m, 3H), 3.22 (t, 2H), 3.42 (t, 2H), 3.5-3.8 (m, 7H), 3.94 (m, 1H), 4.58 (m, 1H), 6.99 (s, 1H), 7.04 (d, J=15.6 Hz, 1H), 7.14 (d, 1H), 7.28 (s, 1H), 7.64 (d, J=15.6 Hz, 1H), 8.85 (d, 1H)
- MS (ES+) m/z 568 (M++1)
- tert-Butyl (E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-piperazino-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (206 mg, 0.405 mmol) was dissolved in methylene chloride (8 ml), added with triethylamine (170 ml) and chloroacetyl chloride (64 ml) at −78° C., and then stirred overnight at room temperature in the dark. The reaction solution was diluted with methylene chloride, washed with water, 5% aqueous citric acid, saturated aqueous sodium hydrogencarbonate and then with saturated brine, and the solution was dried over magnesium sulfate. Then, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (260 mg).
- 1H-NMR (CDCl3): 1.28 (d, 6H), 1.51 (s, 9H), 3.06 (m, 1H), 3.21 (m, 2H), 3.37 (m, 2H), 3.62 (brm, 6H), 3.78 (brm, 2H), 4.10 (s, 2H), 6.72 (s, 1H), 6.89 (d, 1H), 7.07 (d, 1H), 7.24 (d, 1H), 7.49 (d, 1H), 8.88 (d, 1H)
- The tert-butyl (E)-3-{2-[4-(2-chloroacetyl)piperazino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (240 mg, 0.405 mmol) obtained in (A) and NaI (300 mg, 2.03 mmol) were refluxed by heating in acetone (8 ml) for 3 hours in the dark. The reaction solution was cooled, then diluted with methylene chloride, washed with water and saturated brine, and dried over sodium sulfate. Then, the solvent was evaporated under reduced pressure to obtain the title compound (226 mg) as a yellow amorphous substance.
- 1H-NMR (CDCl3): 1.28 (d, 6H), 1.52 (s, 9H), 3.10 (m, 1H), 3.22 (m, 2H), 3.38 (m, 2H), 3.60 (m, 4H), 3.79 (s, 2H), 6.73 (s, 1H), 6.90 (d, 1H), 7.08 (d, 1H), 7.50 (d, 1H), 8.88 (d, 1H)
- The tert-butyl (E)-3-{2-[4-(2-iodoacetyl)piperazino]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (226 mg, 0.33 mmol) obtained in (B) and 1,4-diazabicyclo[2.2.2]octane (187 mg, 1.67 mmol) were stirred overnight in tetrahydrofuran (9 ml) under nitrogen atmosphere, then the solvent was evaporated, and the residue was stirred in trifluoroacetic acid (TFA, 4 ml) for 1 hour. The solvent was evaporated under reduced pressure, and the residue was purified by medium pressure reverse phase chromatography (Amberkron column, gradient 100% 0.1% TFA in H2O to 100% CH3CN over 80 minutes, 3 ml/minute) to obtain the title compound (150 mg, 75%, for the two steps).
- 1H-NMR (CD3OD) δ: 1.27 (d, 6H), 3.02 (m, 1H), 3.26 (t, 2H), 3.43 (t, 2H), 3.62 (m, 5H), 3.78 (m, 6H), 4.43 (s, 2H), 7.00 (s, 1H), 7.02 (d, J=15.6 Hz, 1H), 7.13 (d, J=7 Hz, 1H), 7.29 (s, 1H), 7.63 (d, J=15.6 Hz, 1H), 8.85 (d, J=7 Hz, 1H)
- MS (ES+) m/z 606 (M++1)
- The compounds of Examples 93 to 97 mentioned below were synthesized in the same manner as in Example 92.
- 1H-NMR (CDCl3+CD3OD) δ: 1.23 (d, J=7 Hz, 6H), 3.02 (m, 1H), 3.17 (t, 2H), 3.34 (t, 2H), 3.57 (m, 2H), 3.6-3.8 (m, 6H), 3.92 (s, 3H), 5.40 (s, 2H), 6.72 (s, 1H), 6.88 (d, J=7.2 Hz, 1H), 7.00 (d, J=15.6 Hz, 1H), 7.20 (m, 2H), 7.37 (s, 1H), 7.55 (d, J=15.6 Hz, 1H), 8.81 (d, J=7.2 Hz, 1H), 9.24 (s, 1H)
- MS (ES+) m/z 576 (M++1)
- 1H-NMR (CD3OD): 1.26 (d, 6H), 2.05 (brm, 7H), 2.19 (m, 1H), 3.03 (m, 1H), 3.22 (m, 2H), 3.39 (m, 2H), 3.61 (brm, 6H), 3.67 (m, 8H), 4.26 (s, 2H), 6.97 (s, 1H), 6.99 (d, 1H), 7.12 (d, 1H), 7.28 (s, 1H), 7.62 (d, 1H), 8.86 (d, 1H)
- MS (ES+): 605
- 1H-NMR (CD3OD): 1.27 (d, 6H), 3.02 (m, 1H), 3.25 (m, 2H), 3.40 (m, 2H), 5.80 (s, 2H), 6.98 (s, 1H), 7.02 (d, 1H), 7.17 (d, 1H), 7.31 (s, 1H), 7.65 (d, 1H), 8.20 (m, 2H), 8.65 (m, 1H), 8.88 (m, 2H)
- MS (ES+): 573
- 1H-NMR (CD3OD): 1.25 (d, 6H), 2.07 (m, 1H), 2.58 (m, 1H), 3.02 (m, 1H), 3.20-3.80 (m, 24H), 6.99 (s, 1H), 7.02 (d, 1H), 7.12 (d, 1H), 7.28 (s, 1H), 7.64 (d, 1H), 8.86 (d, 1H)
- 1H-NMR (CD3OD): 1.29 (s, 9H), 3.20-3.41 (m, 5H), 3.50-3.79 (m, 20H), 4.39 (s, 2H), 6.96 (s, 1H), 7.02 (d, 1H), 7.13 (d, 1H), 7.29 (s, 1H), 7.64 (d, 1H), 8.86 (d, 1H)
- MS (ES+): 620
- (E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid (24 mg) was dissolved in dimethylformamide (2 ml), added with methanesulfonamide (15 mg), dimethylaminopyridine (20 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (31 mg), and then the mixture was stirred at room temperature for 24 hours. The reaction solution was added with ethyl acetate and hexane, washed with 0.2 M hydrochloric acid, and dried over sodium over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (14 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.21 (d, 6H), 3.02 (m, 1H), 3.15 (m, 2H), 3.19 (s, 3H), 3.36 (m, 2H), 3.53 (m, 4H), 3.70 (m, 4H), 6.78 (s, 1H), 6.86 (d, 1H), 6.92 (d, J=16 Hz, 1H), 7.17 (s, 1H), 7.53 (d, J=16 Hz, 1H), 8.67 (d, 1H)
- MS (ES+) m/z 532 (M++1)
- 1H-NMR (CDCl3) δ: 1.28 (d, 6H), 3.04 (m, 1H), 3.11 (s, 3H), 3.37 (m, 4H), 6.73 (s, 1H), 7.19 (d, J=7 Hz, 1H), 7.32 (d, J=14 Hz, 1H), 7.59 (s, 1H), 7.72 (d, J=14 Hz, 1H), 8.48 (s, 1H), 9.08 (d, J=7 Hz, 1H)
- MS (ES+) m/z 447 (M++1); MS (ES−) m/z 445 (M+−1)
- (E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid (53 mg) was dissolved in dimethylformamide (2 ml), added with 3-(N-tert-butoxycarbonylamino)propanesulfonamide (55 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (67 mg), and the mixture was stirred at room temperature for 24 hours. The reaction solution was added with ethyl acetate and hexane, washed with 0.2 M hydrochloric acid, and dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (32 mg) as yellow powder.
- 1H-NMR (300 MHz) δ: 1.22 (d, J=7.2 Hz, 6H), 1.40 (s, 9H), 1.90-2.05 (m, 2H), 3.00-3.80 (m, 17H), 6.70 (s, 1H), 6.85 (d, J=7.5 Hz, 1H), 7.20 (s, 1H), 7.35 (d, J=15.4 Hz, 1H), 7.65 (d, J=15.4 Hz, 1H), 9.00-9.10 (m, 2H)
- The N-((E)-3-[(8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoyl)-3-(tert-butoxycarbonylamino)-1-propane-sulfonamide (32 mg) obtained in (A) was dissolved in trifluoroacetic acid (2 ml) and stirred for 40 minutes. The solvent was evaporated under reduced pressure, and the residue was purified by medium pressure reverse phase column chromatography to obtain the title compound (quantitative).
- 1H-NMR (CD3OD) δ: 1.25 (d, 6H), 2.18 (m, 2H), 3.02 (m, 1H), 3.1-3.45 (m, with CHD2OD), 3.60 (m, 4H), 3.80 (m, 4H), 6.98 (s, 1H), 7.12 (s, 1H), 7.16 (d, J=16 Hz, 1H), 7.26 (s, 1H), 7.75 (d, J=16 Hz, 1H), 8.82 (d, 1H)
- MS (ES+) m/z 575 (M++1); MS (ES−) m/z 573 (M+−1)
- 4-[(E)-2-(4-Isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridinamine (100 mg, 0.408 mmol) was dissolved in xylene (1.2 ml), added with trichlorophenyl malonate (208 mg, 0.448 mmol), and then the mixture was refluxed by heating for 1.3 hours. The reaction mixture was added with n-hexane, and the deposited solid was collected by filtration. Dimethylformamide (110 μl) was added with phosphorus oxychloride (190 μl, 2.04 mmol) under ice cooling and stirred at room temperature for 30 minutes. The mixture was added with the solid dissolved in dichloromethane (3.0 ml) under ice cooling, and stirred at room temperature for 1.5 hours. The reaction mixture was added with saturated aqueous sodium hydrogencarbonate and extracted with chloroform. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was suspended in anhydrous tetrahydrofuran (4.0 ml), added with (tert-butoxycarbonylmethylene)triphenyl-phosphorane (460 mg, 1.22 mmol), and stirred at 80° C. for 5 days. The reaction solution was concentrated, and then the residue was purified by silica gel column chromatography (chloroform:methanol=100:0→100:10, v/v) and thin layer chromatography (chloroform:methanol=10:1, v/v). The resulting compound was dissolved in anhydrous tetrahydrofuran (600 μl) and dimethylformamide (600 μl), added with 4-dimethylaminopyridine (10.2 mg, 0.0831 mmol) and p-toluenesulfonyl chloride (13.4 mg, 0.0703 mmol), and stirred at room temperature for 2 hours. The reaction mixture was added with water and extracted with chloroform. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by thin layer chromatography (n-hexane:ethyl acetate=2:1, v/v) to obtain the title compound (9.0 mg, 3.7%).
- 1H-NMR (CDCl3) δ: 1.37 (6H, d, J=6.8 Hz), 1.51 (9H, s), 2.48 (3H, s), 3.14-3.21 (1H, m), 7.03 (1H, s), 7.18 (1H, d, J=15.9 Hz), 7.38-7.42 (4H, m), 7.52 (1H, d, J=1.5 Hz), 7.56 (1H, d, J=16.1 Hz), 7.67 (1H, d, J=15.9 Hz), 8.05 (2H, d, J=8.3 Hz), 9.02 (1H, d, J=7.6 Hz)
- The tert-butyl (E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-{[(4-methylphenyl)sulfonyl]oxy}-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (9.0 mg, 0.0152 mmol) obtained in (A) was dissolved in dimethylformamide (0.75 ml), added with morpholine (13.2 μl, 0.152 mmol), and stirred overnight at room temperature. The reaction mixture was concentrated, and then the residue was purified by thin layer chromatography (n-hexane:ethyl acetate=1:1, v/v) to obtain the title compound (6.7 mg, 87%).
- 1H-NMR (CDCl3) δ: 1.33 (6H, d, J=6.8 Hz), 1.52 (9H, s), 3.12-3.19 (1H, m), 3.62-3.64 (4H, m), 3.73-3.75 (4H, m), 6.97 (1H, s), 7.08 (1H, d, J=15.9 Hz), 7.16 (1H, dd, J=1.5, 7.6 Hz), 7.34-7.38 (2H, m), 7.50 (2H, d, J=15.9 Hz), 8.91 (1H, d, J=7.6 Hz)
- The tert-butyl (E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (6.7 mg, 0.0132 mmol) obtained in (B) was dissolved in 1,4-dioxane (260 μl), added with 4 N hydrochloric acid solution in 1,4-dioxane (260 μl), and stirred at room temperature for 7 hours. The reaction solution was concentrated, and the residue was purified by thin layer chromatography (chloroform:methanol=10:1, v/v) to obtain the title compound (4.8 mg, 81%).
- 1H-NMR (CDCl3+CD3OD) δ: 1.36 (6H, d, J=6.8 Hz), 3.13-3.20 (1H, m), 3.67 (4H, t, J=4.4 Hz), 3.86 (4H, t, J=4.4 Hz), 7.04 (1H, d, J=15.6 Hz), 7.07 (1H, s), 7.33 (1H, dd, J=1.6, 7.5 Hz), 7.40 (1H, d, J=16.2 Hz), 7.47 (1H, d, J=6.6 Hz), 7.58 (1H, d, J=16.2 Hz), 7.62 (1H, d, J=15.6 Hz), 8.89 (1H, d, J=7.5 Hz)
- FAB-MS; m/z: 453 (M++1)
- FAB-HRMS; Calcd. for C23H25O4N4S+H+: 453.1597, Found: 453.1602
- (4-Isopropyl-1,3-thiazol-2-yl)methanol (5.20 g, 33.0 mmol) was dissolved in methylene chloride (100 ml), added with pyridinium dichromate (14.9 g, 39.7 mmol), and stirred at room temperature for 19 hours stirred. After insoluble solids were removed, the reaction solution was evaporated, and the residue was purified by silica gel column chromatography (chloroform) to obtain the title compound (3.32 g, 65%).
- 1H-NMR (CDCl3) δ: 1.37 (6H, d, J=6.8 Hz), 3.18-3.25 (1H, m), 7.34 (1H, s), 9.98 (1H, s)
- tert-Butyl N-(4-methyl-2-pyridyl)carbamate (6.24 g, 30.0 mmol) was dissolved in anhydrous tetrahydrofuran (100 ml), added with n-butyl lithium (1.59 M in n-hexane, 47.1 ml, 74.9 mmol) at −78° C. under argon atmosphere, and then stirred at room temperature for 1.5 hours. The reaction solution was cooled to −78° C. again, then added with a solution of the 4-isopropyl-1,3-thiazole-2-carbaldehyde (4.65 g, 30.0 mmol) obtained in (A) in anhydrous tetrahydrofuran (50.0 ml), and then the mixture was stirred for 3 hours. The reaction mixture was added with saturated aqueous ammonium chloride, warmed to room temperature, and then extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=3:1→1:1, v/v) to obtain the title compound (5.42 g, 50%).
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 1.53 (9H, s), 3.03-3.11 (2H, m), 3.28-3.32 (2H, m), 5.24 (1H, dd, J=4.2, 8.5 Hz), 6.82 (1H, d, J=0.7 Hz), 6.85 (1H, dd, J=1.6, 5.2 Hz), 7.90 (1H, s), 8.10 (1H, s), 8.14 (1H, d, J=5.2 Hz)
- ESI-MS; m/z: 364 (M++1)
- The tert-butyl N-4-[2-hydroxy-2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridyl-carbamate (5.30 g, 14.6 mmol) obtained in (B) was dissolved in anhydrous tetrahydrofuran (100 ml), added with triethylamine (5.08 ml, 36.5 mmol)+ and methanesulfonyl chloride (1.35 ml, 17.5 mmol), and then the mixture was stirred at room temperature for 1 hour. After insoluble solids were removed, the reaction solution was washed with tetrahydrofuran, and the solvent was evaporated under reduced pressure. The residue was dissolved in toluene (100 ml), added with 1,8-diazabicyclo[5.4.0]undec-7-ene (10.9 ml, 72.9 mmol), and refluxed by heating for 30 minutes. The reaction solution was concentrated, then added with 1 N hydrochloric acid and extracted with chloroform. The organic layer was washed with saturated aqueous sodium hydrogencarbonate and dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=5:1→3:1, v/v) to obtain the title compound (3.76 g, 75%).
- 1H-NMR (CDCl3) δ: 1.34 (6H, d, J=6.8 Hz), 1.56 (9H, s), 3.07-3.18 (1H, m), 6.87 (1H, s), 7.07 (1H, dd, J=1.2, 5.1 Hz), 7.31 (1H, d, J=16.1 Hz), 7.50 (1H, d, J=16.1 Hz), 8.12 (1H, s), 8.25 (1H, s), 8.26 (1H, s)
- The tert-butyl N-4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridylcarbamate (3.75 g, 10.9 mmol) obtained in (C) was dissolved in dichloromethane (50.0 ml), added with trifluoroacetic acid (50.0 ml), and then the mixture was stirred at room temperature for 30 minutes. The reaction solution was concentrated, then neutralized with saturated aqueous sodium hydrogencarbonate, and extracted with chloroform. The organic layer was dried over magnesium sulfate, and then the solvent was evaporated under reduced pressure to obtain the title compound (2.65 g, 100%).
- 1H-NMR (CDCl3) δ: 1.34 (6H, d, J=6.8 Hz), 3.09-3.16 (1H, m), 4.67 (1H, br s), 6.57 (1H, s), 6.80 (1H, dd, J=1.3, 5.5 Hz), 6.87 (1H, s), 7.18 (1H, d, J=16.1 Hz), 7.37 (1H, d, J=16.1 Hz), 8.04 (1H, d, J=5.5 Hz)
- The 4-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-pyridinamine (2.65 g, 10.8 mmol) obtained in (D) was dissolved in toluene (100 ml), added with trichlorophenyl malonate (5.50 g, 11.9 mmol), and refluxed by heating for 1.5 hours. After the reaction mixture was concentrated, the deposited solid was collected by filtration and washed with n-hexane and ether to obtain the title compound (3.14 g, 93%) as yellow solid.
- 1H-NMR (CDCl3) δ: 1.37 (6H, d, J=6.8 Hz), 3.14-3.21 (1H, m), 5.41 (1H, s), 7.05 (1H, s), 7.40 (1H, dd, J=1.5, 7.4 Hz), 7.46 (1H, d, J=16.1 Hz), 7.51 (1H, d, J=1.5 Hz), 7.66 (1H, d, J=16.1 Hz), 9.09 (1H, d, J=7.4 Hz)
- The 2-hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido[1,2-a]-pyrimidin-4-one (1.00 g, 3.19 mmol) obtained in (E) was dissolved in anhydrous tetrahydrofuran (15.0 ml) and anhydrous dimethylformamide (15.0 ml), added with 4-dimethylaminopyridine (585 mg, 4.79 mmol) and p-toluenesulfonyl chloride (730 mg, 3.83 mmol), and then the mixture was stirred at room temperature for 50 minutes. Subsequently, the reaction solution was added with 3-hydroxypiperidine (646 mg, 6.38 mmol) and stirred at room temperature for 16 hours, and then added with 3-hydroxypiperidine (968 mg, 9.57 mmol) and stirred at 60° C. for 1.5 hours. After the reaction mixture was concentrated, the residue was purified by silica gel column chromatography (chloroform:methanol=100:0→100:1→100:2→100:5→100:10, v/v) to obtain the title compound (865 mg, 68%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=7.1 Hz), 1.54-1.72 (1H, m), 1.86-2.01 (3H, m), 3.11-3.21 (1H, m), 3.39-3.45 (1H, m), 3.55 (1H, dd, J=7.1,13.2 Hz), 3.73-3.78 (1H, m), 3.85-3.89 (1H, m), 4.00 (1H, dd, J=3.1,12.9 Hz), 5.65 (1H, m), 6.94 (1H, m), 7.03 (1H, dd, J=2.0, 7.6 Hz), 7.32 (1H, d, J=16.1 Hz), 7.45 (1H, d, J=16.1 Hz), 8.82 (1H, d, J=7.3 Hz)
- ESI-MS; m/z: 397 (M++1)
- Dimethylformamide (15.0 ml) was added with phosphorus oxychloride (608 μl, 6.52 mmol) under ice cooling and stirred at room temperature for 40 minutes. The mixture was added to a solution of the 2-(3-hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido[1,2-a]pyrimidin-4-one (862 mg, 2.17 mmol) obtained in (F) in dimethylformamide (15.0 ml) under ice cooling, and then the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was added with saturated aqueous sodium hydrogencarbonate and extracted with chloroform. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was suspended in anhydrous tetrahydrofuran (20 ml) and anhydrous N,N-dimethylformamide (10 ml), added with (tert-butoxycarbonyl-methylene)triphenylphosphorane (1.64 g, 4.35 mmol), and stirred at 50° C. for 16 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (n-hexane:ethyl acetate 10:1→5:1→3:1→2:1, v/v) to obtain the title compound (488 mg, 41%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.52 (9H, s), 1.72-1.75 (1H, m), 1.81-1.85 (1H, m), 1.94-2.03 (2H, m), 3.12-3.18 (1H, m), 3.51-3.60 (2H, m), 3.71 (1H, dd, J=6.3, 13.4 Hz), 3.82 (1H, dd, J=3.1,13.4 Hz), 5.13-5.16 (1H, m), 6.97 (1H, s), 7.07 (1H, d, J=15.6 Hz), 7.15 (1H, dd, J=1.7, 7.6 Hz), 7.34-7.37 (2H, m), 7.49 (1H, d, J=16.1 Hz), 7.51 (1H, d, J=15.6 Hz), 8.10 (1H, s), 8.89 (1H, d, J=7.6 Hz)
- ESI-MS; m/z: 551 (M++1)
- The tert-butyl (E)-3-{2-(3-formyloxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (184 mg, 0.334 mmol) obtained in (G) was dissolved in methanol (3.0 ml), added with 1 N aqueous sodium hydroxide (1.0 ml), and then the mixture was stirred at room temperature for 10 minutes. The reaction mixture was added with 1 N hydrochloric acid (1.0 ml) and extracted with chloroform. The organic layer was dried over magnesium sulfate and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=2:1→2:1→1:2, v/v) to obtain the title compound (174 mg, 100%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.52 (9H, s), 1.68-1.89 (4H, m), 3.12-3.18 (1H, m), 3.55-3.66 (3H, m), 3.93-3.96 (1H, m), 4.03 (1H, br s), 6.97 (1H, s), 7.06 (1H, d, J=15.6 Hz), 7.16 (1H, dd, J=1.6, 7.5 Hz), 7.34 (1H, d, J=16.1 Hz), 7.34 (1H, d, J=1.6 Hz), 7.49 (1H, d, J=16.1 Hz), 7.50 (1H, d, J=15.6 Hz), 8.89 (1H, d, J=7.5 Hz)
- ESI-MS; m/z: 523 (M++1)
- The tert-Butyl (E)-3-{2-(3-hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (43.4 mg, 0.0830 mmol) obtained in (H) was dissolved in 1,4-dioxane (200 μl), added with 4 N hydrochloric acid solution in 1,4-dioxane, and stirred at room temperature for 3.5 hours. The reaction solution was concentrated, and the residue was purified by thin layer chromatography (chloroform:methanol:water=10:1:0→8:3:0.1→7:3:1, v/v) to obtain the title compound (18.9 mg, 49%).
- 1H-NMR (DMSO-d6) δ: 1.29 (6H, d, J=6.6 Hz), 1.42-1.47 (1H, m), 1.55-1.59 (1H, m), 1.81 (1H, m), 1.90-1.95 (1H, m), 2.97-3.74 (4H, m), 3.89-3.92 (1H, m), 4.95 (1H, br s), 6.89 (1H, d, J=15.1 Hz), 7.42-7.46 (2H, m), 7.54-7.62 (3H, m), 7.87 (1H, d, J=16.6 Hz), 8.76 (1H, d, 7.8 Hz)
- ESI-MS; m/z: 467 (M++1)
- tert-Butyl (E)-3-{2-(3-hydroxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (138 mg, 0.264 mmol) was dissolved in ethyl acetate (2.6 ml), added with trichloroacetyl isocyanate (62.6 μl, 0.528 mmol) under ice cooling, and then the mixture was stirred at room temperature for 15 minutes. The reaction mixture was concentrated, dissolved in methanol (5.0 ml) and water (0.5 ml), and then added with sodium formate (71.8 mg, 1.06 mmol), and stirred overnight at room temperature. The reaction mixture was further added with chloroform (3.0 ml) and sodium formate (71.8 mg, 1.06 mmol) and stirred overnight. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform:methanol=100:0→100:1→100:2, v/v) to obtain the title compound (150 mg, 100%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.50 (9H, s), 1.70-2.04 (4H, m), 3.11-3.18 (1H, m), 3.27-3.33 (1H, m), 3.52-3.56 (1H, m), 3.68-3.74 (2H, m), 4.85 (1H, br s), 5.15 (2H, br s), 6.97 (1H, s), 7.11 (1H, d, J=15.6 Hz), 7.15 (1H, dd, J=1.8, 7.6 Hz), 7.34 (1H, d, J=16.5 Hz), 7.37 (1H, s), 7.49 (1H, d, J=16.5 Hz), 7.72 (1H, d, J=15.6 Hz), 8.89 (1H, d, J=7.6 Hz)
- ESI-MS; m/z: 566 (M++1)
- The tert-butyl (E)-3-(2-{3-[(aminocarbonyl)oxy]piperidino}-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate obtained in (B) was dissolved in 1,4-dioxane (100 μl), added with 4 N hydrochloric acid solution in 1,4-dioxane (400 μl), and stirred at room temperature for 15 hours. The reaction solution was further added with 4 N hydrochloric acid solution in 1,4-dioxane (400 μl) and stirred at room temperature for 7 hours. The reaction solution was concentrated, and the residue was subjected to azeotropy with toluene. The product was added with saturated aqueous sodium hydrogencarbonate, neutralized with phosphate buffer (pH 7-8), and extracted with a mixture of chloroform/methanol (10:1, v/v). The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by thin layer chromatography (chloroform:methanol=20:1, v/v) to obtain the title compound (8.1 mg, 36%).
- 1H-NMR (CDCl3+CD3OD) δ: 1.35 (6H, d, J=7.1 Hz), 1.71 (1H, m), 1.90-1.96 (3H, m), 3.12-3.19 (1H, m), 3.38-3.40 (1H, m), 3.58-3.81 (3H, m), 4.87 (1H, br s), 6.99 (1H, s), 7.11 (1H, d, J=15.6 Hz), 7.21 (1H, d, J=7.7 Hz), 7.35 (1H, d, J=16.1 Hz), 7.40 (1H, s), 7.52 (1H, d, J=16.1 Hz), 7.76 (1H, d, J=15.6 Hz), 8.88 (1H, d, J=7.7 Hz)
- ESI-MS; m/z: 510 (M++1)
- tert-Butyl (E)-3-{2-(3-formyloxypiperidino)-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (115 mg, 0.209 mmol) was dissolved in methanol (2.0 ml), added with 1 N aqueous sodium hydroxide (627 μl), and stirred at room temperature for 10 minutes. The reaction solution was added with 1 N hydrochloric acid (627 μl) and extracted with chloroform. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane (2.0 ml), added with 4-dimethylaminopyridine (51.0 mg, 0.418 mmol) and acetic anhydride (29.6 μl), and then the mixture was stirred at room temperature for 10 minutes. The reaction mixture was added with 1 N hydrochloric acid and extracted with chloroform. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=5:1→3:1→2:1, v/v) to obtain the title compound (121 mg, quantitative).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.52 (9H, s), 1.70-1.78 (2H, m), 1.90-2.02 (2H, m), 2.06 (3H, s), 3.12-3.19 (1H, m), 3.47-3.52 (1H, m), 3.61 (2H, dd, J=7.1, 13.2 Hz), 3.88 (1H, dd, J=3.3, 13.2 Hz), 4.96-5.00 (1H, m), 6.96 (1H, s), 7.06 (1H, d, J=15.6 Hz), 7.13 (1H, dd, J=2.0, 7.6 Hz), 7.33-7.37 (2H, m), 7.48 (1H, d, J=16.1 Hz), 7.50 (1H, d, J=15.6 Hz), 7.50 (1H, d, J=15.6 Hz), 8.89 (1H, d, J=7.6 Hz)
- ESI-MS; m/z: 565 (M++1)
- The tert-Butyl (E)-3-{2-[(3-acetyloxy)piperidino]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (121 mg, 0.214 mmol) obtained in (A) was dissolved in 1,4-dioxane (1.0 ml), added with 4 N hydrochloric acid solution in 1,4-dioxane, and then the mixture was stirred overnight at room temperature. The reaction mixture was concentrated, and the residue was suspended in dichloromethane (2.0 ml), added with 2-cyanoethylamine (79 μl, 1.07 mmol), BOPCl (109 mg, 0.429 mmol) and diisopropylethylamine (187 μl, 1.07 mmol), and stirred for 1 hour. The reaction solution was further added with 2-cyanoethylamine (79 μl, 1.07 mmol), BOPCl (109 mg, 0.429 mmol) and diisopropylethylamine (187 μl, 1.07 mmol) and stirred overnight. The reaction mixture was added with saturated aqueous sodium hydrogencarbonate and extracted with a mixture of chloroform/methanol (10:1, v/v). The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography (chloroform:methanol, 100:0→100:1→100:2, v/v) to obtain the title compound (53.3 mg, 48%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.70-1.79 (2H, m), 1.90-1.93 (1H, m), 2.01-2.04 (1H, m), 2.06 (3H, s), 2.71 (2H, t, J=6.5 Hz), 3.11-3.18 (1H, m), 3.46-3.51 (1H, m), 3.56-3.68 (4H, m), 3.92 (1H, dd, J=3.1,13.1 Hz), 4.95-5.00 (1H, m), 6.58-6.61 (1H, m), 6.96 (1H, s), 7.13 (1H, d, J=7.6 Hz), 7.25 (1H, d, J=15.1 Hz), 7.31-7.34 (2H, m), 7.47 (1H, d, J=16.4 Hz), 7.47 (1H, d, J=15.1 Hz), 7.52 (1H, d, J=15.1 Hz), 8.83 (1H, d, J=7.6 Hz)
- ESI-MS; m/z: 561 (M++1)
- The 1-(3-{(E)-3-[(2-cyanoethyl)amino]-3-oxo-1-propenyl}-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)-3-piperidyl acetate (57.3 mg, 0.102 mmol) obtained in (B) was suspended in acetonitrile (3.0 ml), added with sodium azide (13.3 mg, 0.204 mmol) and trifluoromethanesulfonic acid anhydride (25.8 μl, 0.153 mmol) under ice cooling, and then the mixture was stirred at room temperature for 1 hour. The reaction mixture was further added with sodium azide (13.3 mg, 0.204 mmol) and trifluoromethanesulfonic acid anhydride (25.8 μl, 0.153 mmol), and stirred for 3 hours. The reaction mixture was added with saturated aqueous sodium hydrogencarbonate and extracted with chloroform, and the organic layer was dried over magnesium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by thin layer chromatography (hexane:ethyl acetate=1:2→1:3→0:1, v/v) to obtain the title compound (26.8 mg, 45%).
- 1H-NMR (CDCl3) b: 1.36 (6H, d, J=6.9 Hz), 1.73-1.80 (4H, m), 2.04 (3H, s), 3.10 (2H, t, J=7.0 Hz), 3.13-3.19 (1H, m), 3.57-3.73 (3H, m), 3.91 (1H, dd, J=2.8, 13.1 Hz), 4.69 (2H, t, J=7.0 Hz), 4.95-4.98 (1H, m), 6.97 (1H, s), 7.17 (1H, dd, J=1.5, 7.5 Hz), 7.36 (1H, d, J=1.5 Hz), 7.36 (1H, d, J=16.0 Hz), 7.50 (1H, d, J=16.0 Hz), 7.75 (1H, d, J=15.3 Hz), 7.83 (1H, d, J=15.3 Hz), 8.86 (1H, d, J=7.5 Hz)
- The 1-(3-{(E)-2-[1-(2-cyanoethyl)-1H-1,2,3,4-tetraazol-5-yl]-1-ethenyl}-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)-3-piperidyl acetate (25.9 mg, 0.0442 mmol) obtained in (C) was suspended in methanol (0.5 ml) and anhydrous tetrahydrofuran (1.0 ml), added with sodium methoxide (4.8 mg, 0.0884 mmol) under ice cooling, and then stirred for 4 hours. The reaction solution was further added with sodium methoxide (4.8 mg, 0.0884 mmol) and stirred for 1 hour. The reaction mixture was added with saturated aqueous ammonium chloride and extracted with chloroform, and the organic layer was dried over magnesium sulfate. Then, the solvent was evaporated under reduced pressure, and the residue was purified by thin layer chromatography (chloroform:methanol=10:1, v/v) to obtain the title compound (12.7 mg, 59%).
- 1H-NMR (CD3OD) δ: 1.32 (6H, d, J=7.1 Hz), 1.56-1.61 (1H, m), 1.67-1.71 (1H, m), 1.89-1.92 (1H, m), 2.03-2.07 (1H, m), 3.08-3.19 (2H, m), 3.45 (1H, s), 3.76-3.80 (1H, m), 3.84-3.88 (1H, m), 4.00 (1H, dd, J=2.9, 12.9 Hz), 7.19 (1H, s), 7.34-7.36 (2H, m), 7.39 (1H, d, J=16.4 Hz), 7.51 (1H, d, J=16.1 Hz), 7.57 (1H, d, J=16.4 Hz), 7.74 (1H, d, J=16.1 Hz), 8.76 (1H, d, J=7.6 Hz)
- ESI-MS; m/z: 491 (M++1)
- 2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido[1,2-a]-pyrimidin-4-one (500 mg, 1.60 mmol) was treated in the same manner as in Example 102, (F) and (G) to obtain the title compound (488 mg, 56%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.52 (9H, s), 1.73-1.75 (1H, m), 1.83-1.85 (1H, m), 1.95-2.03 (2H, m), 3.13-3.17 (1H, m), 3.54-3.60 (2H, m), 3.71 (1H, dd, J=6.2, 13.5 Hz), 3.82 (1H, dd, J=3.2, 13.5 Hz), 5.14-5.16 (1H, m), 6.97 (1H, s), 7.07 (1H, d, J=15.6 Hz), 7.14 (1H, dd, J=1.6, 7.6 Hz), 7.34-7.37 (2H, m), 7.49 (1H, d, J=16.0 Hz), 7.51 (1H, d, J=15.6 Hz), 8.10 (1H, s), 8.89 (1H, d, J=7.6 Hz)
- The tert-butyl (E)-3-{2-[(3R)-3-formyloxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (488 mg, 0.886 mmol) obtained in (A) was treated in the same manner as in Example 102, (H) to obtain the title compound (373 mg, 81%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.52 (9H, s), 1.82-1.88 (4H, m), 3.11-3.18 (1H, m), 3.54-3.67 (3H, m), 3.95-3.98 (1H, m), 4.03 (1H, br s), 6.97 (1H, s), 7.05 (1H, d, J=15.7 Hz), 7.16 (1H, dd, J=1.8, 7.6 Hz), 7.34 (1H, d, J=16.1 Hz), 7.34 (1H, s), 7.49 (1H, d, J=16.1 Hz), 7.50 (1H, d, J=15.7 Hz), 8.89 (1H, d, J=7.6 Hz)
- tert-Butyl (E)-3-{2-[(3R)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (105 mg, 0.201 mmol) obtained in (B) was treated in the same manner as in Example 102, (I) to obtain the title compound (64.0 mg, 68%).
- 1H-NMR (DMSO-d6) δ: 1.27 (6H, d, J=6.8 Hz), 1.40-1.45 (1H, m), 1.54-1.57 (1H, m), 1.80-1.83 (1H, m), 1.89-1.93 (1H, m), 2.96-3.19 (2H, m), 3.60 (1H, m), 3.88-3.90 (1H, m), 4.92 (1H, br s), 6.87 (1H, d, J=15.5 Hz), 7.40 (1H,S), 7.43 (1H, d, J=15.5 Hz), 7.54 (1H, d, J=16.1 Hz), 7.58-7.59 (2H, m), 7.85 (1H, d, J=16.1 Hz), 8.74 (1H, d, 8.1 Hz)
- 2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido[1,2-a]-pyrimidin-4-one (500 mg, 1.60 mmol) was treated in the same manner as in Example 102, (F) and (G) to obtain the title compound (164 mg, 19%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.9 Hz), 1.52 (9H, s), 1.73-1.75 (1H, m), 1.81-1.85 (1H, m), 1.96-2.05 (2H, m), 3.11-3.18 (1H, m), 3.54-3.57 (2H, m), 3.70 (1H, dd, J=6.5, 13.1 Hz), 3.82 (1H, d, J=13.5 Hz), 5.15 (1H, m), 6.96 (1H, s), 7.06 (1H, d, J=15.4 Hz), 7.14 (1H, dd, J=1.6, 7.4 Hz), 7.32-7.36 (2H, m), 7.48 (1H, d, J=15.9 Hz), 7.51 (1H, d, J=15.4 Hz), 8.10 (1H, s), 8.87 (1H, d, J=7.4 Hz)
- The tert-butyl (E)-3-{2-[(3S)-3-formyloxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo 4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (164 mg, 0.298 mmol) obtained in (A) was treated in the same manner as in Example 102, (H) to obtain the title compound (156 mg, 100%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.52 (9H, s), 1.81-1.91 (4H, m), 3.11-3.18 (1H, m), 3.60-3.63 (3H, m), 3.86-3.89 (1H, m), 4.02 (1H, brs), 6.97 (1H, s), 7.04 (1H, d, J=15.6 Hz), 7.13 (1H, dd, J=1.7, 7.6 Hz), 7.31 (1H, d, J=1.7 Hz), 7.32 (1H, d, J=16.0 Hz), 7.48 (1H, d, J=16.0 Hz), 7.49 (1H, d, J=15.6 Hz), 8.87 (1H, d, J=7.6 Hz)
- The tert-butyl (E)-3-{2-[(3S)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (72.7 mg, 0.139 mmol) obtained in (B) was treated in the same manner as in Example 102, (I) to obtain the title compound (35.5 mg, 55%).
- 1H-NMR (DMSO-d6) δ: 1.29 (6H, d, J=6.8 Hz), 1.42-1.45 (1H, m), 1.56-1.59 (1H, m), 1.81-1.85 (1H, m), 1.93-1.95 (1H, m), 2.97-3.20 (3H, m), 3.62 (1H, m), 3.69-3.74 (1H, m), 3.89-3.92 (1H, m), 4.90 (1H, br s), 6.89 (1H, d, J=15.4 Hz), 7.42-7.46 (1H, m), 7.55 (1H, d, J=16.2 Hz), 7.61-7.62 (2H, m), 7.87 (1H, d, J=16.2 Hz), 8.76 (1H, d, 7.6 Hz), 11.84 (1H, br s)
- The tert-butyl (E)-3-{2-[(3R)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (109 mg, 0.209 mmol) was treated in the same manner as in Example 103, (A) and (B) to obtain the title compound (89.7 mg, 84%).
- 1H-NMR (DMSO-d6) δ: 1.29 (6H, d, J=6.9 Hz), 1.66 (2H, m), 1.88-1.98 (2H, m), 3.05-3.12 (1H, m), 3.36-3.54 (3H, m), 3.86 (1H, d, J=10.0 Hz), 4.60 (1H, m), 6.47 (2H, br s), 6.90 (1H, d, J=15.2 Hz), 7.42 (1H, s), 7.45 (1H, d, J=15.2 Hz), 7.55 (1H, d, J=16.2 Hz), 7.62-7.64 (2H, m), 7.88 (1H, d, J=16.2 Hz), 8.77 (1H, d, J=7.3 Hz), 11.90 (1H, br s)
- The tert-butyl (E)-3-{2-[(3S)-3-hydroxyhexahydro-1-pyridinyl]-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (83.6 mg, 0.160 mmol) was treated in the same manner as in Example 103 (A) and (B) to obtain the title compound (59.4 mg, 73%).
- 1H-NMR (DMSO-d6) δ: 1.29 (6H, d, J=6.6 Hz), 1.66 (2H, m), 1.88 (1H, m), 1.98 (1H, m), 3.06-3.13 (1H, m), 3.43-3.51 (3H, m), 3.86 (1H, d, J=11.7 Hz), 4.61 (1H, m), 6.47 (2H, brs), 6.90 (1H, d, J=15.6 Hz), 7.42 (1H, s), 7.46 (1H, d, J=15.6 Hz), 7.55 (1H, d, J=16.1 Hz), 7.62-7.64 (2H, m), 7.88 (1H, d, J=16.1 Hz), 8.77 (1H, d, J=7.3 Hz), 11.90 (1H, brs)
- The 2-hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido-[1,2-a]pyrimidin-4-one (164 mg, 0.523 mmol) obtained in Example 101, (E) was dissolved in anhydrous tetrahydrofuran (2.5 ml) and anhydrous dimethylformamide (2.5 ml), added with 4-dimethylaminopyridine (83.0 mg, 0.680 mmol) and p-toluenesulfonyl chloride (110 mg, 0.576 mmol), and then the mixture was stirred at 0° C. for 3 hours. Subsequently, the reaction solution was added with triethylamine (729 μl, 5.23 mmol) and N3,N3-dimethyl-3-piperidinecarboxamide trifluoroacetic acid salt (707 mg, 2.62 mmol) and stirred at 0° C. for 1 hour, at room temperature for 30 minutes and at 60° C. for 19 hours. Then, the reaction solution was added with triethylamine (40.0 μl, 0.287 mmol) and N3,N3-dimethyl-3-piperidinecarboxamide trifluoroacetic acid salt (400 mg, 1.48 mmol) and stirred at 60° C. for 5 hours. The reaction mixture was concentrated, added with saturated aqueous ammonium chloride, and then extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:1→100:3, v/v) to obtain the title compound (168 mg, 71%).
- 1H-NMR (CDCl3) δ: 1.36 (6H, d, J=6.4 Hz), 1.52-1.62 (1H, m), 1.73 (1H, s), 1.81-1.97 (3H, m), 2.70-2.76 (1H, m), 2.99 (3H, s), 3.14 (3H, s), 3.04-3.18 (2H, m), 4.35 (1H, m), 4.65 (1H, m), 5.63 (1H, s), 6.95 (1H, s), 7.03 (1H, d, J=7.3 Hz), 7.23 (1H, s), 7.32 (1H, d, J=16.1 Hz), 7.45 (1H, d, J=16.1 Hz), 8.82 (1H, d, J=7.3 Hz)
- Dimethylformamide (3.0 ml) was added with phosphorus oxychloride (104 μl, 1.12 mmol) under ice cooling and stirred at room temperature for 30 minutes. This was added to the N3,N3-dimethyl-1-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl]-3-piperidinecarboxamide (168 mg, 0.372 mmol) obtained in (A) and dissolved in dimethylformamide (4.0 ml) under ice cooling, and stirred at room temperature for 2 hours. The reaction mixture was concentrated, added with saturated aqueous sodium hydrogencarbonate, and then extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was suspended in anhydrous tetrahydrofuran (3 ml) and anhydrous N,N-dimethylformamide (3 ml), added with (tert-butoxycarbonylmethylene)triphenylphosphorane (280 mg, 0.744 mmol), and stirred at 50° C. for 37 hours. The reaction mixture was further added with (tert-butoxycarbonylmethylene)triphenylphosphorane (280 mg, 0.744 mmol), stirred at 80° C. for 5 hours, and then concentrated, and the residue was purified by silica gel column chromatography (chloroform:methanol=100:1→100:2, v/v) to obtain the title compound (167 mg, 78%).
- 1H-NMR (CDCl3) δ: 1.36 (6H, d, J=6.8 Hz), 1.51 (9H, s), 1.65-1.68 (1H, m), 1.81-1.84 (1H, m), 1.89-1.94 (2H, m), 2.98 (3H, s), 3.04-3.17 (4H, m), 3.22 (3H, s), 4.05 (1H, m), 4.24 (1H, m), 6.96 (1H, s), 7.06 (1H, d, J=15.6 Hz), 7.25 (1H, d, J=7.6), 7.34 (1H, d, J=16.1 Hz), 7.46 (1H, s), 7.47 (1H, d, J=16.1 Hz), 7.52 (1H, d, J=15.6), 8.89 (1H, d, J=7.6 Hz)
- The tert-butyl (E)-3-(2-{3-[(dimethylamino)carbonyl]piperidino}-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (71.0 mg, 0.123 mmol) obtained in (B) was added with trifluoroacetic acid (3.0 ml) and stirred at room temperature for 2 hours. The trifluoroacetic acid in the reaction mixture was evaporated under reduced pressure, and the residue was neutralized with 0.1 N sodium hydroxide and phosphate buffer (pH 7-8) and extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by thin layer chromatography (chloroform:methanol and chloroform:methanol:water, 8:3:1, v/v, lower layer) to obtain the title compound (39.0 mg, 61%).
- 1H-NMR (DMSO-d6) δ: 1.29 (6H, d, J=6.8 Hz), 1.64 (1H, m), 1.72 (2H, m), 1.87 (1H, m), 2.84 (3H, s), 3.04 (2H, m), 3.07-3.11 (2H, m), 3.15 (3H, s), 3.92 (1H, m), 4.08 (1H, m), 6.89 (1H, d, J=15.4), 7.42 (1H, s), 7.43 (1H, d, J=15.4 Hz), 7.56 (1H, d, J=16.1 Hz), 7.60 (1H, s), 7.62 (1H, d, J=7.8 Hz), 7.87 (1H, d, J=16.1 Hz), 8.77 (1H, d, J=7.8 Hz)
- EI-MS; m/z: 522 (M++1)
- 2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido[1,2-a]-pyrimidin-4-one (157 mg, 0.501 mmol) was dissolved in anhydrous tetrahydrofuran (2.5 ml) and anhydrous dimethylformamide (2.5 ml), added with 4-dimethylamino-pyridine (80.0 mg, 0.651 mmol) and p-toluenesulfonyl chloride (105 mg, 0.551 mmol), and stirred at 0° C. for 1.5 hours. Subsequently, the reaction mixture was added with triethylamine (698 μl, 5.01 mmol) and N3-methyl-3-piperidinecarboxamide hydrochloride (448 mg, 2.50 mmol), and then the mixture was stirred at 60° C. for 5.5 hours. The reaction mixture was concentrated, added with saturated aqueous ammonium chloride, and then extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:2→100:3, v/v) to obtain the title compound (174 mg, 79%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=6.8 Hz), 1.60 (1H, m), 1.73 (1H, m), 1.94 (1H, m), 2.02-2.05 (1H, m), 2.36-2.38 (1H, m), 2.83 (3H, d, J=4.9), 3.13-3.20 (2H, m), 3.59 (1H, dd, J=8.8, 13.7), 4.00 (1H, m), 4.24 (1H, m), 5.62 (1H, s), 6.95 (1H, s), 7.05 (1H, d, J=7.8 Hz), 7.27 (1H, s), 7.33 (1H, d, J=16.1 Hz), 7.46 (1H, d, J=16.1 Hz), 8.83 (1H, d, J=7.8 Hz)
- Dimethylformamide (3.0 ml) was added with phosphorus oxychloride (111 μl, 1.19 mmol) under ice cooling and stirred at room temperature for 30 minutes. The mixture was added to the N3-methyl-1-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl)-3-piperidinecarboxamide (174 mg, 0.398 mmol) obtained in (A) and dissolved in dimethylformamide (4.0 ml) under ice cooling, and then the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated, added with saturated aqueous sodium hydrogencarbonate, and then extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was suspended in anhydrous tetrahydrofuran (3 ml) and dimethylformamide (3 ml), added with (tert-butoxycarbonylmethylene)triphenylphosphorane (449 mg, 1.19 mmol) and stirred at 75° C. for 24 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform:methanol=100:0→100:3, v/v) to obtain the title compound (192 mg, 86%).
- 1H-NMR (CDCl3) δ: 1.35 (6H, d, J=7.1 Hz), 1.54 (9H, m), 1.65-1.68 (1H, m), 1.85-1.90 (1H, m), 1.95-2.00 (2H, m), 2.77 (3H, d, J=4.6), 2.82 (1H, m), 2.92 (1H, m), 3.11-3.17 (2H, m), 3.90-4.00 (1H, m), 4.45-4.50 (1H, m), 6.97 (1H, s), 7.09 (1H, d, J=15.6 Hz), 7.12 (1H, d, J=1.7), 7.30 (1H, d, J=1.7 Hz), 7.34 (1H, d, J=16.1 Hz), 7.40-7.70 (2H, m), 8.86 (1H, d, J=7.3 Hz)
- The tert-butyl (E)-3-(8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-{3-[(methylamino)carbonyl]piperidino)-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (192 mg, 0.341 mmol) obtained in (B) was added with trifluoroacetic acid (5.0 ml) and stirred at room temperature for 1.5 hours. After the reaction was completed, the trifluoroacetic acid was evaporated under reduced pressure, and the residue was neutralized with 0.1 N sodium hydroxide and phosphate buffer (pH 7-8) and extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by thin layer chromatography (chloroform:methanol and chloroform:methanol:water=8:3:1, v/v, lower layer) to obtain the title compound (49.0 mg, 28%).
- 1H-NMR (DMSO-d6) δ: 1.29 (6H, d, J=6.8 Hz), 1.62-1.71 (2H, m), 1.77 (1H, m), 1.90 (1H, m), 2.58 (3H, d, J=4.6 Hz), 3.05-3.13 (3H, m), 3.27 (1H, m), 3.89 (1H, m), 4.08 (1H, m), 6.89 (1H, d, J=15.6 Hz), 7.42 (1H, s), 7.42 (1H, d, J=15.6 Hz), 7.54 (1H, d, J=16.1 Hz), 7.62 (1H, d, J=7.6 Hz), 7.67 (1H, s), 7.79 (1H, s), 7.88 (1H, d, J=16.1 Hz), 8.77 (1H, d, J=7.6 Hz)
- EI-MS; m/z: 508 (M++1)
- Ethyl thiooxamate (4.94 g, 37.1 mmol) was dissolved in anhydrous ethanol (250 ml), added with 1-bromopinacolone (4.99 ml, 37.1 mmol), and refluxed by heating for 4 hours. The reaction mixture was concentrated, neutralized with saturated aqueous sodium hydrogencarbonate, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and then the solvent was evaporated under reduced pressure. The residue was dissolved in anhydrous ethanol (200 ml), added with sodium hydroboride (2.10 g, 55.6 mmol), and stirred at room temperature for 16 hours. The reaction solution was further added with sodium borohydride (500 mg, 13.2 mmol) and stirred at room temperature for 4 hours, and then the solvent was evaporated under reduced pressure. The residue was cooled to −78° C., and the resulting white solid was taken by filtration to obtain the title compound (2.77 g, 44%).
- 1H-NMR (CDCl3) δ: 1.33 (9H, s), 4.92 (2H, s), 6.86 (1H, s)
- [4-(tert-Butyl)-1,3-thiazol-2-yl]methanol (2.77 g, 16.2 mmol) obtained in (A) was dissolved in methylene chloride (45 ml), added with pyridinium dichromate (12.2 g, 32.3 mmol), and stirred at room temperature for 13.5 hours. After insoluble solids were removed, the reaction solution was evaporated, and the residue was purified by silica gel column chromatography (dichloromethane) to obtain the title compound (2.71 g, 99%).
- 1H-NMR (CDCl3) δ: 1.40 (9H, s), 7.36 (1H, s), 9.98 (1H, s)
- tert-Butyl N-(4-methyl-2-pyridyl)carbamate (3.11 g, 14.9 mmol) was dissolved in anhydrous tetrahydrofuran (50 ml), added with n-butyl lithium (1.59 M in n-hexane, 19.7 ml, 31.3 mmol) at −78° C. under argon atmosphere, and stirred at room temperature for 1.5 hours. The reaction mixture was cooled to −78° C. again, then added with a solution of the 4-(tert-butyl)-1,3-thiazol-2-carbaldehyde (2.30 g, 13.6 mmol) obtained in (B) in anhydrous tetrahydrofuran (10 ml), and stirred for 30 minutes. The reaction mixture was added with saturated aqueous ammonium chloride, warmed to room temperature and extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=2:1→1:1, v/v) to obtain the title compound (2.29 g, 45%).
- 1H-NMR (CDCl3) δ: 1.32 (9H, s), 1.53 (9H, s), 3.08 (1H, dd, J=8.4, 13.8 Hz), 3.29 (1H, dd, J=4.2, 13.8), 5.23 (1H, dd, J=4.2, 8.4 Hz), 6.83 (1H, s), 6.85 (1H, dd, J=1.5, 5.1 Hz), 7.67 (1H, s), 7.87 (1H, s), 8.13 (1H, d, J=5.1 Hz)
- The tert-butyl N-(4-{2-[4-(tert-butyl)-1,3-thiazol-2-yl]-2-hydroxyethyl]-2-pyridyl)carbamate (1.80 g, 4.77 mmol) obtained in (C) was dissolved in anhydrous tetrahydrofuran (20 ml), added with triethylamine (2.33 ml, 16.7 mmol) and methanesulfonyl chloride (738 μl, 9.54 mmol), and stirred at 0° C. for 3.5 hours. After insoluble solids were removed, the reaction mixture was washed with tetrahydrofuran, and the solvent was evaporated under reduced pressure. The residue was dissolved in toluene (30 ml), added with 1,8-diazabicyclo[5.4.0]undec-7-ene (1.07 ml, 7.15 mmol), and refluxed by heating for 1 hour. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=3:1→2:1, v/v) to obtain the title compound (1.23 g, 72%).
- 1H-NMR (CDCl3) δ: 1.37 (9H, s), 1.55 (9H, s), 6.89 (1H, s), 7.08 (1H, dd, J=1.5, 5.4 Hz), 7.29 (1H, d, J=16.4 Hz), 7.51 (1H, d, J=16.4 Hz), 8.12 (1H, s), 8.09 (1H, s), 8.21 (1H, d, J=5.4 Hz)
- The tert-butyl N-(4-(E)-2-[4-(tert-butyl)-1,3-thiazol-2-yl]-1-ethenyl-2-pyridyl)-carbamate (585 mg, 1.63 mmol) obtained in (D) was dissolved in trifluoroacetic acid (15 ml) and stirred at room temperature for 1 hour. The reaction mixture was concentrated, neutralized with saturated aqueous sodium hydrogencarbonate, and extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to obtain the title compound (422 mg, 100%).
- 1H-NMR (CDCl3) δ: 1.38 (9H, s), 6.62 (1H, s), 6.84 (1H, d, J=6.0 Hz), 6.93 (1H, s), 7.17 (1H, d, J=16.2 Hz), 7.42 (1H, d, J=16.2 Hz), 7.92 (1H, d, J=6.0 Hz)
- Ethyl 3-(dimethylamino)-2-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetraazol-5-yl]-2-propenoate (150 mg, 0.453 mmol) was dissolved in propionic acid (2.0 ml), added to the 4-(E)-2-[4-(tert-butyl)-1,3-thiazol-2-yl]-1-ethenyl-2-pyridinamine (98.0 mg, 0.378 mmol) obtained in (E), and refluxed by heating for 3 hours. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform) to obtain the title compound (175 mg, 93%).
- 1H-NMR (CDCl3) δ: 1.40 (9H, s), 3.79 (3H, s), 5.81 (2H, s), 6.89 (2H, d, J=8.3 Hz), 7.02 (1H, s), 7.41 (1H, d, J=16.2 Hz), 7.42 (2H, d, J=8.3 Hz), 7.46 (1H, d, J=7.5 Hz), 7.60 (1H, d, J=16.2 Hz), 7.74 (1H, s), 9.21 (1H, d, J=7.5 Hz), 9.21 (1H, s)
- The 8-(E)-2-[4-(tert-butyl)-1,3-thiazol-2-yl]-1-ethenyl-3-(2H-1,2,3,4-tetraazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one (170 mg, 0.340 mmol) obtained in (F) was added with trifluoroacetic acid (4.0 ml) and stirred at 60° C. for 3 hours. After the reaction was completed, the trifluoroacetic acid was evaporated under reduced pressure, and the residue was neutralized with 0.1 N sodium hydroxide and phosphate buffer (pH 7-8) and extracted with chloroform. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The yellow solid deposited from the residue was collected by filtration to obtain the title compound (20.0 mg, 15%).
- 1H-NMR (DMSO-d6) δ: 1.35 (9H, s), 7.47 (1H, s), 7.67 (1H, d, J=16.1 Hz), 8.03 (1H, d, J=16.1 Hz), 8.04 (1H, d, J=1.9 Hz), 8.13 (1H, d, J=1.9 Hz), 9.11 (1H, d, J=7.3 Hz), 9.17 (1H, s)
- EI-MS; m/z: 380 (M++1)
- tert-Butyl (E)-3-(2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (17 mg) was added with dimethylformamide (3 ml), diisopropylethylamine (500 ml) and 3-(iodomethyl)tetrahydrofuran (50 ml), and then the mixture was stirred at 80° C. for 16 hours. The reaction mixture was added with ethyl acetate and saturated brine, and the organic layer was further washed twice with saturated brine and dried over magnesium sulfate. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (14 mg).
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=7.1 Hz), 1.52 (9H, s), 1.75 (1H, m), 2.16 (1H, m), 2.82 (1H, m), 3.07 (1H, m), 3.26 (2H, m), 3.39 (2H, m), 3.71 (1H, m), 3.80 (1H, m), 3.92 (2H, m), 4.42 (2H, m), 6.74 (1H, s), 7.02 (1H, m), 7.13 (1H, d, J=15.8 Hz), 7.34 (1H, s), 7.91 (1H, d, J=15.8 Hz), 8.99 (1H, d, J=7.3 Hz)
- The tert-butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(tetrahydro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (10 mg) obtained in (A) was dissolved in methylene chloride (1 ml) and formic acid (1 ml), and then the mixture was stirred for 5 hours. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (14 mg).
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.6 Hz), 1.79 (1H, m), 2.16 (1H, m), 2.83 (1H, m), 3.07 (1H, m), 3.26 (2H, m), 3.39 (2H, m), 3.73 (2H, m), 3.81 (1H, m), 3.93 (2H, m), 4.42 (2H, m), 6.73 (1H, s), 7.02 (1H, m), 7.15 (1H, d, J=15.8 Hz), 7.33 (1H, s), 8.05 (1H, d, J=15.8 Hz), 8.99 (1H, d, J=6.5 Hz)
- (E)-2-{2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-1-ethenylcyanide (100 mg) was added with dimethylformamide (5 ml), diisopropylethylamine (500 ml) and 3-(iodomethyl)tetrahydrofuran (200 ml), and then the mixture was stirred at 80° C. for 2 hours and further stirred overnight at room temperature. After the reaction mixture was distributed between chloroform and water, the organic layer was dried over magnesium sulfate. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (51 mg).
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 1.78 (1H, m), 2.16 (1H, m), 2.79 (1H, m), 3.05 (1H, m), 3.29 (2H, m), 3.38 (2H, m), 3.71 (1H, m), 3.82 (1H, m), 3.93 (2H, m), 4.42 (2H, m), 6.74 (1H, s), 6.68 (1H, d, J=16.3 Hz), 7.07 (1H, d, J=7.3 Hz), 7.37 (1H, s), 7.64 (1H, d, J=16.3 Hz), 8.97 (1H, d, J=7.3 Hz)
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 1.80 (1H, m), 2.18 (1H, m), 2.86 (1H, m), 3.08 (1H, m), 3.27 (2H, m), 3.42 (2H, m), 3.80 (2H, m), 3.96 (2H, m), 4.47 (2H, m), 6.76 (1H, s), 7.04 (1H, m), 7.34 (1H, s), 7.90 (1H, d, J=16.3 Hz), 8.04 (1H, d, J=16.3 Hz), 8.99 (1H, d, J=7.0 Hz)
- 1H-NMR (CD3OD-CDCl3) δ: 1.42 (6H, d, J=6.8 Hz), 3.29 (1H, m), 3.40 (2H, m), 3.77 (2H, m), 5.96 (2H, s), 7.18 (1H, d, J=15.9 Hz), 7.37 (1H, m), 7.44 (1H, s), 7.80 (1H, s), 8.02 (1H, d, J=15.9 Hz), 8.07 (1H, m), 8.31 (1H, m), 8.68 (1H, m), 8.92 (1H, m), 9.04 (1H, d, J=7.3 Hz)
- 1H-NMR (CD3OD-CDCl3) δ: 1.42 (6H, d, J=6.8 Hz), 3.29 (1H, m), 3.45 (2H, m), 3.83 (2H, m), 5.85 (2H, s), 7.07 (1H, d, J=15.9 Hz), 7.39 (1H, d, J=7.3 Hz), 7.46 (1H, s), 7.78 (1H, s), 7.93 (1H, d, J=15.9 Hz), 8.18 (1H, m), 8.82 (2H, m), 9.01 (1H, d, J=7.1 Hz), 9.24 (1H, s)
- 1H-NMR (CD3OD) δ: 1.35 (6H, d, J=6.8 Hz), 3.29 (1H, m), 3.37 (2H, m), 3.70 (2H, m), 5.97 (2H, s), 7.16 (1H, d, J=15.9 Hz), 7.38 (1H, d, J=7.0 Hz), 7.52 (2H, s), 8.08 (1H, d, J=15.9 Hz), 8.20 (2H, m), 8.88 (2H, m), 9.06 (1H, d, J=7.0 Hz)
- 2-Hydroxy-8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4H-pyrido[1,2-a]-pyrimidin-4-one (210 mg, 0.670 mmol) was suspended in dimethylformamide (6.0 ml), added with diisopropylethylamine (600 μl) and 3-(iodomethyl)tetrahydrofuran (334 μl), and stirred overnight at 80° C. The reaction solution was further added with diisopropylethylamine (600 μl) and 3-(iodomethyl)tetrahydrofuran (334 μl) and stirred overnight at 80° C. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (chloroform:methanol=100:0 100:1→100:2→100:5, v/v) to obtain the title compound (277 mg, quantitative).
- Dimethylformamide (3.0 ml) was added with phosphorus oxychloride (187 μl, 2.02 mmol) under ice cooling and stirred at room temperature for 30 minutes. The mixture was added to 8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-2-(tetrahydro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-4-one (277 mg) obtained in (A) and dissolved in dimethylformamide (3.0 ml) under ice cooling, and then the mixture was stirred at room temperature for 4 hours. The reaction mixture was added with saturated aqueous sodium hydrogencarbonate and extracted with chloroform. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was suspended in anhydrous tetrahydrofuran (6.0 ml) and anhydrous N,N-dimethylformamide (3.0 ml), added with (tert-butoxycarbonyl-methylene)triphenylphosphorane (505 mg, 1.34 mmol) and stirred at 50° C. for 16 hours. The reaction mixture was concentrated, and then the residue was purified by silica gel column chromatography (n-hexane:ethyl acetate, 5:1→3:1→2:1→1:1, v/v) to obtain the title compound (215 mg, 61%).
- 1H-NMR (CDCl3) δ: 1.36 (6H, d, J=6.8 Hz), 1.53 (9H, s), 1.80 (1H, dt, J=7.3, 12.8 Hz), 2.12-2.21 (1H, m), 2.80-2.87 (1H, m), 3.12-3.19 (1H, m), 3.73 (1H, dd, J=5.4, 8.8 Hz), 3.81 (1H, dd, J=7.7, 15.2 Hz), 3.91-3.97 (2H, m), 4.44-4.47 (2H, m), 6.99 (1H, s), 7.16 (1H, d, J=16.3 Hz), 7.31 (1H, d, J=1.8, 7.5 Hz), 7.39 (1H, d, J=16.2 Hz), 7.48 (1H, d, J=1.5 Hz), 7.54 (1H, d, J=16.2 Hz), 7.92 (1H, d, J=16.3 Hz), 9.04 (1H, d, J=7.5 Hz)
- ESI-MS; m/z: 524 (M++1)
- The tert-butyl (E)-3-{8-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-2-(tetrahydro-3-furanylmethoxy)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (101 mg, 0.193 mmol) obtained in (B) was dissolved in 1,4-dioxane (1.6 ml), added with 4 N hydrochloric acid in 1,4-dioxane (3.2 ml), and then the mixture was stirred at room temperature for 16.25 hours. The reaction solution was concentrated, added with saturated aqueous sodium hydrogencarbonate, neutralized with phosphate buffer (pH 7-8), and then extracted with a mixture of chloroform/methanol (10:1, v/v). The organic layer was dried over magnesium sulfate, and then the solvent was evaporated under reduced pressure. The residue was purified by thin layer chromatography (chloroform:methanol=20:1, v/v) to obtain the title compound (77.1 mg, 86%).
- 1H-NMR (CDCl3+CD3OD) δ: 1.36 (6H, d, J=6.8 Hz), 1.17-1.85 (1H, m), 2.13-2.22 (1H, m), 2.82-2.89 (1H, m), 3.13-3.19 (1H, m), 3.74 (1H, dd, J=5.4, 8.8 Hz), 3.82 (1H, dd, J=7.7, 15.5 Hz), 3.93-3.98 (2H, m), 4.44-4.52 (2H, m), 7.01 (1H, s), 7.16 (1H, d, J=15.9 Hz), 7.36-7.41 (2H, m), 7.50 (1H, s), 7.57 (1H, d, J=16.1 Hz), 8.03 (1H, d, J=15.9 Hz), 9.03 (1H, d, J=7.3 Hz)
- ESI-MS; m/z: 468 (M++1)
- 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine (50 mg) and diethyl 2-[1-(4-methoxybenzyl)tetrazol-5-yl]malonate (141 mg) were heated to 150° C. in bromobenzene with stirring for 4 hours. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound (73 mg) as cream solid.
- 1H-NMR (CDCl3) δ: 1.22 (d, J=6.6 Hz, 6H), 3.02 (m, 1H), 3.20-3.40 (m, 4H), 3.70 (s, 3H), 5.80 (s, 2H), 6.70 (s, 1H), 6.80 (bs, 2H), 7.00 (s, 1H), 7.30-7.50 (m, 3H), 9.00 (bs, 1H)
- MS(−), m/z, 502 (M−H+)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-3-[(4-methoxybenzyl)-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one (73 mg) obtained in (A) was dissolved in methylene chloride (2 ml), added with dimethylaminopyridine (5 mg), triethylamine (40 ml) and p-toluenesulfdnyl chloride (83 mg) at 0° C., and then the mixture was stirred at room temperature for 6 hours. The reaction solution was directly purified by silica gel column chromatography to obtain the title compound (61 mg, 64%) as pale yellow powder.
- 1H-NMR (CDCl3) δ: 1.22 (d, J=6.6 Hz, 6H), 2.42 (s, 3H), 3.05 (m, 1H), 3.25-3.32 (m, 4H), 3.80 (s, 3H), 5.75 (s, 2H), 6.75 (s, 1H), 6.85 (d, J=7.2 Hz, 2H), 7.15 (d, J=7.5 Hz, 1H), 7.24 (d, J=7.2 Hz, 2H), 7.35 (d, J=7.2 Hz, 2H), 7.42 (s, 1H), 7.90 (d, J=7.2 Hz, 2H), 9.01 (d, J=7.5 Hz, 1H)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-tosyloxy-3-[(4-methoxybenzyl)-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one (61 mg) obtained in (B) was dissolved in tetrahydrofuran (1 ml), added with morpholine (40 ml) at room temperature, and stirred overnight at the same temperature. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (31 mg, 59%).
- 1H-NMR (CDCl3) δ: 1.28 (d, J=6.6 Hz, 6H), 3.06 (m, 1H), 3.30-3.70 (m, 12H), 3.78 (s, 3H), 5.76 (s, 2H), 6.72 (s, 1H), 6.77 (d, J=7.5 Hz, 1H), 6.86 (d, J=7.2 Hz, 2H), 7.14 (s, 1H), 7.36 (d, J=7.2 Hz, 2H), 8.88 (m, J=7.5 Hz, 1H)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-3-(1-p-methoxy-benzyl-1,2,3,4-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one (10 mg) obtained in (C) was dissolved in trifluoroacetic acid (1 ml) and added with anisole (50 ml), and then stirred at room temperature for 4 hours. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound (7 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.25 (d, 6H), 3.04 (m, 1H), 3.22 (t, 2H), 3.38 (t, 2H), 3.66 (m, 4H), 3.82 (m, 4H), 6.73 (s, 1H), 6.89 (m, 1H), 7.22 (m, 1H), 8.83 (d, 1H)
- MS (ES−) m/z 451 (M+−1)
- In the following Examples 119 to 121, synthesis was performed in the same manner as in Example 118.
- 1H-NMR (CDCl3) δ: 1.21 (d, 6H), 2.98 (m, 1H), 3.25 (t, 2H), 3.36 (t, 2H), 5.73 (s, 2H), 6.71 (s, 1H), 7.16 (d, 1H), 7.31 (m, 1H), 7.42 (s, 1H), 8.10 (d, 1H), 8.41 (d, 1H), 8.69 (s, 1H), 8.99 (d, 1H)
- MS (ES+) m/z 475 (M++1); MS (ES−) m/z 473 (M+−1)
- 1H-NMR (CD3OD) δ: 1.24 (d, 6H), 2.95 (s, 6H), 3.01 (m, 1H), 3.21 (t, 2H), 3.41 (t, 2H), 6.95 (s, 1H), 7.00 (m, 1H), 7.23 (s, 1H), 8.80 (d, 1H)
- MS (ES+) m/z 512 (M++1); MS (ES−) m/z 510 (M+−1)
- 1H-NMR (CDCl3) δ: 1.33 (d, 6H), 2.02 (m, 2H), 2.10 (m, 2H), 2.95 (m, 1H), 3.20 (m, 4H), 3.45 (m, 2H), 3.62 (m, 1H), 3.79 (m, 2H), 6.82 (s, 1H), 6.90 (d, 1H), 7.18 (s, 1H), 8.85 (d, 1H)
- MS (ES−) m/z 476 (M++1); 474 (M+−1)
- 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine (300 mg) and methyl 2-(t-butoxycarbonyl)amino-3-dimethylaminopropenoate (445 mg) were added with xylene (2 ml) and heated at 140° C. for 6.5 hours with stirring. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound (200 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.21 (d, J=6.9 Hz, 6H), 3.01 (m, 1H), 3.22 (t, J=7.8 Hz, 2H), 3.37 (t, J=7.8 Hz, 2H), 6.72 (s, 1H), 6.96 (d, J=7.2 Hz, 1H), 7.25 (s, 1H), 7.47 (s, 1H), 8.83 (d, J=7.5 Hz, 1H), 9.14 (s, 1H)
- MS(+), m/z, 415 (M+H+), 829 (2M+H+)
- The tert-butyl N-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-ylcarbamate (200 mg) obtained in (A) was treated with 2 ml of trifluoroacetic acid at room temperature for 1 hour, and the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate, washed with saturated sodium hydrogencarbonate and dried over sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (quantitative) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.28 (d, J=6.9 Hz, 6H), 3.06 (m, 1H), 3.23 (t, J=7.8 Hz, 2H), 3.39 (t, J=7.8 Hz, 2H), 6.75 (s, 1H), 6.95 (d, J=7.5 Hz, 1H), 7.50 (s, 1H), 7.47 (s, 1H), 7.94 (s, 1H), 8.80 (d, J=7.5 Hz, 1H)
- MS(+), m/z, 315 (M+H+)
- The 3-amino-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]-pyrimidin-4-one (44 mg) obtained in (B) and p-toluenesulfonyl isocyanate (42 mg) were dissolved in toluene (0.5 ml) and refluxed by heating for 2.5 hours. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound (33 mg) as white powder.
- 1H-NMR (CDCl3) δ: 1.26 (d, 6H), 2.41 (s, 3H), 3.05 (m, 1H), 3.25 (t, 2H), 3.39 (t, 2H), 6.73 (s, 1H), 7.19 (dd, 1H), 7.31 (d, 1H), 7.56 (s, 1H), 7.96 (d, 1H), 8.71 (s, 1H), 9.04 (d, 1H), 9.39 (s, 1H)
- MS (ES+) m/z 411 (M++1)
- 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine (200 mg), diethyl 4-dimethylaminomethyleneglutaconate (265 mg) was added with bromobenzene (2 ml) and heated at 120° C. for 1 hour and at 160° C. for 4 hours with stirring. The residue was purified by silica gel column chromatography to obtain the title compound (20 mg) as white powder.
- 1H-NMR (CDCl3) δ: 1.20-1.40 (m, 9H), 3.05 (m, 1H), 3.32 (t, J=6.6 Hz, 2H), 3.40 (t, J=6.6 Hz, 2H), 4.27 (q, J=7.2 Hz, 2H), 6.73 (s, 1H), 7.11 (d, J=7.2 Hz, 1H), 7.18 (d, J=15.9 Hz, 1H), 7.51 (s, 1H), 7.66 (d, J=15.9 Hz, 1H), 8.45 (s, 1H), 9.08 (s, 1H) MS(+), m/z, 398 (M+H+), 420 (M+Na+), MS(−), m/z, 396 (M−H+)
- The ethyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoate (15 mg) obtained in (A) was dissolved in tetrahydrofuran (1 ml) and methanol (0.5 ml), added with a solution of 8 mg of lithium hydroxide dissolved in 0.5 ml of water, and stirred at room temperature for 3.5 hours, and the solvent was concentrated under reduced pressure. The residue was distributed between ether and water, and the aqueous layer was separated, made pH 3 with hydrochloric acid, extracted with ethyl acetate, and dried over sodium sulfate. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound.
- 1H-NMR (CDCl3) δ: 1.21 (d, 6H), 2.41 (s, 3H), 3.00 (m, 1H), 3.25 (t, 2H), 3.34 (t, 2H), 6.67 (s, 1H), 7.06-7.19 (m, 2H), 7.48 (s, 1H), 7.68 (d, J=16 Hz, 1H), 8.40 (s, 1H), 9.03 (d, J=7.5 Hz, 1H)
- MS (ES+) m/z 370 (M++1); MS (ES−) m/z 368 (M+−1)
- 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine (100 mg) and ethyl 2-ethoxycarbonylmethoxy-3-methoxy-3-dimethylaminopropenoate (150 mg) were heated at 140° C. in xylene (1 ml) for 7 hours with stirring. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (41 mg).
- 1H-NMR(CDCl3, 300 MHz) δ: 1.20-1.30 (m, 9H), 3.04 (m, 1H), 3.23 (t, J=7.8 Hz, 2H), 3.40 (t, J=7.8 Hz, 2H), 4.25 (q, J=7.2 Hz, 2H), 4.86 (s, 2H), 6.72 (s, 1H), 6.98 (d, J=7.5 Hz, 1H), 7.45 (s, 1H), 8.29 (s, 1H), 8.90 (d, J=7.5 Hz, 1H)
- MS(+), m/z, 401 (M+H+)
- The ethyl 2-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimidin-3-yloxy)acetate (41 mg) obtained in (A) was dissolved in tetrahydrofuran (1 ml) and methanol (300 ml), added with a solution of lithium hydroxide (5 mg) dissolved in water (300 ml), and then the mixture was stirred at room temperature for 1 hour, and the solvent was concentrated under reduced pressure. The residue was distributed between ether and water, and the aqueous layer was separated and made pH 3 with hydrochloric acid, and then extracted with ethyl acetate. The organic layer was dried over sodium sulfate. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound (quantitative).
- 1H-NMR (DMSO-d6) δ: 1.23 (d, 6H), 3.00 (m, 1H), 3.21 (t, 2H), 3.40 (t, 2H), 4.54 (s, 2H), 6.96 (s, 1H), 7.18 (d, 1H), 7.38 (s, 1H), 8.12 (s, 1H), 8.85 (d, 1H)
- MS (ES−) m/z 372 (M+−1)
- Methyl 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimidin-3-carboxylate (22 mg) and hydrazine (4 ml) were refluxed by heating in methanol (3 ml) for 2.5 hours under nitrogen atmosphere. The reaction mixture was further added with hydrazine (10 ml) and refluxed by heating for 2 days. After the reaction mixture was cooled, insoluble solids were collected by filtration and suspended in methylene chloride (5 ml). The suspension was added with diphosgene (7 ml) and stirred for 30 minutes. Insoluble solids were removed by filtration, and the reaction mixture was concentrated to obtain the title compound (11 mg).
- 1H-NMR (CD3OD) δ: 1.36 (s, 3H), 1.39 (s, 3H), 3.22 (m, 1H), 3.53 (m, 2H), 3.77 (m, 2H); 7.58 (s, 1H); 7.75 (d, 1H), 7.91 (s, 1H), 8, 84 (s, 1H), 9.31 (d, 1H)
- MS (ES+) m/z 384 (M++1); MS (ES−) m/z 382 (M+−1)
- tert-Butyl 2-(diethylphosphono)propionate (70 mg) was dissolved in tetrahydrofuran (5 ml), added with sodium hydride (60% in oil, 40 mg), and stirred for 10 minutes. The reaction mixture was added with 8-(2-(4-isopropyl-1,3-thiazol-2-yl)-ethyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde (56 mg), stirred for 10 minutes and added with acetic acid (0.2 ml), and then distributed between ethyl acetate and saturated aqueous sodium hydrogencarbonate. The organic layer was concentrated, and the residue was purified by silica gel column chromatography to obtain the title compound (70 mg) as yellow oil.
- 1H-NMR (CDCl3) δ: 1.27 (d, 6H), 1.51 (s, 9H), 2.07 (s, 3H), 3.05 (m, 1H), 3.3-3.5 (m, 4H), 6.72 (s, 1H), 7.07 (d, 1H), 7.52 (s, 1H), 7.68 (s, 1H), 8.41 (s, 1H), 9.00 (s, 1H)
- The tert-butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoate (70 mg) obtained in (A) was dissolved in trifluoroacetic acid (1 ml) and stirred at room temperature for 1 hour, and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (21 mg).
- 1H-NMR (CDCl3+CD3OD) δ: 1.25 (d, 6H), 2.10 (s, 3H), 3.04 (m, 1H), 3.28 (t, 2H), 3.35-3.45 (m, with CD3OD), 6.74 (s, 1H), 7.15 (d, 1H), 7.59 (s, 1H), 7.79 (s, 1H), 8.45 (s, 1H), 9.01 (d, 1H)
- 1H-NMR (CDCl3) δ: 1.28 (d, 6H), 2.10 (m, 2H), 2.70 (m, 2H), 3.05 (m, 1H), 3.30 (t, 2H), 3.40 (t, 2H), 3.60 (m, 2H), 6.75 (s, 1H), 7.10 (d, 1H), 7.54 (s, 1H), 7.94 (s, 1H), 8.51 (s, 1H), 9.03 (d, 1H)
- MS (ES+) m/z 446 (M++1); MS (ES−) m/z 444 (M+−1)
- 2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]-pyrimidin-4-one (400 mg) and DMAP (310 mg) were dissolved in methylene chloride (8 ml), added with trifluoromethanesulfonic anhydride (427 ml) at −78° C., and then the mixture was stirred overnight while the reaction temperature was gradually returned to room temperature. The reaction mixture was added with 0.2 M hydrochloric acid (50 ml) and extracted with methylene chloride, and the organic layer was dried over sodium sulfate. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound (499 mg, 88%).
- 1H-NMR (CDCl3) δ: 1.22 (d, J=7.5 Hz, 6H), 3.10 (m, 1H), 3.25-3.40 (m, 4H), 6.10 (s, 1H), 6.75 (s, 1H), 7.18 (d, J=7.5 Hz, 1H), 7.55 (s, 1H), 8.95 (d, J=7.5 Hz, 1H)
- The 2-trifluoromethanesulfonyloxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one (82 mg) obtained in (A), phenylboronic acid (45 mg), palladium tetrakistriphenylphosphine (11 mg), potassium bromide (24 mg) and potassium carbonate (38 mg) were stirred at 85° C. overnight in dioxane (4 ml) under a nitrogen flow. The reaction mixture was cooled and added with water (20 ml) and extracted with ethyl acetate, and then the organic layer was dried over sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (65 mg, 94%) as white powder.
- 1H-NMR (CDCl3) δ: 1.22 (d, J=7.5 Hz, 6H), 3.00-3.10 (m, 1H), 3.30-3.50 (m, 4H), 6.72 (s, 1H), 6.85 (s, 1H), 6.99 (d, J=7.5 Hz, 1H), 7.46-7.56 (m, 5H), 8.20-8.40 (m, 1H), 8.96 (d, J=7.5 Hz, 1H)
- Dimethylformamide (1 ml) and phosphorus oxychloride (25 ml) were mixed under ice cooling and stirred at room temperature for 30 minutes. The mixture was added with a solution of the 2-phenyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one (65 mg) obtained in (B) and dissolved in dimethylformamide (1 ml) and stirred at room temperature for 1 hour and at 95° C. for 1.5 hours on an outer bath. The reaction mixture was cooled and then added with ethyl acetate and hexane. Then, the organic layer was washed with saturated aqueous sodium hydrogencarbonate and water and dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was added with tetrahydrofuran (2.5 ml) and dimethylformamide (0.5 ml), further added with (tert-butoxycarbonylmethylidene)triphenylphosphorane (240 mg), and stirred at 80° C. for 10 hours. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (18 mg).
- 1H-NMR (CDCl3) δ: 1.22 (d, J=7.5 Hz, 6H), 3.00-310 (m, 1H), 3.30-3.50 (m, 4H), 6.82 (s, 1H), 6.99 (d, J=7.5 Hz, 1H), 7.40-7.66 (m, 7H), 8.05-8.10 (m, 1H), 8.95 (d, J=7.5 Hz, 1H)
- The tert-butyl (E)-3-{2-phenyl-4-oxo-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (18 mg) obtained in (C) was added with trifluoroacetic acid (1 ml) and stirred at room temperature for 2 hours. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (15 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.25 (d, 6H), 3.05 (m, 1H), 3.28 (t, 2H), 3.39 (t, 2H), 6.75 (s, 1H), 7.12 (d, 1H), 7.39 (d, J=16 Hz, 1H), 7.50 (m, 3H), 7.58 (m, 3H), 7.72 (d, J=16 Hz, 1H), 9.05 (d, 1H)
- 2-Trifluoromethanesulfonyloxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4H-pyrido[1,2-a]pyrimidin-4-one (499 mg), pyridine-3-boronic acid 1,3-propanediol cyclic ester (364 mg), palladium tetrakistriphenylphosphine (65 mg), potassium bromide (146 mg) and potassium carbonate (231 mg) were added with dioxane (8 ml) and stirred overnight at 85° C. under nitrogen atmosphere. The reaction mixture was cooled and then added with ethyl acetate. Insoluble solids were removed by filtration, and the solvent of the filtrate was evaporated. The residue was purified by silica gel column chromatography to obtain the title compound (400 mg).
- 1H-NMR (CDCl3) δ: 1.18 (d, J=7.2 Hz, 6H), 2.98 (m, 1H), 3.05-3.30 (m, 4H), 6.66 (s, 1H), 6.75 (s, 1H), 7.02 (dd, J=7.5, 1.8 Hz, 1H), 7.38 (dd, J=7.5, 7.8 Hz, 1H), 7.49 (d, J=1.2 Hz, 1H), 8.30 (dt, J=7.5, 1.8 Hz, 1H), 8.55 (dd, J=7.5, 1.2 Hz, 1H), 8.86 (d, J=7.8 Hz, 1H), 9.11 (d, J=1.2 Hz, 1H).
- Phosphorus oxychloride (367 ml) was added to dimethylformamide (5 ml) under ice cooling and stirred at the same temperature for 10 minutes. The mixture was added with the 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-(3-pyridyl)-4H-pyrido-[1,2-a]pyrimidin-4-one (336 mg) obtained in (A) and stirred at 950C for 1.5 hours. The mixture was cooled, then slowly added with sodium carbonate and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain yellow powder (58 mg). The resulting powder was dissolved in tetrahydrofuran (2.5 ml) and dimethylformamide (0.5 ml), added with methyl (triphenylphosphoranylidene)acetate (240 mg) and stirred at 90° C. for 10 hours. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (19 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.22 (d, J=7.5 Hz, 6H), 3.05 (m, 1H), 3.30-3.50 (m, 4H), 3.75 (s, 3H), 6.88 (s, 1H), 7.15 (dd, J=7.2, 2.1 Hz, 1H), 7.40-7.60 (m, 4H), 7.93 (dt, J=7.8, 1.8 Hz, 1H), 8.75 (dd, J=5.1,1.5 Hz, 1H), 8.87 (d, J=1.8 Hz, 1H), 9.08 (d, J=7.5 Hz, 1H)
- The methyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-2-(3-pyridyl)-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate obtained in (B) was dissolved in tetrahydrofuran (2 ml) and methanol (0.5 ml), added with a solution (0.5 ml) containing lithium hydroxide (5.5 mg) and stirred at room temperature for 1-hour. The solvent was evaporated under reduced pressure, and the residue was distributed between water and diethyl ether. The aqueous layer was separated, made pH 4-5 with hydrochloric acid, and then extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was evaporated. The residue was purified by silica gel column chromatography to obtain the title compound (6.9 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.18 (d, 6H), 2.95 (m, 1H), 3.21 (t, 2H), 3.32 (t, 2H), 6.67 (s, 1H), 7.15 (d, 1H), 7.23 (d, J=13 Hz, 1H), 7.41 (d, J=13 Hz, 1H), 7.48 (s, 1H), 7.55 (m, 1H), 8.01 (m, 1H), 8.65 (m, 1H), 8.76 (s, 1H), 8.98 (d, 1H)
- MS (ES+) m/z 447 (M++1); MS (ES−) m/z 445 (M+−1)
- 1H-NMR (CD3OD) δ: 1.25 (d, 6H), 3.02 (m, 1H), 3.2-3.5 (m, with CHD2OD), 6.87 (s, 1H), 7.33 (d, J=16 Hz, 1H), 7.38 (m, 1H), 7.45 (d, J=16 Hz, 1H), 7.59 (m, 2H), 7.72 (s, 1H), 8.72 (m, 2H), 9.13 (d, 1H)
- MS (ES+) m/z 447 (M++1); MS (ES−) m/z 445 (M+−1)
- Under nitrogen atmosphere, triethyl 2-phosphonopropionate (155 mg, 0.65 mmol) was dissolved in tetrahydrofuran (2 ml), added with n-butyl lithium (1 M, 0.65 ml) at −78° C., and stirred at the same temperature for 20 minutes. The reaction mixture was added with a solution of 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde (50 mg) dissolved in tetrahydrofuran (1 ml). The cooling bath was removed, and the reaction mixture was warmed to room temperature and stirred overnight at room temperature. The reaction mixture was added with saturated aqueous sodium hydrogencarbonate and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (14 mg).
- 1H-NMR (CDCl3) δ: 1.20-1.30 (m, 9H), 1.79 (s, 3H), 2.95 (m, 1H), 3.11 (t, J=7.5 Hz, 2H), 3.29 (t, J=7.5 Hz, 2H), 3.48 (t, J=4.8 Hz, 4H), 3.66 (t, J=4.8 Hz, 4H), 4.05-4.15 (m, 2H), 6.66 (s, 1H), 6.75 (d, J=7.5 Hz, 1H), 7.12 (s, 1H), 7.45 (s, 1H), 8.75 (d, J=7.5 Hz, 1H)
- The ethyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-methyl-2-propenoate (14 mg) obtained in (A) was dissolved in tetrahydrofuran (4 ml) and methanol (1 ml), added with a solution of lithium hydroxide (1.4 mg) in water (1 ml) and stirred at room temperature for 1.5 hours. The reaction mixture was added with water and washed with ether, and then the aqueous layer was made acidic with diluted hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (4.4 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.24 (d, 6H), 1.86 (s, 3H), 3.05 (m, 1H), 3.19 (t, 2H), 3.38 (t, 2H), 3.58 (m, 4H), 3.74 (m, 4H), 6.74 (s, 1H), 6.82 (d, 1H), 7.20 (s, 1H), 7.63 (s, 1H), 8.83 (d, 1H)
- MS (ES+) m/z 469 (M++1); MS (ES−) m/z 467 (M+−1)
- 1H-NMR (CDCl3) δ: 0.75 (m, 2H), 1.14 (m, 2H), 1.42 (s, 3H), 1.88 (s, 3H), 3.18 (t, 2H), 3.34 (t, 2H), 3.59 (m, 4H), 3.76 (m, 4H), 6.73 (s, 1H), 6.81 (d, 1H), 7.22 (s, 1H), 7.63 (s, 1H), 8.82 (d, 1H)
- MS (ES+) m/z 481
- 1H-NMR (CDCl3) δ: 1.35 (s, 9H), 1.85 (s, 3H), 3.20 (t, 2H), 3.36 (t, 2H), 3.58 (m, 4H), 3.75 (m, 4H), 6.73 (s, 1H), 6.81 (d, 1H), 7.20 (s, 1H), 7.61 (s, 1H), 8.81 (d, 1H)
- MS (ES+) m/z 483 (M++1); MS (ES−) m/z 481 (M+−1)
- 1H-NMR (CD3OD) δ: 1.20 (d, 6H), 1.59 (s, 3H), 1.95 (m, 1H), 2.23 (m, 1H), 2.98 (m, 1H), 3.10 (m, 2H), 3.35 (m, 2H), 3.43 (m, 1H), 3.62 (m, 2H), 3.75 (m, 2H), 6.88 (m, 2H), 7.08 (s, 1H), 7.36 (s, 1H), 8.62 (d, 1H)
- MS (ES+) m/z 468 (M++1)
- 2-Fluoro-2-phosphonoacetic acid triethyl ester (384 mg) was dissolved in tetrahydrofuran (3 ml) and dimethylformamide (1.5 ml), added with n-butyl lithium (1.6 M, 1 ml) at −78° C. under nitrogen atmosphere, and then the mixture was stirred at the same temperature for 20 minutes. The reaction mixture was added with a solution of 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrido[1,2-a]-pyrimidine-3-carbaldehyde (108 mg) dissolved in tetrahydrofuran (2 ml). The reaction temperature was gradually raised to room temperature, and the reaction mixture was stirred overnight at the same temperature. The reaction mixture was added with water and extracted with methylene chloride, and the organic layer was dried over magnesium sulfate. Then, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (35 mg) as a mixture of (E)- and (Z)-isomers.
- 1H-NMR (CDCl3) δ: 1.20-1.30 (m, 9H), 3.05 (m, 1H), 3.20-3.30 (m, 4H), 4.05-4.15 (m, 2H), 6.70-6.80 (m, 2H), 7.14 (d, J=7.5 Hz, 1H), 7.41 (s, 1H), 9.00-9.05 (m, 1H) MS(+), m/z, 382 (M+H+); MS(−), m/z, 380 (M−H+)
- The ethyl 2-fluoro-3-(8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (35 mg) obtained in (A) was dissolved in methylene chloride (2 ml), added with triethylamine (35 ml) and tosyl chloride (46 mg) under ice cooling, and then the mixture was stirred overnight at room temperature. The reaction mixture was added with morpholine (49 ml) and further stirred for 4 hours. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain yellow powder (28 mg). This was dissolved in methylene chloride (1 ml), added with a trace amount of iodine, and then the mixture was stirred at room temperature for 30 minutes, and the solvent was evaporated to obtain the title compound.
- 1H-NMR (CDCl3) δ: 1.20-1.30 (m, 9H), 3.05 (m, 1H), 3.20 (t, J=7.8 Hz, 2H), 3.36 (t, J=7.8 Hz, 2H), 3.55-3.80 (m, 8H), 4.20-4.35 (m, 2H), 6.70-6.82 (m, 2H), 7.19 (d, J=7.5 Hz, 1H), 7.35 (d, J=36.9 Hz, 1H), 8.75-8.85 (m, 1H)
- The ethyl (Z)-2-fluoro-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (28 mg) obtained in (B) was dissolved in tetrahydrofuran (2 ml) and methanol (0.5 ml), added with a solution of lithium hydroxide (5 mg) in water (0.5 ml), and then the mixture was stirred at room temperature for 1 hour. The reaction mixture was added with water and washed with ether. Then, the aqueous layer was made acidic with diluted hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (26 mg) as yellow powder.
- 1H-NMR (CD3OD) δ: 1.24 (d, 6H), 3.03 (m, 1H), 3.18 (t, 2H), 3.37 (t, 2H), 3.62 (m, 4H), 3.72 (m, 4H), 6.88-7.0 (m, 3H), 7.18 (s, 1H), 8.72 (d, 1H)
- MS (ES+) m/z 473 (M++1); MS (ES−) m/z 471 (M+−1)
- 1H-NMR (CD3OD) δ: 1.2-1.4 (m, 7H), 1.52 (m, 2H), 1.80 (m, 1H), 2.0 (m, 1H), 3.0 (m, 2H), 3.2 (t, 2H), 3.38 (t, 2H), 3.65 (m, 1H), 3.9 (m, 1H), 4.15 (m, 1H), 6.97 (m, 2H), 7.15 (d, J=36 Hz, 1H), 7.15 (s, 1H), 8.66 (d, 1H)
- 1H-NMR (CD3OD) δ: 1.24 (d, 6H), 3.0 (m, 2H), 3.2 (m, 3H), 3.38 (t, 2H), 3.68 (m, 1H), 4.0 (m, 3H), 4.46 (d, 1H), 6.97 (s, 1H), 7.03 (d, 1H), 7.13 (s, 1H), 7.19 (d, J=36 Hz, 1H), 7.25 (s, 1H), 8.75 (d, 1H)
- MS (ES−) m/z 514 (M+−1)
- 1H-NMR (CDCl3) δ: 1.22 (d, 6H), 3.0 (m, 1H), 3.15 (m, 2H), 3.25 (m, 4H), 3.70-4.0 (m, 4H), 4.26 (dd, 1H), 6.72 (s, 1H), 6.81 (d, 1H), 6.85 (d, J=36 Hz, 1H), 7.16 (s, 1H), 8.72 (d, 1H)
- MS (ES−) m/z 496 (M+−1)
- 1H-NMR (CD3OD) δ: 1.22 (d, 6H), 3.02 (m, 1H), 3.21 (t, 2H), 3.39 (t, 2H), 3.53 (m, 2H), 3.65 (m, 6H), 3.98 (s, 2H), 6.98 (s, 1H), 7.05 (d, 1H), 7.22 (s, 1H), 7.26 (d, J=37 Hz, 1H), 8.77 (d, 1H)
- MS (ES+) m/z 529 (M++1); MS (ES−) m/z 527 (M+−1)
- 2-Methoxy-2-phosphonoacetic acid triethyl ester (92 mg) was dissolved in tetrahydrofuran (1 ml), added with n-butyl lithium (1.6 M, 0.23 ml) at −78° C. under nitrogen atmosphere, and then the mixture was stirred at the same temperature for 30 minutes. The reaction mixture was added with a solution of 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde (50 mg) dissolved in tetrahydrofuran (1 ml). The reaction temperature was gradually raised to room temperature, and the reaction mixture was stirred overnight at the same temperature. The reaction mixture was added with water and extracted with methylene chloride. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound.
- 1H-NMR (CDCl3) δ: 1.20-1.30 (m, 9H), 3.05 (m, 1H), 3.15-3.35 (m, 4H), 3.50 (s, 3H), 3.55-3.70 (m, 8H), 4.05-4.15 (m, 2H), 6.70-6.80 (m, 2H), 7.14 (s, 1H), 7.21 (s, 1H), 8.78 (d, J=7.5 Hz, 1H)
- The ethyl (Z)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-methoxy-2-propenoate obtained in (A) was dissolved in tetrahydrofuran (2 ml) and methanol (0.5 ml), added with a solution of lithium hydroxide (5 mg) in water (0.5 ml), and then the mixture was stirred at room temperature for 2.5 hours. The reaction mixture was added with water and washed with ether, and then the aqueous layer was made acidic with diluted with hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure to obtain the title compound (6 mg, 10% for the two steps) as yellow powder.
- 1H-NMR (CD3OD) δ: 1.23 (d, 6H), 3.02 (m, 1H), 3.19 (t, 2H), 3.38 (t, 2H), 3.55 (s, 3H), 3.62 (m, 4H), 3.70 (m, 4H), 6.95 (s, 1H), 6.99 (m, 2H), 7.18 (s, 1H), 8.74 (d, 1H)
- MS (ES+) m/z 485 (M++1); MS (ES−) m/z 483 (M+−1)
- 8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-morpholino-4-oxo-4H-pyrido[1,2-a]-pyrimidine-3-carbaldehyde (18 mg) and 2,4-thiazolidinedione (53 mg) were added with benzene (10 ml), piperidine (one drop) and acetic acid (two drops) and refluxed by heating for 3 hours in a vessel provided with a Dean-Stark trap. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (17 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.26 (d, 6H), 3.01 (m, 1H), 3.22 (t, 2H), 3.38 (t, 2H), 3.63 (m, 4H), 3.80 (m, 4H), 6.73 (s, 1H), 6.87 (d, 1H), 7.23 (s, 1H), 7.78 (s, 1H), 8.80 (d, 1H)
- MS (ES−) m/z 510 (M+−1)
- tert-Butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (20 mg) and triethylamine (63 ml) were dissolved in dimethylformamide (1.5 ml) and stirred at room temperature for 20 minutes under nitrogen atmosphere. The reaction mixture was added with dimethyl sulfate (4.3 ml) and stirred in the dark for 2 days. The reaction mixture was further added with dimethyl sulfate (4.3 ml) and stirred for 2 days in the same manner. The reaction mixture was added with water and extracted with ethyl acetate. The organic layer was washed with 1% aqueous solution of lithium chloride and dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (6.7 mg) as yellow powder. The starting material (7.6 mg) was also recovered.
- 1H-NMR (CDCl3): 1.28 (s, 3H), 1.29 (s, 3H), 1.51 (s, 9H), 3.07 (m, 1H), 3.21 (m, 2H), 3.42 (m, 2H), 4.06 (s, 3H), 6.74 (s, 1H), 7.01 (d, 1H), 7.11 (d, 1H), 7.37 (s, 1H), 7.94 (d, 1H), 9.00 (d, 1H)
- The tert-butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (6.7 mg) obtained in (A) was treated with trifluoroacetic acid (0.5 ml) in the dark for 30 minutes, and then the solvent was evaporated. The residue was added with methanol and methylene chloride, and insoluble matters were collected by filtration to obtain the title compound (7.2 mg).
- 1H-NMR (CDCl3): 1.30 (s, 3H), 1.32 (s, 3H), 3.11 (m, 1H), 3.31 (m, 2H), 3.45 (m, 2H), 4.07 (s, 3H), 6.77 (s, 1H), 7.05 (d, 1H), 7.18 (d, 1H), 7.39 (s, 1H), 8.10 (d, 1H), 9.02 (d, 1H)
- MS (ES−): 398
- (E)-3-{8-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-4-oxo-4H-pyrido-[1,2-a]pyrimidin-3-yl}-2-propenoic acid (1 mg) was dissolved in CDCl3 (0.5 ml) and irradiated with light from a fluorescent lamp for 19 hours. The solvent was evaporated to obtain the title compound (1 mg).
- 1H-NMR (CDCl3) δ: 1.28 (s, 3H), 1.29 (s, 3H), 3.12 (m, 1H), 3.38 (m, 2H), 3.61 (m, 2H), 4.06 (s, 3H), 6.19 (d, 1H), 6.80 (d, 1H), 6.90 (s, 1H), 7.05 (d, 1H), 7.40 (d, 1H), 7.50 (s, 1H), 9.04 (d, 1H)
- MS (ES−): 398
- tert-Butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (15 mg) was treated with formic acid (1 ml) in the dark for 1 hour, and added with toluene. The solvent was evaporated under reduced pressure to obtain the title compound (22 mg).
- 1H-NMR (DMSO-d6) δ: 1.18 (s, 3H), 1.21 (s, 3H), 2.99 (m, 1H), 3.23-3.40 (m, 4H), 6.82 (d, 1H), 7.10 (s, 1H), 7.20 (s, 1H), 7.42 (d, 1H), 7.85 (d, 1H), 8.91 (d, 1H)
- MS (ES−): 384
- 3-Hydroxy-4-methyl-2-nitropyridine (5 g) was dissolved in dimethylformamide (50 ml), added with cesium carbonate (11.6 g) and methyl iodide (13.7 g), and then the mixture was stirred overnight at room temperature. The reaction mixture was added with ethyl acetate and hexane, washed with water and dried over magnesium sulfate, and then the solvent was evaporated under reduced pressure to obtain the title compound (quantitative).
- 1H-NMR (CDCl3) δ: 2.30 (s, 3H), 3.78 (s, 3H), 7.27 (d, J=4.8 Hz, 1H), 7.98 (d, J=4.8 Hz, 1H)
- The 3-methoxy-4-methyl-2-nitropyridine (1 g) obtained in (A) was dissolved in methanol (50 ml), added with 5% Pd/C (200 mg), and stirred at a pressure of 40 psi for 2 hours under hydrogen atmosphere. After the catalyst was removed by filtration, the solvent was evaporated under reduced pressure to obtain the title compound (850 mg) as yellow oil.
- 1H-NMR (CDCl3) δ: 2.20 (s, 3H), 3.70 (s, 3H), 4.6 (s, 2H), 6.45 (d, J=4.8 Hz, 1H), 7.85 (d, J=4.8 Hz, 1H)
- The 2-amino-3-methoxy-4-methylpyridine (850 mg) obtained in (B) was dissolved in tert-butanol (10 ml), added with di-tert-butyl dicarbonate (2 g), and stirred at room temperature for 72 hours. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (1.1 g).
- 1H-NMR (CDCl3) δ: 1.52 (s, 9H), 2.27 (s, 3H), 3.75 (s, 3H), 4.6 (s, 1H), 6.78 (d, J=4.8 Hz, 1H), 8.05 (d, J=4.8 Hz, 1H)
- The 2-(tert-butoxycarbonylamino)-3-methoxy-4-methylpyridine (2.84 g) obtained in (C) was dissolved in anhydrous tetrahydrofuran (50 ml) and added dropwise with n-butyl lithium (1.6 M, 19 ml) at −78° C. under nitrogen atmosphere. Then, the reaction temperature was raised to room temperature. The reaction mixture was cooled to −78° C. again, added dropwise with a solution of 2-bromomethyl-4-isopropylthiazole (3.94 g) dissolved in tetrahydrofuran (10 ml) and stirred at the same temperature for 1 hour. Then, the reaction mixture was added with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (4.1 g).
- 1H-NMR (CDCl3) δ: 1.20 (d, J=6.9 Hz, 6H), 1.45 (s, 9H), 2.95-3.20 (m, 5H), 3.67 (s, 3H), 6.60 (s, 1H), 6.70 (d, J=4.8 Hz, 1H), 8.05 (d, J=4.8 Hz, 1H)
- The tert-butyl N-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-methoxy-2-pyridylcarbamate (4.1 g) obtained in (D) was added with trifluoroacetic acid (20 ml) at room temperature and stirred overnight. Then, the reaction mixture was added with 50 ml of water and 5 ml of 6 M hydrochloric acid and washed with ether. The aqueous layer was carefully added with sodium hydrogencarbonate to make pH of the aqueous layer weakly alkaline, and then extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to obtain the title compound (2.7 g).
- 1H-NMR (CDCl3) δ: 1.20 (d, J=6.9 Hz, 6H), 3.00-3.30 (m, 5H), 3.70 (s, 3H), 4.6 (s, 2H), 6.50 (s, 1H), 6.70 (d, J=4.8 Hz, 1H), 7.75 (d, J=4.8 Hz, 1H)
- The 2-amino-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-methoxypyridine (2.35 g) obtained in (E) and bis-2,4,6-trichlorophenyl malonate (4.3 g) were refluxed by heating for 1 hour in toluene (25 ml), and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (2.8 g).
- 1H-NMR (CDCl3) δ: 1.28 (d, J=6.9 Hz, 6H), 2.95-3.05 (m, 1H), 3.30-3.40 (m, 4H), 3.95 (s, 3H), 5.35 (s, 1H), 6.70 (s, 1H), 7.00 (d, J=7.2 Hz, 1H), 8.82 (d, J=7.2 Hz, 1H)
- The 2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-4H-pyrido-[1,2-a]pyrimidin-4-one (1.77 g) obtained in (F) was dissolved in methylene chloride (40 ml), added with triethylamine (1.5 ml) and tosyl chloride (1.96 g) under ice cooling, and then the mixture was stirred at room temperature. After disappearance of the starting material was observed, the reaction mixture was added with morpholine (2.2 ml) and stirred overnight. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (0.99 g) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.28 (d, J=6.9 Hz, 6H), 3.00-3.10 (m, 1H), 3.20 (t, J=7.2 Hz, 2H), 3.30 (t, J=7.2 Hz, 2H), 3.65-3.80 (m, 8H), 4.00 (s, 3H), 5.60 (s, 1H), 6.65-6.70 (m, 2H), 8.80 (d, J=7.2 Hz, 1H)
- Dimethylformamide (2 ml) was added with phosphorus oxychloride (0.6 ml) under ice cooling and stirred at room temperature for 20 minutes. This mixture was cooled again with ice, and added with a solution of the 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one (0.99 g) obtained in (G) in methylene chloride (10 ml). The reaction mixture was stirred at room temperature for 3 hours, added with water, then added with saturated aqueous sodium hydrogencarbonate and extracted with methylene chloride. After the organic layer was dried over sodium sulfate, the solvent was evaporated and the residue was purified by silica gel column chromatography to obtain the title compound (1.54 g).
- 1H-NMR (CDCl3) δ: 1.28 (d, J=6.9 Hz, 6H), 3.00-3.10 (m, 1H), 3.20 (t, J=7.2 Hz, 2H), 3.30 (t, J=7.2 Hz, 2H), 3.70-3.85 (m, 8H), 3.95 (s, 3H), 6.75 (d, J=7.5 Hz, 1H), 8.00 (s, 1H), 8.55 ((d, J=7.5 Hz), 10.05 (s, 1H)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-9-methoxy-2-morpholino-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde (300 mg) obtained in (H) was dissolved in tetrahydrofuran (4 ml) and dimethylformamide (1 ml), added with (tert-butoxy-carbonylmethylene)triphenylphosphorane (767 mg), and stirred at 80° C. for 15 hours. After the solvent was evaporated, the residue was purified by silica gel column chromatography to obtain the title compound (209 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.25 (d, J=6.9 Hz, 6H), 1.5 (s, 9H), 3.00-3.10 (m, 1H), 3.20-3.35 (m, 4H), 3.60-3.85 (m, 8H), 4.00 (s, 3H), 6.70 (s, 1H), 6.80 (d, J=7.5 Hz, 1H), 7.05 (d, J=15.3 Hz, 1H), 7.50 (d, J=15.3 Hz, 1H), 8.65 (d, J=7.5 Hz, 1H)
- The tert-butyl (E)-3-{8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-9-methoxy-2-morpholino-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (209 mg) obtained in (I) was dissolved in trifluoroacetic acid (2 ml) and stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure to obtain the title compound (180 mg) as yellow powder.
- 1H-NMR (CDCl3) δ 1.22 (d, 6H), 3.00 (m, 1H), 3.16 (m, 2H), 3.25 (t, 2H), 3.55 (m, 4H), 3.78 (m, 4H), 3.98 (s, 3H), 6.68 (s, 1H), 6.94 (d, J=16 Hz, 1H), 7.58 (d, J=16 Hz, 1H), 8.58 (d, 1H)
- MS (ES+) m/z 485 (M++1), MS (ES−) m/z 483 (M+−1)
- 4-[2-(4-Isopropyl-1,3-thiazol-2-yl)ethyl]-2-aminopyridine (497 mg) and dimethyl methoxymethylenemalonate (425 mg) were dissolved in methylene chloride, and stirred at 90° C. for 2 hours while the solvent was evaporated. The reaction mixture was added with propionic acid (0.5 ml) and heated at 160C for 10 hours with stirring. The reaction mixture was cooled, then added with ethyl acetate, washed with saturated sodium hydrogencarbonate and dried over sodium over sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (416 mg).
- 1H-NMR (CDCl3) δ: 1.28 (s, 3H), 1.31 (s, 3H), 3.06 (m, 1H), 3.35 (m, 2H), 3.40 (m, 2H), 3.99 (s, 3H), 6.75 (s, 1H), 7.20 (d, 1H), 7.60 (s, 1H), 9.07 (s, 1H), 9.19 (d, 1H)
- The methyl 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]-pyrimidin-3-carboxylate (660 mg) obtained in (A) was dissolved in tetrahydrofuran (30 ml), added dropwise with diisopropylaluminum hydride (1 M solution in tetrahydrofuran, 9.2 ml) at −78° C., and then the mixture was stirred for 2 hours at the same temperature. The reaction mixture was added with saturated aqueous ammonium chloride (1 ml), then added with 12% aqueous hydrochloric acid, and stirred at room temperature for 1 hour. After insoluble solids were removed by filtration through a Celite layer, the solvent of the filtrate was evaporated, and the residue was dissolved in methylene chloride. This solution was added with active manganese dioxide (1.2 g) and stirred at room temperature for 16 hours. Then, insoluble matters were removed by filtration to obtain the title compound (390 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.27 (d, 6H), 3.05 (m, 1H), 3.3-3.5 (m, 4H), 6.74 (s, 1H), 7.25 (d, 1H), 7.63 (s, 1H), 8.87 (s, 1H), 9.16 (d, 1H), 10.36 (s, 1H)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde (70 mg) obtained in (B) and 2,4-thiazolidinedione (360 mg) were added with benzene (10 ml), piperidine (one drop) and acetic acid (two drops) and refluxed by heating for 1 hour in a vessel provided with a Dean-Stark trap. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (62 mg) as yellow powder.
- 1H-NMR (CDCl3+CD3OD) δ: 1.22 (d, 6H), 3.00 (m, 1H), 3.2-3.4 (m, with CD3OD), 6.72 (s, 1H), 7.18 (d, 1H), 7.51 (s, 1H), 7.86 (s, 1H), 8.42 (s, 1H), 8.98 (d, 1H)
- MS (ES+) m/z 427 (M++1), MS (ES−) m/z 425 (M+−1)
- A mixture of methyl 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido-[1,2-a]pyrimidine-3-carboxylate (400 mg), concentrated aqueous ammonia (6 ml) and methanol (9 ml) was stirred overnight. Insoluble solids were collected by filtration to obtain the title compound (117 mg). The reaction mixture was concentrated and the residue was purified by silica gel column chromatography to further obtain the title compound (69 mg).
- 1H-NMR (CDCl3) δ: 1.29 (s, 3H), 1.31 (s, 3H), 3.09 (m, 1H), 3.39 (m, 2H), 3.48 (m, 2H), 5.73 (brs, 1H), 6.79 (s, 1H), 7.29 (d, 1H), 7.66 (s, 1H), 8.71 (brs, 1H), 9.14 (d, 1H), 9.30 (s, 1H)
- MS (ES+) m/z 343 (M++1), MS (ES−) m/z 341 (M+−1)
- A mixture of the 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide (186 mg) obtained in (A), p-toluenesulfonyl chloride (207 mg) and pyridine (0.18 ml) was stirred overnight in methylene chloride. The mixture was added with triethylamine (0.2 ml), further stirred for 2 days, and diluted with methylene chloride. This mixture was washed with saturated aqueous sodium hydrogencarbonate and saturated brine, and dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (98 mg). The starting material was also recovered (73 mg).
- 1H-NMR (CDCl3) δ: 1.29 (s, 3H), 1.31 (s, 3H), 3.09 (m, 1H), 3.37 (m, 2H), 3.49 (m, 2H), 6.79 (s, 1H), 7.31 (d, 1H), 7.65 (s, 1H), 8.58 (s, 1H), 9.09 (d, 1H)
- MS (ES+) m/z 325 (M++1), MS (ES−) m/z 323 (M+−1)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbonitrile (35 mg) obtained in (B), hydroxylamine (9 mg) and triethylamine (28 ml) were refluxed overnight by heating in ethanol. After the reaction mixture was cooled, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain an oxim compound (22 mg). This compound (11 mg), 1,1′-carbodiimidazole (5 mg) and pyridine (2 ml) were dissolved in tetrahydrofuran (0.5 ml), refluxed by heating for 45 minutes, and stirred overnight at room temperature. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography to obtain the title compound (1.6 mg).
- 1H-NMR (CDCl3) δ: 1.26 (s, 3H), 1.30 (s, 3H), 3.08 (m, 1H), 3.40 (m, 4H), 6.75 (s, 1H), 7.18 (brm, 1H), 7.70 (brs, 1H), 9.08 (brm, 1H)
- MS (ES+) m/z 384 (M++1), MS (ES−) m/z 382 (M+−1)
- 2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one (30 mg) was added with anisole (0.15 ml) and trifluoroacetic acid (1 ml) and stirred at room temperature for 20 hours. After the solvent was evaporated under reduced pressure, the residue was added with methanol and toluene and the solvents were evaporated again under reduced pressure. The residue was added with methanol and methylene chloride, and the deposited crystals were collected by filtration to obtain the title compound (15 mg).
- 1H-NMR (CD3OD) δ: 1.25 (s,3H), 1.28 (s,3H), 3.04 (m, 1H), 3.35 (m, 2H), 3.46 (m, 2H), 7.04 (s, 1H), 7.31 (s, 1H), 7.45 (d, 1H), 9.11 (d, 1H)
- MS (ES+) m/z 384 (M++1)
- 2-Hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-3-[2-(4-methoxybenzyl)-2H-1,2,3,4-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one (24 mg) was dissolved in dimethylformamide (1.5 ml), added with triethylamine (1.6 ml) and dimethyl sulfate (22 ml) and stirred overnight at room temperature. The reaction mixture was further added with dimethyl sulfate (5 ml), stirred for 4 hours, and then added with water and extracted with ethyl acetate. After the organic layer was dried over sodium sulfate, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (5 mg).
- 1H-NMR (CDCl3) δ: 1.28 (s, 3H), 1.33 (s, 3H), 3.09 (m, 1H), 3.29 (m, 2H), 3.44 (m, 2H), 3.79 (s, 3H), 4.03 (s, 3H), 5.79 (s, 2H), 6.79 (s, 1H), 6.88 (d, 2H), 7.02 (d, 1H), 7.41 (d, 2H), 9.02 (d, 1H)
- MS (ES+) m/z 518 (M++1), MS (ES−) m/z 516 (M+−1)
- The 8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-methoxy-3-[2-(4-methoxy-benzyl)-2H-1,2,3,4-tetrazol-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one (5 mg) obtained in (A) was added with trifluoroacetic acid (0.3 ml) and anisole (0.1 ml) and stirred for 2 days. The solvent was evaporated under reduced pressure, and the residue was added with hexane and ethyl acetate. Insoluble solids were collected by filtration and dried to obtain the title compound (1.2 mg).
- 1H-NMR (CDCl3) δ: 1.30 (s, 3H), 1.32 (s, 3H), 3.12 (m, 1H), 3.37 (m, 2H), 3.49 (m, 2H), 4.29 (s, 3H), 6.79,(s, 1H), 7.53 (s, 1H), 9.10 (d, 1H)
- MS (ES+) m/z 398 (M++1), MS (ES−) m/z 396 (M+−1)
- tert-Butyl (E)-3-[8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-hydroxy-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (80 mg) was suspended in methylene chloride (40 ml), added with triethylamine (0.13 ml) and diphenylphosphoryl chloride (0.15 ml), and then the mixture was stirred at room temperature for 16 hours. The reaction mixture was washed with saturated aqueous sodium hydrogencarbonate, 5% aqueous hydrochloric acid and saturated brine, and then dried over sodium sulfate and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (104 mg).
- 1H-NMR (CDCl3) δ: 1.26 (d, 6H), 1.51 (s, 9H), 3.05 (m, 1H), 3.2-3.4 (m, 4H), 6.73 (s, 1H), 7.1-7.5 (m, 13H), 7.75 (d, J=15.8 Hz, 1H), 8.96 (d, 1H)
- The tert-butyl (E)-3-{2-[(diphenoxyphosphoryl)oxy]-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (62 mg) obtained in (A) was dissolved in dimethylformamide (1 ml) and added dropwise with a solution of lithium sulfide in ethanol (0.1 g/ml) until the starting material disappeared. Separately, tert-butyl bromoacetate (0.04 ml) was dissolved in dimethylformamide (1 ml), added with sodium iodide (69 mg), and then stirred at room temperature for 40 minutes. These two of solutions were mixed and stirred at room temperature for 2 hours. The reaction mixture was distributed between ethyl acetate and water, and the organic layer was dried. The solvent was evaporated, and the residue was purified by silica gel column chromatography to obtain the title compound (19 mg).
- 1H-NMR (CDCl3) δ: 1.29 (d, 6H), 1.45 (s, 9H), 1.53 (s, 9H), 3.06 (m, 1H), 3.2-3.4 (m, 4H), 3.93 (s, 2H), 6.73 (s, 1H), 6.99 (d, 1H), 7.24 (d, J=15.6 Hz, overlapped with CHCl3, 1H), 7.32 (s, 1H), 7.78 (d, J=15.6 Hz, 1H), 8.95 (d, 1H)
- The tert-butyl (E)-3-{2-(tert-butoxycarbonylmethylthio)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (19 mg) obtained in (B) was dissolved in methylene chloride (2 ml), added with triethylsilane (0.5 ml) and trifluoroacetic acid (0.5 ml), and then the mixture was stirred at room temperature for 5 hours. After the solvent was evaporated under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (4 mg) as yellow powder.
- 1H-NMR (CDCl3) δ: 1.18 (d, 6H), 2.96 (m, 1H), 3.15 (m, 2H), 3.25 (m, 1H), 3.91 (d, 2H), 6.69 (s, 1H), 6.99 (d, 1H), 7.15 (d, J=15 Hz, 1H), 7.31 (s, 1H), 7.77 (d, J=15 Hz, 1H), 8.83 (d, J=7 Hz, 1H)
- MS (ES+) m/z 460 (M++1), MS (ES−) m/z 458 (M+−1)
- 1H-NMR (CDCl3) δ: 1.21 (d, 6H), 2.56 (s, 3H), 3.00 (m, 1H), 3.19 (m, 2H), 3.31 (m, 2H), 6.69 (s, 1H), 6.99 (d, 1H), 7.19 (d, J=15 Hz, 1H), 7.36 (s, 1H), 7.83 (d, J=15 Hz, 1H), 8.87 (d, J=7 Hz, 1H)
- 1H-NMR (CDCl3+CD3OD) δ: 1.23 (d, 6H), 3.02 (m, 1H), 3.1-3.5 (m, with CD3OD), 3.88 (d, 2H), 6.74 (s, 1H), 7.06 (d, 1H), 7.15 (d, J=16 Hz, 1H), 7.41 (s, 1H), 7.74 (d, J=16 Hz, 1H), 8.89 (d, J=8 Hz, 1H)
- MS (ES+) m/z 458 (M++1)
- 1H-NMR (CD3OD) δ: 1.22 (d, 6H), 3.02 (m, 1H), 3.15-3.4 (m, with CHD2OD), 6.95 (s, 1H), 7.02 (s, 1H), 7.28 (d, 1H), 7.32 (d, J=16 Hz, 1H), 7.52 (dd, 1H), 8.02 (d, J=16 Hz, 1H), 8.10 (d, 1H), 8.72 (m, 1H), 8.98 (d, 1H)
- [(4-Isopropyl-1,3-thiazol-2-yl)methyl](triphenyl)phosphonium bromide (723 mg, Chem. Pharm. Bull., 1977, 25, 349-352) was suspended in tetrahydrofuran (20 ml), added dropwise with n-butyl lithium (1.6 M, 1.2 mmol) at −20° C. under nitrogen atmosphere, and stirred at the same temperature for 20 minutes. The reaction mixture was added with a solution of ethyl 1-ethyl-7-formyl-4-oxo-1,4-dihydro-[1,8]naphthylidine-3-carboxylate (316 mg) dissolved in tetrahydrofuran, and stirred for 2 hours. The reaction mixture was added with saturated aqueous ammonium chloride and extracted with ethyl acetate. After the organic layer was dried, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (456 mg).
- 1H-NMR (300 MHz, CDCl3) δ: 1.35 (d, 6H), 1.41 (t, 3H), 1.53 (t, 3H), 3.15 (m, 1H), 4.39 (q, 2H), 4.52 (q, 2H), 6.94 (s, 1H), 7.44 (d, J=15.8 Hz, 1H), 7.47 (d, 1H), 7.94 (d, J=15.8 Hz, 1H), 8.63 (s, 1H), 8.73 (d, 1H)
- The ethyl 1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro[1,8]naphthylidine-3-carboxylate (120 mg) obtained in (A) and lithium hydroxide (26 mg) were added with methanol (10 ml) and water (5 ml), and then the mixture was stirred at room temperature for 16 hours. After the methanol was evaporated, pH of the residue was made 6 by using 5% hydrochloric acid, and insoluble substance was collected by filtration and dried to obtain the title compound (80 mg).
- 1H-NMR (300 MHz, CDCl3) δ: 1.39 (d, 6H), 1.61 (t, 3H), 3.25 (m, 1H), 4.69 (q, 2H), 7.05 (s, 1H), 7.62 (m,2H), 8.13 (d, J=16 Hz, 1H), 8.80 (d, J=8 Hz, 1H), 8.94 (s, 1H)
- MS (ES+) m/z 370 (M++1), MS (ES−) m/z 368 (M+−1)
- Eethyl 1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro[1,8]naphthylidine-3-carboxylate (160 mg) was added with 25% aqueous ammonia (20 ml) and isopropanol (3 ml) and heated at 100° C. for 16 hours in a Parr acid digestion bomb. After the reaction mixture was cooled, the solvent was evaporated to obtain the title compound (148 mg).
- 1H-NMR (300 MHz, CDCl3) δ: 1.36 (d, 6H), 1.56 (t, 3H), 3.18 (m, 1H), 4.61 (q, 2H), 5.75 (brs, 1H)6.97 (s, 1H), 7.47 (d, J=15.8 Hz, 1H), 7.51 (d, 1H), 7.98 (d, J=15.8 Hz, 1H), 8.75 (d, 1H), 8.95 (s, 1H), 9.56 (brs, 1H)
- The 1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro[1,8]naphthylidine-3-carboxamide (32 mg) obtained in (A) was dissolved in 1,2-dichloroethane, added with benzenesulfonyl chloride (0.12 ml), pyridine (0.18 ml) and dimethylaminopyridine (several pieces), and then the mixture was stirred at 40° C. for 24 hours. The reaction mixture was diluted with 1,2-dichloroethane, then washed with 5% hydrochloric acid, saturated aqueous sodium hydrogencarbonate and saturated brine, and then dried and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (19 mg).
- 1H-NMR (300 MHz, CDCl3) δ: 1.36 (d, 6H), 1.56 (t,3H), 3.18 (m, 1H), 4.56 (q,2H), 6.99 (s, 1H), 7.45 (d, J=15.8 Hz, 1H), 7.51 (d, 1H), 7.98 (d, J=15.8 Hz, 1H), 8.20 (s, 1H), 8.69 (d, 1H)
- The 1-ethyl-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro[1,8]naphthylidine-3-carbonitrile (32 mg) obtained in (B) was dissolved in tetrahydrofuran (20 ml), added with sodium azide (100 mg), ammonium chloride (200 mg) and stirred at 80° C. for 2 hours. The reaction mixture was added with water and adjusted to pH 8 with saturated aqueous sodium hydrogencarbonate, and the tetrahydrofuran was evaporated. The residue was added with five drops of 25% aqueous ammonia, and insoluble solids were removed by filtration. The filtrate was adjusted to pH 7 with 12% aqueous hydrochloric acid, loaded on a HP-20 reverse phase column, sufficiently washed with water, and then eluted with water/acetonitrile/aqueous ammonia (80:20:0.2, v/v). After the solvent was evaporated, the residue was added with tert-butyl methyl ketone, and insoluble substance was taken by filtration and dried to obtain the title compound (13 mg) as yellow powder.
- 1H-NMR (300 MHz, CDCl3+CD3OD) δ: 1.24 (d, 6H), 1.50 (t, 3H), 3.02 (m, 1H), 4.61 (q, 2H), 6.92 (s, 1H), 7.40 (d, J=15.8 Hz, 1H), 7.51 (d, J=8 Hz, 1H), 7.91 (d, J=15.8 Hz, 1H), 8.66 (d, J=8 Hz, 1H), 9.04 (s, 1H)
- MS (ES+) m/z 394 (M++1), MS (ES−) m/z 392 (M+−1)
- 4-Methyl-5-nitro-2-pyridinamine (3.69 g, 2.41 mmol) was added with acetic anhydride (10 ml) and stirred at 130° C. for 1.5 hours. The reaction mixture was left stand for cooling, and then added with distilled water (5.4 ml) at 0° C., heated to 130° C., and stirred for 45 minutes. The reaction mixture was left stand for cooling and concentrated, and the deposited crystals were collected by filtration and washed with distilled water to obtain the title compound (4.71 g, quantitative).
- 1H-NMR (CDCl3) δ: 2.26 (3H, s), 2.70 (3H, s), 8.19 (1H, br), 8.23 (1H, s), 8.95 (1H, s)
- MS; m/z: MH−194
- The N1-(4-methyl-5-nitro-2-pyridyl)acetamide (4.70 g, 24.1 mmol) obtained in (A) was dissolved in ethanol (150 ml), added with 10% palladium/carbon (0.95 g) and subjected to catalytic reduction overnight at 1 atm under hydrogen atmosphere. The catalyst was removed by filtration and washed with ethanol. The filtrate was concentrated and the resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=100:5) to obtain the title compound (4.10 g, quantitative) as brown solid.
- 1H-NMR (CD3OD) δ:2.11 (3H, s), 2.18 (3H, s), 7.61 (1H, s), 7.70 (1H, s)
- The N1-(5-amino-4-methyl-2-pyridyl)acetamide (8.00 g, 48.4 mmol) obtained in (B) was dissolved in tetrafluoroboric acid (160 ml) and slowly added dropwise with an aqueous solution (40 ml) of sodium nitrite (3.51 g, 50.8 mmol) at −20° C. under nitrogen atmosphere. The reaction mixture was further stirred at −10° C. for 1 hour and added with diethyl ether (800 ml), and the deposited white solid was collected by filtration and washed with diethyl ether to obtain the title compound (14.7 g, quantitative).
- Toluene (280 ml) heated at 100° C. with stirring was added with the 6-(acetylamino)-4-methyl-3-pyridinediazonium tetrafluoroborate (12.8 g, 48.4 mmol) obtained in (C) and further refluxed by heating for 1 hour. After the reaction mixture was left stand for cooling and the solvent was evaporated, the residue was diluted with chloroform and washed with 1 N aqueous sodium hydroxide. The organic layer was dried over anhydrous magnesium sulfate, then the solvent was evaporated and the resulting residue was purified by silica gel column chromatography (chloroform:methanol=100:1) to obtain the title compound (3.48 g, 43%) as yellow solid.
- 1H-NMR (CDCl3) δ: 2.19 (3H, s), 2.32 (3H, s), 7.93 (1H, br), 7.98 (1H, s), 8.08 (1H, d, J=5.6 Hz)
- MS; m/z: (MH+) 169
- The N1-(5-fluoro-4-methyl-2-pyridyl)acetamide (4.25 g, 25.3 mmol) obtained in (D) was dissolved in ethanol (3 ml), added with 6 M aqueous hydrochloric acid (3 ml) and refluxed by heating for 1 hour and 30 minutes. The reaction mixture was left stand for cooling and the solvent was concentrated. The resulting residue was dissolved in distilled water, and the system was made basic with 1 N aqueous sodium hydroxide and extracted twice with chloroform. The organic layer was dried over anhydrous magnesium sulfate and the solvent was evaporated to obtain the title compound (2.82 g, 88%) as solid.
- 1H-NMR (CD3OD) δ: 2.19 (3H, s), 6.45 (1H, m), 7.65 (1H, m)
- ES-MS; m/z: (MH+) 127
- The 5-fluoro-4-methyl-2-pyridinamine (2.82 g, 22.4 mmol) obtained in (E) was dissolved in tert-butanol (100 ml), slowly added dropwise with a solution of di-tert-butyl dicarbonate (5.12 g, 23.5 mmol) in tetrahydrofuran (10 ml) over 1 hour, and then the mixture was stirred at room temperature. The deposited substance was removed by filtration, and the reaction mixture was concentrated. The resulting residue was purified by silica gel column chromatography (chloroform) to obtain the title compound (3.17 g, 66%) as white solid.
- 1H-NMR (CDCl3) δ: 1.53 (9H, s), 2.30 (3H, s), 7.74 (1H, br), 7.83 (1H, d, J=5.8 Hz), 7.99 (1H, d, J=1.2 Hz)
- MS; m/z: (MH+) 227
- The tert-butyl N-(5-fluoro-4-methyl-2-pyridyl)carbamate (75.6 mg, 0.334 mmol) obtained in (F) was dissolved in tetrahydrofuran (2 ml) and added dropwise with n-butyl lithium (1.5 M solution in hexane, 0.468 ml, 0.702 mmol) at −78° C. under argon atmosphere. The reaction mixture was warmed to room temperature, stirred for 1 hour, cooled to −78° C. again, added dropwise with a solution of 2-(bromomethyl)-4-isopropyl-1,3-thiazole (84.6 mg, 0.384 mmol) in tetrahydrofuran (2 ml), and then warmed to room temperature. The reaction mixture was added with water and extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated. The resulting residue was purified by silica gel column chromatography (chloroform: ethyl acetate=100:1) to obtain the title compound (40.0 mg, 33%).
- 1H-NMR (CDCl3) δ: 1.28 (6H, d, J=7.1 Hz), 1.54 (9H, s), 3.09 (1H, m), 3.15 (2H, m), 3.32 (2H, m), 6.71 (1H, s), 7.90 (1H, d, J=5.6 Hz), 8.05 (1H, d, J=1.5 Hz)8.23 (1H, br)
- MS; m/z: (MH+) 366
- The tert-butyl N-{5-fluoro-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridyl]-carbamate (393 mg, 1.08 mmol) obtained in (G) was dissolved in methylene chloride (10 ml), added with trifluoroacetic acid (10 ml) under ice cooling, and stirred overnight at room temperature. The reaction mixture was concentrated, and the resulting residue was dissolved in chloroform and washed with 1 N aqueous sodium hydroxide. The organic layer was dried over anhydrous magnesium sulfate and the solvent was evaporated. The resulting residue was purified by silica gel column chromatography (chloroform:methanol=100:2) to obtain the title compound (40.0 mg, 33%) as an oil.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 3.05 (3H, m), 3.27 (2H, m), 6.32 (1H, m), 6.72 (1H, m), 7.84 (1H, m)
- The 5-fluoro-4-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-2-pyridinamine (310 mg, 1.15 mmol) obtained in (H) was dissolved in xylene (2.5 ml), added with di(2,4,6-trichlorophenyl)malonate (568 mg, 1.23 mmol), and refluxed by heating for 30 minutes. The reaction mixture was left stand for cooling and then concentrated, and the resulting residue was purified by silica gel column chromatography (chloroform:methanol=100:1) to obtain the title compound (325 mg, 84%) as yellow solid.
- 1H-NMR (CDCl3) δ: 1.27 (6H, d, J=6.8 Hz), 3.05 (1H, m), 3.40 (4H, m), 5.40 (1H, s), 6.75 (1H, s), 7.40 (1H, d, J=5.9 Hz), 9.00 (1H, d, J=4.6 Hz)
- MS; m/z: (MH+) 334, (MH−) 332
- The 7-fluoro-2-hydroxy-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-4-one (150 mg, 0.450 mmol) obtained in (I) was dissolved in a mixed solvent of tetrahydrofuran (3 ml) and dimethylformamide (1 ml), added with p-toluenesulfonyl chloride (129 mg, 0.675 mmol) and 4-dimethylaminopyridine (60.5 mg, 0.494 mmol), and then the mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with chloroform, washed with water and dried over anhydrous magnesium sulfate. The solvent was evaporated and the resulting residue was dissolved in dimethylformamide (3 ml), added with 3-hydroxypiperidine (310 mg, 2.25 mmol) and triethylamine (0.3 ml) and stirred at 80° C. for 2 hours. The reaction mixture was left stand for cooling, diluted with chloroform, washed with water and dried over anhydrous magnesium sulfate. Then, the solvent was evaporated and the resulting residue was purified by preparative TLC (chloroform:methanol=100:3) to obtain the title compound (147 mg, 79%) as yellow solid.
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 1.56 (1H, m), 1.64 (1H, m), 1.86 (1H, m), 1.99 (1H, m), 3.07 (1H, m), 3.21 (2H, m), 3.34 (1H, m), 3.36 (2H, m), 3.38 (1H, m), 3.82 (1H, m), 3.98 (1H, m), 5.66 (1H, s), 6.73 (1H, s), 7.11 (1H, d, J=6.6 Hz), 8.70 (1H, d, J=5.4 Hz)
- Dimethylformamide (3 ml) was added with phosphorus oxychloride (0.083 ml, 0.882 mmol) under ice cooling and stirred for 30 minutes. The mixture was added with a solution of the 7-fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-4-one (147 mg, 0.353 mmol) obtained in (J) in dimethylformamide (2 ml), warmed to room temperature, and then stirred for 1 hour. The reaction mixture was further added with phosphorus oxychloride (0.083 ml, 0.882 mmol) and stirred for 30 minutes. The reaction mixture was added with saturated aqueous sodium hydrogencarbonate and extracted twice with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated. The resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=400:1) and further purified by preparative TLC (chloroform:methanol=100:1) to obtain the title compound (145 mg, 87%) as yellow oil.
- 1H-NMR (CDCl3) δ: 1.28 (6H, d, J=6.8 Hz), 1.69 (1H, m), 1.85 (1H, m), 1.89 (1H, m), 2.02 (1H, m), 3.06 (1H, m), 3.25 (2H, m), 3.37 (2H, m), 3.63 (2H, m), 3.78 (1H, dd, J=13.7 and 6.6 Hz), 3.88 (1H, dd, J=13.7 and 3.2 Hz), 5.06 (1H, m), 6.74 (1H, s), 7.10 (1H, d, J=6.6 Hz), 7.98 (1H, s), 8.69 (1H, d, J=5.4 Hz), 10.1 (1H, s)
- The 1-{7-fluoro-3-formyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl]-3-piperidyl formate (145 mg, 0.307 mmol) obtained in (K) was dissolved in tetrahydrofuran (5 ml), added with tert-butoxycarbonylmethylene-triphenylphosphorane (1.38 g, 3.68 mmol) and refluxed by heating for 2 days. The reaction mixture was concentrated, and the resulting residue was purified by preparative TLC (chloroform:methanol=100:4) to obtain the title compound (147 mg, 84%) as yellow solid.
- 1H-NMR (CDCl3) δ: 1.28 (6H, d, J=6.9 Hz), 1.51 (9H, s), 1.73 (1H, m), 1.85 (1H, m), 1.99 (2H, m), 3.06 (1H, m), 3.26 (2H, m), 3.38 (2H, m), 3.48 (1H, m), 3.52 (1H, m), 3.65 (1H, m), 3.74 (1H, m), 5.12 (1H, m), 6.73 (1H, s), 7.05 (1H, d, J=15.5 Hz), 7.21 (1H, d, J=6.9 Hz), 7.48 (1H, d, J=15.5 Hz), 8.07 (1H, s), 8.80 (1H, d, J=5.4 Hz)
- The tert-butyl (E)-3-{7-fluoro-2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl]-2-propenoate (147 mg, 0.258 mmol) obtained in (L) was dissolved in methanol (3 ml), added with sodium methoxide (33.6 mg, 0.618 mmol), and then stirred at room temperature for 9 hours. The reaction mixture was added with distilled water and extracted with chloroform (twice). The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated. The resulting residue was purified by preparative TLC (chloroform:methanol=100:5) to obtain the title compound (91.6 mg, 65%).
- 1H-NMR (CDCl3) δ: 1.27 (6H, d, J=6.8 Hz), 1-51 (9H, s), 1.60 (2H, m), 1.83 (2H, m), 3.05 (1H, m), 3.26 (2H, m), 3.38 (2H, m), 3.53 (1H, m), 3.57 (2H, m), 3.73 (1H, m), 3.87 (1H, m), 4.01 (1H, m), 6.73 (1H, s), 7.03 (1H, d, J=15.6 Hz), 7.21 (1H, d, J=6.6 Hz), 7.48 (1H, d, J=15.6 Hz), 8.81 (1H, d, J=5.6 Hz)
- The tert-butyl (E)-3-{7-fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (43.6 mg, 0.0803 mmol) obtained in (M) was dissolved in 4 N hydrochloric acid/dioxane (3 ml) and stirred at room temperature for 2 hours. The reaction mixture was concentrated and the resulting residue was purified by preparative TLC (chloroform:methanol=10:1) to obtain the title compound (35.6 mg, 91%) as lyophilized product.
- 1H-NMR (CDCl3) δ: 1.27 (6H, d, J=6.8 Hz), 1.54 (1H, m), 1.71 (1H, m), 1.87 (2H, m), 3.06 (1H, m), 3.23 (2H, m), 3.37 (2H, m), 3.45 (1H, m), 3.62 (3H, m), 3.99 (1H, m), 6.73 (1H, s), 7.00 (1H, d, J=15.4 Hz), 7.18 (1H, d, J=6.6 Hz), 7.56 (1H, d, J=15.4 Hz), 8.73 (1H, d, J=4.9 Hz)
- MS; m/z: (MH+) 487, (MH−) 485
- The tert-butyl (E)-3-{7-fluoro-2-(3-hydroxypiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (48.0 mg, 0.0885 mmol) obtained in Example 156, (M) was dissolved in ethyl acetate (3 ml), added with trichloroacetyl isocyanate (0.052 ml, 0.442 mmol) and stirred at room temperature for 1 hour. The reaction mixture was added with methanol:chloroform (1:10, 10 ml) and concentrated, and the resulting residue was dissolved in a mixed solvent of methanol (3 ml) and distilled water (1 ml), added with sodium formate (12.0 mg, 0.177 mmol) and stirred overnight at room temperature. The solution was further added with sodium formate (12.0 mg, 0.177 mmol), stirred for 5 hours and then concentrated, and the resulting residue was purified by preparative TLC (chloroform:methanol=100:5) to obtain the title compound (71.3 mg, quantitative) as lyophilized product.
- 1H-NMR (CDCl3) δ: 1.27 (6H, d, J=6.8 Hz), 1·51 (9H, s), 1.78 (1H, m), 1.84-2.00 (3H, m), 3.06 (1H, m), 3.26 (2H, m), 3.27 (1H, m), 3.39 (2H, m), 3.52 (1H, m), 3.66 (2H, m), 4.81 (1H, m), 4.90 (1H,br), 6.70 (1H,br), 6.74 (1H, s), 7.08 (1H, d, J=15.6 Hz), 7.26 (1H, d, J=6.8 Hz), 7.68 (1H, d, J=15.6 Hz), 8.81 (1H, d, J=5.4 Hz)
- MS; m/z: (MH+) 586, (MH−) 584
- The tert-butyl (E)-3-{2-{3-[(aminocarbonyl)oxy]piperidino}-7-fluoro-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (51.8 mg, 0.0884 mmol) obtained in (A) was dissolved in 4 N hydrochloric acid in dioxane (3 ml) and stirred at room temperature. The reaction mixture was concentrated and the resulting residue was purified by preparative TLC (chloroform:methanol=10:1) to obtain the title compound (26.8 mg, 57%) as lyophilized product.
- 1H-NMR (CD3OD) δ: 1.25 (6H, d, J=6.8 Hz), 1.68 (1H, m), 1.82 (1H, m), 1.97 (2H, m), 3.02 (1H, m), 3.25 (2H, m), 3.41 (2H, m), 3.48 (1H, m), 3.57 (1H, m), 3.66 (1H, m), 3.77 (1H, m), 4.73 (1H, m), 6.94 (1H, d, J=15.6 Hz), 6.97 (1H, s), 7.29 (1H, d, J=6.8 Hz), 7.55 (1H, d, J=15.6 Hz), 8.71 (1H, d, J=5.6 Hz)
- MS; m/z: (MH+) 530, (MH−) 528
- 1-(3-Formyl-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyr imidin-2-yl)-3-piperidylformate (94.0 mg, 0.207 mmol) and bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl)phosphonoate (0.131 ml, 0.620 mmol) were dissolved in tetrahydrofuran (2 ml), added with DBU (0.085 ml, 0.620 mmol) and lithium chloride (26.3 mg, 0.620 mmol), and then the mixture was stirred at room temperature for 1 hour.
- The reaction mixture was concentrated and the obtained residue was purified by preparative TLC (chloroform:methanol=100:2) to obtain the title compound (80.9 mg, 76%).
- 1H-NMR (CDCl3) δ: 1.28 (6H, d, J=6.8 Hz), 1.74-2.00 (4H, m), 3.07 (1H, m), 3.20 (2H, t, J=7.8 Hz), 3.36 (2H, t, J=7.8 Hz), 3.54 (2H, m), 3.67 (1H, m), 3.76 (1H, m), 3.77 (3H, s), 5.14 (1H, m), 6.73 (1H, s), 6.84 (1H, dd, J=7.3 and 1.7 Hz), 7.10 (1H, d, J=15.6 Hz), 7.20 (1H, s), 7.62 (1H, d, J=15.6 Hz), 8.09 (1H, s), 8.85 (1H, d, J=7.3 Hz)
- The methyl (E)-3-(2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)-ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}-2-propenoate (80.9 mg, 0.158 mmol) obtained in (A) was dissolved in ethanol (3 ml), added with 5% palladium/carbon (30 mg) and stirred at 1 atm for 2 days under hydrogen atmosphere. The catalyst was removed by filtration, and the filtrate was concentrated. The resulting residue was purified by preparative TLC (chloroform:methanol=100:2) to obtain the title compound (23.1 mg, 28%).
- 1H-NMR (CDCl3) δ: 1.29 (6H, d, J=6.8 Hz), 1.74-2.03 (4H, m), 3.07 (1H, m), 3.20 (2H, t, J=7.8 Hz), 2.73 (2H, m), 2.93 (2H, m), 3.15 (1H, m), 3.20 (2H, m), 3.30 (2H, m), 3.35 (2H, m), 3.37 (2H, m), 3.68 (3H, s), 5.12 (1H, m), 6.72 (1H, s), 6.81 (1H, d, J=7.3 Hz), 7.20 (1H, s), 7.26 (1H, s), 8.07 (1H, s), 8.79 (1H, d, J=7.3 Hz)
- MS; m/z: 513 (MH+), 511 (MH−)
- The methyl 3-{2-(3-formylpiperidino)-8-[2-(4-isopropyl-1,3-thiazol-2-yl)ethyl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl}propanoate (23.1 mg, 0.0451 mmol) obtained in (B) was dissolved in a mixed solution of methanol, tetrahydrofuran and water (1:1:1, 3 ml), added with lithium hydroxide monohydrate (3.8 mg, 0.0901 mmol), and stirred overnight at room temperature. The reaction mixture was added with 1 N hydrochloric acid (0.091 ml) to neutralize the system, and then the solvent was evaporated. The resulting residue was purified by preparative TLC (chloroform:methanol=10:1) to obtain the title compound (15.0 mg, 71%) as lyophilized product.
- 1H-NMR (CD3OD) δ: 1.26 (6H, d, J=6.8 Hz), 1.51 (1H, m), 1.67 (1H, m), 1.84 (1H, m), 1.99 (1H, m), 2.64 (2H, m), 2.90 (2H, m), 2.95-3.08 (3H, m), 3.20 (2H, t, J=7.3 Hz), 3.40 (2H, t, J=7.3 Hz), 3.57 (1H, m), 3.78 (2H, m), 6.96 (1H, s), 7.03 (1H, dd, J=7.3 and 2.0 Hz), 7.21 (1H, s), 8.74 (1H, d, J=7.3 Hz)
- MS; m/z: 471 (MH+), 469 (MH−)
- Ethyl 7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylate (368 mg, 1.00 mmol) was dissolved in dimethylformamide (6 ml), added with potassium carbonate (276 mg, 2.00 mmol) and 1-bromo-2-fluoroethane (0.223 ml, 3.00 mmol), and then the mixture was stirred overnight at 65° C. The reaction mixture was left stand for cooling and then diluted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate, and the solvent was evaporated. The resulting residue was purified by silica gel column chromatography (chloroform→chloroform:methanol=100:1) to obtain the title compound (254 mg, 61%) as colorless transparent oil.
- 1H-NMR (CDCl3) δ: 1.34 (6H, d, J=7.1 Hz), 1.39 (3H, t, J=7.1 Hz), 3.13 (1H, m), 4.36 (2H,q), 4.54 (2H, ddd, J=24.9, 4.6 and 4.4 Hz), 4.85 (2H, ddd, J=46.6, 4.6 and 4.4 Hz), 6.86 (1H, s), 7.40 (2H, s), 7.43 (1H, s), 7.57 (1H, dd, J=8.5 and 1.2 Hz), 8.43 (1H, s), 8.47 (1H, dd, J=8.5 and 2.0 Hz)
- MS; m/z: (MH+) 415
- The ethyl 1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylate (254 mg, 0.613 mmol) obtained in (A) was dissolved in a mixed solution of methanol, tetrahydrofuran and water (1:1:1), added with 1 N aqueous sodium hydroxide (1.23 ml, 1.23 mmol), and then the mixture was stirred at room temperature for 8 hours. The reaction mixture was added with 1 N hydrochloric acid (1.23 ml, 1.23 mmol) to neutralize the system, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated to obtain the title compound (174 mg, 73%) as yellow solid.
- The 1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (174 mg, 0.450 mmol) obtained in (B) was dissolved in dimethylformamide (3 ml), added with triethylamine (0.126 ml, 0.900 mmol) and ethyl chloroformate (0.086 ml, 0.900 mmol) under ice cooling, and then the mixture was stirred for 1 hour. The reaction mixture was warmed to room temperature, stirred for 30 minutes and further stirred at 0° C. for 1 hour. The reaction mixture was added with concentrated aqueous ammonia (0.15 ml) and stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate and washed successively with aqueous citric acid, saturated aqueous sodium hydrogencarbonate and saturated brine and dried over anhydrous magnesium sulfate. Then, the solvent was evaporated to obtain the title compound (164 mg, 94%) as pale yellow solid.
- 1H-NMR (CDCl3) δ: 1.36 (6H, d, J=6.8 Hz), 3.17 (1H, m), 4.59 (2H, ddd, J=23.9, 4.9 and 4.6 Hz), 4.87 (2H, ddd, J=46.4, 4.9 and 4.6 Hz), 5.75 (1H,br), 6.92 (1H, s), 7.28 (1H, m), 7.47 (2H, s), 7.69 (1H, d, J=8.6 Hz), 8.54 (1H, d, J=8.6 Hz), 8.79 (1H, s), 9.66 (1H, br)
- MS; m/z: (MH+) 386
- A solution of dimethylformamide (0.109 ml, 1.40 mmol) in acetonitrile (2 ml) was added with oxalyl chloride (0.111 ml, 1.28 mmol) under ice cooling, stirred at the same temperature for 15 minutes, and then added with a solution of the 1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxamide (164 mg, 0.425 mmol) obtained in (C) in acetonitrile (3 ml). The mixture was stirred at the same temperature for 10 minutes. This mixture was added with pyridine (0.206 ml, 2.55 mmol) and stirred at the same temperature for 10 minutes and further at room temperature for 2 hours. The reaction mixture was added with a solution of dimethylformamide (0.109 ml, 1.40 mmol) and oxalyl chloride (0.111 ml, 1.28 mmol) in acetonitrile (1 ml) prepared beforehand at 0° C., then added with pyridine (0.206 ml, 2.55 mmol), and stirred at room temperature for 1 hour. The reaction mixture was added with ethyl acetate and washed with aqueous citric acid, saturated aqueous sodium hydrogencarbonate and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated. The resulting residue was purified by preparative TLC (chloroform:methanol=100:7) to obtain the title compound (179 mg, quantitative) as pale yellow as solid.
- 1H-NMR (CDCl3) δ: 1.36 (6H, d, J=7.1 Hz), 3.15 (1H, m), 4.52 (2H, ddd, J=24.6, 4.6 and 4.4 Hz), 4.85 (2H, ddd, J=46.6, 4.6 and 4.4 Hz), 6.93 (1H, s), 7.43 (1H, s), 7.46 (2H, s), 7.69 (1H, dd, J=8.5 and 1.2 Hz), 8.03 (1H, s), 8.49 (1H, d, J=8.6 Hz)
- A solution of aluminum chloride (55.7 mg, 0.418 mmol) in dimethylformamide (1 ml) was added with sodium azide (81.5 mg, 1.25 mmol) under ice cooling, and then stirred at room temperature for 15 minutes. Then, the reaction mixture was added with a solution of the 1-(2-fluoroethyl)-7-[(E)-2-(4-isopropyl-1,3-thiazol-2-yl)-1-ethenyl]-4-oxo-1,4-dihydro-3-quinolinecarbonitrile (51.2 mg, 0.139 mmol) obtained in (D) in dimethylformamide (1 ml) and stirred overnight at 85-90° C. The reaction mixture was poured into ice water/1 N hydrochloric acid (1 ml) and stirred at room temperature for 1.5 hours. The precipitates were collected by filtration and recrystallized from chloroform/methanol/hexane to obtain the title compound (15.1 mg, 26%) as colorless solid.
- 1H-NMR (DMSO-d6) δ: 1.29 (6H, d, J=7.1 Hz), 3.08 (1H, m), 4.82 (1H, m), 4.94 (2H, m), 4.95 (1H, m), 7.34 (1H, s), 7.64 (1H, d, J=16.2 Hz), 7.84 (1H, d, J=16.2 Hz), 7.96 (1H, d, J=8.6 Hz), 8.23 (1H, s), 8.37 (1H, d, J=8.6 Hz), 9.05 (1H, s)
- LCMS; m/z: 411 (MH+)
- Ethyl 1-cyclopropyl-6,7-difluoro-2-(methylsulfanyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylate (300 mg, 0.976 mmol), which is a known compound [J. Heterocyclic Chem., 27, 839 (1990)], was dissolved in methylene chloride (6 ml), added with metachloroperformic acid (755 mg, 2.93 mmol) and stirred overnight. The reaction mixture was diluted with chloroform and washed successively with saturated aqueous sodium hydrogencarbonate and sodium hydrogensulfite. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated. The resulting residue was developed by silica gel column chromatography (hexane:ethyl acetate=2:1) to obtain the title compound (140 mg, 39%) as white solid. The resulting compound was further developed (chloroform:methanol=100:1) to obtain ethyl 1-cyclopropyl-6,7-difluoro-2-(methylsulfinyl)-4-oxo-1,4-dihydro-3-quinoline-carboxylate (101 mg, 29%) as colorless transparent oil. Sulfone compound (title compound)
- 1H-NMR (CDCl3) δ: 0.88 (2H, m), 1.39 (3H, t, J=7.1 Hz), 1.44 (2H, m), 3.56 (3H, s), 3.92 (1H, m), 4.43 (2H,q, J=7.1 Hz), 7.63 (1H, dd, J=11.5 and 6.4 Hz), 8.01 (1H, dd, J=9.8 and 8.6 Hz)
- ES-MS; m/z: 372 (MH+)
- Sulfoxide Compound
- 1H-NMR (CDCl3) δ: 0.99 (2H, m), 1.39 (3H, t, J=6.9 Hz), 1.46 (2H, m), 3.16 (3H, s), 4.42 (3H, m), 7.66 (1H, dd, J=11.3 and 6.4 Hz), 8.13 (1H, t, J=9.3 Hz)
- ES-MS; m/z: 356 (MH+)
- The ethyl 1-cyclopropyl-6,7-difluoro-2-(methylsulfonyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylate (140 mg, 0.377 mmol) obtained in (A) was dissolved in tetrahydrofuran (5 ml), added with morpholine (0.0395 ml, 0.452 mmol), N,N-diisopropylethylamine (0.131 ml, 0.754 mmol) and magnesium bromide diethyl etherate (389 mg, 1.51 mmol), and then the mixture was refluxed by heating for 2 hours. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by preparative TLC (chloroform:methanol=100:5) to obtain the title compound (89.2 mg, 62%).
- 1H-NMR (CDCl3) δ: 0.80 (2H, m), 1.40 (3H, t, J=7.1 Hz), 1.41 (2H, m), 3.14 (1H, m), 3.36 (4H, t, J=4.4 Hz), 3.84 (4H, t, J=4.4 Hz), 4.38 (2H,q, J=7.1 Hz), 7.47 (1H, dd, J=11.7 and 6.4 Hz), 8.01 (1H, dd, J=10.0 and 9.0 Hz)
- (4-Isopropyl-1,3-thiazol-2-yl)methanol (37.0 mg, 0.235 mmol) was dissolved in dimethylformamide (2 ml), added with 18-crown-6 (68.4 mg, 0.259 mmol) and sodium hydride (95%, 6.5 mg, 0.259 mmol), and stirred for 10 minutes under argon atmosphere. The reaction mixture was added with a solution of the ethyl 1-cyclopropyl-6,7-difluoro-2-morpholino-4-oxo-1,4-dihydro-3-quinolinecarboxylate (89.0 mg, 0.235 mmol) obtained in (B) in dimethylformamide (1 ml), and stirred at room temperature for 1 hour. Then, the reaction mixture was added with aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by preparative TLC (chloroform:methanol=100:5, v/v) to obtain the title compound (102 mg, 84%).
- 1H-NMR (CDCl3) δ: 0.68 (2H, m), 1.29 (2H, m), 1.32 (6H, d, J=6.8 Hz), 1.39 (3H, t, J=7.1 Hz), 3.05 (1H, m), 3.11 (1H, m), 3.32 (4H, t, J=4.4 Hz), 3.82 (4H, t, J=4.4 Hz), 4.39 (2H,q, J=7.1 Hz), 5.52 (2H, s), 6.97 (1H, s), 7.27 (1H, d, J=7.3 Hz), 7.93 (1H, d, J=11.2 Hz)
- ES-MS; m/z: 516 (MH+)
- A solution of aluminum chloride (266 mg, 2.00 mmol) in 1,2-dichloroethane (4 ml) was added with dimethyl sulfide (0.293 ml, 4.00 mmol) and stirred at 0° C. for 30 minutes. Then, the reaction mixture was added with ethyl 1-cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-2-morpholino-4-oxo-1,4-dihydro-3-quinolinecar boxylate (51.5 mg, 0.0999 mmol) and refluxed overnight by heating. The reaction mixture was left stand for cooling, diluted with chloroform, washed with 1 N hydrochloric acid, and dried over anhydrous magnesium sulfate. The solvent was evaporated and the obtained residue was purified by preparative TLC (chloroform:methanol=10:1) to obtain the title compound (1.3 mg, 3%).
- 1H-NMR (CDCl3) δ: 0.58 (2H, m), 1.17 (2H, m), 1.33 (6H, d, J=6.8 Hz), 3.11 (1H, m), 3.29 (1H, m), 3.52 (4H, m), 4.00 (4H, m), 5.55 (2H, s), 6.97 (1H, s), 7.28 (1H, d, J=6.8 Hz), 7.90 (1H, d, J=10.7 Hz)
- LCMS; m/z: 487 (M)
- 1-Cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (1.00 g, 3.77 mmol) was dissolved in dimethylformamide (15 ml), added with triethylamine (0.788 ml, 5.66 mmol) and ethyl chloroformate (0.538 ml, 5.66 mmol) under ice cooling, and stirred for 1 hour. The reaction mixture was warmed to room temperature, stirred for 30 minutes, and further stirred at 0° C. for 1 hour. The reaction mixture was added with concentrated aqueous ammonia (0.75 ml) and stirred overnight at room temperature. The reaction mixture was diluted with ethyl acetate and washed successively with aqueous citric acid, saturated aqueous sodium hydrogencarbonate and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated to obtain the title compound (1.23 g, quantitative) as white solid.
- 1H-NMR (CD3OD) δ: 1.21 (2H, m), 1.42 (2H, m), 3.56 (1H, m), 7.88 (1H, dd, J=11.2 and 6.4 Hz), 8.25 (1H, dd, J=10.5 and 8.5 Hz), 8.88 (1H, s)
- A solution of dimethylformamide (0.712 ml, 9.19 mmol) in acetonitrile (10 ml) was added with oxalyl chloride (0.729 ml, 8.36 mmol) under ice cooling, stirred at the same temperature for 15 minutes, added with a solution of the 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxamide (1.23 g, 4.18 mmol) obtained in (A) in acetonitrile (10 ml) and stirred at the same temperature for 10 minutes. This mixture was added with pyridine (1.35 ml, 16.7 mmol), stirred at the same temperature for 10 minutes, and then stirred overnight at room temperature. The reaction mixture was added with ethyl acetate, washed successively with aqueous citric acid, saturated aqueous sodium hydrogencarbonate and saturated brine, and dried over anhydrous magnesium sulfate to obtain the title compound (714 mg, 77%) as pale yellow solid.
- 1H-NMR (CDCl3) δ: 1.16 (2H, m), 1.42 (2H, m), 3.47 (1H, m), 7.78 (1H, dd, J=11.0 and 6.4 Hz), 8.16 (1H, s), 8.21 (1H, dd, J=10.0 and 8.6 Hz)
- MS; m/z: 247 (MH+)
- The 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile (150 mg, 0.609 mmol) obtained in (B) was dissolved in a mixed solution of acetic acid, water and pyridine (1:1:2, 4 ml), added with Raney Nickel (catalytic amount) and sodium phosphinate monohydrate (258 mg, 2.44 mmol), and then the mixture was stirred overnight at 60° C. The reaction mixture was left stand for cooling and the catalyst was removed by filtration through a Celite layer and washed with hot ethanol. The reaction mixture was concentrated, then diluted with chloroform, and washed with aqueous copper sulfate. The organic layer was dried over anhydrous magnesium sulfate to obtain the title compound (97.0 mg, 64%) as pale yellow solid.
- 1H-NMR (CDCl3) δ: 1.18 (2H, m), 1.39 (2H, m), 3.47 (1H, m), 7.78 (1H, dd, J=11.2 and 6.3 Hz), 8.27 (1H, dd, J=10.2 and 8.8 Hz), 8.42 (1H, s), 10.37 (1H, s)
- LCMS; m/z: 250 (MH+)
- The 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarbaldehyde (97.0 mg, 0.389 mmol) obtained in (C) was dissolved in a mixed solvent of dimethylformamide and tetrahydrofuran (2:1, 3 ml), added with (tert-butoxycarbonyl-methylene)triphenylphosphorane (176 mg, 0.467 mmol), and stirred at 70° C. for 11 hours. The reaction mixture was concentrated, and the resulting residue was separated and purified by preparative TLC (chloroform:methanol=100:5) to obtain Z-isomer of the title compound (68.7 mg, 51%) and E-isomer of the title compound (32.9 mg, 29%) as pale yellow solids.
- (Z-Isomer) Rf=Higher
- 1H-NMR (CDCl3) δ: 1.23 (2H, m), 1.32 (2H, m), 1.50 (9H, s), 3.43 (1H, m), 5.86 (1H, d, J=13.2 Hz), 7.27 (1H, d, J=13.2 Hz), 7.71 (1H, dd, J=11.5 and 6.4 Hz), 8.22 (1H, dd, J=10.0 and 9.1 Hz), 9.36 (1H, s)
- MS; m/z: 348 (MH+)
- (E-Isomer) Rf=Lower
- 1H-NMR (CDCl3) δ: 1.11 (2H, m), 1.33 (2H, m), 1.52 (9H, s), 3.43 (1H, m), 7.14 (1H, d, J=15.8 Hz), 7.39 (1H, d, J=15.8 Hz), 7.70 (1H, dd, J=11.5 and 6.3 Hz), 7.88 (1H, s), 8.24 (1H, dd, J=10.5 and 8.5 Hz)
- MS; m/z: 348 (MH+)
- (4-Isopropyl-1,3-thiazol-2-yl)methanol (31.1 mg, 0.198 mmol) was dissolved in dimethylformamide (1 ml), added with 18-crown-6 (57.5 mg, 0.218 mmol) and sodium hydride (95%, 5.5 mg, 0.218 mmol), and then the mixture was stirred for 15 minutes under argon atmosphere. The reaction mixture was added with a solution of the tert-butyl (Z)-3-(1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolyl)-2-propenoate (68.7 mg, 0.198 mmol) obtained in (D) in dimethylformamide (1 ml) and stirred at room temperature for 2 hours. Then, the reaction mixture was added with aqueous ammonium chloride and extracted with chloroform. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by preparative TLC (chloroform:methanol=100:1) to obtain the title compound (52.4 mg, 55%).
- 1H-NMR (CDCl3) δ: 1.15 (2H, m), 1.29 (2H, m), 1.33 (3H, d, J=6.8 Hz), 1.50 (9H, s), 3.11 (1H, m), 3.36 (1H, m), 5.58 (2H, s), 5.82 (1H, d, J=12.9 Hz), 6.97 (1H, s), 7.27 (1H, d, J=12.9 Hz), 7.55 (1H, d, J=6.8 Hz), 8.11 (1H, d, J=11.5 Hz), 9.32 (1H, s)
- The (Z)-3-(1-cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-4-oxo-1,4-dihydro-3-quinolyl)-2-propenoate (52.4 mg, 0.108 mmol) obtained in (E) was dissolved in 4 N hydrochloric acid in dioxane (2 ml) and stirred overnight. The reaction mixture was concentrated, and the deposited solid was collected by filtration using ether to obtain the title compound (54.3 mg, quantitative) as pale yellow solid.
- 1H-NMR (CD3OD/CDCl3) δ: 1.36 (3H, d, J=7.10 Hz), 1.53 (2H, m), 1.73 (2H, m), 3.18 (1H, m), 4.38 (1H, m), 5.90 (2H, s), 6.77 (1H, d, J=9.6 Hz), 7.26 (1H, s), 8.25 (1H, d, J=9.6 Hz), 8.41 (2H, m), 9.79 (1H, s)
- ES-MS; m/z: 427 (MH−)
- (4-Isopropyl-1,3-thiazol-2-yl)methanol (19.5 mg, 0.124 mmol) was dissolved in dimethylformamide (1 ml), added with 18-crown-6 (35.8 mg, 0.135 mmol) and sodium hydride (95%, 3.4 mg, 0.135 mmol), and stirred for 15 minutes under argon atmosphere. The reaction mixture was added with a solution of tert-butyl (E)-3-(1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolyl)-2-propenoate (39.2 mg, 0.124 mmol) in dimethylformamide (1 ml) and stirred at room temperature for 3 hours. Then, the reaction mixture was added with aqueous ammonium chloride and extracted with chloroform. The organic layer was dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by preparative TLC (chloroform:methanol=100:1) to obtain the title compound (44.7 mg, 82%).
- 1H-NMR (CDCl3) δ: 1.03 (2H, m), 1.30 (2H, m), 1.31 (3H, d, J=6.8 Hz), 1.51 (9H, s), 3.11 (1H, m), 3.36 (1H, m), 5.57 (2H, s), 6.96 (1H, s), 7.12 (1H, d, J=15.8 Hz), 7.37 (1H, d, J=15.8 Hz), 7.53 (1H, d, J=6.8 Hz), 7.79 (1H, s), 8.10 (1H, d, J=11.2 Hz)
- The (E)-3-(1-cyclopropyl-6-fluoro-7-[(4-isopropyl-1,3-thiazol-2-yl)methyl]-4-oxo-1,4-dihydro-3-quinolyl)-2-propenoate (44.7 mg, 0.0992 mmol) obtained in (A) was dissolved in 4 N hydrochloric acid in dioxane (2 ml) and stirred overnight. The reaction mixture was concentrated, and the deposited solid was collected by filtration using ether to obtain the title compound (32.9 mg, 83%) as pale yellow solid.
- 1H-NMR (CD3OD/CDCl3) δ: 1.14 (2H, m), 1.33 (3H, d, J=5.6 Hz), 1.38 (2H, m), 3.15 (1H, m), 3.56 (1H, m), 5.66 (2H, s), 7.13 (1H, d, J=15.6 Hz), 7.17 (1H, s), 7.60 (1H, d, J=15.6 Hz), 7.75 (1H, d, 6.9 Hz), 8.04 (1H, d, J=11.2 Hz), 8.25 (1H, s)
- ES-MS; m/z: 429 (MH+)
- As multidrug resistant Pseudomonas aeruginosa, Pseudomonas aeruginosa PAM 1723 strain highly expressing the drug efflux pump was used. As antimicrobial drugs for the combinational uses, levofloxacin (LVFX) as a quinolone antibacterial agent and aztreonam (AZT) as a monobactam antibiotic were used. Each of the compounds shown in Table 1 with Example No., which falls within the compounds of the present invention, was subjected to the measurement of its minimum concentration (μg/ml) that was required to enhance the antibacterial activity of levofloxacin when the test compound was used in combination with levofloxacin applied at a concentration of ¼, or ⅛ or less of the minimum inhibitory concentration against the PAM 1723 strain. As for aztreonam, a minimum concentration (μg/ml) of each text compound was measured that was required to enhance its antibacterial activity when the test compound was used in combination with azthreonam at a concentration of ⅛ or less of the MIC. Effects as combinational uses for 18 hours was indicated for each of the drugs. Effects were determined by visually observing the turbidity of the medium. The Müller-Hinton broth (MHB, Difco) was used as a medium, and the inoculum of the bacteria was 1×106 CFU/ml. As clearly shown in Table 1, the compounds of the present invention exhibited effect on the drug resistant Pseudomonas aeruginosa in the combinational uses mainly by inhibiting resistance due to the drug efflux pump, and accordingly, it can be concluded that the class of compounds are expected to be useful clinically.
TABLE 1 Example No. MPC4 LVFX MPC8 LVFX MPC8 AZT 5 0.5 8 8 10 2 16 4 18 ≦0.25 1 0.5 26 0.25 1 1 78 0.5 1 1 94 4 16 16 98 1 4 4 104 0.24 1 0.5 117 1 4 4 130 2 8 8 135 4 16 8 141 0.25 16 2 152 2 8 4 155 0.25 2 2 Example No. Chemical Formula 5 10 18 26 78 94 98 104 117 130 135 141 152 155 - By using a drug efflux pump inhibitor in combination with two or more types of antibacterial agents that can be substrates of the drug efflux pump, strong synergistic effect can be obtained and thus an effective therapeutic method can be provided for treatment of infectious diseases caused by Pseudomonas aeruginosa Antibacterial agents for combination include antibacterial agents excreted by Pseudomonas aeruginosa Mex type drug efflux pump such as quinolones, β-lactams, tetracyclines, macrolides, chloramphenicol, sulfonamides, trimethoprim, β-lactamase inhibitors and so forth.
- (1) Effect of Combined Used of a Pump Inhibitor, Levofloxacin (LVFX) and Meropenem (MEPM) Evaluated by the Three-Dimensional Checker Board Method
- The effect was measured by the three-dimensional checker board method by using Pseudomonas aeruginosa wild strain PAM 1020. The test strain was inoculated into Mueller-Hinton broth containing LVFX, MEPM (at 11 concentration levels and 0 μg/ml) and the compound of Example 26 (40-0.625 μg/ml and 0 μg/ml) at a concentration of 106 CFU/ml and cultured at 37° C. for 18 hours. Then, MIC was measured for sole and combined use. Measurement was performed by the checker board method and FIC index was calculated according to the following equation.
FIC index=a/a0+b/b0+c/c0
wherein a0: MIC for Agent A used alone, a: MIC for Agent A when Agents A, B and C are used in combination, b0: MIC for Agent B used alone, b: MIC for Agent B when Agents A, B and C are used in combination, c0: MIC for Agent C used alone, c: MIC for Agent C when Agents A, B and C are used in combination. - It was determined that there was synergistic effect when FIC index was 0.75 or less, additive effect or weak synergistic effect when the index was more than 0.75 but not more than 1.125, no effect of combined use when the index was more than 1.125 but not more than 3.0, and antagonistic effect when the index was more than 3.0.
- The results are shown in the following table. As for the effect of MEPM on the combined use of two types of drugs, LVFX and the compound of Example 26, effects of the addition of MEPM were clearly observed for all of effective concentrations of the compound of Example 26 (0.625-40 μg/ml). As for the effect of combined use of three types of drugs, apparent effects of the addition of MEPM were observed for all of effective concentrations of the compound of Example 26 (0.625-40 μg/ml).
- MIC values of the used agents for the PAM 1020 strain were 0.25 μg/ml for LVFX, 80 μg/ml or more for the compound of Example 26, and 0.5 μg/ml for MEPM.
FIC index provided by combined use of 3 types of drugs FIC index 0.016 0.0313 0.0625 0.125 0.25 (MEPM LVFX (MEPM LVFX (MEPM LVFX (MEPM LVFX (MEPM LVFX Compound of conc. conc. conc. conc. conc. conc. conc. conc. conc. conc. Example 26 μg/ml) (μg/ml) μg/ml) (μg/ml) μg/ml) (μg/ml) μg/ml) (μg/ml) μg/ml) (μg/ml) 40 1.031 0.125 1.0625 0.125 0.750 0.0313 — — — — 20 0.781 0.125 0.8125 0.125 0.500 0.0313 — — — — 10 0.656 0.125 0.6875 0.125 0.500 0.0625 0.766 0.0039 — — 5 0.594 0.125 0.625 0.125 0.438 0.0625 0.563 0.0156 — — 2.5 1.063 0.25 0.59375 0.125 0.656 0.125 0.500 0.0313 — — 1.25 1.047 0.25 1.07813 0.25 0.641 0.125 0.563 0.0625 — — 0.625 1.039 0.25 1.07031 0.25 1.133 0.25 0.781 0.125 1.063 0.0078 0 1.031 0.25 1.0625 0.25 1.125 0.25 1.250 0.25 1.5 2 - By using a drug efflux pump inhibitor in combination with a disinfectant that can be a substrate of the drug efflux pump, effect of combined use can be achieved and an effective disinfection method can be provided.
- Effects of a combined use of a drug efflux pump inhibitor and alkyldiaminoethylglycine hydrochloride (AEG, trade name: Tego 51) or chlorhexidine gluconate (CHG, trade name: Hibiten) on Pseudomonas aeruginosa PAM 1723 (a strain highly expressing MexAB-OprM drug efflux pump) was determined by the broth dilution method. The compound of Example 26 was added at a final concentration of 10 μg/ml to Mueller-Hinton broth (MHB) containing a disinfectant at a concentration after 2-fold serial dilution. The amount of the test bacteria inoculated was 1×106 CFU/ml, and after standing cultivation at 37° C. for 18 hours, the culture was observed by visual inspection. The minimum concentration that gave no turbidity as in the control of MHB was determined as MIC.
- The results are shown in the following table. Evaluation of the effect of the combined use of the disinfectant and the compound of Example 26 revealed that the activities of AEG and CHG on PAM 1723 were enhanced by two times and four times, respectively, by the combined use with 10 μg/ml of the compound of Example 26.
MIC (μg/ml) AEG CHG Single Combined Combined Strain use use Ratio* Single use use Ratio* PAM 64 32 2 16 4 4 1723
*Ratio of MIC values for single use of the disinfectant and combined use with the compound of Example 26
Claims (25)
1. A method for therapeutic treatment of microbial infection comprising administering to a mammal in need thereof a therapeutically effective amount of a compound represented by the following formula (I) or a physiologically acceptable salt, or a hydrate thereof:
wherein, R1 and R2 each independently represent hydrogen atom, a halogen atom, hydroxyl group, a group of OZ1-6 (the group of OZ1-6 represents an alkyl group having 1-6 carbon atoms or a fluoroalkyl group having 1-6 carbon atoms, which bonds via the oxygen atom), a group of S(O)nZ1-4 (Z1-4 represents an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms or an alkylene group derived therefrom), a group of N(R12)(R13) (R12 and R13 each independently represent hydrogen atom, an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms), a group of Z1-8 which may be substituted (Z1-8 represents an alkyl group having 1-8 carbon atoms or a fluoroalkyl group having 1-8 carbon atoms), a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group, or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4));
W1 represents a group selected from the group consisting of —CH═CH—, —N(R12)CO—, —CON(R12)—, —CH2O— and —CH2CH2— (each of the aforementioned groups binds to the thiazole ring at the left end);
R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group;
R4 represents a group selected from the group consisting of hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group having 1-4 carbon atoms, a fluorine-substituted alkylene group having 1-4 carbon atoms or a single bond, and R5 represents a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4)), a group of —S(O)nZ0-4R5, a group of —N(R6)(R7) {R6 and R7 each independently represent hydrogen atom or Z1-4, or they may bind to each other to form a saturated or unsaturated 5- to 7-membered ring (the ring may contain one or two hetero atoms as ring constituting atoms), and R6 and R7 may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OCON(R12)(R13), a group of CON(R12)(R13), a group of N(R12)CON(R12)(R13), a group of Z1-4, a group of OZ1-4, a group S(O)nZ1-4, group of CH2OH, a group of (CH2)mN(R12)(R13), carboxyl group, cyano group, a group of CO-Z1-4(R10)—N(R12)(R13) (R10 is a substituent corresponding to a side chain on an amino acid carbon or a group of -Z1-4-R11 (R11 represents a substituent which forms a quaternary salt) and a group of
a 5- or 6-membered aryl group which may be substituted and a 5- or 6-membered unsaturated heterocyclic group which may be substituted;
W2 represents a single bond or —C(R8)═C(R9)— (R8 and R9 each independently represent hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, cyano group, carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group or a group of N(R12)(R13)), Q represents an acidic group, and W2 and Q may bind together to form vinylidenethiazolidinedione in E- or Z-configuration or an equivalent heterocyclic ring; m and n each independently represent an integer of 0 to 2, and q represents an integer of 0 to 3.
2. The method according to claim 1 , further comprising administering at least one antimicrobial agent.
3. The method according to claim 2 , wherein the compound is an active ingredient in a composition.
4. The method according to claim 3 , wherein the at least one antimicrobial agent is simultaneously administered with the composition.
5. The method according to claim 3 , wherein the at least one antimicrobial agent is separately administered from the composition.
6. The method according to claim 3 , wherein the at least one antimicrobial agent is successively administered with the composition.
7. The method according to claim 1 wherein the mammal is a human.
8. The method according to claim 1 wherein the microbial infection comprises an infection by bacteria having a genetically homologous drug efflux pump to Pseudomonas aeruginosa
9. A method for preventive treatment of a microbial infection comprising administering to a mammal a preventively effective amount of a compound represented by the following formula (I) or a physiologically acceptable salt, or a hydrate thereof:
wherein, R1 and R2 each independently represent hydrogen atom, a halogen atom, hydroxyl group, a group of OZ1-6 (the group of OZ1-6 represents an alkyl group having 1-6 carbon atoms or a fluoroalkyl group having 1-6 carbon atoms, which bonds via the oxygen atom), a group of S(O)nZ1-4 (Z1-4 represents an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms or an alkylene group derived therefrom), a group of N(R12)(R13) (R12 and R13 each independently represent hydrogen atom, an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms), a group of Z1-8 which may be substituted (Z1-8 represents an alkyl group having 1-8 carbon atoms or a fluoroalkyl group having 1-8 carbon atoms), a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group, or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4));
W1 represents a group selected from the group consisting of —CH═CH—, —N(R12)CO—, —CON(R12)—, —CH2O— and —CH2CH2— (each of the aforementioned groups binds to the thiazole ring at the left end);
R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group;
R4 represents a group selected from the group consisting of hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group having 1-4 carbon atoms, a fluorine-substituted alkylene group having 1-4 carbon atoms or a single bond, and R5 represents a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4)), a group of —S(O)nZ0-4R5, a group of —N(R6)(R7) {R6 and R7 each independently represent hydrogen atom or Z1-4, or they may bind to each other to form a saturated or unsaturated 5- to 7-membered ring (the ring may contain one or two hetero atoms as ring constituting atoms), and R6 and R7 may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OCON(R12)(R13), a group of CON(R12)(R13), a group of N(R12)CON(R12)(R13), a group of Z1-4, a group of OZ1-4, a group S(O)nZ1-4, group of CH2OH, a group of (CH2)mN(R12)(R13), carboxyl group, cyano group, a group of CO-Z1-4(R10)—N(R12)(R13) (R10 is a substituent corresponding to a side chain on an amino acid carbon or a group of -Z1-4-R11 (R11 represents a substituent which forms a quaternary salt) and a group of
a 5- or 6-membered aryl group which may be substituted and a 5- or 6-membered unsaturated heterocyclic group which may be substituted;
W2 represents a single bond or —C(R8)═C(R9)— (R8 and R9 each independently represent hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, cyano group, carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group or a group of N(R12)(R13)), Q represents an acidic group, and W2 and Q may bind together to form vinylidenethiazolidinedione in E- or Z-configuration or an equivalent heterocyclic ring; m and n each independently represent an integer of 0 to 2, and q represents an integer of 0 to 3.
10. The method according to claim 9 , further comprising administering at least one antimicrobial agent.
11. The method according to claim 10 , wherein the compound is an active ingredient in a composition.
12. The method according to claim 11 , wherein the at least one antimicrobial agent is simultaneously administered with the composition.
13. The method according to claim 11 , wherein the at least one antimicrobial agent is separately administered from the composition.
14. The method according to claim 11 , wherein the at least one antimicrobial agent is successively administered with the composition.
15. The method according to claim 9 wherein the mammal is a human.
16. The method according to claim 9 wherein the microbial infection comprises an infection by microorganisms selected from Pseudomonas aeruginosa and bacteria having a genetically homologous drug efflux pump to Pseudomonas aeruginosa.
17. A method for therapeutic treatment of a microbial infection comprising administering to a mammal in need thereof a therapeutically effective amount of a compound represented by the following formula (I) or a physiologically acceptable salt, or a hydrate thereof:
wherein, R1 and R2 each independently represent hydrogen atom, a halogen atom, hydroxyl group, a group of OZ1-6 (the group of OZ1-6 represents an alkyl group having 1-6 carbon atoms or a fluoroalkyl group having 1-6 carbon atoms, which bonds via the oxygen atom), a group of S(O)nZ1-4 (Z1-4 represents an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms or an alkylene group derived therefrom), a group of N(R12)(R13) (R12 and R13 each independently represent hydrogen atom, an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms), a group of Z1-8 which may be substituted (Z1-8 represents an alkyl group having 1-8 carbon atoms or a fluoroalkyl group having 1-8 carbon atoms), a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group, or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4));
W1 represents a group selected from the group consisting of —CH═CH—, —N(R12)CO—, —CON(R12)—, —CH2O— and —CH2CH2— (each of the aforementioned groups binds to the thiazole ring at the left end);
R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group;
R4 represents a group selected from the group consisting of hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group having 1-4 carbon atoms, a fluorine-substituted alkylene group having 1-4 carbon atoms or a single bond, and R5 represents a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4)), a group of —S(O)nZ0-4R5, a group of —N(R6)(R7) {R6 and R7 each independently represent hydrogen atom or Z1-4, or they may bind to each other to form a saturated or unsaturated 5- to 7-membered ring (the ring may contain one or two hetero atoms as ring constituting atoms), and R6 and R7 may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OCON(R12)(R13), a group of CON(R12)(R13), a group of N(R12)CON(R12)(R13), a group of Z1-4, a group of OZ1-4, a group S(O)nZ1-4, group of CH2OH, a group of (CH2)mN(R12)(R13), carboxyl group, cyano group, a group of CO-Z1-4(R10)—N(R12)(R13) (R10 is a substituent corresponding to a side chain on an amino acid carbon or a group of -Z1-4-R11 (R11 represents a substituent which forms a quaternary salt) and a group of
a 5- or 6-membered aryl group which may be substituted and a 5- or 6-membered unsaturated heterocyclic group which may be substituted;
W2 represents a single bond or —C(R8)═C(R9)— (R8 and R9 each independently represent hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, cyano group, carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group or a group of N(R12)(R13)), Q represents an acidic group, and W2 and Q may bind together to form vinylidenethiazolidinedione in E- or Z-configuration or an equivalent heterocyclic ring; m and n each independently represent an integer of 0 to 2, and q represents an integer of 0 to 3; R14 represents hydrogen atom, Z1-4, Z1-4R5 or Z1-4OR5; and X represents C—H and Y represents C—H or nitrogen atom.
18. The method according to claim 17 , further comprising administering at least one antimicrobial agent.
19. The method according to claim 18 , wherein the compound is an active ingredient in a composition.
20. The method according to claim 17 , wherein the microbial infection comprises an infection by bacteria having a genetically homologous drug efflux pump to Pseudomonas aeruginosa.
21. The method according to claim 17 , wherein the at least one antimicrobial agent and the compound are present in a composition.
22. A method for preventive treatment of a microbial infection comprising administering to a mammal a preventively effective amount of a compound represented by the following formula (I) or a physiologically acceptable salt, or a hydrate thereof:
wherein, R1 and R2 each independently represent hydrogen atom, a halogen atom, hydroxyl group, a group of OZ1-6 (the group of OZ1-6 represents an alkyl group having 1-6 carbon atoms or a fluoroalkyl group having 1-6 carbon atoms, which bonds via the oxygen atom), a group of S(O)nZ1-4 (Z0-4 represents an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms or an alkylene group derived therefrom), a group of N(R12)(R13) (R12 and R13 each independently represent hydrogen atom, an alkyl group having 1-4 carbon atoms or a fluoroalkyl group having 1-4 carbon atoms), a group of Z1-8 which may be substituted (Z1-8 represents an alkyl group having 1-8 carbon atoms or a fluoroalkyl group having 1-8 carbon atoms), a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group, or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4));
W1 represents a group selected from the group consisting of —CH═CH—, —N(R12)CO—, —CON(R12)—, —CH2O— and —CH2CH2— (each of the aforementioned groups binds to the thiazole ring at the left end);
R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group;
R4 represents a group selected from the group consisting of hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group having 1-4 carbon atoms, a fluorine-substituted alkylene group having 1-4 carbon atoms or a single bond, and R5 represents a 5- to 7-membered cyclic alkyl group, an aryl group, a heteroaryl group or a 4- to 7-membered saturated or partially saturated heterocyclic group (the cyclic alkyl group, aryl group, heteroaryl group and heterocyclic group may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OZ1-4, a group of S(O)nZ1-4, a group of N(R12)(R13), a group of Z1-4, carboxyl group, a group of CO2Z1-4, group of CONH2, a group of CONH(Z1-4) and a group of CON(Z1-4)(Z1-4)), a group of —S(O)nZ0-4R5, a group of —N(R6)(R7) {R6 and R7 each independently represent hydrogen atom or Z1-4, or they may bind to each other to form a saturated or unsaturated 5- to 7-membered ring (the ring may contain one or two hetero atoms as ring constituting atoms), and R6 and R7 may have one to three substituents selected from the group consisting of a halogen atom, hydroxyl group, a group of OCON(R12)(R13), a group of CON(R12)(R13), a group of N(R12)CON(R12)(R13), a group of Z1-4, a group of OZ1-4, a group S(O)nZ1-4, group of CH2OH, a group of (CH2)mN(R12)(R13), carboxyl group, cyano group, a group of CO-Z1-4(R10)—N(R12)(R13) (R10 is a substituent corresponding to a side chain on an amino acid carbon or a group of -Z1-4-R11 (R1 represents a substituent which forms a quaternary salt) and a group of
a 5- or 6-membered aryl group which may be substituted and a 5- or 6-membered unsaturated heterocyclic group which may be substituted;
W2 represents a single bond or —C(R8)═C(R9)— (R8 and R9 each independently represent hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, cyano group, carboxyl group, hydroxymethyl group, cyanomethyl group, vinyl group or a group of N(R12)(R13)), Q represents an acidic group, and W2 and Q may bind together to form vinylidenethiazolidinedione in E- or Z-configuration or an equivalent heterocyclic ring; m and n each independently represent an integer of 0 to 2, and q represents an integer of 0 to 3; R14 represents hydrogen atom, Z1-4, Z1-4R5 or Z1-4OR5; and X represents C—H and Y represents C—H or nitrogen atom.
23. The method according to claim 22 , wherein the compound is an active ingredient in a composition.
24. The method according to claim 22 , wherein the microbial infection comprises an infection by microorganisms selected from Pseudomonas aeruginosa and bacteria having a genetically homologous drug efflux pump to Pseudomonas aeruginosa.
25. The method according to claim 22 , wherein the at least one antimicrobial agent and the compound are present in a composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/320,229 US20060106034A1 (en) | 2001-04-26 | 2005-12-29 | Drug efflux pump inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/842,234 US7056917B2 (en) | 2001-04-26 | 2001-04-26 | Drug efflux pump inhibitor |
US11/320,229 US20060106034A1 (en) | 2001-04-26 | 2005-12-29 | Drug efflux pump inhibitor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/842,234 Continuation US7056917B2 (en) | 2001-04-26 | 2001-04-26 | Drug efflux pump inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060106034A1 true US20060106034A1 (en) | 2006-05-18 |
Family
ID=25286829
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/842,234 Expired - Fee Related US7056917B2 (en) | 2001-04-26 | 2001-04-26 | Drug efflux pump inhibitor |
US11/320,229 Abandoned US20060106034A1 (en) | 2001-04-26 | 2005-12-29 | Drug efflux pump inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/842,234 Expired - Fee Related US7056917B2 (en) | 2001-04-26 | 2001-04-26 | Drug efflux pump inhibitor |
Country Status (1)
Country | Link |
---|---|
US (2) | US7056917B2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2002087589A1 (en) * | 2001-04-26 | 2004-08-12 | 第一製薬株式会社 | Drug efflux pump inhibitor |
WO2005089738A2 (en) * | 2004-03-17 | 2005-09-29 | Mpex Pharmaceuticals, Inc. | Use and administration of bacterial efflux pump inhibitors |
US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
US7879795B2 (en) | 2004-05-21 | 2011-02-01 | Mpex Pharmaceuticals, Inc. | Enhancement of tigecycline potency using efflux pump inhibitors |
EP1758920A1 (en) * | 2004-05-21 | 2007-03-07 | Mpex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors and methods of treating bacterial infections |
WO2007091395A1 (en) * | 2006-02-10 | 2007-08-16 | Tokai University | Method or agent for inhibiting the function of efflux pump of pseudomonas aeruginosa |
US8586244B2 (en) * | 2007-04-02 | 2013-11-19 | Eveready Battery Co., Inc. | Alkaline electrochemical cell having a negative electrode with solid zinc oxide and a surfactant |
US8178490B2 (en) * | 2007-05-11 | 2012-05-15 | Rempex Pharmaceuticals, Inc. | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof |
CA2686997A1 (en) * | 2007-05-11 | 2008-11-20 | Mpex Pharmaceuticals, Inc. | Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof |
KR20190082985A (en) | 2009-10-02 | 2019-07-10 | 아벡신 에이에스 | Anti inflammatory 2-oxothiazoles and 2-oxooxazoles |
WO2011056561A1 (en) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
EP2526095A1 (en) | 2010-01-19 | 2012-11-28 | Theravance, Inc. | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents |
WO2012149334A2 (en) | 2011-04-27 | 2012-11-01 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
CA2899137C (en) | 2013-01-29 | 2021-07-13 | Avexxin As | Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds |
GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
CN113444082A (en) * | 2020-03-24 | 2021-09-28 | 中山大学 | Hydroxylammonium and/or compound, method for the production thereof and use thereof as energetic material |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3753993A (en) * | 1971-05-17 | 1973-08-21 | Sterling Drug Inc | 1,4-dihydro-4-oxo-7-pyridyl-3-quinoline-carboxylic acid derivatives |
US3870712A (en) * | 1972-03-17 | 1975-03-11 | Lilly Co Eli | Cinchoninic acid derivatives |
US3907808A (en) * | 1971-05-17 | 1975-09-23 | Sterling Drug Inc | 1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives |
US4013647A (en) * | 1976-03-23 | 1977-03-22 | American Home Products Corporation | Morpholine containing tetrazole-5-carboxamide derivatives |
US4404207A (en) * | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
US4638067A (en) * | 1982-09-09 | 1987-01-20 | Warner-Lambert Co. | Antibacterial agents |
US4665079A (en) * | 1984-02-17 | 1987-05-12 | Warner-Lambert Company | Antibacterial agents |
US4771054A (en) * | 1985-01-23 | 1988-09-13 | Warner-Lambert Company | Antibacterial agents |
US4777252A (en) * | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
US4777175A (en) * | 1982-09-09 | 1988-10-11 | Warner-Lambert Company | Antibacterial agents |
US4891428A (en) * | 1985-09-24 | 1990-01-02 | Schering Aktiengesellschaft | Imidazolinyl derivatives, having herbicidal activity |
US4902700A (en) * | 1985-10-16 | 1990-02-20 | Mitsubishi Kasei Corporation | Thiazole derivative and leukotriene antagonist containing the same as the effective ingredients |
US4992434A (en) * | 1987-01-30 | 1991-02-12 | Ciba-Geigy Corporation | Microbicidal composition |
US5135927A (en) * | 1987-01-30 | 1992-08-04 | Ciba-Geigy Corporation | Microbicidal composition |
US5206235A (en) * | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
US5273986A (en) * | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
US5281612A (en) * | 1982-09-09 | 1994-01-25 | Warner-Lambert Company | Naphthyridine antibacterial agents |
US5368771A (en) * | 1991-12-26 | 1994-11-29 | Kashima Oil Company | Optically active tetrahydropyrane derivatives, liquid crystal composition and liquid crystal device containing the same |
US5443755A (en) * | 1991-12-26 | 1995-08-22 | Kashima Oil Company | Optically active tetrahydropyrane derivatives, liquid crystal composition and liquid crystal device containing the same |
US5508408A (en) * | 1993-09-10 | 1996-04-16 | Ciba-Geigy Corporation | Quinoline compound |
US5512581A (en) * | 1994-07-18 | 1996-04-30 | Abbott Laboratories | Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis |
US5643932A (en) * | 1990-11-30 | 1997-07-01 | Otsuka Pharmaceutical Co., Ltd. | Superoxide radical inhibitor |
US5935977A (en) * | 1996-09-25 | 1999-08-10 | Ss Pharmaceutical Co., Ltd. | Substituted vinyl pyridine derivative and drugs containing the same |
US5981559A (en) * | 1994-10-14 | 1999-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Azole derivative with leukotriene (LTs) antagonizing activity and thromboxane (TX) A2 antagonizing activity |
US6114310A (en) * | 1998-01-23 | 2000-09-05 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US6204279B1 (en) * | 1998-06-03 | 2001-03-20 | Microcide Pharmaceuticals, Inc. | Peptidomimetic efflux pump inhibitors |
US6245746B1 (en) * | 1998-01-23 | 2001-06-12 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US6255321B1 (en) * | 1997-06-17 | 2001-07-03 | Kaken Pharmaceutical Co., Ltd. | 2-sulfamoylbenzoic acid derivatives |
US6376671B1 (en) * | 1997-06-17 | 2002-04-23 | Kaken Pharmaceutical Co., Ltd. | 2-sulfamoylbenzoic acid derivatives |
US20020049235A1 (en) * | 1996-07-11 | 2002-04-25 | Akiyoshi Kawai | Pyridylpyrrole compounds useful as interleukin-and tnf antagonists |
US20050009843A1 (en) * | 2001-04-26 | 2005-01-13 | Kiyoshi Nakayama | Medicine for inhibiting drug elimination pump |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1458066A (en) | 1963-03-20 | 1966-03-04 | Boehringer & Soehne Gmbh | Process for the preparation of new nitrofuran derivatives |
GB1305820A (en) | 1970-09-28 | 1973-02-07 | ||
JPS54144397A (en) * | 1978-04-27 | 1979-11-10 | Chinoin Gyogyszer Es Vegyeszet | Novel manufacture of compound having nitrogen bridge head |
JPS57144264A (en) | 1981-03-03 | 1982-09-06 | Kanebo Ltd | 6-fluoro-1,4-dihydro-4-oxocinnoline-3-carboxylic acid derivative |
DE3417840A1 (en) * | 1983-05-17 | 1984-11-22 | Ciba-Geigy Ag, Basel | Tetrazole compounds |
JPS60197686A (en) | 1984-03-19 | 1985-10-07 | Dai Ichi Seiyaku Co Ltd | 1,8-naphthyridine derivative |
JPS6192597A (en) * | 1984-10-09 | 1986-05-10 | Kobayashi Seiyaku Kk | Method of examining sensitivity of bacterium to drug |
JPS6212760A (en) | 1984-12-14 | 1987-01-21 | Dai Ichi Seiyaku Co Ltd | 1-(2-halogenocyclopropyl)quinolinecarboxylic acid derivative |
JPS61246188A (en) | 1985-08-27 | 1986-11-01 | Dai Ichi Seiyaku Co Ltd | Pyrido-1,4-benzoxazine derivative |
DE3875750D1 (en) * | 1987-01-30 | 1992-12-17 | Ciba Geigy Ag | MICROBICIDAL AGENTS. |
DE68905845T2 (en) | 1988-02-19 | 1993-08-05 | Lilly Co Eli | TETRAZOLE COMPOUNDS AS ANTAGONISTS OF THE EXCITATORIC AMINO ACID RECEPTORS. |
JPH02219892A (en) * | 1989-02-22 | 1990-09-03 | Dainippon Ink & Chem Inc | Ferroelectric liquid crystal composition |
JPH03207789A (en) * | 1990-01-09 | 1991-09-11 | Dainippon Ink & Chem Inc | Ferromagnetic liquid crystal composition |
JPH0543878A (en) * | 1991-08-15 | 1993-02-23 | Dainippon Ink & Chem Inc | Ferroelectric liquid crystal composition containing lowly viscous liquid crystal |
WO1993007141A1 (en) | 1991-10-11 | 1993-04-15 | Smithkline Beecham Corporation | Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production |
WO1993022312A1 (en) | 1992-04-29 | 1993-11-11 | Sri International | Deazaaminopterins for treatment of inflammation |
WO1993022315A1 (en) | 1992-04-29 | 1993-11-11 | Sri International | Heteroaroyl-10-deazaaminopterins for treatment of inflammation |
US5989832A (en) * | 1995-04-21 | 1999-11-23 | Microcide Pharmaceuticals, Inc. | Method for screening for non-tetracycline efflux pump inhibitors |
AU5347496A (en) | 1995-04-21 | 1996-11-07 | Daiichi Pharmaceutical Co., Ltd. | Ethynylthiazole derivative |
WO1997003967A1 (en) | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
KR20040084945A (en) | 1996-07-25 | 2004-10-06 | 바이오겐 아이덱 엠에이 인코포레이티드 | Cell adhesion inhibitors |
JPH10195063A (en) | 1996-10-21 | 1998-07-28 | Dai Ichi Seiyaku Co Ltd | Ethynylthiazole derivative |
WO1998017625A1 (en) * | 1996-10-22 | 1998-04-30 | Daiichi Pharmaceutical Co., Ltd. | Novel remedies for infectious diseases |
JPH10310578A (en) * | 1996-11-13 | 1998-11-24 | Yoshitomi Pharmaceut Ind Ltd | 3-phenylpyrazole compound |
WO1998057957A1 (en) | 1997-06-18 | 1998-12-23 | Nissan Chemical Industries, Ltd. | Pyridine compounds and herbicides |
WO1999036422A1 (en) | 1998-01-14 | 1999-07-22 | The Uab Research Foundation | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme |
AU2337599A (en) * | 1998-01-23 | 1999-08-09 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
DE19817459A1 (en) | 1998-04-20 | 1999-10-21 | Basf Ag | New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc. |
JP3754993B2 (en) * | 1999-02-04 | 2006-03-15 | 国立感染症研究所長 | Method for distinguishing metallo-β-lactamase producing bacteria |
EP1227084B1 (en) | 1999-10-28 | 2005-12-14 | Trine Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
JP2002128768A (en) * | 2000-10-26 | 2002-05-09 | Dai Ichi Seiyaku Co Ltd | Compound having medicine drainage pump-inhibiting action |
-
2001
- 2001-04-26 US US09/842,234 patent/US7056917B2/en not_active Expired - Fee Related
-
2005
- 2005-12-29 US US11/320,229 patent/US20060106034A1/en not_active Abandoned
Patent Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3907808A (en) * | 1971-05-17 | 1975-09-23 | Sterling Drug Inc | 1,4-Dihydro-4-oxo-7-pyridyl-3-quinolinecarboxylic acid derivatives |
US3753993A (en) * | 1971-05-17 | 1973-08-21 | Sterling Drug Inc | 1,4-dihydro-4-oxo-7-pyridyl-3-quinoline-carboxylic acid derivatives |
US3870712A (en) * | 1972-03-17 | 1975-03-11 | Lilly Co Eli | Cinchoninic acid derivatives |
US4013647A (en) * | 1976-03-23 | 1977-03-22 | American Home Products Corporation | Morpholine containing tetrazole-5-carboxamide derivatives |
US4057632A (en) * | 1976-03-23 | 1977-11-08 | American Home Products Corporation | Method of treatment using tetrazole-5-carboxamide derivatives |
US4116960A (en) * | 1976-03-23 | 1978-09-26 | American Home Products Corporation | Tetrazole-5-carboxamide derivatives |
US4123432A (en) * | 1976-03-23 | 1978-10-31 | American Home Products Corporation | Tetrazole-5-carboxamide derivatives |
US4129735A (en) * | 1976-03-23 | 1978-12-12 | American Home Products Corporation | Process for preparing tetrazole-5-carboxamide derivatives |
US4404207A (en) * | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
US4777175A (en) * | 1982-09-09 | 1988-10-11 | Warner-Lambert Company | Antibacterial agents |
US4638067A (en) * | 1982-09-09 | 1987-01-20 | Warner-Lambert Co. | Antibacterial agents |
US5281612A (en) * | 1982-09-09 | 1994-01-25 | Warner-Lambert Company | Naphthyridine antibacterial agents |
US4665079A (en) * | 1984-02-17 | 1987-05-12 | Warner-Lambert Company | Antibacterial agents |
US4771054A (en) * | 1985-01-23 | 1988-09-13 | Warner-Lambert Company | Antibacterial agents |
US4891428A (en) * | 1985-09-24 | 1990-01-02 | Schering Aktiengesellschaft | Imidazolinyl derivatives, having herbicidal activity |
US4902700A (en) * | 1985-10-16 | 1990-02-20 | Mitsubishi Kasei Corporation | Thiazole derivative and leukotriene antagonist containing the same as the effective ingredients |
US4992434A (en) * | 1987-01-30 | 1991-02-12 | Ciba-Geigy Corporation | Microbicidal composition |
US5135927A (en) * | 1987-01-30 | 1992-08-04 | Ciba-Geigy Corporation | Microbicidal composition |
US4777252A (en) * | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
US6080764A (en) * | 1990-11-30 | 2000-06-27 | Otsuka Pharmaceutical Co., Ltd. | Superoxide radical inhibitor |
US5643932A (en) * | 1990-11-30 | 1997-07-01 | Otsuka Pharmaceutical Co., Ltd. | Superoxide radical inhibitor |
US5677319A (en) * | 1990-11-30 | 1997-10-14 | Otsuka Pharmaceutical Co., Ltd. | Superoxide radical inhibitor |
USRE37556E1 (en) * | 1990-11-30 | 2002-02-19 | Otsuka Pharmaceutical Co., Ltd. | Superoxide radical inhibitor |
US5206235A (en) * | 1991-03-20 | 1993-04-27 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
US5310737A (en) * | 1991-03-20 | 1994-05-10 | Merck & Co., Inc. | Benzo-fused lactams that promote the release of growth hormone |
US5368771A (en) * | 1991-12-26 | 1994-11-29 | Kashima Oil Company | Optically active tetrahydropyrane derivatives, liquid crystal composition and liquid crystal device containing the same |
US5443755A (en) * | 1991-12-26 | 1995-08-22 | Kashima Oil Company | Optically active tetrahydropyrane derivatives, liquid crystal composition and liquid crystal device containing the same |
US5273986A (en) * | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
US5508408A (en) * | 1993-09-10 | 1996-04-16 | Ciba-Geigy Corporation | Quinoline compound |
US5512581A (en) * | 1994-07-18 | 1996-04-30 | Abbott Laboratories | Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis |
US5981559A (en) * | 1994-10-14 | 1999-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Azole derivative with leukotriene (LTs) antagonizing activity and thromboxane (TX) A2 antagonizing activity |
US20020049235A1 (en) * | 1996-07-11 | 2002-04-25 | Akiyoshi Kawai | Pyridylpyrrole compounds useful as interleukin-and tnf antagonists |
US5935977A (en) * | 1996-09-25 | 1999-08-10 | Ss Pharmaceutical Co., Ltd. | Substituted vinyl pyridine derivative and drugs containing the same |
US6255321B1 (en) * | 1997-06-17 | 2001-07-03 | Kaken Pharmaceutical Co., Ltd. | 2-sulfamoylbenzoic acid derivatives |
US6376671B1 (en) * | 1997-06-17 | 2002-04-23 | Kaken Pharmaceutical Co., Ltd. | 2-sulfamoylbenzoic acid derivatives |
US6114310A (en) * | 1998-01-23 | 2000-09-05 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US6245746B1 (en) * | 1998-01-23 | 2001-06-12 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
US6204279B1 (en) * | 1998-06-03 | 2001-03-20 | Microcide Pharmaceuticals, Inc. | Peptidomimetic efflux pump inhibitors |
US6436980B1 (en) * | 1998-06-03 | 2002-08-20 | Essential Therapeutics, Inc. | Peptidomimetic efflux pump inhibitors |
US20050009843A1 (en) * | 2001-04-26 | 2005-01-13 | Kiyoshi Nakayama | Medicine for inhibiting drug elimination pump |
Also Published As
Publication number | Publication date |
---|---|
US7056917B2 (en) | 2006-06-06 |
US20030092720A1 (en) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060106034A1 (en) | Drug efflux pump inhibitor | |
US20050009843A1 (en) | Medicine for inhibiting drug elimination pump | |
JP6670333B2 (en) | 3-Tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-β-lactamase inhibitors | |
KR102667828B1 (en) | Beta-lactamase inhibitor compounds | |
JP6122484B2 (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
US11433055B2 (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
JP5977344B2 (en) | Phosphate esters of gyrase and topoisomerase inhibitors | |
AU2017316742A1 (en) | Antibiotic compounds | |
US10183943B2 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
TW201815390A (en) | Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections | |
KR20190065326A (en) | Heterocyclic compounds and their use for the prevention or treatment of bacterial infections | |
KR20080004571A (en) | 2-thioethenyl carbapenem derivative | |
CN113272302A (en) | Antibiotic compounds, process for their manufacture, pharmaceutical compositions containing them and their use | |
WO1998034936A1 (en) | Carbapenem compounds, use thereof, and intermediate compounds of the same | |
US20230365551A1 (en) | Inhibitors of human respiratory syncytial virus and metapneumovirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |